Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.1.3.48 - protein-tyrosine-phosphatase and Organism(s) Homo sapiens and UniProt Accession P54829

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Non-digestible fraction of beans (Phaseolus vulgaris L.) modulates signalling pathway genes at an early stage of colon cancer in Sprague-Dawley rats.
Abortion, Spontaneous
Rapamycin prevents spontaneous abortion by triggering decidual stromal cell autophagy-mediated NK cell residence.
Acalculous Cholecystitis
Gallbladder epithelial acid hydrolases in human cholecystitis.
Achondroplasia
Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes.
Acidosis
Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.
Influence of CO2 pneumoperitoneum on intracellular pH and signal transduction in cancer cells.
Acne Vulgaris
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved?
The systemic autoinflammatory diseases: inborn errors of the innate immune system.
Acquired Immunodeficiency Syndrome
A126: Clusters of Autoimmune Diseases in Children and the Role of PTPN22 C1858T Gene Polymorphism in Pediatric Polyautoimmunity.
Role of the F-BAR Family Member PSTPIP2 in Autoinflammatory Diseases.
[Common genetic factors in autoimmunity].
Acromegaly
Human nasal septal cartilage: local distribution of different enzyme activities in healthy adults and acromegalic patients.
Acute Coronary Syndrome
Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease.
Increased PTPN22 expression and defective CREB activation impair regulatory T-cell differentiation in non-ST-segment elevation acute coronary syndromes.
Protein tyrosine phosphatase receptor-type O expression as a prognostic marker in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A prospective study.
Acute Kidney Injury
Chronic nicotine exposure augments renal oxidative stress and injury through transcriptional activation of p66shc.
Eriocitrin attenuates ischemia reperfusion-induced oxidative stress and inflammation in rats with acute kidney injury by regulating the dual-specificity phosphatase 14 (DUSP14)-mediated Nrf2 and nuclear factor-?B (NF-?B) pathways.
p66shc and Gender-specific Dimorphism in Acute Renal Injury.
SIRT2 is involved in cisplatin-induced acute kidney injury through regulation of mitogen-activated protein kinase phosphatase-1.
Acute Lung Injury
MAP Kinase Phosphatase 5 Protects Against Sepsis-induced Acute Lung Injury.
Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury.
Protein phosphatase 2A activation attenuates inflammation in murine models of acute lung injury.
Addison Disease
Association of Autoimmune Addison's Disease with Alleles of STAT4 and GATA3 in European Cohorts.
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease.
Novel homozygous AIRE mutation in a German patient with severe APECED.
Pathogenesis of primary adrenal insufficiency.
Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency.
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population.
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
The tryptophan 620 allele of the lymphoid tyrosine phosphatase (PTPN22 gene) predisposes to autoimmune Addison's disease.
Adenocarcinoma
Allyl isothiocyanate induces G2/M arrest in human colorectal adenocarcinoma SW620 cells through down-regulation of Cdc25B and Cdc25C.
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Bicarbonate is essential for protein-tyrosine phosphatase 1B (PTP1B) oxidation and cellular signaling through EGF-triggered phosphorylation cascades.
Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system.
Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family.
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17?-estrodial-induced cell growth in endometrial adenocarcinoma cell.
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.
Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73.
Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis.
Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Genome Wide Methylome Alterations in Lung Cancer.
Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture.
Helicobacter Pylori CagA and Gastric Carcinogenesis.
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma.
Immunological detection of metastases from prostatic adenocarcinoma.
Increase in receptor-like protein tyrosine phosphatase activity and expression level on density-dependent growth arrest of endothelial cells.
Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma.
Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer.
Inhibitory Effect of Artesunate on Growth and Apoptosis of Gastric Cancer Cells.
Involvement of beta3A subunit of adaptor protein-3 in intracellular trafficking of receptor-like protein tyrosine phosphatase PCP-2.
Label-free biosensor: a novel phage-modified Light Addressable Potentiometric Sensor system for cancer cell monitoring.
MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases.
Nuclear binding of androgens and acid phosphatase activity in prostatic tumors of Nb rats.
Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells.
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Phosphatase of Regenerating Liver-3 Induces Angiogenesis by Increasing Extracellular Signal-Regulated Kinase Phosphorylation in Endometrial Adenocarcinoma.
Physical and functional interaction between receptor-like protein tyrosine phosphatase PCP-2 and beta-catenin.
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma.
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.
R3327 prostate adenocarcinoma clonogenic cells: epithelial properties and hormone response.
Rapid rise of serum acid phosphatase after irradiation of metastatic carcinoma of prostate.
Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells.
Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma.
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Significance of PTPRZ1 and CIN85 expression in cervical carcinoma.
The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats.
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
The phosphatase PRL-3 affects intestinal homeostasis by altering the crypt cell composition.
Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues.
[Down regulation of mitogen activated protein kinase phosphatase-1 mediate acquired multidrug resistance in pancreatic adenocarcinoma cell line SW1990/Fu]
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Adenocarcinoma of Lung
17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.
MicroRNA-183 promotes migration and invasion of CD133(+)/CD326(+) lung adenocarcinoma initiating cells via PTPN4 inhibition.
MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma.
MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A.
miR-146b Reverses epithelial-mesenchymal transition via targeting PTP1B in cisplatin-resistance human lung adenocarcinoma cells.
miR-516a-3p promotes proliferation, migration, and invasion and inhibits apoptosis in lung adenocarcinoma by targeting PTPRD.
Overexpression of PTPRN Promotes Metastasis of Lung Adenocarcinoma and Suppresses NK Cell Cytotoxicity.
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data.
Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans.
Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors.
SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration.
Somatic mutations affect key pathways in lung adenocarcinoma.
The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
[LB100 reverses the acquired resistance to gefitinib in lung adenocarcinoma cells with EGFR mutation].
Adenoma
Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
Downregulation of PTPRH (Sap-1) in colorectal tumors.
Expression of cdc25A and cdc25B proteins in thyroid neoplasms.
Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Immunohistochemical and Western blot analysis of two protein tyrosine phosphatase receptors, R and Z1, in colorectal carcinoma, colon adenoma and normal colon tissues.
Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
miRNA-7a-2-3p Inhibits Neuronal Apoptosis in Oxygen-Glucose Deprivation (OGD) Model.
Mkp-1 is required for chemopreventive activity of butylated hydroxyanisole and resveratrol against colitis-associated colon tumorigenesis.
p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.
Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status.
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
[Expression of the zinc finger transcriptional factor Snail in colorectal carcinoma and its significance]
Adenoma, Pleomorphic
Ultrastructural cytochemistry of phosphatases in the ductal component of pleomorphic adenoma of human parotid and submandibular salivary glands.
Adenomatous Polyposis Coli
Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac.
APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase.
ARM domain-dependent nuclear import of adenomatous polyposis coli protein is stimulated by the B56 alpha subunit of protein phosphatase 2A.
BI2536 induces mitotic catastrophe and radiosensitization in human oral cancer cells.
Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein.
GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin.
Inhibition of Wnt signaling pathway by a novel axin-binding protein.
The ?-catenin destruction complex.
The mechanism of binding of the second PDZ domain from the Protein Tyrosine Phosphatase-BL to the Adenomatous Polyposis Coli tumor suppressor.
Wnt signalling in mammalian development and cancer.
Adenoviridae Infections
Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
African Swine Fever
Evidence for an acid phosphatase in African swine fever virus.
Albuminuria
Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury.
PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice.
Tyrosine phosphatase 1B and leptin receptor genes and their interaction in type 2 diabetes.
Alopecia
p66Shc Is a Negative Regulator of Fc{varepsilon}RI-Dependent Signaling in Mast Cells.
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Alopecia Areata
Association between PTPN22 C1858T polymorphism and alopecia areata risk.
Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata.
Protein tyrosine phosphatase nonreceptor type 22 gene polymorphism in alopecia areata: Does it have an association with disease severity?
PTPN22 gene polymorphism in Egyptian alopecia areata patients and its impact on response to diphencyprone immunotherapy.
PTPN22 profile indicates a novel risk group in Alopecia areata.
The association between rs2476601 polymorphism in PTPN22 gene and risk of alopecia areata: A meta-analysis of case-control studies.
The non-synonymous C1858T substitution in the PTPN22 gene is associated with susceptibility to the severe forms of alopecia areata.
The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata.
alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase deficiency
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Alveolar Bone Loss
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
Functionalized nanoparticles containing MKP-1 agonists reduce periodontal bone loss.
Alzheimer Disease
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
A Rare Variant Nonparametric Linkage Method for Nuclear and Extended Pedigrees with Application to Late-Onset Alzheimer Disease via WGS Data.
Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.
Acid phosphatase activity in senile plaques and cerebrospinal fluid of patients with Alzheimer's disease.
Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.
Alterations of low molecular weight acid phosphatase protein level in Alzheimer's disease.
Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology.
Altered nociception in Alzheimer disease is associated with striatal-enriched protein tyrosine phosphatase signaling.
Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice.
Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol.
Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease.
CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.
CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease.
Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer's disease.
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
Dedicated to inge grundke-iqbal.
Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).
Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal Models.
Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1.
Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.
Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis.
Dynein cleavage and microtubule accumulation in okadaic acid-treated neurons.
Enhanced expression of protein phosphatase 2A associated with hyper-phosphorylation of histone H1 in Alzheimer's disease brain.
Erratum to: Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Exploring the Therapeutic Potential of Protein Tyrosine Phosphatase 1B in hAPP-J20 Mouse Model of Alzheimer's Disease.
Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3.
Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model.
I1PP2A Affects Tau Phosphorylation via Association with the Catalytic Subunit of Protein Phosphatase 2A.
Immunohistochemical Localization of Fas-associated phosphatase-1 (FAP-1) in Alzheimer disease hippocampus.
Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease.
Implication of novel bis-imidazopyridines for management of Alzheimer's disease and establishment of its role on protein phosphatase 2A activity in brain.
Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease.
Inhibitory evaluation of oligonol on ?-glucosidase, protein tyrosine phosphatase 1B, cholinesterase, and ?-secretase 1 related to diabetes and Alzheimer's disease.
Lanthionine ketimine-5-ethyl ester provides neuroprotection in a zebrafish model of okadaic acid-induced Alzheimer's disease.
Leucine Carboxyl Methyltransferase 1 (LCMT1)-dependent Methylation Regulates the Association of Protein Phosphatase 2A and Tau Protein with Plasma Membrane Microdomains in Neuroblastoma Cells.
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms.
Metabolically active rat brain slices as a model to study the regulation of protein phosphorylation in mammalian brain.
Microcystin-Leucine-Arginine Induces Tau Pathology Through B? Degradation via Protein Phosphatase 2A Demethylation and Associated Glycogen Synthase Kinase-3? Phosphorylation.
MKP-1 reduces A? generation and alleviates cognitive impairments in Alzheimer's disease models.
Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid ?-Associated Alzheimer's Disease in Mice.
Neuroprotective effects of donepezil against A?42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3? and nAChRs activity.
Novel therapeutic strategies for neurodegenerative disease.
Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer's disease pathology.
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.
Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology.
Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.
PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus.
Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells.
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Protein phosphatase 2A dysfunction in Alzheimer's disease.
Protein phosphatase 2A in Alzheimer's disease.
Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease.
Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus.
Reduced levels of the tyrosine phosphatase STEP block ? amyloid-mediated GluA1/GluA2 receptor internalization.
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.
Role of Protein Phosphatase 2A in Alzheimer's Disease.
Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A.
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Striatal-enriched protein tyrosine phosphatase in Alzheimer's disease.
Substrate-Based Fragment Identification for the Development of Selective, Nonpeptidic Inhibitors of Striatal-Enriched Protein Tyrosine Phosphatase.
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Synthesis of benzopentathiepin analogs and their evaluation as inhibitors of the phosphatase STEP.
Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A.
The cell cycle Cdc25A tyrosine phosphatase is activated in degenerating postmitotic neurons in Alzheimer's disease.
The Implication of STEP in Synaptic Plasticity and Cognitive Impairments in Alzheimer's Disease and Other Neurological Disorders.
The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition.
Tyrosine phosphatase PTP1B impairs presynaptic NMDA receptor-mediated plasticity in a mouse model of Alzheimer's disease.
Tyrosine phosphatase STEP61 negatively regulates amyloid ?-mediated ERK/CREB signaling pathways via ?7 nicotinic acetylcholine receptors.
Weighted burden analysis of exome-sequenced late-onset Alzheimer's cases and controls provides further evidence for a role for PSEN1 and suggests involvement of the PI3K/Akt/GSK-3? and WNT signalling pathways.
X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors.
Amyotrophic Lateral Sclerosis
Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.
Anaphylaxis
Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids.
PEST-domain-enriched tyrosine phosphatase and glucocorticoids as regulators of anaphylaxis in mice.
Protein tyrosine phosphatase 1B (PTP1B) is dispensable for IgE-mediated cutaneous reaction in vivo.
SHP-1 regulation of mast cell function in allergic inflammation and anaphylaxis.
Sirt1 negatively regulates Fc?RI-mediated mast cell activation through AMPK- and PTP1B-dependent processes.
TU-572, a potent and selective CD45 inhibitor, suppresses IgE-mediated anaphylaxis and murine contact hypersensitivity reactions.
Anemia
A naturally occurring point substitution in Cdc25A, and not Fv2/Stk, is associated with altered cell-cycle status of early erythroid progenitor cells.
Chicken anemia virus VP2 is a novel dual specificity protein phosphatase.
Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.
Mechanisms of anemia in SHP-1 protein tyrosine phosphatase-deficient "viable motheaten" mice.
Phenotypic and quantitative relationship of red cell acid phosphatase with haemoglobin, haptoglobin, and G6PD phenotypes.
[Studies of the acid phosphatase activity of erythrocytes in anemia.]
Anemia, Aplastic
PTPN22 620W allele is not associated with aplastic anemia.
Anemia, Hemolytic, Autoimmune
Histiocytic medullary reticulosis with parallel increases in serum acid phosphatase and disease activity.
The role of glucocorticoid in SIRP alpha and SHP-1 gene expression in AIHA patients.
The role of glucocorticoid in SIRPalpha and SHP-1 gene expression in AIHA patients.
Anemia, Pernicious
Genome-wide association study identifies five risk loci for pernicious anemia.
Anemia, Sickle Cell
Phenotypic and quantitative relationship of red cell acid phosphatase with haemoglobin, haptoglobin, and G6PD phenotypes.
Aneurysm
Atypical coronary artery aneurysms due to Kawasaki disease in Noonan syndrome with a novel PTPN11 mutation.
Ankylosis
Microarray Analysis of Differential Gene Expression Between Traumatic Temporomandibular Joint Fibrous and Bony Ankylosis in a Sheep Model.
Anodontia
Orodental, Facial and Clinical Features of Mutation-Positive Noonan Syndrome: A Monocentric Study.
Anthrax
Reduced Expression of CD45 Protein-tyrosine Phosphatase Provides Protection against Anthrax Pathogenesis.
Anti-Glomerular Basement Membrane Disease
Podocyte involvement in human immune crescentic glomerulonephritis.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
The PTPN22 R620W polymorphism in anti-neutrophil cytoplasmic antibody-associated vasculitis in Mexican Mestizos.
Antiphospholipid Syndrome
Protein Phosphatase 2A Activation Via ApoER2 in Trophoblasts Drives Preeclampsia in a Mouse Model of the Antiphospholipid Syndrome.
PTPN22 1858C>T gene polymorphism in patients with SLE: association with serological and clinical results.
Aortic Aneurysm
Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm.
Aortic Coarctation
Alteration of p66shc is associated with endothelial dysfunction in the abdominal aortic coarctation of rats.
PTPN11 mutations play a minor role in isolated congenital heart disease.
Aortic Valve Stenosis
Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.
Arrhythmias, Cardiac
[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].
Arteriovenous Malformations
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia.
Arteritis
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis.
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.
PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis.
Arthritis
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
A Highly Sensitive Electrochemiluminescence Biosensor for Pyrophosphatase Detection Based on Click Chemistry-Triggered Hybridization Chain Reaction in Homogeneous Solution.
Abnormal PTPN11 enhancer methylation promotes rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and joint inflammation.
Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases.
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Association of juvenile idiopathic arthritis with PTPN22 rs2476601 is specific to females in a Greek population.
Association of PTPN22 Gene Polymorphisms with Susceptibility to Juvenile Idiopathic Arthritis in Iranian Population.
Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis.
Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.
Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Differential Expression of CD148 on leucocyte subsets in inflammatory arthritis.
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis.
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis.
Frequency of human leukocyte antigens class II-DR alleles (HLA-DRB1) in Argentinian patients with early arthritis.
Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis.
Genome-wide analysis of histone H3 lysine 4 trimethylation by ChIP-chip in peripheral blood mononuclear cells of systemic lupus erythematosus patients.
In situ formation of fluorescent polydopamine catalyzed by peroxidase-mimicking FeCo-LDH for pyrophosphate ion and pyrophosphatase activity detection.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis.
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice.
Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Molecular cytogenetic characterization of two independent karyotypic anomalies in a patient with severe mental retardation and juvenile idiopathic arthritis.
mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis.
No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
Novel protective role for MAP kinase phosphatase 2 in inflammatory arthritis.
Overlap of disease susceptibility loci for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis.
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
PTPN22: the archetypal non-HLA autoimmunity gene.
Receptor Protein Tyrosine Phosphatase ?-Mediated Enhancement of Rheumatoid Synovial Fibroblast Signaling and Promotion of Arthritis in Mice.
Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity.
Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase.
Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
Role of HLA-DRB1 and PTPN22 genes in susceptibility to juvenile idiopathic arthritis in Hungarian patients.
Role of PTPN22 1858 C/T Polymorphisms in Juvenile Idiopathic Arthritis in Egyptian Patients.
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
SHP-1, a novel peptide isolated from seahorse inhibits collagen release through the suppression of collagenases 1 and 3, nitric oxide products regulated by NF-kappaB/p38 kinase.
Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population.
STAT4 rs7574865 G/T and PTPN22 rs2488457 G/C polymorphisms influence the risk of developing juvenile idiopathic arthritis in Han Chinese patients.
Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators.
The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population.
The Association between PTPN22 Genetic Polymorphism and Juvenile Idiopathic Arthritis (JIA) Susceptibility: An Updated Meta-Analysis.
The association between the functional PTPN22 1858 C/T and MIF -173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis.
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females.
The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis.
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.
The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome.
The relationship of the immune response mediator genes polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis.
The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1.
The systemic autoinflammatory diseases: inborn errors of the innate immune system.
[Anti-inflammatory effect of Cu-Zn superoxide dismutase on carrageenin-induced arthritis in rabbits]
[Study of acid phosphatase activity in synovial fluid and serum of patients with rheumatoid polyarthritis]
Arthritis, Experimental
Expression of peptidylarginine deiminase 4 and protein tyrosine phosphatase nonreceptor type 22 in the synovium of collagen-induced arthritis rats.
IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance.
Inhibition of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 reduces the severity of collagen-induced arthritis.
Arthritis, Infectious
[Content of desoxyribose and acid phosphatase activity in the blood serum of patients with infectious arthritis during electrosleep therapy]
Arthritis, Juvenile
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Acid phosphatase activity in the synovial fluid of children with juvenile rheumatoid arthritis.
Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases.
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Association of juvenile idiopathic arthritis with PTPN22 rs2476601 is specific to females in a Greek population.
Association of PTPN22 Gene Polymorphisms with Susceptibility to Juvenile Idiopathic Arthritis in Iranian Population.
Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis.
Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis.
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Molecular cytogenetic characterization of two independent karyotypic anomalies in a patient with severe mental retardation and juvenile idiopathic arthritis.
No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
Overlap of disease susceptibility loci for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Protein tyrosine phosphatase PTPN22 in human autoimmunity.
PTPN22: the archetypal non-HLA autoimmunity gene.
Role of HLA-DRB1 and PTPN22 genes in susceptibility to juvenile idiopathic arthritis in Hungarian patients.
Role of PTPN22 1858 C/T Polymorphisms in Juvenile Idiopathic Arthritis in Egyptian Patients.
STAT4 rs7574865 G/T and PTPN22 rs2488457 G/C polymorphisms influence the risk of developing juvenile idiopathic arthritis in Han Chinese patients.
The Association between PTPN22 Genetic Polymorphism and Juvenile Idiopathic Arthritis (JIA) Susceptibility: An Updated Meta-Analysis.
The association between the functional PTPN22 1858 C/T and MIF -173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis.
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females.
The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis.
The relationship of the immune response mediator genes polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis.
The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1.
Arthritis, Psoriatic
Association between the PTPN22 +1858 C/T polymorphism and psoriatic arthritis.
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.
Male restricted genetic association of variant R620W in PTPN22 with psoriatic arthritis.
PTPN22 C1858T and the risk of psoriasis: a meta-analysis.
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.
[Progress in genetic research on psoriatic arthritis].
Arthritis, Rheumatoid
1858 C/T Polymorphism of the Protein Tyrosine Phosphatase Nonreceptor 22 Gene and Rheumatoid Arthritis Risk in Europeans: A Meta-analysis.
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.
A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22.
A non-parametric method for building predictive genetic tests on high-dimensional data.
Abnormal PTPN11 enhancer methylation promotes rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and joint inflammation.
Acid phosphatase activity in the synovial fluid of patients with rheumatoid arthritis and other joint disorders.
Activity of lysosomal enzymes and glycogen content of phytohemagglutinin-stimulated lymphocytes in patients with rheumatoid arthritis.
An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum.
Anti-tumour necrosis factor-alpha response associated with combined CD226 and HLA-DRB1[*]0404 haplotype in rheumatoid arthritis.
Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Application of bivariate mixed counting process models to genetic analysis of rheumatoid arthritis severity.
Application of sequential haplotype scan methods to case-control data.
Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis.
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.
Association of protein tyrosine phosphatase non-receptor 22 (PTPN22) rs2476601 and Kruppel-like factor 12 (KLF12) rs1324913 single nucleotide polymorphisms with rheumatoid arthritis in a Latvian population.
Association of PTPN22 (rs2476601) and STAT4 (rs7574865) polymorphisms with Rheumatoid Arthritis in the Western Algerian population.
Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients.
Association of PTPN22 1858C?T polymorphism, HLA-DRB1 shared epitope and autoantibodies with rheumatoid arthritis.
Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population.
Association of PTPN22 Haplotypes (-1123G>C/+1858C>T) with Rheumatoid Arthritis in Western Mexican Population.
Association of PTPN22 haplotypes with Graves' disease.
Association of PTPN22 rs2476601 and EGFR rs17337023 Gene polymorphisms and rheumatoid arthritis in Zahedan, Southeast Iran.
Association of PTPN22 rs2476601 and STAT4 rs7574865 polymorphisms with rheumatoid arthritis: A meta-analysis update.
Association of PTPN22 rs2476601 Polymorphism with Rheumatoid Arthritis and Celiac Disease in Khuzestan Province, Southwestern Iran.
Association of PTPN22 single nucleotide polymorphism with rheumatoid arthritis but not with allergic asthma.
Association of PTPN22 with Rheumatoid Arthritis Among South Asians in the UK.
Association of R602W in a protein tyrosine phosphatase gene with a high risk of rheumatoid arthritis in a British population: evidence for an early onset/disease severity effect.
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
Association of STAT4 rs7574865 and PTPN22 rs2476601 polymorphisms with rheumatoid arthritis and non-systemically reacting antibodies in Egyptian patients.
Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort.
Association of the PTPN22 gene (-1123G > C) polymorphism with rheumatoid arthritis in Chinese patients.
Association of the PTPN22 gene polymorphism with autoantibody positivity in Turkish rheumatoid arthritis patients.
Association of the PTPN22 locus with rheumatoid arthritis in a New Zealand Caucasian cohort.
Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes.
Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study.
Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis.
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Biomarker Approach Towards Rheumatoid Arthritis Treatment.
CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians.
Computational Molecular Phenotypic Analysis of PTPN22 (W620R), IL6R (D358A), and TYK2 (P1104A) Gene Mutations of Rheumatoid Arthritis.
Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Corrigendum to "CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians" [Hum. Immunol. 77 (2016) 522-526].
Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.
Death Receptor 5-Targeted Depletion of Interleukin-23-Producing Macrophages, Th17, and Th1/17 Associated With Defective Tyrosine Phosphatase in Mice and Patients With Rheumatoid Arthritis.
Development and application of a PCR-HRM molecular diagnostic method of SNPs linked with TNF inhibitor efficacy.
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population.
Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients.
EOMES-positive CD4
Epidemiology: Interpreting studies of interactions between RA risk factors.
Essential role of MAPK phosphatase-1 in the negative control of innate immune responses.
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort.
Evidence for PTPN22 R620W polymorphism as the sole common risk variant for rheumatoid arthritis in the 1p13.2 region.
Evidence of cis-acting regulatory variation in PTPN22 in patients with rheumatoid arthritis.
Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids.
Expression of peptidylarginine deiminase 4 and protein tyrosine phosphatase nonreceptor type 22 in the synovium of collagen-induced arthritis rats.
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis.
Frequency of human leukocyte antigens class II-DR alleles (HLA-DRB1) in Argentinian patients with early arthritis.
Functional polymorphisms of PTPN22 and FcgR genes in Tunisian patients with rheumatoid arthritis.
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis.
Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes.
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
Genetic epidemiology of rheumatoid arthritis.
Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking.
Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility.
Genome-wide gene-based analysis of rheumatoid arthritis-associated interaction with PTPN22 and HLA-DRB1.
Genome-wide Study Identifies Association between HLA-B?55:01 and Self-Reported Penicillin Allergy.
Genomic DNA pooling for whole-genome association scans in complex disease: empirical demonstration of efficacy in rheumatoid arthritis.
Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population.
Identification of novel putative rheumatoid arthritis susceptibility genes via analysis of rare variants.
Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeans.
Influence of female hormonal factors, in relation to autoantibodies and genetic markers, on the development of rheumatoid arthritis in northern Sweden: a case-control study.
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Inhibition of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 reduces the severity of collagen-induced arthritis.
Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis.
Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK.
IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis.
Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene.
Lymphoid-specific tyrosine phosphatase (Lyp): a potential drug target for treatment of autoimmune diseases.
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Meta-analysis reveals PTPN22 1858C/T polymorphism confers susceptibility to rheumatoid arthritis in Caucasian but not in Asian population.
Meta-genetic association of rheumatoid arthritis and PTPN22 using PedGenie 2.1.
Metaanalysis of the association of smoking and PTPN22 R620W genotype on autoantibody status and radiological erosions in rheumatoid arthritis.
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
Modeling of PTPN22 and HLA-DRB1 susceptibility to rheumatoid arthritis.
Modeling the effect of PTPN22 in rheumatoid arthritis.
Modeling the effect of susceptibility factors (HLA and PTPN22) in rheumatoid arthritis.
Modulation of PTPN2/22 Function by Spermidine in CRISPR-Cas9-Edited T-Cells Associated with Crohn's Disease and Rheumatoid Arthritis.
Need for clarification of data in the recent meta-analysis about 1858 C/T Polymorphism of the Protein Tyrosine Phosphatase Nonreceptor 22 Gene and Rheumatoid Arthritis Risk.
NLRP1, PTPN22 and PADI4 gene polymorphisms and rheumatoid arthritis in ACPA-positive Singaporean Chinese.
No association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey.
Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis.
Pathogenesis and treatment of autoimmune rheumatic diseases.
Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond.
Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis.
Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis.
Protective Effect of Pinitol Against Inflammatory Mediators of Rheumatoid Arthritis via Inhibition of Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22).
Protein tyrosine phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian subjects.
Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis.
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) +1858 C>T gene polymorphism in Egyptian cases with rheumatoid arthritis.
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.
Protein tyrosine phosphatase PTPN22 in human autoimmunity.
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
PTPN14 phosphatase and YAP promote TGF? signalling in rheumatoid synoviocytes.
PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis.
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity.
PTPN22 -1123G>C polymorphism and anti-cyclic citrullinated protein antibodies in rheumatoid arthritis.
PTPN22 1858 C/T polymorphism is associated with alteration of cytokine profiles as a potential pathogenic mechanism in rheumatoid arthritis.
PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis.
PTPN22 1858C>T polymorphism is associated with increased CD154 expression and higher CD4+ T cells percentage in rheumatoid arthritis patients.
PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy.
PTPN22 and rheumatoid arthritis: gratifying replication.
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
PTPN22 gene polymorphism and susceptibility to rheumatoid arthritis (RA): Updated systematic review and meta-analysis.
PTPN22 gene polymorphism in Behçet's disease.
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis.
PTPN22 Is a Critical Regulator of Fc? Receptor-Mediated Neutrophil Activation.
Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation.
PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease.
PTPN22 polymorphisms, but not R620W, were associated with the genetic susceptibility of systemic lupus erythematosus and rheumatoid arthritis in a Chinese Han population.
PTPN22 R620W genotype-phenotype correlation analysis and gene-environment interaction study in early rheumatoid arthritis: results from the ESPOIR cohort.
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
PTPN22 splice forms: a new role in rheumatoid arthritis.
PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes.
PTPN22.6, a dominant negative isoform of PTPN22 and potential biomarker of rheumatoid arthritis.
PTPN22: its role in SLE and autoimmunity.
PTPN22: the archetypal non-HLA autoimmunity gene.
PTPN22?+788 G>A (R263Q) Polymorphism is Associated with mRNA Expression but it is not a Susceptibility Marker for Rheumatoid Arthritis Patients from Western Mexico.
PTPome profile of rheumatoid arthritis fibroblast-like synoviocytes: a novel role for SHP-2 as a modulator of invasion and survival.
PTPRC mutation associated with response to anti-tNF therapy in rheumatoid arthritis.
PTPRC rheumatoid arthritis risk allele is also associated with response to anti-TNF therapy.
Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity.
Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population.
Regulation of autoimmune and anti-tumour T cell responses by PTPN22.
Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase.
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4.
Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population.
Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors.
Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele.
Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
rs2476601 in PTPN22 gene in rheumatoid arthritis and periodontitis-a possible interface?
Single Nucleotide Polymorphism rs 2476601 of PTPN22 Gene and Susceptibility to Rheumatoid Arthritis in Iranian Population.
Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population.
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis.
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis.
T cells are influenced by a long non-coding RNA in the autoimmune associated PTPN2 locus.
Targeting Protein Tyrosine Phosphatase PTP-PEST for Therapeutic Intervention in Acute Myocardial Infarction.
Testing for linkage and association with rheumatoid arthritis a ptpn22 promoter polymorphism reported to be associated and linked with type 1 diabetes in the Caucasian population.
The +1858C/T PTPN22 gene polymorphism confers genetic susceptibility to rheumatoid arthritis in Mexican population from the Western Mexico.
The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population.
The association between the PTPN22 C1858T polymorphism and rheumatoid arthritis: a meta-analysis update.
The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis.
The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals.
The autoimmunity risk variant LYP-W620 cooperates with CSK in the regulation of TCR signaling.
The balance of expression of PTPN22 splice forms is significantly different in rheumatoid arthritis patients compared with controls.
The functional PTPN22 C1858T polymorphism confers risk for rheumatoid arthritis in patients from Central Mexico.
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
The non-major histocompatibility complex quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation, and joint damage.
The potential of PTPN22 as a therapeutic target for rheumatoid arthritis.
The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity.
The protein tyrosine phosphatase PTPN22 negatively regulates presentation of immune complex derived antigens.
The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
The PTPN22 C1858T polymorphism and rheumatoid arthritis: a meta-analysis.
The PTPN22 C1858T variant as a risk factor for rheumatoid arthritis and systemic lupus erythematosus but not for systemic sclerosis in the Colombian population.
The PTPN22 locus and rheumatoid arthritis: no evidence for an effect on risk independent of Arg620Trp.
The PTPN22 promoter polymorphism -1123G>C association cannot be distinguished from the 1858C>T association in a Norwegian rheumatoid arthritis material.
The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in caucasian case-control samples.
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples.
The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status.
The PTPN22 susceptibility risk variant is not associated with the rate of joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis.
The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome.
The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population.
The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation.
The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.
The TT Genotype of the STAT4 rs7574865 Polymorphism Is Associated with High Disease Activity and Disability in Patients with Early Arthritis.
The W620 Polymorphism in PTPN22 Disrupts Its Interaction With Peptidylarginine Deiminase Type 4 and Enhances Citrullination and NETosis.
TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.
Understanding the genetic contribution to rheumatoid arthritis.
Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.
Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis.
[Acid phosphatase activity and the autoimmune processes in rheumatism and rheumatoid arthritis]
[Association of polymorphisms of PTPN22 and PADI4 genes with rheumatoid arthritis in Yunnan].
[Genetics and genomics in rheumatoid arthritis (RA): An update].
[Polymorphic markers of certain genes in the development of dry keratoconjunctivitis in patients with rheumatoid arthritis and Sjogren's syndrome].
[PTPN22 1858C/T polymorphism is associated with rheumatoid arthritis susceptibility in Caucasian population: a meta-analysis].
[Relevance of the gene variant PTPN22 620W for rheumatology]
Asphyxia Neonatorum
Changes in lysosomal hydrolases from cord blood of vigorous and asphyxiated Nigerian newborn infants.
Asthma
Analyses of shared genetic factors between asthma and obesity in children.
Association between PTPN22/CTLA-4 Gene Polymorphism and Allergic Rhinitis with Asthma in Children.
Association of PTPN22 single nucleotide polymorphism with rheumatoid arthritis but not with allergic asthma.
Body mass and glucocorticoid response in asthma.
Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages.
Corticosteroids and ?(2) -agonists upregulate mitogen-activated protein kinase phosphatase 1: in vitro mechanisms.
Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma.
Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review.
Exposure to violence, chronic stress, nasal DNA methylation, and atopic asthma in children.
Genes to diseases (G2D) computational method to identify asthma candidate genes.
Impact of ozone exposure on the response to glucocorticoid in a mouse model of asthma: involvements of p38 MAPK and MKP-1.
Impaired anti-inflammatory action of glucocorticoid in neutrophil from patients with steroid-resistant asthma.
Inhibitors of PDE4, but Not PDE3, Increase ?2-agonist-induced Expression of Anti-inflammatory MKP-1 in Airway Smooth Muscle Cells.
LncRNA PTPRE-AS1 modulates M2 macrophage activation and inflammatory diseases by epigenetic promotion of PTPRE.
Long-Acting ?2-Agonists Increase Fluticasone Propionate-Induced Mitogen-Activated Protein Kinase Phosphatase 1 (MKP-1) in Airway Smooth Muscle Cells.
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms.
Mechanism of glutamine inhibition of cytosolic phospholipase A2 (cPLA2 ): Evidence of physical interaction between glutamine-induced MAPK phosphatase-1 and cPLA2.
Microarray data analysis to identify differentially expressed genes and biological pathways associated with asthma.
Network study of nasal transcriptome profiles reveals master regulator genes of asthma.
Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion.
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma.
Repeated Allergen Exposure in A/J Mice Causes Steroid-Insensitive Asthma via a Defect in Glucocorticoid Receptor Bioavailability.
SHP-1 As a Critical Regulator of Mycoplasma pneumoniae-Induced Inflammation in Human Asthmatic Airway Epithelial Cells.
SHP-1 deficient mast cells are hyperresponsive to stimulation and critical in initiating allergic inflammation in the lung.
src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation.
Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators.
The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.
The Effects of Airway Microbiome on Corticosteroid Responsiveness in Asthma.
The GPx1-PTP1B-PP2A Axis: A Key Determinant of Airway Inflammation and Alveolar Destruction.
The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases.
The polymorphisms of protein-tyrosine phosphatase receptor-type delta gene and its association with pediatric asthma in the Taiwanese population.
The role of protein tyrosine phosphatases in the regulation of allergic asthma: implication of TC-PTP and PTP-1B in the modulation of disease development.
Tyrosine phosphatase SHP-1 in oxidative stress and development of allergic airway inflammation.
Vitamin D levels, lung function, and steroid response in adult asthma.
[Acid phosphatase activity of bronchial asthma patients during treatment at a health resort]
Astrocytoma
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase micro.
An acid phosphatase in the plasma membranes of human astrocytoma showing marked specificity toward phosphotyrosine protein.
CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFR? activation.
Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
Cytokine-induced transcription of protein-tyrosine-phosphatases in human astrocytoma cells.
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
Expression and activation of signal regulatory protein alpha on astrocytomas.
Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas.
Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues.
FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.
Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes.
Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Optic nerve pilomyxoid astrocytoma in a patient with Noonan syndrome.
Pilocytic astrocytoma in a child with Noonan syndrome.
Prognostic significance of CDC25B expression in gliomas.
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Ataxia
Analysis of the CHK2 gene in lymphoid malignancies.
Caveolin-1 expression is required for the development of pulmonary emphysema through activation of the ATM-p53-p21 pathway.
Caveolin-1, cellular senescence and pulmonary emphysema.
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Disrupted ATP synthase activity and mitochondrial hyperpolarisation-dependent oxidative stress is associated with p66Shc phosphorylation in fibroblasts of NARP patients.
Gallic acid induces G2/M phase cell cycle arrest via regulating 14-3-3beta release from Cdc25C and Chk2 activation in human bladder transitional carcinoma cells.
Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C.
Ataxia Telangiectasia
4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway.
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells.
Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation.
Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A.
Chk2 activation dependence on Nbs1 after DNA damage.
Erbb2 Suppresses DNA Damage-Induced Checkpoint Activation and UV-Induced Mouse Skin Tumorigenesis.
Ethanol metabolism activates cell cycle checkpoint kinase, Chk2.
Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells.
Hypoxic preconditioning decreases nuclear factor ?B activity via Disrupted in Schizophrenia-1.
Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.
Latex of Euphorbia antiquorum-induced S-phase arrest via active ATM kinase and MAPK pathways in human cervical cancer HeLa cells.
Microwave hyperthermia promotes caspase?3-dependent apoptosis and induces G2/M checkpoint arrest via the ATM pathway in non?small cell lung cancer cells.
N-Hydroxycinnamide derivatives of osthole presenting genotoxicity and cytotoxicity against human colon adenocarcinoma cells in vitro and in vivo.
PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice.
PTEN enhances G2/M arrest in etoposide-treated MCF?7 cells through activation of the ATM pathway.
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells.
The molecular mechanism of G2M cell cycle arrest induced by AFB1 in the jejunum.
TLC388 Induces DNA Damage and G2 Phase Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cells.
Atherosclerosis
Activity of two enzymes associated with apoptosis and cell aging in arterial hypertension.
Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study.
Association of protein tyrosine phosphatase-n1 polymorphisms with coronary calcified plaque in the diabetes heart study.
Atheroma development in apolipoprotein E-null mice is not affected by partial inactivation of PTEN.
Atherosclerosis and PTPN22: A Study in Coronary Artery Disease.
Autoimmunity and atherosclerosis: functional polymorphism of PTPN22 is associated with phenotypes related to the risk of atherosclerosis. The Cardiovascular Risk in Young Finns Study.
Correlation between SHP-1 and carotid plaque vulnerability in humans.
Decreased p66Shc promoter methylation in patients with end-stage renal disease.
Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice.
Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet.
Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease.
Harmine alleviates atherogenesis by inhibiting disturbed flow-mediated endothelial activation via protein tyrosine phosphatase PTPN14 and YAP.
Increased endothelial mitogen-activated protein kinase phosphatase-1 expression suppresses proinflammatory activation at sites that are resistant to atherosclerosis.
Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B.
Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis.
Lack of mitogen-activated protein kinase phosphatase-1 protects ApoE-null mice against atherosclerosis.
Mitochondrial DAMPs and altered mitochondrial dynamics in OxLDL burden in atherosclerosis.
Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels.
Monocytic MKP-1 is a Sensor of the Metabolic Environment and Regulates Function and Phenotypic Fate of Monocyte-Derived Macrophages in Atherosclerosis.
Myeloid protein tyrosine phosphatase 1B (PTP1B) deficiency protects against atherosclerotic plaque formation in the ApoE(-/-) mouse model of atherosclerosis with alterations in IL10/AMPK? pathway.
Overexpression of PTPN2 in Visceral Adipose Tissue Ameliorated Atherosclerosis via T Cells Polarization Shift in Diabetic Apoe-/- Mice.
P66shc and its role in ischemic cardiovascular diseases.
p66Shc deletion confers vascular protection in advanced atherosclerosis in hypercholesterolemic apolipoprotein E knockout mice.
Pharmacological inhibition of protein tyrosine phosphatase 1B (PTP1B) protects against atherosclerotic plaque formation in the LDLR(-/-) mouse model of atherosclerosis.
Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models.
Protein tyrosine phosphatase LMW-PTP exhibits distinct roles between vascular endothelial and smooth muscle cells.
Protein tyrosine phosphatase SHP-2 is positively involved in platelet-derived growth factor-signaling in vascular neointima formation via the reactive oxygen species-related pathway.
Protein Tyrosine Phosphatase SHP-2 Is Positively Involved in Platelet-Derived Growth Factor-Signaling in Vascular Neointima Formation via the Reactive Oxygen Species-Related Pathway.
PTPN2 negatively regulates macrophage inflammation in atherosclerosis.
PTPN22 Gene Polymorphisms Are Associated with Susceptibility to Large Artery Atherosclerotic Stroke and Microembolic Signals.
Regulation of Src homology 2-containing protein tyrosine phosphatase by advanced glycation end products: the role on atherosclerosis in diabetes.
Role of PTP-1B in aortic smooth muscle cell motility and tyrosine phosphorylation of focal adhesion proteins.
Search for genetic variants in the p66Shc longevity gene by PCR-single strand conformational polymorphism in patients with early-onset cardiovascular disease.
Serum protein signature of coronary artery disease in type 2 diabetes mellitus.
Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab.
Tyrosine phosphatase epsilonM stimulates migration and survival of porcine aortic endothelial cells by activating c-Src.
Atrial Fibrillation
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.
Autoimmune Diseases
1858 C/T Polymorphism of the Protein Tyrosine Phosphatase Nonreceptor 22 Gene and Rheumatoid Arthritis Risk in Europeans: A Meta-analysis.
A biosynthetic pathway for anandamide.
A case-control study of tyrosine phosphatase (PTPN22) confirms the lack of association with Crohn's disease.
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
A functional PTPN22 polymorphism associated with several autoimmune diseases is not associated with IgA deficiency in the Spanish population.
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes.
A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.
A switch-variant model integrates the functions of an autoimmune variant of the phosphatase PTPN22.
A three-dimensional chemical phase pharmacophore mapping, QSAR modelling and electronic feature analysis of benzofuran salicylic acid derivatives as LYP inhibitors.
A variant of PTPN22 gene conferring risk to autoimmune diseases may protect against tuberculosis.
A126: Clusters of Autoimmune Diseases in Children and the Role of PTPN22 C1858T Gene Polymorphism in Pediatric Polyautoimmunity.
Allele and haplotype frequency distribution in PTPN22 gene across variable ethnic groups: Implications for genetic association studies for autoimmune diseases.
An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum.
Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.
Analysis of PTPN22, ZFAT and MYO9B polymorphisms in Turner Syndrome and risk of autoimmune disease.
Anti-ganglioside autoantibodies in type 1 diabetes.
Anti-parietal cell antibodies and pernicious anemia in patients with type 1 diabetes mellitus and multiethnic background.
Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome.
Are other protein tyrosine phosphatases than PTPN22 associated with autoimmunity?
Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases.
Association analysis of the PTPN22 gene in childhood-onset systemic lupus erythematosus in Mexican population.
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease.
Association between a gain-of-function variant of PTPN22 and rejection in liver transplantation.
Association between PTPN22 C1858T and type 1 diabetes: a replication in continental Italy.
Association between PTPN22 C1858T polymorphism and alopecia areata risk.
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Association between the PTPN22 +1858 C/T polymorphism and psoriatic arthritis.
Association between the PTPN22 1858C/T gene polymorphism and tuberculosis resistance.
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Association of Functional Polymorphism in Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Gene with Vitiligo.
Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.
Association of protein tyrosine phosphatase, non-receptor type 22 +1858C?T polymorphism and susceptibility to vitiligo: Systematic review and meta-analysis.
Association of PTPN22 1858C/T Polymorphism with Autoimmune Diseases: A Systematic Review and Bayesian Approach.
Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population.
Association of PTPN22 haplotypes with Graves' disease.
Association of PTPN22 haplotypes with type 1 diabetes in the Japanese population.
Association of PTPN22 rs2476601 Polymorphism with Rheumatoid Arthritis and Celiac Disease in Khuzestan Province, Southwestern Iran.
Association of PTPN22 Single Nucleotide Polymorphisms with Celiac Disease.
Association of PTPN22+1858C/T polymorphism with Type 1 diabetes in the North Indian population.
Association of susceptible genetic markers and autoantibodies in rheumatoid arthritis.
Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations.
Association of the FAM167A-BLK region with systemic sclerosis.
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Association of the protein tyrosine phosphatase nonreceptor 22 haplotypes with autoimmune thyroid disease in the Japanese population.
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete.
Association of TNF-?, CTLA4, and PTPN22 polymorphisms with type 1 diabetes and other autoimmune diseases in Brazil.
Associations of single nucleotide polymorphisms of PTPN22 and Ctla4 genes with the risk of allergic rhinitis in a Chinese Han population.
Autoantibodies specific for different isoforms of CD45 in systemic lupus erythematosus.
Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis.
Autoimmunity and atherosclerosis: functional polymorphism of PTPN22 is associated with phenotypes related to the risk of atherosclerosis. The Cardiovascular Risk in Young Finns Study.
Autoimmunity in primary antibody deficiency is associated with protein tyrosine phosphatase nonreceptor type 22 (PTPN22).
Autoimmunity risk alleles: hotspots in B cell regulatory signaling pathways.
Autoimmunity-associated protein tyrosine phosphatase PEP negatively regulates IFN-? receptor signaling.
Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset.
Biochemical and Functional Studies of Lymphoid-Specific Tyrosine Phosphatase (Lyp) Variants S201F and R266W.
C1858T functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition.
C1858T Polymorphism of Protein Tyrosine Phosphatase Non-receptor Type 22 (PTPN22): an eligible target for prevention of type 1 diabetes?
Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci.
Classical Examples of the Concept of the ASIA Syndrome.
Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening.
Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.
Conjugation of Antisense Oligonucleotides to PEGylated Carbon Nanotubes Enables Efficient Knockdown of PTPN22 in T Lymphocytes.
Contribution of the R620W polymorphism of protein tyrosine phosphatase non-receptor 22 to systemic lupus erythematosus in Poland.
Crispr/Cas Mediated Deletion of PTPN22 in Jurkat T Cells Enhances TCR Signaling and Production of IL-2.
Current concepts in the genetic diagnostics of rheumatoid arthritis.
Cutting Edge: Protein Phosphatase 2A Confers Susceptibility to Autoimmune Disease through an IL-17-Dependent Mechanism.
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Design, synthesis and biological evaluation of imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as lymphoid-specific tyrosine phosphatase inhibitors.
Different modulation of Ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice.
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population.
Differential nanoscale organisation of LFA-1 modulates T cell migration.
Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells.
Do inhibitory immune receptors play a role in the etiology of autoimmune disease?
Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children.
Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells.
Enhanced frequency of a PTPRC (CD45) exon A mutation (77C-->G) in systemic sclerosis.
EOMES-positive CD4
Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis.
Evaluation of PTPN22 polymorphisms and Vogt-Koyanagi-Harada disease in Japanese patients.
Evidence for PTPN22 R620W polymorphism as the sole common risk variant for rheumatoid arthritis in the 1p13.2 region.
Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients.
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis.
Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients.
Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes.
Gender-specific association of the PTPN22 C1858T polymorphism with achalasia.
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Genetic progress towards the molecular basis of autoimmunity.
Genetics of type 1 diabetes in Asian and Caucasian populations.
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci.
Genome-wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A, and Identification of ZBTB10 and Three Distinct HLA Associations.
Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils.
Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort.
GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility.
Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population.
Hematopoietic cell phosphatase, SHP-1, is constitutively associated with the SH2 domain-containing leukocyte protein, SLP-76, in B cells.
Identification and structure-function analyses of an allosteric inhibitor of the tyrosine phosphatase PTPN22.
Immunologic response to vaccine challenge in pregnant PTPN22 R620W carriers and non-carriers.
Important roles of protein tyrosine phosphatase PTPN12 in tumor progression.
In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation.
Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.
Influence of PTPN22 Allotypes on Innate and Adaptive Immune Function in Health and Disease.
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Involvement of the protein tyrosine phosphatase SHP-1 in Ras-mediated activation of the mitogen-activated protein kinase pathway.
IRF5, PTPN22, CD28, IL2RA, KIF5A, BLK and TNFAIP3 genes polymorphisms and lupus susceptibility in a cohort from the Egypt Delta; relation to other ethnic groups.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Lack of association of the PTPN22 gene polymorphism R620W with systemic sclerosis.
Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function.
Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene.
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice.
Lymphoid-specific tyrosine phosphatase (Lyp): a potential drug target for treatment of autoimmune diseases.
MAP kinase phosphatase 1 is necessary for T cell activation and function.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
MicroRNA-101, mitogen-activated protein kinases and mitogen-activated protein kinases phosphatase-1 in systemic lupus erythematosus.
Multi-color Molecular Visualization of Signaling Proteins Reveals How C-Terminal Src Kinase Nanoclusters Regulate T Cell Receptor Activation.
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
Multifunctional roles of the autoimmune disease-associated tyrosine phosphatase PTPN22 in regulating T cell homeostasis.
Multiplex family-based study in systemic lupus erythematosus: association between the R620W polymorphism of PTPN22 and the FcgammaRIIa (CD32A) R131 allele.
Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease.
New developments in genetics of myositis.
No association of PTPN22 R620 W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus.
No evidence for association between 1858 C/T single-nucleotide polymorphism of PTPN22 gene and primary Sjögren's syndrome.
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.
Novel associations for hypothyroidism include known autoimmune risk loci.
Novel missense mutation in PTPN22 in a Chinese pedigree with Hashimoto's thyroiditis.
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.
Overexpression of the PTPN22 Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T Cell Activation.
Overlap of disease susceptibility loci for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease.
p66Shc Is a Negative Regulator of Fc{varepsilon}RI-Dependent Signaling in Mast Cells.
Pathogenesis of primary adrenal insufficiency.
Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A.
Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity.
Proline-serine-threonine phosphatase interacting protein 1 inhibition of T-cell receptor signaling depends on its SH3 domain.
Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures.
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene polymorphism in pulmonary tuberculosis in the Indian population.
Protein tyrosine phosphatase PTPN22 in human autoimmunity.
Protein tyrosine phosphatase PTPN22 regulates IL-1? dependent Th17 responses by modulating dectin-1 signaling in mice.
Protein tyrosine phosphatase PTPN22 regulates LFA-1 dependent Th1 responses.
Protein tyrosine phosphatases in autoimmunity.
PTPN22 1858 C/T Exon Polymorphism is not Associated with Graves' Disease in Kashmiri population.
PTPN22 1858T is not a risk factor for North American Pemphigus vulgaris.
PTPN22 620W allele is not associated with aplastic anemia.
PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion.
PTPN22 allele polymorphisms in 15 Chinese populations.
PTPN22 alters the development of regulatory T cells in the thymus.
PTPN22 and autoimmune disease.
Ptpn22 and Cd2 Variations Are Associated with Altered Protein Expression and Susceptibility to Type 1 Diabetes in Nonobese Diabetic Mice.
PTPN22 and CTLA-4 gene polymorphisms in resected thymomas and thymus for myasthenia gravis.
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data.
PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes.
PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases.
PTPN22 C1858T polymorphism in women with endometriosis.
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.
PTPN22 gene polymorphism as a genetic risk factor for primary immune thrombocytopenia in Egyptian children.
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis.
PTPN22 inhibition resets defective human central B cell tolerance.
PTPN22 Is a Critical Regulator of Fc? Receptor-Mediated Neutrophil Activation.
PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not.
Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation.
PTPN22 Modulates Macrophage Polarization and Susceptibility to Dextran Sulfate Sodium-Induced Colitis.
PTPN22 phosphorylation acts as a molecular rheostat for the inhibition of TCR signaling.
PTPN22 polymorphism is related to autoimmune disease risk in patients with Turner syndrome.
PTPN22 profile indicates a novel risk group in Alopecia areata.
PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits.
PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
PTPN22 Single-Nucleotide Polymorphisms in Iranian Patients with Type 1 Diabetes Mellitus.
PTPN22 splice forms: a new role in rheumatoid arthritis.
PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes.
PTPN22: its role in SLE and autoimmunity.
PTPN22: the archetypal non-HLA autoimmunity gene.
R620W polymorphism of protein tyrosine phosphatase PTPN22 in Egyptian children and adolescents with systemic lupus erythematosus: relation to thyroid autoimmunity.
Recent advances in genetic predisposition of myasthenia gravis.
Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity.
Regulation of autoimmune and anti-tumour T cell responses by PTPN22.
Regulation of signal transduction by the Fc gamma receptor family members and their involvement in autoimmunity.
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus.
Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes.
Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages.
Role of C1858T polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian children and adolescents with type 1 diabetes.
Role of PTPN22 in type 1 diabetes and other autoimmune diseases.
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
Single Nucleotide Polymorphism rs 2476601 of PTPN22 Gene and Susceptibility to Rheumatoid Arthritis in Iranian Population.
Single Nucleotide Polymorphisms of PTPN22 Gene in Iranian Patients with Ulcerative Colitis.
Single-cell profiling reveals dendritic cell signatures associated with autoimmune inflammation.
Small amplicons high resolution melting analysis (SA-HRMA) allows successful genotyping of acid phosphatase 1 (ACP1) polymorphisms in the Italian population.
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
STAT4 rs7574865 G/T and PTPN22 rs2488457 G/C polymorphisms influence the risk of developing juvenile idiopathic arthritis in Han Chinese patients.
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
Substrate Specificity of Lymphoid-specific Tyrosine Phosphatase (Lyp) and Identification of Src Kinase-associated Protein of 55 kDa Homolog (SKAP-HOM) as a Lyp Substrate.
Susceptibility influence of a PTPN22 haplotype with thyroid autoimmunity in Koreans.
Systemic inhibition of PTPN22 augments anticancer immunity.
T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
T cells are influenced by a long non-coding RNA in the autoimmune associated PTPN2 locus.
The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population.
The association of PTPN22 (rs2476601) and IL2RA (rs11594656) polymorphisms with T1D in Egyptian children.
The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females.
The association of the PTPN22 620W polymorphism with Behcet's disease.
The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals.
The Autoimmune-Associated Single Nucleotide Polymorphism Within PTPN22 Correlates With Clinical Outcome After Lung Transplantation.
The autoimmunity risk variant LYP-W620 cooperates with CSK in the regulation of TCR signaling.
The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis.
The balance of expression of PTPN22 splice forms is significantly different in rheumatoid arthritis patients compared with controls.
The codon 620 single nucleotide polymorphism of the protein tyrosine phosphatase-22 gene does not contribute to autoimmune thyroid disease susceptibility in the Japanese.
The common, autoimmunity-predisposing 620Arg > Trp variant of PTPN22 modulates macrophage function and morphology.
The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus.
The genetic basis of autoantibody production.
The Genotype and Phenotype (GaP) registry: a living biobank for the analysis of quantitative traits.
The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes.
The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.
The protein tyrosine phosphatase PTPN22 negatively regulates presentation of immune complex derived antigens.
The protein tyrosine phosphatase, non-receptor type 22 R620W polymorphism does not confer susceptibility to psoriasis in the genetic homogeneous population of Crete.
The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis.
The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans.
The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.
The PTPN22 locus and rheumatoid arthritis: no evidence for an effect on risk independent of Arg620Trp.
The PTPN22 promoter polymorphism -1123G>C association cannot be distinguished from the 1858C>T association in a Norwegian rheumatoid arthritis material.
The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.
The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.
The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity.
The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population.
The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
The Role of Heat Shock Proteins in Type 1 Diabetes.
The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura.
The role of PTPN22 in autoimmunity: learning from mice.
The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.
The role of PTPN22 risk variant in the development of autoimmunity: finding common ground between mouse and human.
The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1.
Transethnic associations among immune-mediated diseases and single-nucleotide polymorphisms of the aryl hydrocarbon response gene ARNT and the PTPN22 immune regulatory gene.
Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.
Use of short interfering RNA delivered by cationic liposomes to enable efficient down-regulation of PTPN22 gene in human T lymphocytes.
Variants in PTPN22 and SMOC2 genes and the risk of thyroid disease in the Jordanian Arab population.
Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?
[Latent forms of adult-onset autoimmune polyglandular syndrome: diagnosis and management of patients].
Azoospermia
Decreased Expression of CDC25A in Azoospermia as the Etiology of Spermatogenesis Failure.
Bacterial Infections
Acute Dietary Restriction Acts via TOR, PP2A, and Myc Signaling to Boost Innate Immunity in Drosophila.
Correlation of acid phosphatase activity with degree of bacterial infection in HELA cells.
Dual-Specificity Phosphatase 12 Targets p38 MAP Kinase to Regulate Macrophage Response to Intracellular Bacterial Infection.
IL-34 regulates the inflammatory response and anti-bacterial immune defense of Japanese flounder Paralichthys olivaceus.
Knockout of MAPK Phosphatase-1 Exaggerates Type I IFN Response during Systemic Escherichia coli Infection.
MAP kinase phosphatase-1, a critical negative regulator of the innate immune response.
MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response.
Moesin and myosin IIA modulate phagolysosomal biogenesis in macrophages.
Protein tyrosine phosphatase 1B inhibition as a potential therapeutic target for chronic wounds in diabetes.
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene polymorphism in pulmonary tuberculosis in the Indian population.
PTPN22 and invasive bacterial disease.
SHP-1 suppresses the antiviral innate immune response by targeting TRAF3.
The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.
[Classification and etiology of hyperthyroidism].
Basal Cell Nevus Syndrome
Expression and chromosomal assignment of PTPH1 gene encoding a cytosolic protein tyrosine phosphatase homologous to cytoskeletal-associated proteins.
Behcet Syndrome
A case of Behcet's disease associated with myelodysplastic syndrome involving trisomy 8 and a gain-of-function mutation in SHP-2.
Association of genetic variations in PTPN2 and CD122 with ocular Behcet's disease.
No Association of PTPN22 Polymorphisms with Susceptibility to Ocular Behcet's Disease in Two Chinese Han Populations.
The association of the PTPN22 620W polymorphism with Behcet's disease.
beta-Thalassemia
Red cell acid phosphatase activity in carriers of beta-thalassemia trait and glucose-6-phosphate dehydrogenase deficiency.
Blast Crisis
Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation.
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Redirecting traffic using the XPO1 police.
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation.
Blister
Acid hydrolases in blister fluid. I. Characterization and quantification of acid phosphatase.
Inhibition of 5-alpha-reductase activity induces stromal remodeling and smooth muscle de-differentiation in adult gerbil ventral prostate.
Programmed cell death in the larval salivary glands of Apis mellifera (Hymenoptera, Apidae).
Blood Group Incompatibility
[Acid phosphatase activity in the neutrophils and peripheral lymphocytes in normal pregnancy and pregnancies complicated by RH-HR blood group incompatibility and toxemia]
Bluetongue
Cellular Casein Kinase 2 and Protein Phosphatase 2A Modulate Replication Site Assembly of Bluetongue Virus.
Bone Diseases
Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates.
MKP-1 Knockout Does not Prevent Glucocorticoid-Induced Bone Disease in Mice.
Bone Diseases, Metabolic
Identification of Differential Genes Expression Profiles and Pathways of Bone Marrow Mesenchymal Stem Cells of Adolescent Idiopathic Scoliosis Patients by Microarray and Integrated Gene Network Analysis.
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice.
Bone Neoplasms
Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia.
Bone Resorption
A quantitative cytochemical assay for osteoclast acid phosphatase activity in foetal rat calvaria.
Alveolar bone loss: mechanisms, potential therapeutic targets, and interventions.
An osteoclastic protein-tyrosine phosphatase may play a role in differentiation and activity of human monocytic U-937 cell-derived, osteoclast-like cells.
Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss.
Biochemical markers of bone turnover for the clinical investigation of osteoporosis.
Biochemical markers of bone turnover.
Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function.
Bone composition and metabolism after hyperbaric oxygenation in rats with 1-hydroxyethylidene-1,1-bisphosphonate-induced rickets.
Bone resorption in chronic otitis media. A light-microscopical and histochemical investigation of acid phosphatase activity.
Bone resorption in experimental otosclerosis in rats.
Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption.
Coumarin Ameliorates Impaired Bone Turnover by Inhibiting the Formation of Advanced Glycation End Products in Diabetic Osteoblasts and Osteoclasts.
Critical role of MKP-1 in lipopolysaccharide-induced osteoclast formation through CXCL1 and CXCL2.
Crocin attenuates methylglyoxal-induced osteoclast dysfunction by regulating glyoxalase, oxidative stress, and mitochondrial function.
Dynamin and PTP-PEST cooperatively regulate Pyk2 dephosphorylation in osteoclasts.
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
Effects of magnesium coating on bone-implant interfaces with and without polyether-ether-ketone particle interference: A rabbit model based on porous Ti6Al4V implants.
Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
Effects of nicotine on bone during orthodontic tooth movement in male rats. Histological and immunohistochemical study.
Galectin-3 is essential for proper bone cell differentiation and activity, bone remodeling and biomechanical competence in mice.
Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone.
Influence of irradiation on the osteoinductive potential of demineralized bone matrix.
Inhibition of osteoclastic acid phosphatase abolishes bone resorption.
Ipriflavone modulates IGF-I but is unable to restore bone in rats.
Morphological changes in periodontal mechanoreceptors of mouse maxillary incisors after the experimental induction of anterior crossbite: a light and electron microscopic observation using immunohistochemistry for PGP 9.5.
Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function.
Osteogenic activity of yellow flag iris (Iris pseudacorus) extract modulating differentiation of osteoblasts and osteoclasts.
Phosphorylation of a Wiscott-Aldrich syndrome protein-associated signal complex is critical in osteoclast bone resorption.
Preventive effects of flaxseed and sesame oil on bone loss in ovariectomized rats.
Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption.
Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts.
PTPRJ promotes osteoclast maturation and activity by inhibiting Cbl-mediated ubiquitination of NFATc1 in late osteoclastogenesis.
Pulsed electromagnetic fields inhibit osteoclast differentiation in RAW264.7 macrophages via suppression of the protein kinase B/mammalian target of rapamycin signaling pathway.
Quantification of osteoclastic resorption of the bovine otic capsule in vitro by an enzyme-linked immunosorbent assay.
Strontium ranelate decreases receptor activator of nuclear factor-?B ligand-induced osteoclastic differentiation in vitro: involvement of the calcium-sensing receptor.
T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice.
T Cell Protein Tyrosine Phosphatase in Osteoimmunology.
T-Cell Protein Tyrosine Phosphatase Regulates Bone Resorption and Whole-Body Insulin Sensitivity through Its Expression in Osteoblasts.
Targeted transgenic expression of an osteoclastic transmembrane protein-tyrosine phosphatase in cells of osteoclastic lineage increases bone resorption and bone loss in male young adult mice.
The Antiosteoporosis Effects of Zhuanggu Guanjie Pill In Vitro and In Vivo.
The effect of carbonic anhydrase inhibition on calcium and bone homeostasis in healthy postmenopausal women.
The effect of dental plaque grown in the presence of xylitol or sucrose on bone resorption in vitro.
The effects of dietary calcium during lactation on lead in bone mobilization: implications for toxicology.
The importance of the prenyl group in the activities of osthole in enhancing bone formation and inhibiting bone resorption in vitro.
The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice.
Tooth hard tissue stimulates bone remodeling as a potential motive force during tooth eruption.
Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo.
Tyrosine-protein phosphatase non-receptor type 2 inhibits alveolar bone resorption in diabetic periodontitis via dephosphorylating CSF1 receptor.
[ALKALINE AND ACID PHOSPHATASE ACTIVITY IN PROCESSES OF BONE FORMATION AND BONE RESORPTION (EXPERIMENTAL STUDY).]
Bradycardia
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.
Protein phosphatase 1b in the solitary tract nucleus is necessary for normal baroreflex function.
SHP-2 deletion in postmigratory neural crest cells results in impaired cardiac sympathetic innervation.
Brain Abscess
[Change in acid phosphatase activity in meningitis and brain abscess.]
Brain Concussion
Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes.
Brain Death
Endoplasmic reticulum stress induces liver cells apoptosis after brain death by suppressing the phosphorylation of protein phosphatase 2A.
Brain Diseases
Developmental epileptic encephalopathy with hypomyelination and brain atrophy associated with PTPN23 variants affecting the assembly of UsnRNPs.
Inhibition of the tyrosine phosphatase STEP61 restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice.
Mechanisms and Disease Associations of Haplotype-Dependent Allele-Specific DNA Methylation.
Mitogen-activated protein kinase phosphatase-2 deletion modifies ventral tegmental area function and connectivity and alters reward processing.
Mutations of PTPN23 in developmental and epileptic encephalopathy.
The 15-deoxy-delta 12,14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1.
Brain Edema
Tristetraprolin attenuates brain edema in a rat model of cerebral hemorrhage.
Brain Injuries
A peptide mimetic of tyrosine phosphatase STEP as a potential therapeutic agent for treatment of cerebral ischemic stroke.
Caveolin-1 is involved in reactive oxygen species-induced SHP-2 activation in astrocytes.
Combinational Approach of Genetic SHP-1 Suppression and Voluntary Exercise Promotes Corticospinal Tract Sprouting and Motor Recovery Following Brain Injury.
Comparison of RPTP zeta/beta, phosphacan, and trkB mRNA expression in the developing and adult rat nervous system and induction of RPTP zeta/beta and phosphacan mRNA following brain injury.
Ferulic acid attenuates the injury-induced decrease of protein phosphatase 2A subunit B in ischemic brain injury.
Melatonin attenuates decrease of protein phosphatase 2A subunit B in ischemic brain injury.
Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke.
Suppression of SHP-1 promotes corticospinal tract sprouting and functional recovery after brain injury.
The protein tyrosine phosphatase SHP-2 is expressed in glial and neuronal progenitor cells, postmitotic neurons and reactive astrocytes.
Tyrosine phosphatase inhibition attenuates early brain injury after subarachnoid hemorrhage in rats.
Brain Injuries, Traumatic
Inhibition of EphA/Ephrin-A signaling using genetic and pharmacologic approaches improves recovery following traumatic brain injury in mice.
P13BP, a calpain-2-mediated breakdown product of PTPN13, is a novel blood biomarker for Traumatic Brain Injury.
Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury.
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Brain Ischemia
Cdc25A Is a Critical Mediator of Ischemic Neuronal Death In Vitro and In Vivo.
Curcumin treatment recovery the decrease of protein phosphatase 2A subunit B induced by focal cerebral ischemia in Sprague-Dawley rats.
Expression and function of striatal enriched protein tyrosine phosphatase is profoundly altered in cerebral ischemia.
Focal Cerebral Ischemia Reduces Protein Phosphatase 2A Subunit B Expression in Brain Tissue and HT22 Cells.
Focal cerebral ischemia upregulates SHP-1 in reactive astrocytes in juvenile mice.
Involvement of the dual-specificity phosphatase M3/6 in c-Jun N-terminal kinase inactivation following cerebral ischemia in the rat hippocampus.
Motheaten (me/me) mice deficient in SHP-1 are less susceptible to focal cerebral ischemia.
Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition.
Neuroprotective effects of protein tyrosine phosphatase 1B inhibitor on cerebral ischemia/reperfusion in mice.
Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia.
Phosphorylation of tau protein over time in rats subjected to transient brain ischemia.
PI3K/Akt-independent negative regulation of JNK signaling by MKP-7 after cerebral ischemia in rat hippocampus.
Src kinase up-regulates the ERK cascade through inactivation of protein phosphatase 2A following cerebral ischemia.
Tyrosine kinase and tyrosine phosphatase participate in regulation of interactions of NMDA receptor subunit 2A with Src and Fyn mediated by PSD-95 after transient brain ischemia.
Tyrosine phosphatase inhibition attenuates early brain injury after subarachnoid hemorrhage in rats.
Brain Neoplasms
A role for receptor tyrosine phosphatase zeta in glioma cell migration.
Acid phosphatase activity in human brain tumours.
Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation.
Association of protein phosphatase 2A with its substrate vimentin intermediate filaments in 9L rat brain tumor cells.
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.
Ras, TrkB, and ShcA Protein Expression Patterns in Pediatric Brain Tumors.
The antiproliferative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway.
[A histochemical study of the acid phosphatase activity of macroglial brain tumors]
Branchio-Oto-Renal Syndrome
Using Drosophila to decipher how mutations associated with human branchio-oto-renal syndrome and optical defects compromise the protein tyrosine phosphatase and transcriptional functions of eyes absent.
Breast Carcinoma In Situ
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Breast Diseases
Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.
The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14.
Breast Neoplasms
17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.
17beta-estradiol (E2) induces cdc25A gene expression in breast cancer cells by genomic and non-genomic pathways.
3,3'-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation.
3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells.
3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells: retraction.
6,7-di-O-acetylsinococuline (FK-3000) induces G2/M phase arrest in breast carcinomas through p38 MAPK phosphorylation and CDC25B dephosphorylation.
A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.
A brake becomes an accelerator: PTP1B--a new therapeutic target for breast cancer.
A high-molecular weight complex with acid phosphatase activity in human breast cancer.
A microtiter enzyme-linked immunosorbent assay for protein tyrosine phosphatase.
A new role of protein phosphatase 2a in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells.
A novel deep autoencoder based survival analysis approach for microarray dataset.
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.
A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis.
Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
Acid phosphatase activity in the cytosol fraction of the breast cancer tissue.
Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase.
Activation of Src and transformation by an RPTP? splice mutant found in human tumours.
Activation of Src by Protein Tyrosine Phosphatase 1B Is Required for ErbB2 Transformation of Human Breast Epithelial Cells.
Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530.
Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer.
An Aza-Cope Reactivity-Based Fluorescent Probe for Imaging Formaldehyde in Living Cells.
An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro.
Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK-dependent p21 signaling pathway.
Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells.
Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation.
Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Association of PTP1B with Outcomes of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy.
Association of PTPN1 polymorphisms with breast cancer risk: A case-control study in Chinese females.
Breast Cancer Cells Proliferation Is Regulated by Tyrosine Phosphatase SHP1 through c-jun N-Terminal Kinase and Cooperative Induction of RFX-1 and AP-4 Transcription Factors.
BSSV: Bayesian based somatic structural variation identification with whole genome DNA-seq data.
c-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer.
Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion.
CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma.
CDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell-cycle regulation.
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.
Cdc25A Regulates Matrix Metalloprotease 1 through Foxo1 and Mediates Metastasis of Breast Cancer Cells.
CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.
Cell cycle dysregulation influences survival in high risk breast cancer patients.
Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors.
Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
Characterization of low molecular weight protein tyrosine phosphatase isoforms in human breast cancer epithelial cell lines.
Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation.
CIP2A is associated with human breast cancer aggressivity.
Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer.
Clinical significance of sCIP2A levels in breast cancer.
Clinicopathological significance of PTPN12 expression in human breast cancer.
Coexpression and coregulation analysis of time-series gene expression data in estrogen-induced breast cancer cell.
Colorectal cancer susceptibility variants alter risk of breast cancer in a Chinese Han population.
Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells.
Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites.
Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products.
Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.
Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica.
D,L-sulforaphane-induced apoptosis in human breast cancer cells is regulated by the adapter protein p66Shc.
Decreased total MKP-1 protein levels predict poor prognosis in breast cancer.
Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer.
Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status.
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.
Docosahexaenoic Acid Inhibits PTP1B Phosphatase and the Viability of MCF-7 Breast Cancer Cells.
Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Downregulation of protein tyrosine phosphatase PTP-BL represses adipogenesis.
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.
EBP50 suppresses the proliferation of MCF-7 human breast cancer cells via promoting Beclin-1/p62-mediated lysosomal degradation of c-Myc.
Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression.
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.
Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors.
Elimination of ALDH+ breast tumor initiating cells by docosahexanoic acid and/or gamma tocotrienol through SHP-1 inhibition of Stat3 signaling.
Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells.
Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells.
Epithelial Protein-Tyrosine Phosphatase 1B (PTP1B) Contributes to the Induction of Mammary Tumors by HER2/Neu but is not Essential for Tumor Maintenance.
erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab.
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.
Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity.
Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation.
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Estrogens and PTP1B Function in a Novel Pathway to Regulate Aromatase Enzymatic Activity in Breast Cancer Cells.
Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer.
Evaluation of drug-targetable genes by defining modes of abnormality in gene expression.
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Exogenous phosphotyrosine modulates epidermal growth factor receptor tyrosine phosphorylation.
Exploring drivers of gene expression in the Cancer Genome Atlas.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors.
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.
Expression of cdc25A and cdc25B phosphatase in breast carcinoma.
Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer.
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro.
Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo.
Expression of receptor protein tyrosine phosphatase ? is a risk factor for triple negative breast cancer relapse.
Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer.
Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Expression Profiling during Mammary Epithelial Cell Three-Dimensional Morphogenesis Identifies PTPRO as a Novel Regulator of Morphogenesis and ErbB2-Mediated Transformation.
Extracellular signal-regulated kinase 1/2 and protein phosphatase 2A are involved in the antiproliferative activity of conjugated linoleic acid in MCF-7 cells.
Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7.
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity.
Functions of Shp2 in cancer.
Further New Gypenosides from Jiaogulan (Gynostemma pentaphyllum).
Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium.
Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
Genome-scale screening of deubiquitinase subfamily identifies USP3 as a stabilizer of Cdc25A regulating cell cycle in cancer.
Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.
Green Tea Catechins Induce Inhibition of PTP1B Phosphatase in Breast Cancer Cells with Potent Anti-Cancer Properties: In Vitro Assay, Molecular Docking, and Dynamics Studies.
Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1.
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/?-catenin signaling.
High-resolution crystal structures of the D1 and D2 domains of protein tyrosine phosphatase epsilon for structure-based drug design.
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines.
Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'.
Identifying the role of PTPN12 expression in predicting the efficacy of capecitabine to neoadjuvant chemotherapy in breast cancer treatment.
IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues.
Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen.
Increased metastasis with loss of E2F2 in Myc-driven tumors.
Induction of G2/M Phase Arrest by Diosgenin via Activation of Chk1 Kinase and Cdc25C Regulatory Pathways to Promote Apoptosis in Human Breast Cancer Cells.
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.
Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase.
Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells.
Inhibitors of Protein Tyrosine Phosphatase PTP1B With Anticancer Potential.
Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis.
Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer.
Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Isolation of two sesquiterpene glycosides from Sapindus mukorossi Gaertn. with cytotoxic properties and analysis of their mechanism based on network pharmacology.
Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells.
Leukocyte common antigen-related tyrosine phosphatase receptor: increased expression and neuronal-type splicing in breast cancer cells and tissue.
Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
Long non-coding RNA UCA1 promotes breast cancer by upregulating PTP1B expression via inhibiting miR-206.
Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer.
Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism.
Low Molecular Weight Protein Tyrosine Phosphatase Slow Isoform Knockdown in MDA-MB-435 Cells Decreases RAW 264.7 Osteoclastic Differentiation.
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation.
Mechanisms of antineoplastic action of somatostatin analogs.
Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.
MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling.
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.
MicroRNA-99a-5p suppresses breast cancer progression and cell-cycle pathway through downregulating CDC25A.
MiR-19b suppresses PTPRG to promote breast tumorigenesis.
miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer.
Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin.
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
MKP-1-induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines: implications in breast cancer.
MKP1 mediates resistance to therapy in HER2-positive breast tumors.
Molecular cloning and characterization of PTP pi, a novel receptor-like protein-tyrosine phosphatase.
MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells.
mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells.
Mutational analysis of PTPRT phosphatase domains in common human cancers.
NCAPG upregulation mediated by four microRNAs combined with activation of the p53 signaling pathway is a predictor of poor prognosis in patients with breast cancer.
Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1.
New prenylated isoflavonoids as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Erythrina addisoniae.
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.
Novel PROTACs for degradation of SHP2 protein.
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Oleanane triterpenes as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Camellia japonica.
Overexpression of CDC25A associated with poor prognosis in breast cancer
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.
Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
Overexpression of the Protein Tyrosine Phosphatase PRL-2 Correlates with Breast Tumor Formation and Progression.
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.
p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression.
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.
Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells.
Pectenotoxin-2 induces G2/M phase cell cycle arrest in human breast cancer cells via ATM and Chk1/2-mediated phosphorylation of cdc25C.
Pez: a novel human cDNA encoding protein tyrosine phosphatase- and ezrin-like domains.
Phosphoproteomic analysis of interacting tumor and endothelial cells identifies regulatory mechanisms of transendothelial migration.
Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: A potential novel prognostic marker for breast cancer.
Physalis angulata induced G2/M phase arrest in human breast cancer cells.
PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications.
PPAR? inhibits breast cancer progression by upregulating PTPRF expression.
PRL-3 disrupts epithelial architecture by altering the post-mitotic midbody position.
PRL-3 promotes breast cancer progression by downregulating p14
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).
Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.
Prognostic Significance of Metastatic Lymph Nodes Ratio (MLNR) Combined with Protein-Tyrosine Phosphatase H1 (PTPH1) Expression in Operable Breast Invasive Ductal Carcinoma.
Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.
Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells.
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells.
Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.
Protein Tyrosine Phosphatase 1B Inhibitors from the Stems of Akebia quinata.
Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.
Protein tyrosine phosphatase activity as a diagnostic parameter in breast cancer.
Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9.
Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting I?B?.
Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer.
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Protein tyrosine phosphatase PTPN9 negatively regulates ErbB2 and EGFR signaling in breast cancer cells.
Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Protein tyrosine phosphatase receptor-type ? acts as a negative regulator suppressing breast cancer.
Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2.
Protein tyrosine phosphatase µ (PTP µ or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis.
Protein tyrosine phosphatase-1B and T-cell protein tyrosine phosphatase regulate IGF-2-induced MCF-7 cell migration.
Protein tyrosine phosphatases as potential therapeutic targets.
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase.
Protein-tyrosine phosphatase H1 increases breast cancer sensitivity to antiestrogens by dephosphorylating estrogen receptor at Tyr537.
Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells.
Proteomic Identification of Protein Tyrosine Phosphatase and Substrate Interactions in Living Mammalian Cells by Genetic Encoding of Irreversible Enzyme Inhibitors.
PTP LAR expression compared to prognostic indices in metastatic and non-metastatic breast cancer.
PTP-PEST phosphatase variations in human cancer.
PTP1B expression is an independent positive prognostic factor in human breast cancer.
PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p.
PTP1B phosphatase as a novel target of oleuropein activity in MCF-7 breast cancer model.
PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
PTP1B Suppresses Prolactin Activation of Stat5 in Breast Cancer Cells.
PTP1B: a double agent in metabolism and oncogenesis.
PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization.
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.
PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
PTPRA facilitates cancer growth and migration via the TNF-?-mediated PTPRA-NF-?B pathway in MCF-7 breast cancer cells.
PTPRJ Haplotypes and Colorectal Cancer Risk.
PTPRN2 and PLC?1 promote metastatic breast cancer cell migration through PI(4,5)P2-dependent actin remodeling.
PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.
PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer.
Purification and characterization of a rat liver protein-tyrosine phosphatase with sequence similarity to src-homology region 2.
Recovery of anoikis in Src-transformed cells and human breast carcinoma cells by restoration of the SIRP ?1/SHP-2 signaling system.
Regulation of acidification and apoptosis by SHP-1 and Bcl-2.
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.
Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.
Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.
Role of intracellular Ca2+ in the epidermal growth factor induced inhibition of protein tyrosine phosphatase activity in a breast cancer cell line.
Role of PRL-3, Snail, Cytokeratin and Vimentin expression in epithelial mesenchymal transition in breast carcinoma.
Role of the Cdc25A phosphatase in human breast cancer.
Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase.
SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment.
SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases.
SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro.
Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells.
Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells.
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.
Targeting protein-tyrosine phosphatases in breast cancer.
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2.
The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.
The correlation of PTPN4 expression with prognosis in breast cancer.
The effect of treatment with 4-hydroxyandrostenedione or medroxyprogesterone acetate on human breast tumour regression.
The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14.
The function of the protein tyrosine phosphatase SHP-1 in cancer.
The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling.
The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer.
The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
The p52 isoform of SHC1 is a key driver of breast cancer initiation.
The plasma peptides of breast versus ovarian cancer.
The prognostic significance of protein tyrosine phosphatase 4A2 in breast cancer.
The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells.
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.
The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer.
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment.
The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
The SIX1-EYA transcriptional complex as a therapeutic target in cancer.
The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.
Total Knockdown of LMW-PTP in MDA-MB-231 Cells Reduces Osteoclastogenesis.
Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.
Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER).
Tyrosine phosphatase PTP? contributes to HER2-evoked breast tumor initiation and maintenance.
Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Tyrosine phosphatase SHP2 regulates the expression of acyl-CoA synthetase ACSL4.
Uncovering a tumor suppressor for triple-negative breast cancers.
Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression.
[Bioinformatic analysis of direct protein targets of aspirin against human breast cancer proliferation].
[Corrigendum] Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
[Inhibitory effect of SHP-1 gene transfer on the proliferation of breast cancer cell line MDA-MB-231]
[PTPL1, a proapoptotic protein tyrosine phosphatase in breast cancers]
[Retrovirus-mediated SHP-1 gene expression in human breast cancer MDA-MB-231 cells]
Bronchiolitis
Alveolar Macrophage Phenotype and Compartmentalization Drive Different Pulmonary Changes in Mouse Strains Exposed to Cigarette Smoke.
Smoking p66Shc knocked out mice develop respiratory bronchiolitis with fibrosis but not emphysema.
Bronchitis
Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus.
Bronchitis, Chronic
[Elastase and acid phosphatase activity in bronchoalveolar lavage fluid during chronic bronchitis]
Bronchopulmonary Dysplasia
Developmental regulation of p66Shc is altered by bronchopulmonary dysplasia in baboons and humans.
Dual-specificity phosphatase (DUSP) genetic variants predict pulmonary hypertension in patients with bronchopulmonary dysplasia.
Brucellosis
A haplotype at intron 8 of PTPRT gene is associated with resistance to Brucella infection in Argentinian creole goats.
PTPN22 C1858T polymorphism and human brucellosis.
Burkitt Lymphoma
A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells.
Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control?
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Fcgamma receptor-mediated inhibition of human B cell activation: the role of SHP-2 phosphatase.
Oncogenic mechanisms in Burkitt lymphoma.
Regulation of CD45 expression in human leukemia cells.
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
calpain-2 deficiency
Calpain 2 regulates Akt-FoxO-p27(Kip1) protein signaling pathway in mammary carcinoma.
Candidiasis
Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis.
DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment.
Candidiasis, Chronic Mucocutaneous
Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis.
Carcinogenesis
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets.
?TrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit.
A brake becomes an accelerator: PTP1B--a new therapeutic target for breast cancer.
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
A Conserved Amino Acid in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and Repression of Epithelial Differentiation.
A novel function of twins, B subunit of protein phosphatase 2A, in regulating actin polymerization.
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.
A regulatory polymorphism at position -309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression.
Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin.
Acetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer.
Alteration of gene expression during radiation-induced resistance and tumorigenesis in NIH3T3 cells revealed by cDNA microarrays: involvement of MDM2 and CDC25B.
Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Association of PTP1B with Outcomes of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy.
Beyond the metabolic function of PTP1B.
BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.
Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis.
CDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell-cycle regulation.
CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability.
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.
Cdc25A serine 123 phosphorylation couples centrosome duplication with DNA replication and regulates tumorigenesis.
CDC25B overexpression stabilises centrin 2 and promotes the formation of excess centriolar foci.
Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis.
Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase.
Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors.
Characterization of low molecular weight protein tyrosine phosphatase isoforms in human breast cancer epithelial cell lines.
Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells.
Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway.
CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Clinicopathological significance of PTPN12 expression in human breast cancer.
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells.
CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability.
Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.
Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.
Differential effects of peripheral and transitional prostatic stromal cells on tumorigenesis.
Differential molecular signature alterations of RBSP3, LIMD1 and CDC25A in normal oral epithelium during oral tumorigenesis.
Differential transmission of the molecular signature of RBSP3, LIMD1 and CDC25A in basal/ parabasal versus spinous of normal epithelium during head and neck tumorigenesis: A mechanistic study.
Dissecting molecular events in thyroid neoplasia provides evidence for distinct evolution of follicular thyroid adenoma and carcinoma.
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation.
Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis.
Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis.
DUSP4 inhibits autophagic cell death in PTC by inhibiting JNK-BCL2-Beclin1 signaling.
Epidermal-specific deletion of TC-PTP promotes UVB-induced epidermal cell survival through the regulation of Flk-1/JNK signaling.
Epithelial Protein-Tyrosine Phosphatase 1B (PTP1B) Contributes to the Induction of Mammary Tumors by HER2/Neu but is not Essential for Tumor Maintenance.
Erbb2 Suppresses DNA Damage-Induced Checkpoint Activation and UV-Induced Mouse Skin Tumorigenesis.
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Evaluation of licorice flavonoids as protein tyrosine phosphatase 1B inhibitors.
Expression Analysis of Tyrosine Phosphatase Genes at Different Stages of Renal Cell Carcinoma.
Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors.
Expression and significance of CDC25B, PED/PEA-15 in esophageal carcinoma.
Expression of CDC25 phosphatases in human gastric cancer.
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Expression of protein tyrosine phosphatases and its significance in esophageal cancer.
Extensive somatic L1 retrotransposition in colorectal tumors.
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.
Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7.
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma.
Functional STR within PTPN11: a novel potential risk factor for colorectal cancer.
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.
Genomic organization and precise physical location of protein phosphatase 2A regulatory subunit A beta isoform gene on chromosome band 11q23.
Ginkgetin Blocks Constitutive STAT3 Activation and Induces Apoptosis through Induction of SHP-1 and PTEN Tyrosine Phosphatases.
Haploinsufficiency of the ESCRT Component HD-PTP Predisposes to Cancer.
Helicobacter Pylori CagA and Gastric Carcinogenesis.
Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis.
Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice.
High-resolution crystal structure of the PDZ1 domain of human protein tyrosine phosphatase PTP-Bas.
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Host genetic factors respond to pathogenic step-specific virulence factors of Helicobacter pylori in gastric carcinogenesis.
Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis.
Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.
Identification of differentially expressed genes and functional annotations associated with metastases of the uveal melanoma.
Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3.
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells.
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).
In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.
Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint.
Increased expression and phosphorylation of sh-ptp2 (syp) in human gastric carcinomas.
Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma.
Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma.
Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis.
Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma.
Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Involvement of the protein tyrosine phosphatase PTP1C in cellular physiology, autoimmunity and oncogenesis.
Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis.
KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.
Kinetic characterization of bovine lung low-molecular-weight protein tyrosine phosphatase.
Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.
LncRNA TCONS_00004099-derived microRNA regulates oncogenesis through PTPRF in gliomas.
Loss of protein phosphatase 2A regulatory subunit B56? promotes spontaneous tumorigenesis in vivo.
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer.
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Loss of the Protein-Tyrosine Phosphatase DEP-1/PTPRJ Drives Meningioma Cell Motility.
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c.
Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism.
Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation.
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.
MiR-19b suppresses PTPRG to promote breast tumorigenesis.
miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B.
miR-383 Down-Regulates the Oncogene CIP2A to Influence Glioma Proliferation and Invasion.
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer.
Mkp-1 is required for chemopreventive activity of butylated hydroxyanisole and resveratrol against colitis-associated colon tumorigenesis.
Molecular Analysis of the Interaction between Human PTPN21 and the Oncoprotein E7 from Human Papillomavirus Genotype 18.
Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.
Molecular events in the early phases of prostate carcinogenesis.
Morin-dependent inhibition of low molecular weight protein tyrosine phosphatase (LMW-PTP) restores sensitivity to apoptosis during colon carcinogenesis: Studies in vitro and in vivo, in an Apc-driven model of colon cancer.
Murine pancreatic ductal adenocarcinoma produced by in vitro transduction of polyoma middle T oncogene into the islets of Langerhans.
NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway.
On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives.
Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
Overexpression of TC-PTP in murine epidermis attenuates skin tumor formation.
p27(kip1) Upregulated by hnRNPC1/2 Antagonizes CagA (a Virulence Factor of Helicobacter pylori)-Mediated Pathogenesis.
p38? Mitogen-activated Protein Kinase Signals through Phosphorylating Its Phosphatase PTPH1 in Regulating Ras Protein Oncogenesis and Stress Response.
p63 regulates cell proliferation and cell cycle progression?associated genes in stromal cells of giant cell tumor of the bone.
p66Shc Aging Protein in Control of Fibroblasts Cell Fate.
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase.
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Phosphorylation of protein phosphatase 2A facilitated an early stage of chemical carcinogenesis.
PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis.
Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma.
Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration.
PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo.
Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
Prevention of liver carcinogenesis by Amarogentin through modulation of G1/S cell cycle check point and induction of apoptosis.
Primary Epithelioid Angiosarcoma of Finger Masquerading as Epithelioid Hemangioma: Report of a Case and Analysis of Mutational Pattern in Epithelioid Hemangiomas and Angiosarcomas by Next-generation Sequencing.
Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p.
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal.
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Prognostic significance of CDC25B expression in gliomas.
Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation.
Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis.
Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice.
Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC.
Protein tyrosine phosphatase Shp2 (Ptpn11) plays an important role in maintenance of chromosome stability.
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Protein-tyrosine Phosphatase DEP-1 Controls Receptor Tyrosine Kinase FLT3 Signaling.
Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A.
PTP1B and TC-PTP: regulators of transformation and tumorigenesis.
PTP1B expression contributes to gastric cancer progression.
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
PTP1B regulates cortactin tyrosine phosphorylation by targeting Tyr446.
PTP1B: a double agent in metabolism and oncogenesis.
PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction.
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
PTPN13/PTPL1: An Important Regulator of Tumor Aggressiveness.
PTPN14 acts as a candidate tumor suppressor in prostate cancer and inhibits cell proliferation and invasion through modulating LATS1/YAP signaling.
PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis.
PTPRA facilitates cancer growth and migration via the TNF-?-mediated PTPRA-NF-?B pathway in MCF-7 breast cancer cells.
PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia.
PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.
PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.
Rapid destruction of human Cdc25A in response to DNA damage.
Recent Patents Related to Phosphorylation Signaling Pathway on Cancer.
Reciprocal allosteric regulation of p38? and PTPN3 involves a PDZ domain-modulated complex formation.
Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTPepsilon C.
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association.
Regulation of TRP channel TRPM2 by the tyrosine phosphatase PTPL1.
Role of PTPRJ genotype in papillary thyroid carcinoma risk.
Role of SHP2 in hematopoiesis and leukemogenesis.
SAP-1 is a microvillus-specific protein tyrosine phosphatase that modulates intestinal tumorigenesis.
Selective elimination of cancer cells by the adenovirus E4orf4 protein in a Drosophila cancer model: a new paradigm for cancer therapy.
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
SHP-2, SH2-containing protein tyrosine phosphatase-2.
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic ?-Catenin, PIK3CA and MET.
Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development.
Silibinin Retards Colitis-associated Carcinogenesis by Repression of Cdc25C in Mouse Model.
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis.
STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
Steroids up-regulate p66Shc longevity protein in growth regulation by inhibiting its ubiquitination.
Structural basis for recognition of the tumor suppressor protein PTPN14 by the oncoprotein E7 of human papillomavirus.
Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Structure and functions of His domain protein tyrosine phosphatase in receptor trafficking and cancer.
Structure and Molecular Dynamics Simulations of Protein Tyrosine Phosphatase Non-Receptor 12 Provide Insights into the Catalytic Mechanism of the Enzyme.
Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.
TAFs contributes the function of PTPN2 in colorectal carcinogenesis through activating JAK/STAT signaling pathway.
Targeted disruption of TC-PTP in the proliferative compartment augments STAT3 and AKT signaling and skin tumor development.
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.
The 48-kDa alternative translation isoform of PP2A:B56epsilon is required for Wnt signaling during midbrain-hindbrain boundary formation.
The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa.
The carcinogen (7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene induces Cdc25B expression in human bronchial and lung cancer cells.
The dual specificity phosphatase Cdc25B, but not the closely related Cdc25C, is capable of inhibiting cellular proliferation in a manner dependent upon its catalytic activity.
The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability.
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
The gene encoding human nuclear protein tyrosine phosphatase, PRL-1. Cloning, chromosomal localization, and identification of an intron enhancer.
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer.
The p53-p66Shc apoptotic pathway is dispensable for tumor suppression whereas the p66Shc-generated oxidative stress initiates tumorigenesis.
The phosphatase PRL-3 affects intestinal homeostasis by altering the crypt cell composition.
The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis.
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis.
The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
The receptor-like protein tyrosine phosphatase alpha: a role in cell proliferation and oncogenesis.
The role of Cdc25A in the regulation of cell proliferation and apoptosis.
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review.
The role of Helicobacter pylori CagA in gastric carcinogenesis.
The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis.
The role of T-cell protein tyrosine phosphatase in epithelial carcinogenesis.
The serologically defined colon cancer antigen-3 interacts with the protein tyrosine phosphatase PTPN13 and is involved in the regulation of cytokinesis.
The two faces of PTP1B in cancer.
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.
The tyrosine343 residue of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Total Knockdown of LMW-PTP in MDA-MB-231 Cells Reduces Osteoclastogenesis.
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma.
TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.
Tumor-suppressive Function of Protein-tyrosine Phosphatase Non-receptor Type 23 in Testicular Germ Cell Tumors Is Lost upon Overexpression of miR142-3p microRNA.
Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells.
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.
Ubiquitin-Specific Protease 29 Regulates Cdc25A-Mediated Tumorigenesis.
Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis.
Unscheduled expression of CDC25B in S-phase leads to replicative stress and DNA damage.
Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.
YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells]
[Corrigendum] Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
[Effect of methylation inhibitor in the treatment of leukemia].
[Establishment of a colorectal cancer cell line with PRL-3 and CDH22 gene knock-down by lentivirus-mediated RNA interference.]
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
[Expressions and significances of PRL-3 and RhoC in A549 cell].
[P66shc action on resistance of colon carcinoma RKO cells to oxidative stress].
[Screening and identification of tumor related genes in early stages of transformed NIH3T3 cells associated with overexpressed PTPalpha]
Carcinoid Tumor
Prostatic acid phosphatase activity in carcinoid tumors.
Transmembrane protein tyrosine phosphatase IA-2 (ICA512) is expressed in human midgut carcinoids but is not detectable in normal enterochromaffin cells.
Carcinoma
A dimeric urea of the bisabolene sesquiterpene from the Okinawan marine sponge Axinyssa sp. inhibits protein tyrosine phosphatase 1B activity in Huh-7 human hepatoma cells.
A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.
A simple immunohistochemical method for the detection of prostatic acid phosphatase.
Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Accessibility to DNA in carcinoma chromatin is promoted by nanomolar okadaic acid: effect on AT-rich DNA binding proteins.
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Acid phosphatase activity as a test for gastric carcinoma.
Acid phosphatase activity in carcinoma of the bronchus.
Acid phosphatase in prostatic tissue homogenates from patients with benign prostatic hyperplasia and prostatic carcinoma.
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
AlloDriver: a method for the identification and analysis of cancer driver targets.
Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene.
Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.
An immunological model connecting the pathogenesis of stress, depression and carcinoma.
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
Aqueous extracts of Fructus Ligustri Lucide induce gastric carcinoma cell apoptosis and G2/M cycle arrest.
Association Between Methylation of SHP-1 Isoform I and SSTR2A Promoter Regions with Breast and Prostate Carcinoma Development.
Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells.
Association of human protein-tyrosine phosphatase kappa with members of the armadillo family.
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer.
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells.
Beta-catenin interacts with low-molecular-weight protein tyrosine phosphatase leading to cadherin-mediated cell-cell adhesion increase.
Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein.
c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas.
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma.
Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.
Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers.
Cdc25A phosphatase suppresses apoptosis induced by serum deprivation.
CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death.
CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR.
Changes of enzyme activities recognized in lymphocytes from patients with carcinoma of the gastrointestinal tract.
Chromosomal location of murine protein tyrosine phosphatase (Ptprj and Ptpre) genes.
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells.
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Comparative evaluation of serum acid phosphatase, urinary cholesterol, and androgens in diagnosis of prostatic cancer.
Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Control of acid phosphatase activity in human prostatic carcinoma cell cultures by serum.
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta.
Decreased acid phosphatase activity in prostate secretion associated with prostatic carcinoma.
Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.
Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma.
DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients.
Detection of ras gene mutations in peripheral blood of carcinoma patients using CD45 immunomagnetic separation and nested mutant allele specific amplification.
Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma.
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles.
Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.
E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression.
Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.
Effect of VTCN1 on progression and metastasis of ovarian carcinoma in vitro and vivo.
Effects of let-7c on the proliferation of ovarian carcinoma cells by targeted regulation of CDC25a gene expression.
Electron microscopic studies on the acid phosphatase activity in rats with transplantable Guerin epithelioma.
Elevated protein-tyrosine-phosphatase activity in human colon-carcinoma.
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts.
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.
Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression.
Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane.
Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma.
Expression Analysis of Tyrosine Phosphatase Genes at Different Stages of Renal Cell Carcinoma.
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma.
Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Expression and significance of CDC25B, PED/PEA-15 in esophageal carcinoma.
Expression of cdc25A and cdc25B proteins in thyroid neoplasms.
Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis.
Expression of cell regulatory proteins in ovarian borderline tumors.
Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro.
Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells.
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
Expression of oxidized protein tyrosine phosphatase and ?H2AX predicts poor survival of gastric carcinoma patients.
Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy.
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Expression of PRL-1 nuclear PTPase is associated with proliferation in liver but with differentiation in intestine.
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.
Expression of the membrane protein tyrosine phosphatase CD148 in human tissues.
Expression of the receptor protein-tyrosine phosphatase, PTPmu, restores E-cadherin-dependent adhesion in human prostate carcinoma cells.
Expression of the transmembrane protein tyrosine phosphatase RPTPalpha in human oral squamous cell carcinoma.
Expression patterns of cyclin E, cyclin A and CDC25 phosphatases in laryngeal carcinogenesis.
Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma.
Extensive alteration in the expression profiles of TGFB pathway signaling components and TP53 is observed along the gastric dysplasia-carcinoma sequence.
FAP-1 and NF-?B expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis.
FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis.
Gallic acid induces G2/M phase cell cycle arrest via regulating 14-3-3beta release from Cdc25C and Chk2 activation in human bladder transitional carcinoma cells.
Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.
Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.
Helicobacter pylori VacA, acting through receptor protein tyrosine phosphatase ?, is crucial for CagA phosphorylation in human duodenum carcinoma cell line AZ-521.
Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: a two-stage case-control study in Chinese.
High expression of Cdc25B and low expression of 14-3-3? is associated with the development and poor prognosis in urothelial carcinoma of bladder.
High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.
High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.
Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases.
Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer.
Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC.
Identification of Differentially Expressed Genes Involved in the Formation of Multicellular Tumor Spheroids by HT-29 Colon Carcinoma Cells.
Identification of pivotal cellular factors involved in HPV-induced dysplastic and neoplastic cervical pathologies.
Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells.
Imbalanced expression of mitogen-activated protein kinase phosphatase-1 and phosphorylated extracellular signal-regulated kinases in lung squamous cell carcinoma.
Immunohistochemical Detection of Hematopoietic Cell-specific Protein-Tyrosine Phosphatase (Tyrosine Phosphatase SHP-1) in a Series of Endometrioid and Serous Endometrial Carcinoma.
Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues.
Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.
Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Increased expression and phosphorylation of sh-ptp2 (syp) in human gastric carcinomas.
Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Increased Expression of the PRL-3 Gene in Human Oral Squamous Cell Carcinoma and Dysplasia Tissues.
Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas.
Increased prostate-type acid phosphatase activity in serum and typical bone lesions simulating the presence of prostatic carcinoma.
Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
Inhibition of a protein tyrosine phosphatase using mesoporous oxides.
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
Inhibition of T24 human bladder carcinoma cell migration by RNA interference suppressing the expression of HD-PTP.
Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.
Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.
Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B.
Label-Free Detection of Protein Tyrosine Phosphatase 1B (PTP1B) by Using a Rationally Designed Förster Resonance Energy Transfer (FRET) Probe.
Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients.
LncRNA HULC promotes lung squamous cell carcinoma by regulating PTPRO via NF-?B.
Loss of Protein Tyrosine Phosphatase Receptor J Expression Predicts an Aggressive Clinical Course in Patients with Esophageal Squamous Cell Carcinoma.
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Methylaervine as Potential Lead Compound against Cervical Carcinoma: Pharmacologic Mechanism Prediction based on Network Pharmacology.
Methylation and expression of PTPN22 in esophageal squamous cell carcinoma.
Methyllucidone inhibits STAT3 activity by regulating the expression of the protein tyrosine phosphatase MEG2 in DU145 prostate carcinoma cells.
MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B.
MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12.
MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A.
MiR-214 inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by targeting CDC25B.
MiR-450a-5p inhibits autophagy and enhances radiosensitivity by targeting dual-specificity phosphatase 10 in esophageal squamous cell carcinoma.
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC).
miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
MiR-96 enhances cellular proliferation and tumorigenicity of human cervical carcinoma cells through PTPN9.
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.
Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents.
Molecular cloning, characterization, and chromosomal localization of a novel protein-tyrosine phosphatase, HPTP eta.
Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584.
Mutational analysis of mononucleotide repeats in dual specificity tyrosine phosphatase genes in gastric and colon carcinomas with microsatellite instability.
Mutational analysis of PTPRT phosphatase domains in common human cancers.
Neutrophil acid phosphatase activity in patients with gastric or rectum carcinoma during surgical treatment.
Overexpression of CDC25A and CDC25B in head and neck cancers.
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery.
Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas.
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Overexpression of immunoglobulin (CD79a) binding protein1 (IGBP-1) in small lung adenocarcinomas and its clinicopathological significance.
Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy.
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas.
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.
PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics.
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma.
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Phosphoamino acid phosphatases in normal and cancerous tissues of the human uterus, cervix and ovary.
Phosphotyrosine Phosphatase Activity in Ovarian Carcinoma Cells : Stimulation by GnRH in Plasma Membrane.
Physalis angulata induced G2/M phase arrest in human breast cancer cells.
Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma.
Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer.
Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
PRL-3 phosphatase is implicated in ovarian cancer growth.
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Prognostication of prostatic carcinoma by serum acid phosphatase activity.
Progress in the correlation between PTPN12 gene expression and human tumors.
Prooxidant Properties of p66shc Are Mediated by Mitochondria in Human Cells.
Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced growth suppression of ovarian carcinoma cells.
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.
Protein tyrosine phosphatase ? enhances proliferation by increasing ?-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.
Protein tyrosine phosphatase alpha regulates cell detachment and cell death profiles induced by nitric oxide donors in the A431 human carcinoma cell line.
Protein tyrosine phosphatase H1 is a target of the E6 oncoprotein of high-risk genital human papillomaviruses.
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting I?B?.
Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma.
PTP-PEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells.
PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity.
PTP1B Contributes to Calreticulin-Induced Metastatic Phenotypes in Esophageal Squamous Cell Carcinoma.
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
PTP1B up-regulates EGFR expression by dephosphorylating MYH9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma.
PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker.
PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation.
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.
PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma.
Purification and characterization of a rat liver protein-tyrosine phosphatase with sequence similarity to src-homology region 2.
Radiotherapy-induced signal transduction.
Rapid (one-shot) staining method for two-color multiparametric DNA flow cytometric analysis of carcinomas using staining for cytokeratin and leukocyte common antigen.
Rapid induction of p21WAF1 but delayed down-regulation of Cdc25A in the TGF-beta-induced cell cycle arrest of gastric carcinoma cells.
Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid.
Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21.
Receptor-type Protein tyrosine phosphatase ? regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors.
Regulation of the expression of prostatic acid phosphatase in LNCaP human prostate carcinoma cells.
Relationship between the Levels of mRNA Expression for Protein Phosphatase 1B and Proteins Involved in Cytoskeleton Remodeling in Squamous Cell Carcinoma of the Larynx and Hypopharynx.
Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo.
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTP? and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Retinoic acid induced repression of AP-1 activity is mediated by protein phosphatase 2A in ovarian carcinoma cells.
Retraction of: Single Nucleotide Polymorphisms in the PTPN1 Gene Are Associated with Susceptibility to Esophageal Squamous Cell Carcinoma: A Case-Control Study in Inner Mongolia, China; DOI: 10.1089/gtmb.2016.0194.
Separation and characterization of epithelial cells from prostates and prostatic carcinomas: a review.
Separation of cells with histochemically demonstrable acid phosphatase activity from suspensions of cells from human prostatic carcinomas in an isokinetic gradient of Ficoll in tissue culture medium.
SHP-1 is involved in neuronal differentiation of P19 embryonic carcinoma cells.
Significance of PTPRZ1 and CIN85 expression in cervical carcinoma.
Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin.
Simultaneous flow cytometric deoxyribonucleic acid and acid phosphatase analysis of benign and malignant lesions of the prostate.
Single Nucleotide Polymorphisms in the PTPN1 Gene Are Associated with Susceptibility to Esophageal Squamous Cell Carcinoma: A Case-Control Study in Inner Mongolia, China.
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Somatic Mutations of PPP2R1A in Ovarian and Uterine Carcinomas.
Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5.
Steroids up-regulate p66Shc longevity protein in growth regulation by inhibiting its ubiquitination.
Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation.
Subcellular localisation of Cdc25A determines cell fate.
Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion.
Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.
Targeting 14-3-3?-CDC25A interactions to trigger apoptotic cell death in skin cancer.
The association and prognostic relevance of cancerous inhibitor of protein phosphatase 2A and inflammation in tongue squamous cell carcinoma.
The carboxyl-terminal tyrosine residue of protein-tyrosine phosphatase alpha mediates association with focal adhesion plaques.
The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
The Chalcone Flavokawain B Induces G(2)/M Cell-Cycle Arrest and Apoptosis in Human Oral Carcinoma HSC-3 Cells through the Intracellular ROS Generation and Downregulation of the Akt/p38 MAPK Signaling Pathway.
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
The receptor-like protein-tyrosine phosphatase DEP-1 is constitutively associated with a 64-kDa protein serine/threonine kinase.
The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
The tyrosine phosphatase HD-PTP (PTPN23) is degraded by calpains in a calcium-dependent manner.
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
The tyrosine phosphatase, SHP-1, is involved in bronchial mucin production during oxidative stress.
Theaflavins induce G2/M arrest by modulating expression of p21(waf1/cip1), cdc25C and cyclin B in human prostate carcinoma PC-3 cells.
Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.
TNFalpha-mediated cell death is independent of cdc25A.
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Tyrosine phosphorylation translocates beta-catenin from cell-->cell interface to the cytoplasm, but does not significantly enhance the LEF-1-dependent transactivating function.
Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Tyrosyl kinase activity is inversely related to prostatic acid phosphatase activity in two human prostate carcinoma cell lines.
Ultrastructural localization of acid phosphatase in human laryngeal carcinoma.
Vitamin K3 induces cell cycle arrest and cell death by inhibiting Cdc25 phosphatase.
[Acid phosphatase activity in breast dysplasias and in carcinomas of the breast]
[Change of acid phosphatase activity in granulocytes from patients with carcinomas of the gastrointestinal tract]
[Construction of a lentiviral vector for RNA interference of PRL-3 gene and its stable expression in SW480 cells]
[Construction of the life cycle of Angiostrongylus cantonensis in laboratory]
[Diurnal variation of the elevated acid phosphatase activity in cases of prostate carcinoma (author's transl)]
[Electron microscopic studies on the acid phosphatase activity in rats with transplantable Guérin epithelioma]
[ERK1/2 and p38 kinases are important regulators in P2Y receptor-mediated prostate cancer invasion]
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
[Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance].
[Expression of tyrosine phosphatase containing C-src homology SH-2 in benign prostate hyperplasia]
[Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma]
[Molecular portrait of human kidney carcinomas: the gene expression profiling of protein-tyrosine kinases and tyrosine phosphatases which controlled regulatory signals in the cells]
[Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
[The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues]
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Carcinoma, Adenoid Cystic
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
Carcinoma, Adenosquamous
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Carcinoma, Ductal
Clinicopathological significance of dual-specificity protein phosphatase 4 expression in invasive ductal carcinoma of the breast.
Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors.
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Prognostic Significance of Metastatic Lymph Nodes Ratio (MLNR) Combined with Protein-Tyrosine Phosphatase H1 (PTPH1) Expression in Operable Breast Invasive Ductal Carcinoma.
Carcinoma, Ehrlich Tumor
[Inhibition of pinocytosis and of acid phosphatase activity caused by lack of serum in the culture medium of Ehrlich ascites tumor cells (author's transl)]
Carcinoma, Embryonal
Characterization of a protein tyrosine phosphatase (RIP) expressed at a very early stage of differentiation in both mouse erythroleukemia and embryonal carcinoma cells.
Differential expression of a novel murine non-receptor protein tyrosine phosphatase during differentiation of P19 embryonal carcinoma cells.
Induction of specific protein tyrosine phosphatase transcripts during differentiation of mouse embryonal carcinoma (F9) cells.
Receptor protein tyrosine phosphatase alpha activates pp60c-src and is involved in neuronal differentiation.
Carcinoma, Endometrioid
Dual-specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression via Activation of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Pathway.
Carcinoma, Hepatocellular
A bromopyrrole-containing diterpene alkaloid from the Okinawan marine sponge Agelas nakamurai activates the insulin pathway in Huh-7 human hepatoma cells by inhibiting protein tyrosine phosphatase 1B.
A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo.
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
A dimeric urea of the bisabolene sesquiterpene from the Okinawan marine sponge Axinyssa sp. inhibits protein tyrosine phosphatase 1B activity in Huh-7 human hepatoma cells.
A fluorescent probe for monitoring PTP-PEST enzymatic activity.
A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Accomplices in Crime: The Diabolical Liaison between PTP1B and Ras in Hepatocellular Carcinoma.
Aggravated Liver Injury but Attenuated Inflammation in PTPRO-Deficient Mice Following LPS/D-GaIN Induced Fulminant Hepatitis.
Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5.
CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells.
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Cell hydration and mTOR-dependent signalling.
Changes of expressions of phosphotyrosine phosphatases in rat hepatocellular carcinoma induced by 3'-methyl-4-dimethylamino-azobenzene.
CIP2A Is Highly Expressed in Hepatocellular Carcinoma and Predicts Poor Prognosis.
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma.
Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma.
Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy.
Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the ?-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study.
Development of a time-resolved fluorescent assay for measuring tyrosine-phosphorylated proteins in cells.
Differential regulation of mRNAs encoding three protein-tyrosine phosphatases by insulin and activation of protein kinase C.
Diosmin induces cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and blocks tumour growth in xenografted nude mice
Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Dissociation of PTPase levels from their modulation of insulin receptor signal transduction.
Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma.
Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells.
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma.
Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma.
Dual-Specificity Phosphatase 9 Regulates Cellular Proliferation and Predicts Recurrence After Surgery in Hepatocellular Carcinoma.
Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation.
Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases.
EGF-mediated migration signaling activated by N-acetylglucosaminyltransferase-V via receptor protein tyrosine phosphatase kappa.
Emodin inhibits the growth of hepatoma cells: finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells.
Enhancement of protein tyrosine phosphatase activity in the proliferation of cloned rat hepatoma H4-II-E cells: suppressive role of endogenous regucalcin.
Enzyme occupancy measurement of intracellular protein tyrosine phosphatase 1B using photoaffinity probes.
Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine?induced liver cancer via inhibition of cell division cycle 25A.
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Essential role of protein-tyrosine phosphatase 1B in the modulation of insulin signaling by acetaminophen in hepatocytes.
Estrogen sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.
Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation.
Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues.
Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.
FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice.
Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.
Functional short tandem repeat polymorphism of PTPN11 and susceptibility to hepatocellular carcinoma in Chinese populations.
Gene expressions of protein tyrosine phosphatases in regenerating rat liver and rat ascites hepatoma cells.
Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma.
Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies.
Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma.
Hepatitis B virus X protein mutant HBx?127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT.
Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
Hyperosmotic induction of the mitogen-activated protein kinase phosphatase MKP-1 in H4IIE rat hepatoma cells.
Identification of CDC25C as a Potential Biomarker in Hepatocellular Carcinoma Using Bioinformatics Analysis.
Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase.
Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta?analysis and cross?species comparison.
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma.
Induction of an interferon-gamma Stat3 response in nerve cells by pre-treatment with gp130 cytokines.
Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs. Significance of protein tyrosine phosphatase inhibition.
Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas.
Inhibition of the transmembrane protein tyrosine phosphatase lar by 3S-peptide-I enhances insulin receptor phosphorylation in intact cells.
Initiation and maintenance of CNTF-Jak/STAT signaling in neurons is blocked by protein tyrosine phosphatase inhibitors.
Insulin dependent apolipoprotein B degradation and phosphatidylinositide 3-kinase activation with microsomal translocation are restored in McArdle RH7777 cells following serum deprivation.
Insulin differentially regulates protein phosphotyrosine phosphatase activity in rat hepatoma cells.
Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR.
Insulin stimulates the phosphorylation of Tyr538 and the catalytic activity of PTP1C, a protein tyrosine phosphatase with Src homology-2 domains.
Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade.
Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma.
Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in Sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone.
IRE1? links Nck1 deficiency to attenuated PTP1B expression in HepG2 cells.
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Leptin increases hepatic insulin sensitivity and protein tyrosine phosphatase 1B expression.
Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment.
Localization of acid phosphatase activity in well-differentiated hepatocellular carcinoma 146.
Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP).
Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma.
MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice.
Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate.
Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
MicroRNA let-7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma.
MicroRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma.
miR-186 Inhibits Liver Cancer Stem Cells Expansion via Targeting PTPN11.
miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.
miR-206 inhibits cell proliferation, invasion, and migration by down-regulating PTP1B in hepatocellular carcinoma.
miR-532-3p promotes hepatocellular carcinoma progression by targeting PTPRT.
miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE.
miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB.
MiR-675 Promotes the Growth of Hepatocellular Carcinoma Cells Through the Cdc25A Pathway.
Mutational analysis of PTPRT phosphatase domains in common human cancers.
NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A.
Okadaic acid promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting protein phosphatase 2A.
Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.
Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway.
Osmotic regulation of insulin-induced mitogen-activated protein kinase phosphatase (MKP-1) expression in H4IIE rat hepatoma cells.
Osmotic regulation of MAP-kinase activities and gene expression in H4IIE rat hepatoma cells.
Osmotic regulation of MG-132-induced MAP-kinase phosphatase MKP-1 expression in H4IIE rat hepatoma cells.
Osmotic regulation of the heat shock response in H4IIE rat hepatoma cells.
Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas.
Overexpression of regucalcin suppresses cell death and apoptosis in cloned rat hepatoma H4-II-E cells induced by insulin or insulin-like growth factor-I.
p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling.
Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes.
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo.
Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma.
PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth.
PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK.
Protein phosphatase 2A activation mechanism contributes to JS-K induced caspase-dependent apoptosis in human hepatocellular carcinoma cells.
Protein phosphatase 2A mediates JS-K-induced apoptosis by affecting Bcl-2 family proteins in human hepatocellular carcinoma HepG2 cells.
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Protein tyrosine phosphatase receptor type D (PTPRD)-mediated signaling pathways for the potential treatment of hepatocellular carcinoma: a narrative review.
Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.
Protein-tyrosine phosphatase activity in human adipocytes is strongly correlated with insulin-stimulated glucose uptake and is a target of insulin-induced oxidative inhibition.
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas.
PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.
Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells.
Reduction of PTP1B by RNAi upregulates the activity of insulin controlled fatty acid synthase promoter.
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.
Rock2 regulates Cdc25A through ubiquitin proteasome system in hepatocellular carcinoma cells.
Role of endogenous regucalcin in protein tyrosine phosphatase regulation in the cloned rat hepatoma cells (H4-II-E).
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
Selective inhibition of protein tyrosine phosphatase activities by H2O2 and vanadate in vitro.
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.
SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.
Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo.
SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma.
Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma.
Suppression of hepatitis B viral gene expression by protein-tyrosine phosphatase PTPN3.
Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells.
Suppression of the dual-specificity phosphatase MKP-1 enhances HIF-1 trans-activation and increases expression of EPO.
Suppression of the protein tyrosine phosphatase LAR reduces apolipoprotein B secretion by McA-RH7777 rat hepatoma cells.
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.
Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.
Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.
TGF-?1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death.
The characteristic gene expressions of MAPK phosphatases 1 and 2 in hepatocarcinogenesis, rat ascites hepatoma cells, and regenerating rat liver.
The effect of receptor protein tyrosine phosphatase kappa on the change of cell adhesion and proliferation induced by N-acetylglucosaminyltransferase V.
The HNF1?-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1.
The MAP kinase phosphatase-1 MKP-1/DUSP1 is a regulator of human liver response to transplantation.
The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes.
The protein tyrosine phosphatase LAR has a major impact on insulin receptor dephosphorylation.
The selective reduction in PTPdelta expression in hepatomas.
The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling.
The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases.
The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
Transient and sustained ERK phosphorylation and nuclear translocation in growth control.
TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.
Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.
Vanadate inhibits transcription of the rat insulin receptor gene via a proximal sequence of the 5'flanking region.
Zanthoxylum avicennae extracts induce cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and block tumor growth in xenografted nude mice.
Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo.
[Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway]
[Effect of PTPRD rs2279776 gene and interaction with hepatitis B virus mutations on the risk of hepatocellular carcinoma].
[Effect of ultraviolet radiation on lysosomal acid phosphatase activity Zajdela ascitic hepatoma]
[Gene therapy using a dominant negative form of the protein phosphatase 2A catalytic subunit a driven by a hepatoma tissue-specific promoter achieves effective growth inhibition of hepatoma cells].
[Mechanism of regulation of hepatoma cell cycle by XPD/P44 subcomplex : an in vitro experiment]
[The distribution of acid phosphatase activity in the ultrastructures of liver cells during the development of induced hepatoma]
Carcinoma, Intraductal, Noninfiltrating
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Carcinoma, Lewis Lung
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion.
Carcinoma, Mucoepidermoid
Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Carcinoma, Non-Small-Cell Lung
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Erratum to: The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis.
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4.
Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU.
MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK.
miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.
MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A.
Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
Molecular Nodal Restaging Based on CEACAM5, FGFR2b and PTPN11 Expression Adds No Relevant Clinical Information in Resected Non-Small Cell Lung Cancer.
Novel PROTACs for degradation of SHP2 protein.
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells.
Tangeretin derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells in vitro and in vivo.
The Nonreceptor-Type Tyrosine Phosphatase PTPN13 Is a Tumor Suppressor Gene in Non-Small Cell Lung Cancer.
The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
[Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer]
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
[Expressions and significances of PRL-3 and RhoC in A549 cell].
Carcinoma, Ovarian Epithelial
Dual specificity phosphatase 6 as a new therapeutic target candidate for epithelial ovarian cancer.
Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.
PTN signaling: Components and mechanistic insights in human ovarian cancer.
[Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays]
Carcinoma, Papillary
Induction of thyroid neoplasms in the rat. A histochemical, immunohistochemical, autoradiographic and ultrastructural study.
Carcinoma, Renal Cell
A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.
D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta.
Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.
Expression Analysis of Tyrosine Phosphatase Genes at Different Stages of Renal Cell Carcinoma.
Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.
Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.
Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B.
Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas.
MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B.
MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A.
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.
Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma.
Progress in the correlation between PTPN12 gene expression and human tumors.
Protein tyrosine phosphatase ? enhances proliferation by increasing ?-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.
Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21.
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTP? and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation.
The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
A combined electron-microscope and cytochemical study of acid phosphatase activity in human cervical squamous carcinoma.
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
AlloDriver: a method for the identification and analysis of cancer driver targets.
Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.
An additional transcript of the cdc25C gene from A431 cells encodes a functional protein.
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death.
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Downregulation of cell division cycle 25 homolog C reduces the radiosensitivity and proliferation activity of esophageal squamous cell carcinoma.
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activity.
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.
Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy.
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.
High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma.
Imbalanced expression of mitogen-activated protein kinase phosphatase-1 and phosphorylated extracellular signal-regulated kinases in lung squamous cell carcinoma.
Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.
Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.
LncRNA HULC promotes lung squamous cell carcinoma by regulating PTPRO via NF-?B.
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Overexpression of CDC25A and CDC25B in head and neck cancers.
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy.
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Partial purification and characterization of phosphotyrosyl-protein phosphatase from Ehrlich ascites tumor cells.
Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cell-substratum adhesion.
PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker.
Receptor-type Protein tyrosine phosphatase ? regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Relationship between the Levels of mRNA Expression for Protein Phosphatase 1B and Proteins Involved in Cytoskeleton Remodeling in Squamous Cell Carcinoma of the Larynx and Hypopharynx.
Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor.
Significance of PTPRZ1 and CIN85 expression in cervical carcinoma.
Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.
Targeting 14-3-3?-CDC25A interactions to trigger apoptotic cell death in skin cancer.
The association and prognostic relevance of cancerous inhibitor of protein phosphatase 2A and inflammation in tongue squamous cell carcinoma.
The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Carcinoma, Transitional Cell
Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma.
Carcinosarcoma
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Cardiomegaly
Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A.
Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes.
Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways.
Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1.
Endothelial deletion of protein tyrosine phosphatase-1B protects against pressure overload-induced heart failure in mice.
Growing old, angiotensin II, cardiac hypertrophy, and death: making the connection with p66Shc.
Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Lack of Contribution of p66shc to Pressure Overload-Induced Right Heart Hypertrophy.
Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes.
mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?
Cardiomyopathies
A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1.
Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway.
Deletion of low molecular weight protein tyrosine phosphatase (Acp1) protects against stress-induced cardiomyopathy.
Dual specificity phosphatase 4 mediates cardiomyopathy caused by lamin A/C (LMNA) gene mutation.
Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival.
Genotype-phenotype correlations in Noonan syndrome.
Hyperthrophic cardiomyopathy and the PTPN11 gene.
Intravenous Gene Therapy With Pim-1 Via a Cardiotropic Viral Vector Halts the Progression of Diabetic Cardiomyopathy Through Promotion of Prosurvival Signaling.
Leopard syndrome: the potential cardiac defect underlying skin phenotypes.
Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome.
Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.
Noonan Syndrome Case Report: PTPN11 and Other Potential Genetic Factors Contributing to Lethal Hypertrophic Right Ventricular Cardiomyopathy.
Noonan syndrome: clinical aspects and molecular pathogenesis.
Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling.
Cardiomyopathy, Dilated
Centrosome-associated CDC25B is a novel disease-causing gene for a syndrome with cataracts, dilated cardiomyopathy, and multiple endocrinopathies.
Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.
Dilated cardiomyopathy in transgenic mice expressing a mutant A subunit of protein phosphatase 2A.
No association between transmembrane protein-tyrosine phosphatase receptor type C (CD45) exon A point mutation (77C>G) and idiopathic dilated cardiomyopathy.
The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity.
Cardiomyopathy, Hypertrophic
A novel heterozygous MAP2K1 mutation in a patient with Noonan syndrome with multiple lentigines.
A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.
A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1.
Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results.
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy.
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Familial aggregation of genetically heterogeneous hypertrophic cardiomyopathy: a boy with LEOPARD syndrome due to PTPN11 mutation and his nonsyndromic father lacking PTPN11 mutations.
Familial LEOPARD Syndrome With Hypertrophic Cardiomyopathy.
Genotype-phenotype correlation analysis in Japanese patients with Noonan syndrome.
Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His.
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Is sudden cardiac death predictable in LEOPARD syndrome?
LEOPARD Syndrome Caused by Tyr279Cys Mutation in the PTPN11 Gene.
LEOPARD syndrome in an infant with severe hypertrophic cardiomyopathy and PTPN11 mutation.
Mutation screening of the PTPN11 gene in hypertrophic cardiomyopathy.
New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.
PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy: what is the link?
PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype".
PTPN11 Mutation Associated with Aortic Dilation and Hypertrophic Cardiomyopathy in a Pediatric Patient with Noonan Syndrome.
PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
PTPN11 mutations play a minor role in isolated congenital heart disease.
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.
Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.
The PTPN11 gene is not implicated in nonsyndromic hypertrophic cardiomyopathy.
The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome.
Cardiotoxicity
Calpain-2 promotes MKP-1 expression protecting cardiomyocytes in both in vitro and in vivo mouse models of doxorubicin-induced cardiotoxicity.
Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein.
Cardiovascular Diseases
Acid phosphatase, genetic polymorphism and cardiovascular risk factors in a pediatric population.
Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm.
Angiotensin (1-7) Inhibits Ang II-mediated ERK1/2 Activation by Stimulating MKP-1 Activation in Vascular Smooth Muscle Cells.
Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.
Atorvastatin enhances endothelial adherens junctions through promoting VE-PTP gene transcription and reducing VE-cadherin-Y731 phosphorylation.
Cardiovascular determinants of life span.
Coronary Artery Disease: Evidence of Interaction between PTPN22 and p53 Genetic Polymorphisms.
DNA methylation of the p66Shc promoter is decreased in placental tissue from women delivering intrauterine growth restricted neonates.
Dual role of endothelial nitric oxide synthase in oxidized LDL-induced, p66Shc-mediated oxidative stress in cultured human endothelial cells.
Effect of genetic factors on the association between coronary artery disease and PTPN22 polymorphism.
Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein.
Lethal presentation of neurofibromatosis and Noonan syndrome.
Linking protein to phenotype with Mendelian Randomization detects 38 proteins with causal roles in human diseases and traits.
Mitogen-activated protein kinase phosphatase 1 (MKP-1) in macrophage biology and cardiovascular disease. A redox-regulated master controller of monocyte function and macrophage phenotype.
Mitogen-activated protein kinase phosphatase-1: A critical phosphatase manipulating mitogen-activated protein kinase signaling in cardiovascular disease (Review).
New aspects of p66Shc in ischemia reperfusion injury and cardiovascular diseases.
Novel role of p66Shc in ROS-dependent VEGF signaling and angiogenesis in endothelial cells.
Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and protein kinase C.
P66shc and its role in ischemic cardiovascular diseases.
Protein tyrosine phosphatase 1B regulates endothelial endoplasmic reticulum stress; role in endothelial dysfunction.
Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders.
Recent advance on PTP1B inhibitors and their biomedical applications.
Role of protein tyrosine phosphatase 1B in cardiovascular diseases.
Search for genetic variants in the p66Shc longevity gene by PCR-single strand conformational polymorphism in patients with early-onset cardiovascular disease.
Structure-functional implications of longevity protein p66Shc in health and disease.
The role of p66Shc deletion in age-associated arterial dysfunction and disease states.
The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance.
Carotid Artery Injuries
Increase of PTP levels in vascular injury and in cultured aortic smooth muscle cells treated with specific growth factors.
Carotid Stenosis
Correlation between SHP-1 and carotid plaque vulnerability in humans.
Cataract
Acid phosphatase localization in the equatorial region of human lenses.
Centrosome-associated CDC25B is a novel disease-causing gene for a syndrome with cataracts, dilated cardiomyopathy, and multiple endocrinopathies.
Expanding the clinical spectrum of ocular anomalies in Noonan syndrome: Axenfeld-anomaly in a child with PTPN11 mutation.
Identification and functional clustering of global gene expression differences between human age-related cataract and clear lenses.
Ultrastructural cytochemistry: effect of Sorbinil on arylsulfatases in cataractous lenses.
Ultrastructure and acid phosphatase activity in hereditary cataracts of deer mice.
Celiac Disease
A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease.
An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum.
Association of PTPN22 rs2476601 Polymorphism with Rheumatoid Arthritis and Celiac Disease in Khuzestan Province, Southwestern Iran.
Association of PTPN22 Single Nucleotide Polymorphisms with Celiac Disease.
C1858T functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition.
Celiac disease as an autoimmune condition.
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population.
Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children.
Environmental factors related to the induction of beta-cell autoantibodies in 1-yr-old healthy children.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Shared and distinct genetic variants in type 1 diabetes and celiac disease.
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
Cell Transformation, Neoplastic
Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1).
Central Nervous System Diseases
The control of oligodendrocyte bioenergetics by interferon-gamma (IFN-?) and Src homology region 2 domain-containing phosphatase-1 (SHP-1).
Cerebellar Ataxia
Chromosomal localization of an SH2 containing tyrosine phosphatase (SH-PTP3) gene to chromosome 12q24.1.
PTPRR Protein Tyrosine Phosphatase Isoforms and Locomotion of Vesicles and Mice.
Cerebral Hemorrhage
A cannabinoid receptor 2 agonist reduces blood-brain barrier damage via induction of MKP-1 after intracerebral hemorrhage in rats.
Dauricine alleviated secondary brain injury after intracerebral hemorrhage by upregulating GPX4 expression and inhibiting ferroptosis of nerve cells.
Noonan Syndrome with Multiple Lentigines and PTPN11 Mutation: A Case with Intracerebral Hemorrhage.
Tristetraprolin attenuates brain edema in a rat model of cerebral hemorrhage.
Cerebral Infarction
Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation.
PTPRG is an ischemia risk locus essential for HCO3--dependent regulation of endothelial function and tissue perfusion.
Cervical Intraepithelial Neoplasia
Relationship between HPV typing and the status of G2 cell cycle regulators in cervical neoplasia.
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-? production.
Chagas Disease
Association study of PTPN22 C1858T polymorphism in Trypanosoma cruzi infection.
Biochemical characterization of a protein tyrosine phosphatase from Trypanosoma cruzi involved in metacyclogenesis and cell invasion.
Structure of the Trypanosoma cruzi protein tyrosine phosphatase TcPTP1, a potential therapeutic target for Chagas' disease.
Chemical and Drug Induced Liver Injury
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Cherubism
Neurofibromatosis presenting with a cherubism phenotype.
Noonan-like syndrome mutations in PTPN11 in patients diagnosed with cherubism.
Cholangiocarcinoma
Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients.
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis.
MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.
Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
PTPN3 acts as a tumor suppressor and boosts TGF-? signaling independent of its phosphatase activity.
PTPN3 mutations and HBV may exert synergistic effects in the origin of the intrahepatic cholangiocarcinoma.
The effect of internal biliary drainage on bile pigment accumulation and acid phosphatase activity in human liver during obstructive jaundice.
The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma.
[Expression and clinical significance of PTPN14 in cholangiocarcinoma].
Cholangitis
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Cholangitis, Sclerosing
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis.
Cholera
Atomic resolution crystal structure of VcLMWPTP-1 from Vibrio cholerae O395: insights into a novel mode of dimerization in the low molecular weight protein tyrosine phosphatase family.
Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages.
Cholesteatoma
Alkaline and acid phosphatase activity in postauricular skin and cholesteatoma epithelium.
[Expression and significance of PTEN, P-ERK and P-AKT in the middle ear cholesteatoma].
Cholesteatoma, Middle Ear
[Expression and significance of PTEN, P-ERK and P-AKT in the middle ear cholesteatoma].
Choline Deficiency
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Chondroma
A rare association of pathological variant of Alport's syndrome caused by hemizygous 5' splice mutation in intron 10 of COL4A5 gene with metachondromatosis due to heterozygous missense variation in protein tyrosine phosphatase nonreceptor type 11 gene.
Chondrosarcoma in Metachondromatosis: A Rare Case Report.
Intraosseous atypical chondroid tumor or chondrosarcoma grade 1 in patients with multiple osteochondromas.
Metachondromatosis: more than just multiple osteochondromas.
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates.
Chondrosarcoma
miRNA-497 Negatively Regulates the Growth and Motility of Chondrosarcoma Cells by Targeting Cdc25A.
Chordoma
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
Upregulation of metastasis-associated PRL-3 initiates chordoma in zebrafish.
Choriocarcinoma
Dampening of IFN-gamma-inducible gene expression in human choriocarcinoma cells is due to phosphatase-mediated inhibition of the JAK/STAT-1 pathway.
The protein-tyrosine phosphatase, SRC homology-2 domain containing protein tyrosine phosphatase-2, is a crucial mediator of exogenous insulin-like growth factor signaling to human trophoblast.
Vanadate regulates the insulin mitogenic effect by modulating SHP-2 association with insulin receptor substrate 1 in JAr human choriocarcinoma cells.
Choroid Plexus Neoplasms
Papillary Tumor of the Pineal Region: A Distinct Molecular Entity.
Ras, TrkB, and ShcA Protein Expression Patterns in Pediatric Brain Tumors.
Chronic Kidney Disease-Mineral and Bone Disorder
Nature of mononuclear cells positive for acid phosphatase activity in bone marrow of patients with renal osteodystrophy.
Chronic Urticaria
Association Between PTPN22 Polymorphisms and IgE Responses to Staphylococcal Superantigens in Chronic Urticaria.
Association of PTPN22 single nucleotide polymorphisms with chronic spontaneous urticaria.
Churg-Strauss Syndrome
PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
Cleft Palate
Inactivation of LAR family phosphatase genes Ptprs and Ptprf causes craniofacial malformations resembling Pierre-Robin sequence.
Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.
[Molecular mechanism of cleft palate induced by retionic acid]
Coinfection
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Evaluation of Primitive Murine Hematopoietic Stem and Progenitor Cell Transduction In Vitro and In Vivo by Recombinant Adeno-Associated Virus Vector Serotypes 1 Through 5.
Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5.
Expression of Toll-like receptor signaling-related genes in pigs co-infected with porcine reproductive and respiratory syndrome virus and porcine circovirus type 2.
Mitogen Activated Protein Kinase Phosphatase 2, MKP-2, regulates the Inflammatory Response in Sepsis.
Signal transduction-mediated adherence and entry of Helicobacter pylori into cultured cells.
Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction.
Colitis
Activation of Protein Tyrosine Phosphatase Non-Receptor Type 2 by Spermidine Exerts Anti-Inflammatory Effects in Human THP-1 Monocytes and in a Mouse Model of Acute Colitis.
Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis.
Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.
Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23.
Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice.
Experimental colitis in IL-10-deficient mice ameliorates in the absence of PTPN22.
Genetic analysis of the Trichuris muris-induced model of colitis reveals QTL overlap and a novel gene cluster for establishing colonic inflammation: Trichuris muris-induced colitis genetic study.
Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis.
Immunohistochemical examination of anti-inflammatory and anti-apoptotic effects of hesperetin on trinitrobenzene sulfonic acid induced colitis in rats.
Increased expression of midkine in the rat colon during healing of experimental colitis.
Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse.
Knockout of Mkp-1 exacerbates colitis in Il-10-deficient mice.
l-Glutamine Attenuates DSS-Induced Colitis via Induction of MAPK Phosphatase-1.
Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis.
Loss of PTPN22 promotes intestinal inflammation by compromising granulocyte-mediated anti-bacterial defense.
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia.
Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis.
Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation.
Network pharmacology-based identification of the protective mechanisms of taraxasterol in experimental colitis.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Nitric Oxide Is Involved in Activation of Toll-Like Receptor 4 Signaling through Tyrosine Nitration of Src Homology Protein Tyrosine Phosphatase 2 in Murine Dextran Sulfate-Induced Colitis.
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
Protein Tyrosine Phosphatase 1B Deficiency Ameliorates Murine Experimental Colitis via the Expansion of Myeloid-Derived Suppressor Cells.
Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner.
Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells.
Protein tyrosine phosphatase SAP-1 protects against colitis through regulation of CEACAM20 in the intestinal epithelium.
Protein-tyrosine phosphatase sigma is associated with ulcerative colitis.
PTPN2 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis.
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
PTPN22 Modulates Macrophage Polarization and Susceptibility to Dextran Sulfate Sodium-Induced Colitis.
Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation.
Selective Sequestration of STAT1 in the Cytoplasm via Phosphorylated SHP-2 Ameliorates Murine Experimental Colitis.
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
SHP-2 Phosphatase Prevents Colonic Inflammation by Controlling Secretory Cell Differentiation and Maintaining Host-Microbiota Homeostasis.
T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities.
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.
The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration.
Titanium Dioxide Presents a Different Profile in Dextran Sodium Sulphate-Induced Experimental Colitis in Mice Lacking the IBD Risk Gene Ptpn2 in Myeloid Cells.
[Free Radical Production and Production Mechanism in the Early and Advanced Stages of Gastrointestinal Lesions].
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Colitis, Ulcerative
Apical junction complex proteins and ulcerative colitis: a focus on the PTPRS gene.
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis.
Associations between PTPN2 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis.
Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease.
Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis.
Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice.
GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
Inflammatory bowel disease: Are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation.
Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese population.
Protein-tyrosine phosphatase sigma is associated with ulcerative colitis.
PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.
PTPN2 is associated with Crohn's disease and its expression is regulated by NKX2-3.
PTPRO exaggerates inflammation in ulcerative colitis through TLR4/NF-?B pathway.
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
rs2476601 polymorphism in PTPN22 is associated with Crohn's disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls.
SHP-2 Phosphatase Prevents Colonic Inflammation by Controlling Secretory Cell Differentiation and Maintaining Host-Microbiota Homeostasis.
Single Nucleotide Polymorphisms of PTPN22 Gene in Iranian Patients with Ulcerative Colitis.
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.
The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration.
Colitis-Associated Neoplasms
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration.
Colonic Neoplasms
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets.
5-fluoro-2'-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells.
A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism.
Activation of PERK Contributes to Apoptosis and G2/M Arrest by Microtubule Disruptors in Human Colorectal Carcinoma Cells ‡.
Association of Shp2 with phosphorylated IL-22R1 is required for interleukin-22-induced MAP kinase activation.
Can dehydroepiandrostenedione (DHEA) target PRL-3 to prevent colon cancer metastasis?
Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3? pathway in colon cancer.
Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells.
CIP2A Is a Predictor of Poor Prognosis in Colon Cancer.
Combined Phenotype of 4 Markers Improves Prognostic Value of Patients With Colon Cancer.
Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichment coupled with multiple-reaction monitoring mass spectrometry.
Cordyceps militaris Grown on Germinated Soybean Induces G2/M Cell Cycle Arrest through Downregulation of Cyclin B1 and Cdc25c in Human Colon Cancer HT-29 Cells.
Cytokine associated sensitivity of colon carcinoma cells to FasR-mediated cytotoxicity of CTL.
Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins.
DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients.
Differential IL-4/Stat6 activities correlate with differential expression of regulatory genes SOCS-1, SHP-1, and PP2A in colon cancer cells.
DNA methylation regulates constitutive expression of Stat6 regulatory genes SOCS-1 and SHP-1 in colon cancer cells.
Down-regulation of Cdc25c, CDK1 and Cyclin B1 and Up-regulation of Wee1 by Curcumin Promotes Human Colon Cancer Colo 205 Cell Entry into G2/M-phase of Cell Cycle.
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Elevated expression of the cdc25A protein phosphatase in colon cancer.
Elevated protein-tyrosine-phosphatase activity in human colon-carcinoma.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
Extracellular domain dependence of PTPalpha transforming activity.
Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3.
Fas-associated phosphatase-1 promotes Fas-mediated apoptosis in human colon cancer cells: novel function of FAP-1.
Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5.
Gene Expression Along with Genomic Copy Number Variation and Mutational Analysis Were Used to Develop a 9-Gene Signature for Estimating Prognosis of COAD.
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
HOXD13 promotes the malignant progression of colon cancer by upregulating PTPRN2.
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21.
Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.
Identification of target proteins of N-acetylglucosaminyl transferase V in human colon cancer and implications of protein tyrosine phosphatase kappa in enhanced cancer cell migration.
Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells.
Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatin.
Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate.
Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer.
Interleukin-2 enhances susceptibility of colon cancer cells to FasR mediated apoptosis by up-regulating Fas receptor level and down-regulating FAP-1 expression.
Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells.
LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase.
microRNA-21 Negatively Regulates Cdc25A and Cell Cycle Progression in Colon Cancer Cells.
miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death.
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Morin-dependent inhibition of low molecular weight protein tyrosine phosphatase (LMW-PTP) restores sensitivity to apoptosis during colon carcinogenesis: Studies in vitro and in vivo, in an Apc-driven model of colon cancer.
Mutational analysis of PTPRT phosphatase domains in common human cancers.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.
NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway.
Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis.
Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells.
Preferential requirement for protein tyrosine phosphatase activity in the 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of human colon cancer cells.
PRL-3 activates NF-?B signaling pathway by interacting with RAP1.
PRL-3 promotes cell adhesion by interacting with JAM2 in colon cancer.
PRL-3 promotes telomere deprotection and chromosomal instability.
PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.
PRL-3: a metastasis-associated phosphatase in search of a function.
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells.
Protein phosphatase 2A is essential to maintain active Wnt signaling and its A? tumor suppressor subunit is not expressed in colon cancer cells.
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
PTP-PEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells.
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction.
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.
PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133.
pTyr(421) Cortactin Is Overexpressed in Colon Cancer and Is Dephosphorylated by Curcumin: Involvement of Non-Receptor Type 1 Protein Tyrosine Phosphatase (PTPN1).
Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression.
Receptor-type protein tyrosine phosphatase ? directly dephosphorylates CD133 and regulates downstream AKT activation.
Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
SHP-2 Interacts with CD81 and Regulates the Malignant Evolution of Colorectal Cancer by Inhibiting Epithelial-Mesenchymal Transition.
SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells.
Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.
Structural modification of Fas C-terminal tripeptide and its effects on the inhibitory activity of Fas/FAP-1 binding.
Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility.
Sulforaphene suppresses growth of colon cancer-derived tumors via induction of glutathione depletion and microtubule depolymerization.
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats.
The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis.
The mycotoxin patulin decreases expression of density-enhanced phosphatase-1 by down-regulating PPAR? in human colon cancer cells.
The serologically defined colon cancer antigen-3 interacts with the protein tyrosine phosphatase PTPN13 and is involved in the regulation of cytokinesis.
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.
Tumour suppressor function of protein tyrosine phosphatase receptor-T.
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
WiNTRLINC1/ASCL2/c-Myc Axis Characteristics of Colon Cancer with Differentiated Histology at Young Onset and Essential for Cell Viability.
[Development of anti cancer drugs targeted on Fas-mediated apoptosis signal]
[Effects of phosphatase of regenerating liver cell-3 gene silence by RNA interference on the expression of matrix metalloproteinases-2,-9 in human colon cancer cells]
[P66shc action on resistance of colon carcinoma RKO cells to oxidative stress].
Colorectal Neoplasms
3'-hydroxy-4'-methoxy-?-methyl-?-nitrostyrene inhibits tumorigenesis in colorectal cancer cells through ROS-mediated DNA damage and mitochondrial dysfunction.
A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.
A missense variant in PTPN12 associated with the risk of colorectal cancer by modifying Ras/MEK/ERK signaling.
A novel platform for detection of CK+ and CK- CTCs.
A phosphatase associated with metastasis of colorectal cancer.
A retrospective cohort study of clinical value of PRL-3 in stage III human colorectal cancer.
A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy.
Candidate genes for hereditary colorectal cancer: Mutational screening and systematic review.
Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels.
CCL26 Participates in the PRL-3-Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration.
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual specificity phosphatase 1.
Circular RNA circ_0007142 Facilitates Colorectal Cancer Progression by Modulating CDC25A Expression via miR-122-5p.
Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer.
Correlation between Liver Metastases and the Level of PRL-3 mRNA Expression in Patients with Primary Colorectal Cancer.
Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer.
Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer: evidence for a second phosphotyrosine substrate recognition pocket.
Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients.
DNA copy number changes at 8q11-24 in metastasized colorectal cancer.
Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression.
Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas.
Downregulation of PTPRH (Sap-1) in colorectal tumors.
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.
Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
Engineering non-natural inhibitor sensitivity in protein tyrosine phosphatase H1.
Erratum: B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A: Erratum.
Expression and chromosomal assignment of PTPH1 gene encoding a cytosolic protein tyrosine phosphatase homologous to cytoskeletal-associated proteins.
Expression levels and associations of five long non-coding RNAs in gastric cancer and their clinical significance.
Expression of Concern: Upregulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3.
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.
Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.
Functional STR within PTPN11: a novel potential risk factor for colorectal cancer.
Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis.
Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer.
High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
Histochemically demonstrable protein tyrosine phosphatase in human breast and colorectal cancer: large decrease in its activity in colorectal cancer suggests a tumor suppressor role in colorectal mucosal cells.
Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness.
Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14.
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T.
Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T.
Immunohistochemical and Western blot analysis of two protein tyrosine phosphatase receptors, R and Z1, in colorectal carcinoma, colon adenoma and normal colon tissues.
Immunohistochemical assessment of PRL-3 (PTP4A3) expression in tumor buds, invasion front, central region of tumor and metastases of colorectal cancer.
Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas.
Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.
Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.
Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer.
Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue.
KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer.
Knockdown of PRL-3 increases mitochondrial superoxide anion production through transcriptional regulation of RAP1.
Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers.
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer.
Loss of tyrosine phosphatase SHP2 activity promotes growth of colorectal carcinoma HCT-116 cells.
Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer.
Mass spectrometry study of PRL-3 phosphatase inactivation by disulfide bond formation and cysteine into glycine conversion.
Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer.
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk.
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review.
miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1.
MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer.
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Morin-dependent inhibition of low molecular weight protein tyrosine phosphatase (LMW-PTP) restores sensitivity to apoptosis during colon carcinogenesis: Studies in vitro and in vivo, in an Apc-driven model of colon cancer.
Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.
Mutational analysis of FLASH and PTPN13 genes in colorectal carcinomas.
Mutational analysis of mononucleotide repeats in dual specificity tyrosine phosphatase genes in gastric and colon carcinomas with microsatellite instability.
Mutational analysis of the tyrosine phosphatome in colorectal cancers.
Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers.
PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.
Polypyrimidine tract-binding protein 1-mediated down-regulation of ATG10 facilitates metastasis of colorectal cancer cells.
Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.
PRL phosphatases as potential molecular targets in cancer.
PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling.
PRL-3 expression in metastatic cancers.
PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism.
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.
PRL-3 phosphatase is implicated in ovarian cancer growth.
PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly.
PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1.
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Protein tyrosine phosphatase receptor-like genes are frequently hypermethylated in sporadic colorectal cancer.
PTP4A3 expression increases strongly in lymph node metastases from colorectal carcinoma.
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
PTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis.
PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation.
PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma.
PTPN6 promotes chemosensitivity of colorectal cancer cells via inhibiting the SP1/MAPK signalling pathway.
PTPN9 induces cell apoptosis by mitigating the activation of Stat3 and acts as a tumor suppressor in colorectal cancer.
PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition.
PTPRJ Haplotypes and Colorectal Cancer Risk.
PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC.
PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation.
PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients.
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma.
Retraction: Upregulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3.
RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer.
SHP-1 is a target of regorafenib in colorectal cancer.
SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases.
SHP-2 Interacts with CD81 and Regulates the Malignant Evolution of Colorectal Cancer by Inhibiting Epithelial-Mesenchymal Transition.
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
SIRT6 inhibits colorectal cancer stem cell proliferation by targeting CDC25A.
Snail as a key regulator of PRL-3 gene in colorectal cancer.
Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer.
Structural insights into molecular function of the metastasis-associated phosphatase PRL-3.
The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer.
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
The Expression of the Phosphatase Regenerating Liver 3 Gene is Associated with Outcome in Patients with Colorectal Cancer.
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
The function of the protein tyrosine phosphatase SHP-1 in cancer.
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation.
The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth.
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis.
The PTPN13 Y2081D (T>G) (rs989902) polymorphism is associated with an increased risk of sporadic colorectal cancer.
The Suppressing Effects of Dkk3 Expression on Aggressiveness and Tumorigenesis of Colorectal Cancer.
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas.
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.
Tumor-associated macrophages (TAMs) depend on Shp2 for their anti-tumor roles in colorectal cancer.
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells.
Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis.
Up-regulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3.
Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review.
Vemurafenib downmodulates aggressiveness mediators of colorectal cancer (CRC): Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP), Protein Tyrosine Phosphatase 1B (PTP1B) and Transforming Growth Factor ? (TGF?).
[Cloning of human PRL-3 gene and construction of its prokaryotic expression vector]
[Construction of a lentiviral vector for RNA interference of PRL-3 gene and its stable expression in SW480 cells]
[Construction of the life cycle of Angiostrongylus cantonensis in laboratory]
[Establishment of a colorectal cancer cell line with PRL-3 and CDH22 gene knock-down by lentivirus-mediated RNA interference.]
[Expression of cancerous inhibitor of protein phosphatase 2A in tissue microarray of colorectal cancer and its clinical significance].
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
[Expression of the zinc finger transcriptional factor Snail in colorectal carcinoma and its significance]
[Tumor markers for colorectal cancer]
Colorectal Neoplasms, Hereditary Nonpolyposis
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Communicable Diseases
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.
Congenital Abnormalities
Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity and calvarial defects in mice.
Effects of mechanical loading on the expression of pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in a rat spinal deformity model.
Genotype-phenotype correlations in Noonan syndrome.
Pathogenesis of adolescent idiopathic scoliosis in girls - a double neuro-osseous theory involving disharmony between two nervous systems, somatic and autonomic expressed in the spine and trunk: possible dependency on sympathetic nervous system and hormones with implications for medical therapy.
Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Congenital Disorders of Glycosylation
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus.
Shp2 function in hematopoietic stem cell biology and leukemogenesis.
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Connective Tissue Diseases
PTPN22: the archetypal non-HLA autoimmunity gene.
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
Corneal Dystrophies, Hereditary
Association of common variants in TCF4 and PTPRG with Fuchs' corneal dystrophy: a systematic review and meta-analysis.
Association of Transcription Factor 4 (TCF4) and Protein Tyrosine Phosphatase, Receptor Type G (PTPRG) with Corneal Dystrophies in Southern Chinese.
Coronary Artery Disease
Atherosclerosis and PTPN22: A Study in Coronary Artery Disease.
Coronary Artery Disease: Evidence of Interaction between PTPN22 and p53 Genetic Polymorphisms.
Effect of genetic factors on the association between coronary artery disease and PTPN22 polymorphism.
Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease.
Genetic colocalization atlas points to common regulatory sites and genes for hematopoietic traits and hematopoietic contributions to disease phenotypes.
Modulation of bone marrow-derived endothelial progenitor cell activity by protein tyrosine phosphatases.
Search for genetic variants in the p66Shc longevity gene by PCR-single strand conformational polymorphism in patients with early-onset cardiovascular disease.
The 981C>T polymorphism in protein tyrosine phosphatase 1B is associated with decreased risk of coronary artery disease in Chinese Han population.
The p66shc gene expression in peripheral blood monocytes is increased in patients with coronary artery disease.
The protein tyrosine phosphatase receptor type f (PTPRF) locus is associated with coronary artery disease in type 2 diabetes.
Coronary Disease
The expression of p66shc in peripheral blood monocytes is increased in patients with coronary heart disease and correlated with endothelium-dependent vasodilatation.
Costello Syndrome
Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Exclusion of PTPN11 mutations in Costello syndrome: further evidence for distinct genetic etiologies for Noonan, cardio-facio-cutaneous and Costello syndromes.
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
No mutation in the gene for Noonan syndrome, PTPN11, in 18 patients with Costello syndrome.
Spectrum of Mutations in Noonan Syndrome and Their Correlation with Phenotypes.
Craniofacial Abnormalities
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.
Craniosynostoses
A de novo balanced translocation t(7;12)(p21.2;p12.3) in a patient with Saethre-Chotzen-like phenotype downregulates TWIST and an osteoclastic protein-tyrosine phosphatase, PTP-oc.
Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.
Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability.
Crohn Disease
A case-control study of tyrosine phosphatase (PTPN22) confirms the lack of association with Crohn's disease.
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution.
A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease.
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Association Between the PTPN2 Gene and Crohn's Disease: Dissection of Potential Causal Variants.
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Associations between PTPN2 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis.
Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease.
Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis.
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Expression of the membrane protein tyrosine phosphatase CD148 in human tissues.
Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with Crohn's Disease: On the Way to Personalized Medicine?
Genetic colocalization atlas points to common regulatory sites and genes for hematopoietic traits and hematopoietic contributions to disease phenotypes.
Genetic Variations of PTPN2 and PTPN22: Role in the Pathogenesis of Type 1 Diabetes and Crohn's Disease.
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
Inflammatory bowel disease: Are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase.
Inflammatory Bowel Diseases: the genetic revolution.
Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion.
Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon-?-Induced Signaling in Human Monocytes.
Loss of PTPN22 promotes intestinal inflammation by compromising granulocyte-mediated anti-bacterial defense.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation.
Modulation of PTPN2/22 Function by Spermidine in CRISPR-Cas9-Edited T-Cells Associated with Crohn's Disease and Rheumatoid Arthritis.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Protection of epithelial barrier function by the Crohn's disease associated gene, protein tyrosine phosphatase N2.
Protein tyrosine phosphatase N2 regulates TNF?-induced signalling and cytokine secretion in human intestinal epithelial cells.
Protein Tyrosine Phosphatase non-Receptor Type 2 regulates IFN-?-induced cytokine signaling in THP-1 monocytes.
Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells.
PTPN2 but not PTPN22 is associated with Crohn's disease in a New Zealand population.
PTPN2 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis.
PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.
PTPN2 is associated with Crohn's disease and its expression is regulated by NKX2-3.
PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity.
PTPN22 Modulates Macrophage Polarization and Susceptibility to Dextran Sulfate Sodium-Induced Colitis.
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
rs2476601 polymorphism in PTPN22 is associated with Crohn's disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls.
T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.
The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.
Variants of CARD15, TNFA and PTPN22 and susceptibility to Crohn's disease in the Czech population: high frequency of the CARD15 1007fs.
Cross Infection
A Potential Mechanism for Immune Suppression by Beta-Adrenergic Receptor Stimulation following Traumatic Injury.
Cryptorchidism
Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
New Mutations Associated with Rasopathies in a Central European Population and Genotype-Phenotype Correlations.
[Clinical and genetic analysis of Noonan syndrome in 20 children].
Cutis Laxa
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Cystadenoma
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
Cystic Fibrosis
Activation of cardiac chloride conductance by the tyrosine kinase inhibitor, genistein.
Cysteine string protein interacts with and modulates the maturation of the cystic fibrosis transmembrane conductance regulator.
Cysteine string protein monitors late steps in cystic fibrosis transmembrane conductance regulator biogenesis.
Cysteine string protein promotes proteasomal degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) by increasing its interaction with the C terminus of Hsp70-interacting protein and promoting CFTR ubiquitylation.
Expression and regulation of chloride channels in neonatal rat cardiomyocytes.
Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin.
Interaction of the protein phosphatase 2A with the regulatory domain of the cystic fibrosis transmembrane conductance regulator channel.
Parallel single nucleotide polymorphism genotyping by surface invasive cleavage with universal detection.
Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis.
The cystic fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A.
The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line.
The +1858 C/T Polymorphism in the PTPN22 Gene Is Associated with Cystic Fibrosis Patients in Northeast Mexico.
ZnT8 antibodies in patients with cystic fibrosis: An expression of secondary beta-cell damage?
Cysts
Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
Characterization of low molecular weight protein tyrosine phosphatases of Entamoeba histolytica.
Excystation of Giardia muris induced by a phosphate-bicarbonate medium: localization of acid phosphatase.
Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.
Histochemistry and ultrastructure of the metacercarial cyst of Bolbogonotylus corkumi (Trematoda: Cryptogonimidae).
MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
MicroRNAs in cholangiociliopathies.
PRL-3 disrupts epithelial architecture by altering the post-mitotic midbody position.
Therapeutic Targets In Polycystic Liver Disease.
[The characteristics of chemical composition of content of unicameral bone cysts depending on their growth stage].
Dandy-Walker Syndrome
Array-based molecular karyotyping in fetuses with isolated brain malformations identifies disease-causing CNVs.
Deafness
A C-terminal nonsense mutation links PTPRQ with autosomal-dominant hearing loss, DFNA73.
A reduction in Ptprq associated with specific features of the deafness phenotype of the miR-96 mutant mouse diminuendo.
Deafness and vestibular dysfunction in a Doberman Pinscher puppy associated with a mutation in the PTPRQ gene.
Hair Bundle Defects and Loss of Function in the Vestibular End Organs of Mice Lacking the Receptor-Like Inositol Lipid Phosphatase PTPRQ.
Identification of a novel compound heterozygous mutation in PTPRQ in a DFNB84 family with prelingual sensorineural hearing impairment.
Identification of Novel PTPRQ and MYO1A Mutations in An Iranian Pedigree with Autosomal Recessive Hearing Loss.
Identification of Two Novel Compound Heterozygous PTPRQ Mutations Associated with Autosomal Recessive Hearing Loss in a Chinese Family.
IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function.
Leopard syndrome: the potential cardiac defect underlying skin phenotypes.
Mutations in PTPRQ are a cause of autosomal-recessive nonsyndromic hearing impairment DFNB84 and associated with vestibular dysfunction.
Proband Whole-Exome Sequencing Identified Genes Responsible for Autosomal Recessive Non-Syndromic Hearing Loss in 33 Chinese Nuclear Families.
PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome.
Death, Sudden, Cardiac
Is sudden cardiac death predictable in LEOPARD syndrome?
Dehydration
Cell hydration and mTOR-dependent signalling.
Glucagon-induced expression of the MAP kinase phosphatase MKP-1 in rat hepatocytes.
Importance of inositols and their derivatives in cowpea under root dehydration: An omics perspective.
Dementia
Anti-CD45RO suppresses human immunodeficiency virus type 1 replication in microglia: role of Hck tyrosine kinase and implications for AIDS dementia.
Beneficial Effect of Protein Tyrosine Phosphatase Inhibitor and Phytoestrogen in Dyslipidemia-Induced Vascular Dementia in Ovariectomized Rats.
Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.
Expression changes of growth-associated protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment rats.
Intracerebroventricular administration of okadaic acid induces hippocampal glucose uptake dysfunction and tau phosphorylation.
Protective effects of Salvia miltiorrhiza injection against learning and memory impairments in streptozotocin-induced diabetic rats.
The Implication of STEP in Synaptic Plasticity and Cognitive Impairments in Alzheimer's Disease and Other Neurological Disorders.
Dementia, Vascular
Attenuation of hyperhomocysteinemia induced vascular dementia by sodium orthovanadate perhaps via PTP1B: Pertinent downstream outcomes.
Beneficial Effect of Protein Tyrosine Phosphatase Inhibitor and Phytoestrogen in Dyslipidemia-Induced Vascular Dementia in Ovariectomized Rats.
Demyelinating Diseases
A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.
Accelerated Axonal Loss Following Acute CNS Demyelination in Mice Lacking Protein Tyrosine Phosphatase Receptor Type Z.
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.
Developmental expression and function analysis of protein tyrosine phosphatase receptor type D in oligodendrocyte myelination.
Exosomal Circular RNA as a Biomarker Platform for the Early Diagnosis of Immune-Mediated Demyelinating Disease.
Inactivation of Protein Tyrosine Phosphatase Receptor Type Z by Pleiotrophin Promotes Remyelination through Activation of Differentiation of Oligodendrocyte Precursor Cells.
Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.
Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.
Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia.
Protein tyrosine phosphatase receptor type z negatively regulates oligodendrocyte differentiation and myelination.
SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.
The control of reactive oxygen species production by SHP-1 in oligodendrocytes.
Dengue
Protein tyrosine phosphatase, opisthorchiasis and dengue: A proteomics interrelationship.
Tyrosine kinase/phosphatase inhibitors decrease dengue virus production in HepG2 cells.
Dental Calculus
[Deposition of tartar in human teeth and acid phosphatase activity in saliva]
[Tartar deposit and salivary acid phosphatase activity in man]
Dental Caries
Dental caries: Genetic and protein interactions.
[The correlation between salivary acid phosphatase activity and dental caries]
Dental Plaque
The effect of dental plaque grown in the presence of xylitol or sucrose on bone resorption in vitro.
Dermatitis
Critical role for mast cell Stat5 activity in skin inflammation.
GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1-derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis-like and psoriasis-like dermatitis.
Dermatitis, Atopic
Genetic control of serum IgE levels: a study of low molecular weight protein tyrosine phosphatase.
Licoricidin Abrogates T-Cell Activation by Modulating PTPN1 Activity and Attenuates Atopic Dermatitis In Vivo.
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
PTPN22 polymorphisms may indicate a role for this gene in atopic dermatitis in West Highland white terriers.
Dermatitis, Contact
GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
Machine-learning-driven biomarker discovery for the discrimination between allergic and irritant contact dermatitis.
Dermatitis, Phototoxic
Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
Dermatomyositis
Concomitance of basophilia, ribonucleic acid and acid phosphatase activity in regenerating muscle fibres.
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
Diabetes Complications
Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms.
Inhibitory activity of Aralia continentalis roots on protein tyrosine phosphatase 1B and rat lens aldose reductase.
Marine algae as a prospective source for antidiabetic compounds - A brief review.
p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications.
Protein Tyrosine Phosphatase 1B and ?-Glucosidase Inhibitory Phlorotannins from Edible Brown Algae, Ecklonia stolonifera and Eisenia bicyclis.
Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing.
Diabetes Insipidus
Acid phosphatase activity in the rat neurohypophysis during increased levels of gonadothrophic hormones, in diabetes insipidus (Bratteboro strain) and after water loading.
Diabetes Mellitus
25-Hydroxyvitamin D
A Computer-Driven Scaffold-Hopping Approach Generating New PTP1B Inhibitors from the Pyrrolo[1,2-a]quinoxaline Core.
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes.
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
A transmembrane protein-tyrosine phosphatase receptor type C (CD45) exon A point mutation (77 C to G) is not associated with the development of type 1 diabetes mellitus in a German population.
Age-specific levels of diabetes-related GAD and IA-2 antibodies in healthy children and adults.
Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes.
Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
An Integrated Computational Approach for Plant-Based Protein Tyrosine Phosphatase Non-Receptor Type 1 Inhibitors.
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.
Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome.
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Association of genetic variants with chronic kidney disease in Japanese individuals with or without hypertension or diabetes mellitus.
Association of protein tyrosine phosphatase non-receptor type 22 gene functional variant C1858T, HLA-DQ/DR genotypes and autoantibodies with susceptibility to type-1 diabetes mellitus in Kuwaiti Arabs.
Association of PTPN1 polymorphisms with breast cancer risk: A case-control study in Chinese females.
Association of PTPN22 gene polymorphism with type 1 diabetes mellitus in Chinese children and adolescents.
Association of the PTPN22 gene (+1858C/T, -1123G/C) polymorphisms with type 1 diabetes mellitus: A systematic review and meta-analysis.
Autoimmunity-Associated PTPN22 Polymorphisms in Latent Autoimmune Diabetes of the Adult Differ from Those of Type 1 Diabetes Patients.
Bioactivity-guided isolation of 1,2,3,4,6-Penta-O-galloyl-D-glucopyranose from Paeonia lactiflora roots as a PTP1B inhibitor.
Carbazole alkaloids from the fruits of Clausena anisum-olens with potential PTP1B and ?-glucosidase inhibitory activities.
Change of glutamic acid decarboxylase antibody and protein tyrosine phosphatase antibody in Chinese patients with acute-onset type 1 diabetes mellitus.
Characteristics of the interaction mechanisms of procyanidin B1 and procyanidin B2 with protein tyrosine phosphatase-1B: Analysis by kinetics, spectroscopy methods and molecular docking.
Concurrent extrahepatic autoimmune disorders: unexplored dimension of autoimmune liver disease in children.
Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKC?/p66Shc axis and activation of FOXO-3a.
Cytosolic Low Molecular Weight Protein-Tyrosine Phosphatase Activity and Clinical Manifestations of Diabetes.
Deletion of AT2 Receptor Prevents SHP-1-Induced VEGF Inhibition and Improves Blood Flow Reperfusion in Diabetic Ischemic Hindlimb.
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors.
Detection of proteolytic cleavages of diabetes-associated protein IA-2 beta in the pancreas and the brain using novel anti-IA-2 beta monoclonal antibodies.
Discovery of 2-ethoxy-4-(methoxymethyl)benzamide derivatives as potent and selective PTP1B inhibitors.
Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties.
Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent.
Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity.
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents.
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: a new insight into its antidiabetic mechanism.
Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2 diabetes in Birmingham, United Kingdom.
Functional genetic variants in the 3'UTR of PTPRD associated with the risk of gestational diabetes mellitus.
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Genetic Variants of PTPN2 Gene in Chinese Children with Type 1 Diabetes Mellitus.
Genistein-derivatives from Tetracera scandens stimulate glucose-uptake in L6 myotubes.
Genomic structure of mouse IA-2: comparison with its human homologue.
Glucose Uptake Activities of Bis (2, 3-Dibromo-4, 5-Dihydroxybenzyl) Ether, a Novel Marine Natural Product from Red Alga Odonthaliacorymbifera with Protein Tyrosine Phosphatase 1B Inhibition, In Vitro and In Vivo.
Glutamic acid decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual beta-cell function and glycemic control in young type 1 diabetic patients.
Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2',3,3'-Tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS db Mice.
Human protein tyrosine phosphatase 1B inhibitors: QSAR by genetic function approximation.
Humoral autoreactivity to an alternatively spliced variant of ICA512/IA-2 in Type I diabetes.
IA-2A positivity rate at manifestation of type 1 diabetes mellitus in Slovak children culminates in September.
Identification and evaluation of magnolol and chrysophanol as the principle protein tyrosine phosphatase-1B inhibitory compounds in a Kampo medicine, Masiningan.
Identification of lipid-like salicylic acid-based derivatives as potent and membrane-permeable PTP1B inhibitors.
Identification of protein tyrosine phosphatase 1B (PTP1B) inhibitors through De Novo Evoluton, synthesis, biological evaluation and molecular dynamics simulation.
Identification of PTP1B regulators from Cymbopogon citratus and its enrichment analysis for diabetes mellitus.
In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications-A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B.
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
In vitro anti-diabetic effect of flavonoids and pheophytins from Allophylus cominia Sw. on the glucose uptake assays by HepG2, L6, 3T3-L1 and fat accumulation in 3T3-L1 adipocytes.
In vitro effects of cinnamic acid derivatives on protein tyrosine phosphatase 1B.
Influence of sex and age at onset on autoantibodies against insulin, GAD65 and IA2 in recent onset type 1 diabetic patients.
Inhibition of protein tyrosine phosphatase 1B by flavonoids: A structure - activity relationship study.
Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
Inhibitors of protein tyrosine phosphatase 1B (PTP1B).
Inhibitors of Protein Tyrosine Phosphatase 1B from Marine Natural Products.
Inhibitory Effects of Secondary Metabolites from the Lichen Stereocaulon evolutum on Protein Tyrosine Phosphatase 1B.
Insulin autoantibody could help to screen latent autoimmune diabetes in adults in phenotypic type 2 diabetes mellitus in Chinese.
Insulin gene profile cycles with season of birth of future diabetic children and their relatives.
Integration of network and experimental pharmacology to decipher the antidiabetic action of Duranta repens L.
Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
Isolation and Characterization of Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitory Polyphenolic Compounds From
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus.
Mechanism of attenuation of diabetes mellitus and hypercholesterolemia induced vascular endothelial dysfunction by protein tyrosine phosphatase inhibition.
Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
Methylation pattern variation between goats and rats during the onset of puberty.
Novel homozygous AIRE mutation in a German patient with severe APECED.
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application.
Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control.
Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methanesulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic.
NOX4 Pathway as a Source of Selective Insulin Resistance and Responsiveness.
Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.
Optimization of extraction parameters of PTP1? (protein tyrosine phosphatase 1?), inhibitory polyphenols, and anthocyanins from Zea mays L. using response surface methodology (RSM).
P66Shc expression in diabetic rat retina.
Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder.
Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus.
Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551.
Potential Inhibitors of Protein Tyrosine Phosphatase (PTP1B) Enzyme: Promising Target for Type-II Diabetes Mellitus.
Potential Utility of Sodium Selenate as an Adjunct to Metformin in Treating Type II Diabetes Mellitus in Rats: A Perspective on Protein Tyrosine Phosphatase.
Prediction of future rheumatoid arthritis.
Protein tyrosine Phosphatase (PTP1B): A promising Drug Target against life threatening ailments.
Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus.
Protein Tyrosine Phosphatase 1B inhibitors: a novel therapeutic strategy for the management of type 2 diabetes mellitus.
Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.
Protein tyrosine phosphatase 1B, a major regulator of leptin-mediated control of cardiovascular function.
Protein tyrosine phosphatase activity in insulin-resistant rodent Psammomys obesus.
Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.
Protein tyrosine phosphatase regulation in fibroblasts from patients with an insulin receptor gene mutation.
Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling.
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction.
PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
PTPN2 gene polymorphisms are associated with type 1 diabetes mellitus in Brazilian subjects?
PTPN22 Single-Nucleotide Polymorphisms in Iranian Patients with Type 1 Diabetes Mellitus.
QSAR Study on a Series of Protein Tyrosine Phosphatase 1B Inhibitors.
Rhododendric acid A, a new ursane-type PTP1B inhibitor from the endangered plant Rhododendron brachycarpum G. Don.
Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits.
Serum acid phosphatase activity in diabetes mellitus.
Sesquiterpenoids with PTP1B Inhibitory Activity and Cytotoxicity from the Edible Mushroom Pleurotus citrinopileatus.
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population.
Steroidal Alkaloids from Veratrum nigrum Enhance Glucose Uptake in Skeletal Muscle Cells.
Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors.
Synthesis of oleanolic acid derivatives: In vitro, in vivo and in silico studies for PTP-1B inhibition.
T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus.
The -1123G>C Variant of PTPN22 Gene Promoter is Associated with Latent Autoimmune Diabetes in Adult Chinese Hans.
The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity.
The genetic basis of graves' disease.
The IA-2 gene family: homologs in Caenorhabditis elegans, Drosophila and zebrafish.
The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population.
The Role of MKP-5 in Adipocyte-Macrophage Interactions during Obesity.
The Role of PTPN22 C1858T Gene Polymorphism in Diabetes Mellitus Type 1: First Evaluation in Greek Children and Adolescents.
The rs1893217 (T/C) polymorphism in PTPN2 gene is not associated with type 1 diabetes mellitus in subjects from Southern Brazil.
Thyroid autoimmunity in 72 children with type 1 diabetes mellitus: relationship with pancreatic autoimmunity and child growth.
Type 1 diabetes mellitus. Comparison between the association with PTPN22 genotype and the association with ACP1-ADA1 joint genotype.
Validation Of Formylchromane Derivatives As Ptp 1b Inhibitors By Pharmacophore Modeling, Atom Based 3d-Qsar And Docking Studies.
Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research.
[Association of -6735T-->C variant of glucokinase-associated dual-specificity phosphatase 12 gene with type 2 diabetes in Chinese]
[Association of the C1858T polymorphism of the PTPN22 gene with type 1 diabetes]
[Content of different cytokines in the blood of healthy children and their siblings who are either.positive or negative for diabetes-associated autoantibodies (GADA, 1A-2A, IAA)]
[Effects of rare islet autoantibodies on islet function in patients with latent autoimmune diabetes in adults].
[PTP1B inhibitory activities of bromophenol derivatives from algae]
[STUDY OF THE PTPN22 GENE IN CHILDREN WITH TYPE 1 DIABETES MELLITUS IN THE AZERBAIJANI POPULATION].
Diabetes Mellitus, Experimental
Differential regulation of multiple hepatic protein tyrosine phosphatases in alloxan diabetic rats.
Diabetes Mellitus, Type 1
A comparison of serum and EDTA plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet antigen-2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits.
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
A functional polymorphism of Ptpn22 is associated with type 1 diabetes in the BioBreeding rat.
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes.
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
A Haplotype-Based Analysis of the PTPN22 Locus in Type 1 Diabetes.
A novel single nucleotide polymorphism in the protein tyrosine phosphatase N22 gene (PTPN22) is associated with Type 1 diabetes in a Chinese population.
A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes.
A radioligand-binding assay for detecting antibodies specific for proinsulin and insulin using 35S-proinsulin.
A Simple Screening Method for Individuals at Risk of Developing Type 1 Diabetes: Measurement of Islet Cell Autoantibodies (GADA, IA-2A, and IAA) on Dried Capillary Blood Spots Collected on Filter Paper.
A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes.
A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion.
A transmembrane protein-tyrosine phosphatase receptor type C (CD45) exon A point mutation (77 C to G) is not associated with the development of type 1 diabetes mellitus in a German population.
A type 1 diabetes subgroup with a female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene.
A variable degree of autoimmunity in the pedigree of a patient with type 1 diabetes homozygous for the PTPN22 1858T variant.
Absence of avidity maturation of autoantibodies to the protein tyrosine phosphatase-like IA-2 molecule and glutamic acid decarboxylase (GAD65) during progression to type 1 diabetes.
Age-specific levels of diabetes-related GAD and IA-2 antibodies in healthy children and adults.
Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis.
An inverse association between history of childhood eczema and subsequent risk of type 1 diabetes that is not likely to be explained by HLA-DQ, PTPN22, or CTLA4 polymorphisms.
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
An islet-cell protein tyrosine phosphatase is a likely precursor to the 37-kDa autoantigen in type 1 diabetes: human and macaque sequences, tissue distribution, unique and shared epitopes, and predictive autoantibodies.
Analysis of candidate susceptibility genes in canine diabetes.
Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases.
Analysis of PTPN22 C1858T gene polymorphism in cases with type 1 diabetes of Azerbaijan, Northwest Iran.
Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality.
Antibodies to the protein tyrosine phosphatases IAR and IA-2 are associated with progression to insulin-dependent diabetes (IDDM) in first-degree relatives at-risk for IDDM.
Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome.
Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes?
Assessment of type 1 diabetes risk conferred by HLA-DRB1, INS-VNTR and PTPN22 genes using the Bayesian network approach.
Assignment of Ptprn2, the gene encoding receptor-type protein tyrosine phosphatase IA-2beta, a major autoantigen in insulin-dependent diabetes mellitus, to mouse chromosome region 12F.
Association analysis of PTPN22, CTLA4 and IFIH1 genes with type 1 diabetes in Colombian families.
Association between IA-2 autoantibody epitope specificities and age of onset in Japanese patients with autoimmune diabetes.
Association between PTPN22 C1858T and type 1 diabetes: a replication in continental Italy.
Association between the 1858T allele of the protein tyrosine phosphatase nonreceptor type 22 and type 1 diabetes in a Brazilian population.
Association of common type 1 and type 2 diabetes gene variants with latent autoimmune diabetes in adults: A meta-analysis.
Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population.
Association of IL13 with total IgE: evidence against an inverse association of atopy and diabetes.
Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population.
Association of PTPN22 C1858T and CTLA-4 A49G polymorphisms with type 1 diabetes in Croatians.
Association of PTPN22 C1858T polymorphism and type 1 diabetes: a meta-analysis.
Association of PTPN22 gene polymorphism with type 1 diabetes mellitus in Chinese children and adolescents.
Association of PTPN22 haplotypes with type 1 diabetes in the Japanese population.
Association of PTPN22+1858C/T polymorphism with Type 1 diabetes in the North Indian population.
Association of TCR/CD3, PTPN22, CD28 and ZAP70 gene polymorphisms with type 1 diabetes risk in Tunisian population: family based association study.
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Association of the PTPN22 gene (+1858C/T, -1123G/C) polymorphisms with type 1 diabetes mellitus: A systematic review and meta-analysis.
Association of the PTPN22/LYP gene with type 1 diabetes.
Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes.
Association of TNF-?, CTLA4, and PTPN22 polymorphisms with type 1 diabetes and other autoimmune diseases in Brazil.
Association of variants in PTPN22, CTLA-4, IL2-RA, and INS genes with type 1 diabetes in Emiratis.
Association Studies of the GPR103 and BCL2L15 Genes in Autoimmune Thyroid Disease in the Japanese Population.
Associations of GWAS-Supported Non-MHC Genes with Autoimmune Thyroiditis in Patients with Type 1 Diabetes.
Autoantibodies and HLA susceptibility markers in Canadian first-degree relatives of patients with type 1 diabetes.
Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: association with IA-2 and islet cell autoantibodies.
Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2.
Autoantibodies to multiple islet autoantigens in patients with abrupt onset type 1 diabetes and diabetes diagnosed with urinary glucose screening.
Autoantibodies to sympathetic ganglia, GAD, or tyrosine phosphatase in long-term IDDM with and without ECG-based cardiac autonomic neuropathy.
Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of "A+" Subtypes of Ketosis-Prone Diabetes.
Autoantibodies to tissue transglutaminase in patients from eastern India with malnutrition-modulated diabetes mellitus, insulin-dependent diabetes mellitus, and non-insulin-dependent diabetes mellitus.
Autoimmune diagnostics in diabetes mellitus.
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Autoimmunity-Associated PTPN22 Polymorphisms in Latent Autoimmune Diabetes of the Adult Differ from Those of Type 1 Diabetes Patients.
Autonomic function and autoantibodies to autonomic nervous structures, glutamic acid decarboxylase and islet tyrosine phosphatase in adolescent patients with IDDM.
Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility.
BACH2, a candidate risk gene for type 1 diabetes, regulates apoptosis in pancreatic ?-cells via JNK1 modulation and crosstalk with the candidate gene PTPN2.
Biochemical markers of type 1 diabetes: clinical use.
BLOCK-BASED BAYESIAN EPISTASIS ASSOCIATION MAPPING WITH APPLICATION TO WTCCC TYPE 1 DIABETES DATA.
Boswellic extracts and 11-keto-ß-boswellic acids prevent type 1 and type 2 diabetes mellitus by suppressing the expression of proinflammatory cytokines.
CD11a expression and soluble ICAM-1 levels in peripheral blood in high-risk and overt type 1 diabetes subjects.
Change of glutamic acid decarboxylase antibody and protein tyrosine phosphatase antibody in Chinese patients with acute-onset type 1 diabetes mellitus.
Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children.
Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes.
Characterization of the humoral immune response to islet antigen 2 in children with newly diagnosed type 1 diabetes.
Cloning of candidate autoantigen carboxypeptidase H from a human islet library: sequence identity with human brain CPH.
Coincidence of PTPN22 c.1858CC and FCRL3 -169CC genotypes as a biomarker of preserved residual ?-cell function in children with type 1 diabetes.
Combined measurement of diabetes mellitus immunological markers: an assessment of its benefits in adult-onset patients.
Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. The DENIS Study Group. Deutsche Nikotinamid Interventions-Studie.
Comparison of IA-2 with IA-2beta and with six other members of the protein tyrosine phosphatase family: recognition of antigenic determinants by IDDM sera.
Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 diabetes in a family based study.
Conjugation of Antisense Oligonucleotides to PEGylated Carbon Nanotubes Enables Efficient Knockdown of PTPN22 in T Lymphocytes.
Conserved epitopes in the protein tyrosine phosphatase family of diabetes autoantigens.
Contribution of PTPN22, CD28, CTLA-4 and ZAP-70 variants to the risk of type 1 diabetes in Tunisians.
Cord blood insulinoma-associated protein 2 autoantibodies are associated with increased risk of type 1 diabetes in the population-based Diabetes Prediction in Skåne study.
Course of islet autoantibody titers during Ig-immunoadsorption in a patient with newly diagnosed type 1 diabetes.
COVID-19 infection as a trigger for new-onset type 1 diabetes in a susceptible individual - or just coincidence?
CRISPR-Cas9-Mediated Modification of the NOD Mouse Genome With Ptpn22R619W Mutation Increases Autoimmune Diabetes.
Cross reactivity between IA-2 and phogrin/IA-2beta in binding of autoantibodies in IDDM.
CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry.
Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKC?/p66Shc axis and activation of FOXO-3a.
Daily vegetable intake during pregnancy negatively associated to islet autoimmunity in the offspring-The ABIS study.
Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes.
Deletion of the secretory vesicle proteins IA-2 and IA-2{beta} disrupts circadian rhythms of cardiovascular and physical activity.
Dense-core vesicle proteins IA-2 and IA-2{beta} affect renin synthesis and secretion through the {beta}-adrenergic pathway.
Detection of autoantibodies to the diabetes-associated antigen IA-2 by a sensitive enzyme-linked immunosorbent assay.
Developmental expression and localization of IA-2 mRNA in mouse neuroendocrine tissues.
Dietary risk factors for the emergence of type 1 diabetes-related autoantibodies in 21/2 year-old Swedish children.
Differences in prevalence of antibodies to GAD and IA-2 and their titers at diagnosis in children with slowly and rapidly progressive forms of type 1 diabetes.
Different modulation of Ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice.
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population.
Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies.
Disease-associated autoantibodies during pregnancy and at birth in families affected by type 1 diabetes.
Disruption of the transmembrane dense core vesicle proteins IA-2 and IA-2beta causes female infertility.
Distinct genetic and immunological features in patients with onset of IDDM before and after age 40.
Disturbances in the secretion of neurotransmitters in IA-2/IA-2beta null mice: changes in behavior, learning and lifespan.
Do non-HLA genes influence development of persistent islet autoimmunity and type 1 diabetes in children with high-risk HLA-DR,DQ genotypes?
Does the relative risk for type 1 diabetes conferred by HLA-DQ, INS, and PTPN22 polymorphisms vary with maternal age, birth weight, or cesarean section?
Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children.
Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes.
Effect of the PTPN22 and INS Risk Genotypes on the Progression to Clinical Type 1 Diabetes After the Initiation of ?-cell Autoimmunity.
Effects of Non-HLA Gene Polymorphisms on Development of Islet Autoimmunity and Type 1 Diabetes in a Population With High-Risk HLA-DR,DQ Genotypes.
Engineering and expression of the intracellular domain of insulinoma-associated tyrosine phosphatase (IA-2ic), a type 1 diabetes autoantigen, in plants.
Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis.
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Evidence That HLA Class I and II Associations With Type 1 Diabetes, Autoantibodies to GAD and Autoantibodies to IA-2, Are Distinct.
Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient down-regulation of variant PTPN22 gene in T lymphocytes.
Expression and function of IA-2 family proteins, unique neuroendocrine-specific protein-tyrosine phosphatases.
Expression, characterization, processing and immunogenicity of an insulin-dependent diabetes mellitus autoantigen, IA-2, in Sf-9 cells.
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Fine mapping of diabetes-associated IA-2 specific autoantibodies.
Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients.
Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes.
GADA Titer-Related Risk for Organ-Specific Autoimmunity in LADA Subjects Subdivided according to Gender (NIRAD Study 6).
GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives.
Gammadelta T-cells alterations in the peripheral blood of high risk diabetes type 1 subjects with subclinical pancreatic B-cells impairment.
Genetic Analysis of Adult-Onset Autoimmune Diabetes.
Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes.
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West.
Genetic developments in autoimmune thyroid disease: an evolutionary process.
Genetic differences between type 1 diabetes with and without other autoimmune diseases.
Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes.
Genetic susceptibility to type 1 diabetes.
Genetic Variants of PTPN2 Gene in Chinese Children with Type 1 Diabetes Mellitus.
Genetic Variations of PTPN2 and PTPN22: Role in the Pathogenesis of Type 1 Diabetes and Crohn's Disease.
Genetics of type 1 diabetes in Asian and Caucasian populations.
Genetics of type 1 diabetes: similarities and differences between Asian and Caucasian populations.
Genomic structure and promoter sequence of the insulin-dependent diabetes mellitus autoantigen, IA-2 (PTPRN).
Genotypes of cytosolic low-molecular-weight protein-tyrosine-phosphatase correlate with age at onset of type 1 diabetes in a sex-specific manner.
Glutamic acid decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual beta-cell function and glycemic control in young type 1 diabetic patients.
Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds.
High frequency of diabetes-specific autoantibodies in parents of children with type 1 diabetes. DENIS study group.
High T cell responses to the glutamic acid decarboxylase (GAD) isoform 67 reflect a hyperimmune state that precedes the onset of insulin-dependent diabetes.
HLA-DR, HLA-DQB1 and PTPN22 gene polymorphism: association with age at onset for autoimmune diabetes.
Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes.
Humoral immune response to islet autoantigens in Japanese patients with type 1 diabetes.
IA-2 and IA-2beta: the immune response in IDDM.
IA-2 antibodies--a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group.
IA-2 antibody epitopes and isotypes during the prediabetic process in siblings of children with type 1 diabetes.
IA-2 autoantibodies restricted to the IgG4 subclass are associated with protection from type 1 diabetes.
IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes.
IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus.
IA-2A positivity rate at manifestation of type 1 diabetes mellitus in Slovak children culminates in September.
IA-2beta, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion.
Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes.
Identification and functional analysis of mutations in the hepatocyte nuclear factor-1alpha gene in anti-islet autoantibody-negative Japanese patients with type 1 diabetes.
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment.
Identification of monogenic gene mutations in Japanese subjects diagnosed with type 1B diabetes between >5 and 15.1 years of age.
Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2.
Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2.
In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation.
Increased Plasma Soluble Interleukin-2 Receptor Alpha Levels in Patients With Long-Term Type 1 Diabetes With Vascular Complications Associated With IL2RA and PTPN2 Gene Polymorphisms.
Influence of PTPN22 Allotypes on Innate and Adaptive Immune Function in Health and Disease.
Influence of sex and age at onset on autoantibodies against insulin, GAD65 and IA2 in recent onset type 1 diabetic patients.
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Insulin autoantibody could help to screen latent autoimmune diabetes in adults in phenotypic type 2 diabetes mellitus in Chinese.
Insulin gene profile cycles with season of birth of future diabetic children and their relatives.
Insulin secretion in islets from mice with a double knockout for the dense core vesicle proteins islet antigen-2 (IA-2) and IA-2beta.
Interplay between PTPN22 C1858T polymorphism and cow's milk formula exposure in type 1 diabetes.
Investigation of the vitamin D receptor gene (VDR) and its interaction with protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2) on risk of islet autoimmunity and type 1 diabetes: The Diabetes Autoimmunity Study in the Young (DAISY).
Islet autoantibodies in Latvian subjects with non-insulin-dependent diabetes mellitus: slow-onset type 1 diabetes or polyendocrine autoimmunity?
Islet cell related antibodies and type 1 diabetes associated with echovirus 30 epidemic: a case report.
Joint effects of HLA, INS, PTPN22 and CTLA4 genes on the risk of type 1 diabetes.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice.
Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years.
Low Frequencies of Autoimmunity-Associated PTPN22 Polymorphisms in MODY Patients, Including Those Transiently Expressing Islet Cell Autoantibodies.
Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes.
Lymphoid-specific tyrosine phosphatase (Lyp): a potential drug target for treatment of autoimmune diseases.
Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2.
MDA5 and PTPN2, two candidate genes for type 1 diabetes, modify pancreatic {beta}-cell responses to the viral by-product double stranded RNA.
Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories.
Meta-analysis of the family-based association between the PTPN22 C1858T polymorphism and type 1 diabetes.
Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes.
Molecular cloning and characterization of the human transmembrane protein tyrosine phosphatase homologue, phogrin, an autoantigen of type 1 diabetes.
Molecular mechanisms of autoimmunity.
Monoclonal antibody 76F distinguishes IA-2 from IA-2beta and overlaps an autoantibody epitope.
Multimerization of the protein-tyrosine phosphatase (PTP)-like insulin-dependent diabetes mellitus autoantigens IA-2 and IA-2beta with receptor PTPs (RPTPs). Inhibition of RPTPalpha enzymatic activity.
Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population.
No evidence for association of PTPN22 R620W functional variant C1858T with type 1 diabetes in Asian Indians.
No evidence of autoimmunity in 6-year-old children immunized at birth with recombinant hepatitis B vaccine.
No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies.
Novel homozygous AIRE mutation in a German patient with severe APECED.
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application.
Overexpression of the PTPN22 Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T Cell Activation.
Pancreatic autoantibodies, HLA DR and PTPN22 polymorphisms in first degree relatives of patients with type 1 diabetes and multiethnic background.
Pancreatic T cell protein-tyrosine phosphatase deficiency affects beta cell function in mice.
Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder.
Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood.
Polymorphism rs2476601 in the PTPN22 gene is associated with type 1 diabetes in children from the South Region of Brazil.
Population-based and family-based studies on the protein tyrosine phosphatase non-receptor 22 gene polymorphism and type 1 diabetes: a meta-analysis.
Predicting progression to diabetes in islet autoantibody positive children.
Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers.
Prediction of type 1 diabetes among siblings of affected children and in the general population.
Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study.
Predictive value of human leukocyte antigen class II typing for the development of islet autoantibodies and insulin-dependent diabetes postpartum in women with gestational diabetes.
Preserved Proinsulin Production in Homozygous PTPN 22 C1858T Variant Type 1 Diabetes: A Possible Explanation for Absence of Overt Ketoacidosis Despite Omission of Exogenous Insulin.
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus.
Prevalence of ZnT8 antibody in relation to phenotype and SLC30A8 polymorphism in adult autoimmune diabetes: results from the HUNT study, Norway.
Prevalence, characteristics and diabetes risk associated with transient maternally acquired islet antibodies and persistent islet antibodies in offspring of parents with type 1 diabetes.
Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk.
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Protein tyrosine phosphatase PTPN22 in human autoimmunity.
Protein tyrosine phosphatases and type 1 diabetes: genetic and functional implications of PTPN2 and PTPN22.
PTPN2 gene polymorphisms are associated with type 1 diabetes mellitus in Brazilian subjects?
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
PTPN2, a candidate gene for type 1 diabetes, modulates interferon-gamma-induced pancreatic beta-cell apoptosis.
PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic ?-cell apoptosis via regulation of the BH3-only protein Bim.
PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity.
PTPN22 1858T Allele is Associated with Younger Age at Onset of Type 1 Diabetes and Unrelated to Subsequent Thyroid Autoimmunity.
Ptpn22 and Cd2 Variations Are Associated with Altered Protein Expression and Susceptibility to Type 1 Diabetes in Nonobese Diabetic Mice.
PTPN22 and CTLA-4 Polymorphisms are Associated with Polyglandular Autoimmunity.
PTPN22 and islet-specific autoimmunity: What have the mouse models taught us?
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
PTPN22 Gene Polymorphism (C1858T) Is Associated with Susceptibility to Type 1 Diabetes: A Meta-Analysis of 19,495 Cases and 25,341 Controls.
Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation.
PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits.
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
PTPN22 Silencing in the NOD Model Indicates the Type 1 Diabetes-Associated Allele Is Not a Loss-of-Function Variant.
PTPN22 Single-Nucleotide Polymorphisms in Iranian Patients with Type 1 Diabetes Mellitus.
PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes.
PTPN22, PDCD1 and CYP27B1 polymorphisms and susceptibility to type 1 diabetes in Polish patients.
PTPN22: its role in SLE and autoimmunity.
Regulation of autoimmune and anti-tumour T cell responses by PTPN22.
Regulation of B cell homeostasis by Ptpn22 contributes to type 1 diabetes in NOD mice.
Regulation of the diabetes-associated autoantigen IA-2 in INS-1 pancreatic beta-cells.
Relation between cellular and humoral immunity to islet cell antigens in type 1 diabetes.
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus.
Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis.
Risk genes and autoantibodies in Egyptian children with type 1 diabetes - low frequency of autoantibodies in carriers of the HLA-DRB1*04:05-DQA1*03-DQB1*02 risk haplotype.
Role of C1858T polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian children and adolescents with type 1 diabetes.
Role of PTPN22 in type 1 diabetes and other autoimmune diseases.
Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes.
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
Screening for preclinical type 1 diabetes in a discrete population with an apparent increased disease incidence.
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population.
Sex-specific association of the human PTPN22 1858T-allele with type 1 diabetes.
Shared and distinct genetic variants in type 1 diabetes and celiac disease.
Significance of IA-2 antibody in Japanese type 1 diabetes: its association with GAD antibody.
Single-cell profiling reveals dendritic cell signatures associated with autoimmune inflammation.
Soluble adhesion molecules in Finnish schoolchildren with signs of preclinical type 1 diabetes.
Spontaneous peripheral T-cell responses to the IA-2beta (phogrin) autoantigen in young nonobese diabetic mice.
Stability of proICA512/IA-2 and Its Targeting to Insulin Secretory Granules Require ?4-Sheet-Mediated Dimerization of Its Ectodomain in the Endoplasmic Reticulum.
Strategies for identifying and predicting islet autoantigen T-cell epitopes in insulin-dependent diabetes mellitus.
Susceptibility influence of a PTPN22 haplotype with thyroid autoimmunity in Koreans.
Susceptibility to type 1 diabetes conferred by the PTPN22 C1858T polymorphism in the Spanish population.
Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): Association between a promoter polymorphism and type 1 diabetes in Asian populations.
Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): Association between a promoter polymorphism and type 1 diabetes in Asian populations. American Journal of Medical Genetics 140A:586-593 (2006).
T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
T cell reactivity to DR*0401- and DQ*0302-binding peptides of the putative autoantigen IA-2 in type 1 diabetes.
T-cell epitope analysis on the autoantigen phogrin (IA-2beta) in the nonobese diabetic mouse.
T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents.
T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus.
T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities.
Targeted Deep Sequencing in Multiple-Affected Sibships of European Ancestry Identifies Rare Deleterious Variants in PTPN22 That Confer Risk for Type 1 Diabetes.
Targeted disruption of the IA-2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice.
Temporal trends of HLA, CTLA-4 and PTPN22 genotype frequencies among type 1 diabetes in Continental Italy.
Testing for linkage and association with rheumatoid arthritis a ptpn22 promoter polymorphism reported to be associated and linked with type 1 diabetes in the Caucasian population.
The -1123G>C Variant of PTPN22 Gene Promoter is Associated with Latent Autoimmune Diabetes in Adult Chinese Hans.
The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population.
The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2.
The association between rs1893217, rs478582 in PTPN2 and T1D risk with different diagnosed age, and related clinical characteristics in Chinese Han population.
The association between the PTPN22 1858C>T variant and type 1 diabetes depends on HLA risk and GAD65 autoantibodies.
The association of PTPN22 rs2476601 polymorphism and CTLA-4 rs231775 polymorphism with LADA risks: a systematic review and meta-analysis.
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females.
The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2?, Are Crucial to Autoantibody Binding in Type 1 Diabetes.
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
The genetic basis of graves' disease.
The IA-2 interactome.
The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes.
The Melbourne Pre-Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing.
The Potential Role of PTPN-22 C1858T Gene Polymorphism in the Pathogenesis of Type 1 Diabetes in Saudi Population.
The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes.
The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.
The protein tyrosine phosphatase PTPN22 negatively regulates presentation of immune complex derived antigens.
The PTPN22 1858T allele but not variants in the proximal promoter region of IL-21 gene is associated with the susceptibility to type 1 diabetes and the presence of autoantibodies in a Brazilian cohort.
The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual beta-cell function and worse metabolic control.
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
The PTPN22 C1858T gene variant is associated with proinsulin in new-onset type 1 diabetes.
The PTPN22 promoter polymorphism -1123G>C association cannot be distinguished from the 1858C>T association in a Norwegian rheumatoid arthritis material.
The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity.
The relationship between humoral and cellular immunity to IA-2 in IDDM.
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.
The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation.
The Role of Heat Shock Proteins in Type 1 Diabetes.
The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.
The rs1893217 (T/C) polymorphism in PTPN2 gene is not associated with type 1 diabetes mellitus in subjects from Southern Brazil.
Thyroid autoimmunity in 72 children with type 1 diabetes mellitus: relationship with pancreatic autoimmunity and child growth.
Time-resolved fluorescence imaging in islet cell autoantibody quantitation.
Time-resolved immunofluorometric dual-label assay for simultaneous detection of autoantibodies to GAD65 and IA-2 in children with type 1 diabetes.
Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes.
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Two distinctly HLA-associated contiguous linear epitopes uniquely expressed within the islet antigen 2 molecule are major autoantibody epitopes of the diabetes-specific tyrosine phosphatase-like protein autoantigens.
Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives.
Type 1 diabetes in the BB rat: a polygenic disease.
Type 1 diabetes linked PTPN22 gene polymorphism is associated with the frequency of circulating regulatory T cells.
Type 1 diabetes mellitus. Comparison between the association with PTPN22 genotype and the association with ACP1-ADA1 joint genotype.
Type 1 diabetes-related antibodies in the fetal circulation: prevalence and influence on cord insulin and birth weight in offspring of mothers with type 1 diabetes.
Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.
Vaccinations may induce diabetes-related autoantibodies in one-year-old children.
Women diagnosed with gestational diabetes mellitus do not carry antibodies against minor islet cell antigens.
Young age and HLA markers enhance the risk of progression to type 1 diabetes in antibody-positive siblings of diabetic children.
[Association of the C1858T polymorphism of the PTPN22 gene with type 1 diabetes]
[Content of different cytokines in the blood of healthy children and their siblings who are either.positive or negative for diabetes-associated autoantibodies (GADA, 1A-2A, IAA)]
[IA-2 and anti-GAD antibodies in patients with newly diagnosed type 1 diabetes and their first degree relatives]
[Molecular genetics of autoimmune diabetes.]
[Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies]
[Relevance of the gene variant PTPN22 620W for rheumatology]
[Research progress of several protein tyrosine phosphatases in diabetes.]
[STUDY OF THE PTPN22 GENE IN CHILDREN WITH TYPE 1 DIABETES MELLITUS IN THE AZERBAIJANI POPULATION].
Diabetes Mellitus, Type 2
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population.
25-Hydroxyvitamin D
3D-QSAR Studies on a Series of 2,4-Thiazolidinedione Derivatives: A Self-Organizing Molecular Field Analysis Approach to Design Novel PTP 1B Inhibitors.
4-Quinolone-3-carboxylic acids as cell-permeable inhibitors of protein tyrosine phosphatase 1B.
A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants.
A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes.
A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway.
A P387L variant in protein tyrosine phosphatase-1B (PTP-1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro.
A polysaccharide extract of mulberry leaf ameliorates hepatic glucose metabolism and insulin signaling in rats with type 2 diabetes induced by high fat-diet and streptozotocin.
A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice.
A simple and visible colorimetric method through Zr(4+)-phosphate coordination for the assay of protein tyrosine phosphatase 1B and screening of its inhibitors.
Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans.
Adenine nucleotide-mediated regulation of hepatic PTP1B activity in mouse models of type 2 diabetes.
Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes.
Altered basal and insulin-stimulated phosphotyrosine phosphatase (PTPase) activity in skeletal muscle from NIDDM patients compared with control subjects.
Altered PTPRD DNA methylation associates with restricted adipogenesis in healthy first-degree relatives of Type 2 diabetes subjects.
Amelioration of insulin resistance in diabetic ob/ob mice by a new type of orally active insulin-mimetic vanadyl complex: bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) with VO(S(2)O(2)) coordination mode.
An Integrated Computational Approach for Plant-Based Protein Tyrosine Phosphatase Non-Receptor Type 1 Inhibitors.
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.
An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro.
Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population.
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Antidiabetic and Antioxidant Properties of Alkaloids from Catharanthus roseus (L.) G. Don.
Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice.
Antihyperglycemic effect of Annona squamosa hexane extract in type 2 diabetes animal model: PTP1B inhibition, a possible mechanism of action?
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies.
Association of common type 1 and type 2 diabetes gene variants with latent autoimmune diabetes in adults: A meta-analysis.
Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes.
Association of the PTPN1 gene with type 2 diabetes and insulin resistance.
Association testing of the protein tyrosine phosphatase 1B gene (PTPN1) with type 2 diabetes in 7,883 people.
Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes.
Autoimmunity-Associated PTPN22 Polymorphisms in Latent Autoimmune Diabetes of the Adult Differ from Those of Type 1 Diabetes Patients.
Binding properties of marine bromophenols with human protein tyrosine phosphatase 1B: Molecular docking, surface plasmon resonance and cellular insulin resistance study.
Cellular effects of small molecule PTP1B inhibitors on insulin signaling.
Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update.
Characteristics of the interaction mechanisms of procyanidin B1 and procyanidin B2 with protein tyrosine phosphatase-1B: Analysis by kinetics, spectroscopy methods and molecular docking.
Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors.
Combined Neural Inactivation of SOCS-3 and PTP-1B Reveal Additive, Synergistic, and Factor-Specific Roles in the Regulation of Body Energy Balance.
CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors.
Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach.
Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.
Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP.
Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential.
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Design and Synthesis of Imidazolidine-2,4-Dione Derivatives as Selective Inhibitors by Targeting Protein Tyrosine Phosphatase-1B Over T-Cell Protein Tyrosine Phosphatase.
Design, synthesis, and biological evaluation of novel 2-ethyl-5-phenylthiazole-4-carboxamide derivatives as protein tyrosine phosphatase 1B inhibitors with improved cellular efficacy.
Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes.
Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors.
Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin-enhancing vanadium(IV) and zinc(II) complexes.
Developmental switch from prolonged insulin action to increased insulin sensitivity in protein tyrosine phosphatase 1B-deficient hepatocytes.
Discovery of 2-ethoxy-4-(methoxymethyl)benzamide derivatives as potent and selective PTP1B inhibitors.
Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties.
Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent.
Discovery of novel high potent and cellular active ADC type PTP1B inhibitors with selectivity over TC-PTP via modification interacting with C site.
Discovery of novel inhibitor of human leukocyte common antigen-related phosphatase.
Discovery of Novel PTP1B Inhibitors Derived from the BH3 Domain of Proapoptotic Bcl-2 Proteins with Antidiabetic Potency.
Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity.
Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle.
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Dual targeting of PTP1B and glucosidases with new bifunctional iminosugar inhibitors to address type 2 diabetes.
Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes.
Effects of adenovirus-mediated liver-selective overexpression of protein tyrosine phosphatase-1b on insulin sensitivity in vivo.
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.
Establishment of a cell-based drug screening model for identifying down-regulators of Protein Tyrosine Phosphatase 1B expression.
Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents.
Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: a new insight into its antidiabetic mechanism.
Flavonoids as potent allosteric inhibitors of protein tyrosine phosphatase 1B: molecular dynamics simulation and free energy calculation.
Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2 diabetes in Birmingham, United Kingdom.
Functional genetic variants in the 3'UTR of PTPRD associated with the risk of gestational diabetes mellitus.
Functional properties of Claramine: A novel PTP1B inhibitor and insulin-mimetic compound.
Furanoterpenes, new types of protein tyrosine phosphatase 1B inhibitors, from two Indonesian marine sponges, Ircinia and Spongia spp.
GADA Titer-Related Risk for Organ-Specific Autoimmunity in LADA Subjects Subdivided according to Gender (NIRAD Study 6).
Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes.
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Genetic variants in PTPRD and risk of gestational diabetes mellitus.
Genetic variation in receptor protein tyrosine phosphatase {sigma} is associated with type 2 diabetes in Swedish Caucasians.
Genistein-derivatives from Tetracera scandens stimulate glucose-uptake in L6 myotubes.
Haplo-Insufficiency of the Insulin Receptor in the presence of a splice-site mutation in Ppp2r2a results in a novel di-genic mouse model of type 2 diabetes.
High-Resolution PTP1B Inhibition Profiling Combined with HPLC-HRMS-SPE-NMR for Identification of PTP1B Inhibitors from Miconia albicans.
Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2',3,3'-Tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS db Mice.
Hypoglycemic mechanism of a novel proteoglycan, extracted from Ganoderma lucidum, in hepatocytes.
Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGFbeta/Smad2 signaling.
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).
Identification and characterization of potent and selective inhibitors targeting protein tyrosine phosphatase 1B (PTP1B).
Identification of Autoantibody Negative Autoimmune Type 2 Diabetes Patients.
Identification of Cyanidin-3-arabinoside Extracted from Blueberry as a Selective Protein Tyrosine Phosphatase 1B Inhibitor.
Identification of lipid-like salicylic acid-based derivatives as potent and membrane-permeable PTP1B inhibitors.
Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling.
Improved glucose-stimulated insulin secretion by intra-islet inhibition of protein-tyrosine phosphatase 1B expression in rats fed a high-fat diet.
In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
In silico modeling of protein tyrosine phosphatase 1B inhibitors with cellular activity.
In silico modelling and molecular dynamics simulation studies of thiazolidine based PTP1B inhibitors.
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
In vitro anti-diabetic effect of flavonoids and pheophytins from Allophylus cominia Sw. on the glucose uptake assays by HepG2, L6, 3T3-L1 and fat accumulation in 3T3-L1 adipocytes.
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.
Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum.
Inhibition of protein tyrosine phosphatase 1B by flavonoids: A structure - activity relationship study.
Inhibition of protein tyrosine phosphatase 1B by lignans from Myristica fragrans.
Inhibition of protein tyrosine phosphatase 1B by lupeol and lupenone isolated from Sorbus commixta.
Inhibition of Protein Tyrosine Phosphatase 1B by Prenylated Isoflavonoids Isolated from the Stem Bark of Erythrina addisoniae1.
Inhibition of Protein Tyrosine Phosphatase 1B by Ursane-Type Triterpenes Isolated from Symplocos paniculata.
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
Inhibitors for proteins endowed with catalytic and non-catalytic activity which recognize pTyr.
Inhibitors of protein tyrosine phosphatase 1B (PTP1B).
Inhibitory Effects of Secondary Metabolites from the Lichen Stereocaulon evolutum on Protein Tyrosine Phosphatase 1B.
Insight into the PTP1B Inhibitory Activity of Arylbenzofurans: An In Vitro and In Silico Study.
Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity.
Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
Islet autoantibodies in Latvian subjects with non-insulin-dependent diabetes mellitus: slow-onset type 1 diabetes or polyendocrine autoimmunity?
Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes.
Kinetics and molecular docking studies of pimarane-type diterpenes as protein tyrosine phosphatase (PTP1B) inhibitors from Aralia continentalis roots.
Lack of association between polymorphisms in the gene encoding protein tyrosine phosphatase 1B (PTPN1) and risk of Type 2 diabetes.
Lack of association of PTPN1 gene polymorphisms with type 2 diabetes in south Indians.
Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years.
LMW-PTP modulates glucose metabolism in cancer cells.
Low Frequencies of Autoimmunity-Associated PTPN22 Polymorphisms in MODY Patients, Including Those Transiently Expressing Islet Cell Autoantibodies.
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus.
Measuring gene-gene interaction using Kullback-Leibler divergence.
Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
Missense mutation of Pro387Leu in protein tyrosine phosphatase-1B (PTP-1B) is not associated with type 2 diabetes in a Chinese Han population.
New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting ?-glucosidase and the PTP-1B signaling pathway.
New prenylated flavanones from Erythrina abyssinica with Protein tyrosine phosphatase 1B (PTP1B) inhibitory activity.
Norathyriol reverses obesity- and high-fat-diet-induced insulin resistance in mice through inhibition of PTP1B.
Novel heteroaryl phosphonicdiamides PTPs inhibitors as anti-hyperglycemic agents.
Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking.
Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control.
Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methanesulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic.
NOX4 Pathway as a Source of Selective Insulin Resistance and Responsiveness.
Oleanane triterpenes as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Camellia japonica.
Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.
Optimization of extraction parameters of PTP1? (protein tyrosine phosphatase 1?), inhibitory polyphenols, and anthocyanins from Zea mays L. using response surface methodology (RSM).
p66Shc, a multifaceted protein linking Erk signalling, glucose metabolism, and oxidative stress.
Palmitate action to inhibit glycogen synthase and stimulate protein phosphatase 2A increases with risk factors for type 2 diabetes.
Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus.
Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551.
Phloridzin Acts as an Inhibitor of Protein-Tyrosine Phosphatase MEG2 Relevant to Insulin Resistance.
Polymorphisms in the glucokinase-associated, dual-specificity phosphatase 12 (DUSP12) gene under chromosome 1q21 linkage peak are associated with type 2 diabetes.
Polymorphisms within the protein tyrosine phosphatase 1B (PTPN1) gene promoter: functional characterization and association with type 2 diabetes and related metabolic traits.
Positive Association Between Type 2 Diabetes Risk Alleles Near CDKAL1 and Reduced Birthweight in Chinese Han Individuals.
PPAR-?2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China.
Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).
Protein tyrosine phosphatase 1B (PTP1B) inhibitory constituents from the aerial parts of Tradescantia spathacea Sw.
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Protein tyrosine phosphatase 1B inhibitors for diabetes.
Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus.
Protein Tyrosine Phosphatase 1B inhibitors: a novel therapeutic strategy for the management of type 2 diabetes mellitus.
Protein tyrosine phosphatase 1B inhibitory activity of amentoflavone and its cellular effect on tyrosine phosphorylation of insulin receptors.
Protein tyrosine phosphatase 1B inhibitory by dammaranes from Vietnamese Giao-Co-Lam tea.
Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.
Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.
Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities.
Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity.
Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.
Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population.
Protein tyrosine phosphatase regulation in fibroblasts from patients with an insulin receptor gene mutation.
Protein tyrosine phosphatase-1B in diabetes.
Protein tyrosine phosphatase-1B modulates pancreatic ?-cell mass.
Protein tyrosine phosphatases as potential therapeutic targets.
Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling.
Protein tyrosine phosphatases: the quest for negative regulators of insulin action.
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
Protein-tyrosine phosphatase 1B substrates and metabolic regulation.
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance.
PTP1B and TC-PTP: regulators of transformation and tumorigenesis.
PTP1B and TCPTP: Non-redundant phosphatases in insulin signaling and glucose homeostasis.
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice.
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery.
PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta).
PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity.
PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 - 2014).
PTP1B inhibitory effect of abietane diterpenes isolated from Salvia miltiorrhiza.
PTP1B inhibitory effects of tridepside and related metabolites isolated from the Antarctic lichen Umbilicaria antarctica.
PTP1B Inhibitory Secondary Metabolites from Marine-Derived Fungal Strains Penicillium spp. and Eurotium sp.
PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
PTPRD silencing by DNA hypermethylation decreases insulin receptor signaling and leads to type 2 diabetes.
QSAR Studies of PTP1B Inhibitors: Recent Advances and Perspectives.
Quantitative evaluation of PTPN22 copy number variation by digital droplet PCR and association with type 2 diabetes risk.
Reactions of 1,3-Diketones with a Dipeptide Isothiazolidin-3-one: Toward Agents That Covalently Capture Oxidized Protein Tyrosine Phosphatase 1B.
Recent advances in protein tyrosine phosphatase 1B inhibitors.
Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes.
Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes.
Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice.
Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice.
Replication study for the association of rs391300 in SRR and rs17584499 in PTPRD with susceptibility to type 2 diabetes in a Japanese population.
Rhododendric acid A, a new ursane-type PTP1B inhibitor from the endangered plant Rhododendron brachycarpum G. Don.
Role of protein tyrosine phosphatase-1B in diabetes and obesity.
Screening and identification of potential PTP1B allosteric inhibitors using in silico and in vitro approaches.
Sensitivity of protein tyrosine phosphatase activity to the redox environment, cytochrome C, and microperoxidase.
Sesquiterpenoids with PTP1B Inhibitory Activity and Cytotoxicity from the Edible Mushroom Pleurotus citrinopileatus.
SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes.
Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance.
Steroidal Alkaloids from Veratrum nigrum Enhance Glucose Uptake in Skeletal Muscle Cells.
Structure determination of T cell protein-tyrosine phosphatase.
Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors.
Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues.
Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: a three-dimensional quantitative structure-activity relationship study using self-organizing molecular field analysis approach.
Synthesis and biological evaluation of 4,4-dimethyl lithocholic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B.
Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors.
Synthesis and biological evaluation of novel N-aryl-?-(benzoazol-2-yl)-sulfanylalkanamides as dual inhibitors of ?-glucosidase and protein tyrosine phosphatase 1B.
Synthesis of triazole-linked beta-C-glycosyl dimers as inhibitors of PTP1B.
Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors.
Synthesis, In Vitro Evaluation and Molecular Docking of the 5-Acetyl-2-aryl-6-hydroxybenzo[b]furans against Multiple Targets Linked to Type 2 Diabetes.
T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice.
Technology evaluation: ISIS-113715, Isis.
The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity.
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
The mechanism of allosteric inhibition of protein tyrosine phosphatase 1B.
The protein tyrosine phosphatase receptor type f (PTPRF) locus is associated with coronary artery disease in type 2 diabetes.
The Role of MKP-5 in Adipocyte-Macrophage Interactions during Obesity.
The role of protein-tyrosine phosphatase 1B in integrin signaling.
The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding.
The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.
The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates.
The two faces of PTP1B in cancer.
Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors.
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Type 2 diabetes risk gene Dusp8 regulates hypothalamic Jnk signaling and insulin sensitivity.
Tyrosine phosphatase 1B and leptin receptor genes and their interaction in type 2 diabetes.
Ursolic acid derivatives as potential antidiabetic agents: In vitro, in vivo, and in silico studies.
Using yeast to screen for inhibitors of protein tyrosine phosphatase 1B.
Validation Of Formylchromane Derivatives As Ptp 1b Inhibitors By Pharmacophore Modeling, Atom Based 3d-Qsar And Docking Studies.
Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus.
Vindogentianine, a hypoglycemic alkaloid from Catharanthus roseus (L.) G. Don (Apocynaceae).
Virtual screening, optimization, and identification of a novel specific PTP-MEG2 inhibitor with potential therapy for T2DM.
Water-molecule network and active-site flexibility of apo protein tyrosine phosphatase 1B.
Zinc Supplementation and Strength Exercise in Rats with Type 2 Diabetes: Akt and PTP1B Phosphorylation in Nonalcoholic Fatty Liver.
[Association of -6735T-->C variant of glucokinase-associated dual-specificity phosphatase 12 gene with type 2 diabetes in Chinese]
[Effects of rare islet autoantibodies on islet function in patients with latent autoimmune diabetes in adults].
[Multivariate logistic regression analysis on the risk factors of type 2 diabetes mellitus]
[PTP1B inhibitory activities of bromophenol derivatives from algae]
[Research progress of several protein tyrosine phosphatases in diabetes.]
[Role of protein tyrosine phosphatase 1B in the type 2 diabetes and obesity]
[Search for Protein Tyrosine Phosphatase 1B Inhibitors from Marine Organisms and Induced Production of New Fungal Metabolites by Modulating Culture Methods].
[Single nucleotide polymorphism of protein tyrosine phosphatase 1B (PTP-1B) gene. Clinical implications in type 2 diabetes]
Diabetes, Gestational
Expression of Dual-Specificity Phosphatase 9 in Placenta and Its Relationship with Gestational Diabetes Mellitus.
Functional genetic variants in the 3'UTR of PTPRD associated with the risk of gestational diabetes mellitus.
Genetic variants in PTPRD and risk of gestational diabetes mellitus.
MiR-6869-5p Induces M2 Polarization by Regulating PTPRO in Gestational Diabetes Mellitus.
Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood.
[Association of DUSP9 gene polymorphisms with gestational diabetes mellitus].
Diabetic Angiopathies
N?-carboxymethyllysine-mediated endoplasmic reticulum stress promotes endothelial cell injury through Nox4/MKP-3 interaction.
Diabetic Cardiomyopathies
Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene.
Diabetic cardiomyopathy: a "cardiac stem cell disease" involving p66Shc, an attractive novel molecular target for heart failure therapy.
Expression changes of mitogen-activated protein kinase phosphatase-1 (MKP-1) in myocardium of streptozotocin-induced diabetic rats.
Diabetic Foot
Chinese medicine ulcer oil promotes the healing of diabetic foot ulcers.
Diabetic Ketoacidosis
Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual ?-cell function 1 year after diagnosis of type 1 diabetes.
Diabetic Nephropathies
A novel biphenyl compound, VMNS2e, ameliorates streptozotocin induced diabetic nephropathy in rats.
Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc.
Author Correction: p66Shc: A novel biomarker of tubular oxidative injury in patients with diabetic nephropathy.
Diabetic nephropathy: Role of podocyte SHP-1 in hyperglycaemic memory.
Dioscorea zingiberensis ameliorates diabetic nephropathy by inhibiting NLRP3 inflammasome and curbing the expression of p66Shc in high-fat diet/streptozotocin-induced diabetic mice.
Expression of SHP-1 Induced by Hyperglycemia Prevents Insulin Actions in Podocytes.
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Hyperglycaemia Stress-Induced Renal Injury is Caused by Extensive Mitochondrial Fragmentation, Attenuated MKP1 Signalling, and Activated JNK-CaMKII-Fis1 Biological Axis.
Inactivation of p66Shc Decreases Afferent Arteriolar KATP Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats.
Increased SHP-1 protein expression by high glucose levels reduces nephrin phosphorylation in podocytes.
Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients.
p66Shc mediates high-glucose and angiotensin II-induced oxidative stress renal tubular injury via mitochondrial-dependent apoptotic pathway.
p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K/Akt/mTOR pathway.
p66Shc-mediated hydrogen peroxide production impairs nephrogenesis causing reduction of number of glomeruli.
p66Shc: A novel biomarker of tubular oxidative injury in patients with diabetic nephropathy.
Perturbations in mitochondrial dynamics by p66Shc lead to renal tubular oxidative injury in human diabetic nephropathy.
PKC? promotes high glucose induced renal tubular oxidative damage via regulating activation and translocation of p66Shc.
Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc.
Protein phosphatases and podocyte function.
PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy.
PTPN2 improved renal injury and fibrosis by suppressing STAT-induced inflammation in early diabetic nephropathy.
Targeting VE-PTP phosphatase protects the kidney from diabetic injury.
The CREB/KMT5A complex regulates PTP1B to modulate high glucose-induced endothelial inflammatory factor levels in diabetic nephropathy.
The PKC?-p66shc-NADPH oxidase pathway plays a crucial role in diabetic nephropathy.
TRIM18-Regulated STAT3 Signaling Pathway via PTP1B Promotes Renal Epithelial-Mesenchymal Transition, Inflammation, and Fibrosis in Diabetic Kidney Disease.
Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
VE-PTP phosphatase: a new target for diabetic kidney disease.
Diabetic Neuropathies
Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn of rats attenuated diabetic neuropathic pain.
Diabetic Retinopathy
9-cis-retinoic acid improves sensitivity to platelet-derived growth factor-BB via RXR? and SHP-1 in diabetic retinopathy.
?A1-crystallin regulates glucose metabolism and mitochondrial function in mouse retinal astrocytes by modulating PTP1B activity.
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy.
Adaptor Protein p66Shc: A Link Between Cytosolic and Mitochondrial Dysfunction in the Development of Diabetic Retinopathy.
P66Shc expression in diabetic rat retina.
Vasoinhibins: novel inhibitors of ocular angiogenesis.
[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]
Digestive System Neoplasms
[Acid phosphatase activity and non-specific esterase D of alpha-naphthyl acetate in the lymphocytes of patients with digestive system neoplasms after surgical treatment]
Distemper
Accumulation of Extracellular Matrix in Advanced Lesions of Canine Distemper Demyelinating Encephalitis.
Diverticulitis
RNA-seq implicates deregulation of the immune system in the pathogenesis of diverticulitis.
Down Syndrome
CD26 surface antigen expression on peripheral blood T lymphocytes from children with Down's syndrome (trisomy 21).
Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome.
Phosphotyrosine phosphatase activity and haematologic changes in Down's syndrome patients.
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
Ductus Arteriosus, Patent
PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
Duodenal Ulcer
Helicobacter Pylori CagA and Gastric Carcinogenesis.
[CagA tyrosine phosphorylation motif structure and SHP-2 binding ability of Helicobacter pylori studied in stomach cancer and duodenal ulcer cell lines]
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Dwarfism
Murine models of life span extension.
Study on pathogenic genes of dwarfism disease by next-generation sequencing.
Dysentery, Amebic
Acid phosphatase activity in the intestinal wall in experimental amebic colitis.
Dyskinesias
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Dyslipidemias
ACP1 genotype, glutathione reductase activity, and riboflavin uptake affect cardiovascular risk in the obese.
Cyclocarya paliurus Leaves Tea Improves Dyslipidemia in Diabetic Mice: A Lipidomics-Based Network Pharmacology Study.
Deletion of Protein Tyrosine Phosphatase 1b Improves Peripheral Insulin Resistance and Vascular Function in Obese, Leptin-Resistant Mice via Reduced Oxidant Tone.
Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies.
Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2',3,3'-Tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS db Mice.
Increased hepatic FAT/CD36, PTP1B and decreased HNF4A expression contributes to dyslipidemia associated with ethanol-induced liver dysfunction: Rescue effect of ginger extract.
Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine.
Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population.
Eczema
An inverse association between history of childhood eczema and subsequent risk of type 1 diabetes that is not likely to be explained by HLA-DQ, PTPN22, or CTLA4 polymorphisms.
Ellis-Van Creveld Syndrome
Genomic structure and localization of the human protein phosphatase 2A BRgamma regulatory subunit.
Encephalitis
A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation.
Encephalomyelitis
A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.
Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice.
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.
CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis.
MAP kinase phosphatase 2 deficient mice develop attenuated experimental autoimmune encephalomyelitis through regulating dendritic cells and T cells.
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.
Protein tyrosine phosphatase ? regulates autoimmune encephalomyelitis development.
Resistance to experimental autoimmune encephalomyelitis and impaired T cell priming by dendritic cells in Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 mutant mice.
The P66Shc/mitochondrial permeability transition pore pathway determines neurodegeneration.
Encephalomyelitis, Autoimmune, Experimental
A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.
Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice.
CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis.
MAP kinase phosphatase 2 deficient mice develop attenuated experimental autoimmune encephalomyelitis through regulating dendritic cells and T cells.
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Resistance to experimental autoimmune encephalomyelitis and impaired T cell priming by dendritic cells in Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 mutant mice.
The P66Shc/mitochondrial permeability transition pore pathway determines neurodegeneration.
Encephalomyelitis, Venezuelan Equine
Acid phosphatase activity in mouse brain infected with Venezuelan equine encephalomyelitis virus.
Enchondromatosis
Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.
Endocrine System Diseases
[Latent forms of adult-onset autoimmune polyglandular syndrome: diagnosis and management of patients].
Endometrial Hyperplasia
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability.
Endometrial Neoplasms
Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer.
Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1.
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Immunohistochemical Detection of Hematopoietic Cell-specific Protein-Tyrosine Phosphatase (Tyrosine Phosphatase SHP-1) in a Series of Endometrioid and Serous Endometrial Carcinoma.
Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
miR-152 inhibits proliferation of human endometrial cancer cells via inducing G2/M phase arrest by suppressing CDC25B expression.
MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A.
Phosphotyrosine phosphatase-activity in membranes from endometrial carcinoma.
PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells.
Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
Prolactin receptor-linked tyrosine-phosphorylation of membrane-proteins is mediated by GTP-binding protein in endometrial carcinoma and endometrium.
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Regulation of PTP1D mRNA by peptide growth factors in the human endometrial cell line HEC-1-A.
Relationship Between CIP2A and Endometrium Cancer.
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.
The Highly Recurrent PP2A A?-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer.
Endometriosis
An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression.
Association between PTPN22 and endometriosis.
Association of p53 codon 72 polymorphism with endometriosis.
Association of the protein tyrosine phosphatase non-receptor 22 polymorphism (PTPN22) with endometriosis: a meta-analysis.
Elevated phosphatase of regenerating liver 3 (PRL-3) promotes cytoskeleton reorganization, cell migration and invasion in endometrial stromal cells from endometrioma.
Identification of global transcriptome abnormalities and potential biomarkers in eutopic endometria of women with endometriosis: A preliminary study.
Phosphatase of regenerating liver-3: a novel and promising marker in human endometriosis.
PRL-3 Is Involved in Estrogen- and IL-6-Induced Migration of Endometrial Stromal Cells From Ectopic Endometrium.
PTPN22 C1858T polymorphism in women with endometriosis.
SMURF1-mediated ubiquitylation of SHP-1 promotes cell proliferation and invasion of endometrial stromal cells in endometriosis.
The association of PTPN22 polymorphism with endometriosis: effect of genetic and clinical factors.
The effect of ACP1, ADA6 and PTPN22 genetic polymorphisms on the association between p53 codon 72 polymorphism and endometriosis.
Endotoxemia
Development and Characterization of an Endotoxemia Model in Zebra Fish.
Hepatocyte SHP-1 is a Critical Modulator of Inflammation During Endotoxemia.
Mitogen-activated protein kinase phosphatase-1 expression in macrophages is controlled by lymphocytes during macrophage activation.
Mitogen-activated protein kinase phosphatase-1 inhibits myocardial TNF-? expression and improves cardiac function during endotoxemia.
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
Protein phosphatase 2A contributes to the cardiac dysfunction induced by endotoxemia.
Enteritis
Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-?B activation.
Supplementation exogenous bile acid improved growth and intestinal immune function associated with NF-?B and TOR signalling pathways in on-growing grass carp (Ctenopharyngodon idella): Enhancement the effect of protein-sparing by dietary lipid.
Vitamin A deficiency suppresses fish immune function with differences in different intestinal segments: the role of transcriptional factor NF-?B and p38 mitogen-activated protein kinase signalling pathways.
Enterocolitis, Necrotizing
Single nucleotide polymorphisms in the dual specificity phosphatase genes and risk of necrotizing enterocolitis in premature infant.
Enterotoxemia
[Activity of various enzymes of the intestinal mucosa in spontaneous colibacteriosis in pigs]
Enterovirus Infections
Enterovirus infection can induce immune responses that cross-react with beta-cell autoantigen tyrosine phosphatase IA-2/IAR.
Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans.
Enzootic Bovine Leukosis
Bovine leukemia virus transmembrane protein gp30 physically associates with the down-regulatory phosphatase SHP-1.
Eosinophilia
Endothelial cell PTP1B regulates leukocyte recruitment during allergic inflammation.
Expression on human eosinophils of CD148: a membrane tyrosine phosphatase. Implications in the effector function of eosinophils.
Histological and histochemical examinations of the myocardium of rats kept on low-magnesium diet and treated with cyclophosphamide.
The expression of cancerous inhibitor protein phosphatase 2A in chronic rhinosinusitis with nasal polyps.
Ependymoma
Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
Epidermodysplasia Verruciformis
The Protein Tyrosine Phosphatase H1 PTPH1 Supports Proliferation of Keratinocytes and is a Target of the Human Papillomavirus Type 8 E6 Oncogene.
Epilepsies, Myoclonic
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Epilepsy
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Genetic diagnoses in epilepsy: The impact of dynamic exome analysis in a pediatric cohort.
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
Large De Novo Microdeletion in Epilepsy with Intellectual and Developmental Disabilities, with a Systems Biology Analysis.
Nucleophosmin/B23 activates Aurora A at the centrosome through phosphorylation of serine 89.
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Transient expression of the mitogen-activated protein kinase phosphatase MKP-1 (3CH134/ERP1) in the rat brain after limbic epilepsy.
Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex.
Upregulated SHP-2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model.
Epilepsy, Post-Traumatic
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Epilepsy, Temporal Lobe
Upregulated SHP-2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model.
Epstein-Barr Virus Infections
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.
Erectile Dysfunction
Argirein alleviates corpus cavernosum dysfunction by suppressing pro-inflammatory factors p66Shc and ER stress chaperone Bip in diabetic rats.
Escherichia coli Infections
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Knockout of MAPK Phosphatase-1 Exaggerates Type I IFN Response during Systemic Escherichia coli Infection.
Esophageal Achalasia
Association of IL10 promoter polymorphisms with idiopathic achalasia.
Gender-specific association of the PTPN22 C1858T polymorphism with achalasia.
Esophageal Neoplasms
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Artesunate induces apoptosis and inhibits growth of Eca109 and Ec9706 human esophageal cancer cell lines in vitro and in vivo.
CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers.
Expression and significance of CDC25B, PED/PEA-15 in esophageal carcinoma.
Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells.
Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery.
Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
Esophageal Squamous Cell Carcinoma
Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma.
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC.
Loss of Protein Tyrosine Phosphatase Receptor J Expression Predicts an Aggressive Clinical Course in Patients with Esophageal Squamous Cell Carcinoma.
Methylation and expression of PTPN22 in esophageal squamous cell carcinoma.
MiR-214 inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by targeting CDC25B.
MiR-450a-5p inhibits autophagy and enhances radiosensitivity by targeting dual-specificity phosphatase 10 in esophageal squamous cell carcinoma.
Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery.
p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy.
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer.
Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma.
PTP1B Contributes to Calreticulin-Induced Metastatic Phenotypes in Esophageal Squamous Cell Carcinoma.
PTP1B up-regulates EGFR expression by dephosphorylating MYH9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma.
PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.
Retraction of: Single Nucleotide Polymorphisms in the PTPN1 Gene Are Associated with Susceptibility to Esophageal Squamous Cell Carcinoma: A Case-Control Study in Inner Mongolia, China; DOI: 10.1089/gtmb.2016.0194.
Single Nucleotide Polymorphisms in the PTPN1 Gene Are Associated with Susceptibility to Esophageal Squamous Cell Carcinoma: A Case-Control Study in Inner Mongolia, China.
The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Essential Hypertension
Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension.
Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population.
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Single nucleotide polymorphisms in protein tyrosine phosphatase 1beta (PTPN1) are associated with essential hypertension and obesity.
Exanthema
Asthma and allergic symptoms and type 1 diabetes-related autoantibodies in 2.5-yr-old children.
Exostoses
SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates.
Exostoses, Multiple Hereditary
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Extranodal Extension
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
Eye Burns
[Changes in the acid phosphatase activity of the cornea in the dynamics of a chemical eye burn]
Eye Diseases
Exploring the effect of inhibitor AKB-9778 on VE-PTP by molecular docking and molecular dynamics simulation.
Familial Mediterranean Fever
Lack of the Association of the PTPN22 C1858T Gene Polymorphism With Susceptibility to Familial Mediterranean Fever.
Fanconi Anemia
Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature.
Fasciculation
Chondroitin sulfate proteoglycan phosphacan associates with parallel fibers and modulates axonal extension and fasciculation of cerebellar granule cells.
Receptor tyrosine phosphatases guide vertebrate motor axons during development.
Fatty Liver
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma.
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Polymorphism of Receptor-Type Tyrosine-Protein Phosphatase Delta gene in the development of non-alcoholic fatty liver disease.
Protective Function of Mitogen-Activated Protein Kinase Phosphatase 5 in Aging- and Diet-Induced Hepatic Steatosis and Steatohepatitis.
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling.
PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis.
Structure-functional implications of longevity protein p66Shc in health and disease.
Fatty Liver, Alcoholic
The p66Shc protein controls redox signaling and oxidation-dependent DNA damage in human liver cells.
The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
Favism
Small amplicons high resolution melting analysis (SA-HRMA) allows successful genotyping of acid phosphatase 1 (ACP1) polymorphisms in the Italian population.
Fetal Death
Early fetal death associated with compound heterozygosity for Noonan syndrome-causative PTPN11 mutations.
Fetal Diseases
Activation of oxidative stress signaling that is implicated in apoptosis with a mouse model of diabetic embryopathy.
Fetal Growth Retardation
Intrauterine Growth Restriction Affects Hippocampal Dual Specificity Phosphatase 5 Gene Expression and Epigenetic Characteristics.
Intrauterine growth restriction alters T-lymphocyte cell number and dual specificity phosphatase 1 levels in the thymus of newborn and juvenile rats.
Fibroma
Phosphoamino acid phosphatases in normal and cancerous tissues of the human uterus, cervix and ovary.
Fibromatosis, Gingival
Association of mutation in PTPN14 gene and gingival fibromatosis with distinctive facies: a novel finding in whole exome sequencing.
Fibrosarcoma
Attenuation of p38 MAPK activity upon contact inhibition in fibroblasts.
ERK regulation upon contact inhibition in fibroblasts.
The fibrinogen-like globe of tenascin-C mediates its interactions with neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta.
Filariasis
Study of human and parasitic factors in relation to bancroftian filariasis in Egypt.
Fluorosis, Dental
MAP kinase phosphatase MKP-1 regulates p-ERK1/2 signaling pathway with fluoride treatment.
Moderating Role of TSHR and PTPN22 Gene Polymorphisms in Effects of Excessive Fluoride on Thyroid: a School-Based Cross-Sectional Study.
Food Hypersensitivity
Asthma and allergic symptoms and type 1 diabetes-related autoantibodies in 2.5-yr-old children.
Foot Ulcer
Chinese medicine ulcer oil promotes the healing of diabetic foot ulcers.
Fractures, Spontaneous
Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
Fragile X Syndrome
Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).
The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition.
Frontotemporal Dementia
Extended investigation of tau and mutation screening of other candidate genes on chromosome 17q21 in a Swedish FTDP-17 family.
Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations.
Funnel Chest
Giant Cell Lesions in Noonan Syndrome: Case Report and Review of The Literature.
Ganglion Cysts
Induction of protein tyrosine phosphatase epsilon transcripts during NGF-induced neuronal differentiation of PC12D cells and during the development of the cerebellum.
Ganglioneuroma
Recurrent ganglioneuroma in PTPN11-associated Noonan syndrome: A case report and literature review.
Gastritis
Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression.
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori.
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Gastritis, Atrophic
SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis.
The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa.
The effects of cure of Helicobacter pylori infection on the signal transduction of gastric epithelial cells.
Gastroenteritis
Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes.
Gastrointestinal Diseases
Cytotoxicity and recognition of receptor-like protein tyrosine phosphatases, RPTPalpha and RPTPbeta, by Helicobacter pylori m2VacA.
Dynamics of the WPD loop of the Yersinia protein tyrosine phosphatase.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Gastrointestinal Neoplasms
Molecular cloning of a human transmembrane-type protein tyrosine phosphatase and its expression in gastrointestinal cancers.
Sap-1/PTPRH activity is regulated by reversible dimerization.
Gastrointestinal Stromal Tumors
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Gaucher Disease
ACID PHOSPHATASE ACTIVITY OF SERUM, THROMBOCYTES AND ERYTHROCYTES IN A JUVENILE FORM OF GAUCHER'S DISEASE.
Acid phosphatase in Gaucher's disease.
Age dependency of serum acid phosphatase in controls and Gaucher patients.
Biochemical properties of the tartrate-resistant acid phosphatase activity in Gaucher disease.
Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate.
Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
Multiple forms of acid phosphatase activity in Gaucher's disease.
Sodium taurocholate effect on beta-glucosidase activity: a new approach for identification of Gaucher disease using the synthetic substrate and leucocytes.
The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis.
Genetic Diseases, Inborn
Chondrosarcoma in Metachondromatosis: A Rare Case Report.
Clinical exome sequencing: results from 2819 samples reflecting 1000 families.
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
Engineering Cell-Permeable Proteins through Insertion of Cell-Penetrating Motifs into Surface Loops.
Fetal hydrops and the Incremental yield of Next generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis.
Metachondromatosis: more than just multiple osteochondromas.
Noonan Syndrome and Related Disorders: Genetics and Pathogenesis.
Noonan syndrome and related disorders: genetics and pathogenesis.
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.
Severe aortic valvar stenosis in familial Noonan syndrome with mutation of the PTPN11 gene.
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
The regulation of male fertility by the PTPN11 tyrosine phosphatase.
Giant Cell Arteritis
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis.
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.
PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis.
Giant Cell Tumor of Bone
Localization of acid phosphatase activity in a giant cell tumor of bone.
Giant Cell Tumors
Localization of acid phosphatase activity in a giant cell tumor of bone.
New model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone.
Glaucoma
Early remodelling of the extracellular matrix proteins tenascin-C and phosphacan in retina and optic nerve of an experimental autoimmune glaucoma model.
Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to Improved Retinal Ganglion Cell Neuroprotection.
Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma.
Glaucoma, Open-Angle
Extracellular Matrix Remodeling in the Retina and Optic Nerve of a Novel Glaucoma Mouse Model.
Glioblastoma
A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells.
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase micro.
A role for receptor tyrosine phosphatase zeta in glioma cell migration.
CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
ceRNA Network Analysis Shows That lncRNA CRNDE Promotes Progression of Glioblastoma Through Sponge mir-9-5p.
Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha.
Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma.
Contactin is expressed in human astrocytic gliomas and mediates repulsive effects.
Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies.
Differential induction of glioblastoma migration and growth by two forms of pleiotrophin.
Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.
Do phosphatase of regenerating liver-3, matrix metalloproteinases-2, matrix metalloproteinases-9, and epidermal growth factor receptor-1 predict response to therapy and survival in glioblastoma multiforme?
Dual-specificity phosphatase (DUSP6) in human glioblastoma: epithelial-to-mesenchymal transition (EMT) involvement.
Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
Euxanthone represses the proliferation, migration, and invasion of glioblastoma cells by modulating STAT3/SHP-1 signaling.
Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas.
Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche.
Functional comparison of long and short splice forms of RPTPbeta: implications for glioblastoma treatment.
Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway.
Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines.
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-? pathway.
miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma.
Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Molecular Basis of the Interaction of the Human Protein Tyrosine Phosphatase Non-receptor Type 4 (PTPN4) with the Mitogen-activated Protein Kinase p38?.
Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.
Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Nox4 redox regulation of PTP1B contributes to the proliferation and migration of glioblastoma cells by modulating tyrosine phosphorylation of coronin-1C.
Ouabain elicits human glioblastoma cells apoptosis by generating reactive oxygen species in ERK-p66SHC-dependent pathway.
Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma.
Peptides targeting the PDZ domain of PTPN4 are efficient inducers of glioblastoma cell death.
Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma.
PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis.
PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways.
Prognosis of patients with multifocal glioblastoma: a case-control study.
Prognostic significance of CDC25B expression in gliomas.
Proteasome mediated degradation of CDC25C and Cyclin B1 in Demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest.
Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia.
Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo.
Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R?2-Promoted Invasion and Metastasis in Cancer Cells.
Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration.
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.
PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3? and PTP1B in situ.
PTPRM methylation induced by FN1 promotes the development of glioblastoma by activating STAT3 signalling.
Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy.
RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo.
Role of GalNAc4S-6ST in astrocytic tumor progression.
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
SHP2 regulates proliferation and tumorigenicity of glioma stem cells.
Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma.
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
The antiproliferative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway.
The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1.
The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth.
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.
Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation.
Glioma
?1,6 GlcNAc branches-modified protein tyrosine phosphatase Mu attenuates its tyrosine phosphatase activity and promotes glioma cell migration through PLC?-PKC pathways.
A novel PTPRZ1-ETV1 fusion in gliomas.
A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells.
A role for receptor tyrosine phosphatase zeta in glioma cell migration.
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Activation of Jak-Stat and MAPK2 pathways by oncostatin M leads to growth inhibition of human glioma cells.
An alternative role for the src-homology-domain-containing phosphotyrosine phosphatase (SH-PTP2) in regulating epidermal-growth-factor-dependent cell growth.
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.
Cadmium specifically induces MKP-1 expression via the glutathione depletion-mediated p38 MAPK activation in C6 glioma cells.
CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples.
Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma.
Constitutive CHK1 expression drives a pSTAT3-CIP2A circuit that promotes glioblastoma cell survival and growth.
Cytochemical distribution of acid phosphatase activity in gliomas cultured in vitro.
Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism.
Dynamin 2 mediates PDGFR?-SHP-2-promoted glioblastoma growth and invasion.
EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Endoplasmic Reticulum Stress Contributes to Indomethacin-Induced Glioma Apoptosis.
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
Expression of a receptor protein tyrosine phosphatase in human glial tumors.
Genomic changes in progression of low-grade gliomas.
Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
Gossypin Induces G2/M Arrest in Human Malignant Glioma U251 Cells by the Activation of Chk1/Cdc25C Pathway.
High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response.
Incidence and prognostic value of multiple gene promoter methylations in gliomas.
Inhibition of SHP-2 promotes radiosensitivity in glioma.
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Interactions of the chondroitin sulfate proteoglycan phosphacan, the extracellular domain of a receptor-type protein tyrosine phosphatase, with neurons, glia, and neural cell adhesion molecules.
Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue.
Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility.
Linc00152 promotes malignant progression of glioma stem cells by regulating miR-103a-3p/FEZF1/CDC25A pathway.
LncRNA TCONS_00004099-derived microRNA regulates oncogenesis through PTPRF in gliomas.
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Lysosomal enzymic activity of astroglial cells.
Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation.
MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
miR-34c inhibits proliferation of glioma by targeting PTP1B.
Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
Novel LncRNA OXCT1-AS1 indicates poor prognosis and contributes to tumorigenesis by regulating miR-195/CDC25A axis in glioblastoma.
PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis.
Potent and selective inhibition of T-cell protein tyrosine phosphatase (TCPTP) by a dinuclear copper(II) complex.
PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells.
Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p.
Prognostic significance of CDC25B expression in gliomas.
Proteasome mediated degradation of CDC25C and Cyclin B1 in Demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest.
Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility.
Protein tyrosine phosphatases in glioma biology.
PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
Pten signaling in gliomas.
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
PTPH1 promotes tumor growth and metastasis in human glioma.
PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.
PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3? and PTP1B in situ.
PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
PTPN2 induced by inflammatory response and oxidative stress contributed to glioma progression.
PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.
Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo.
Reduced expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the Aalpha and Abeta subunit genes.
Reduced phosphorylation of Stat3 at Ser-727 mediated by Casein Kinase 2 - Protein Phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells.
Roles and potential clinical applications of intermediate filament proteins in brain tumors.
Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells.
SHP-2 Activating Mutation Promotes Malignant Biological Behaviors of Glioma Cells.
SHP-2-upregulated ZEB1 is important for PDGFR?-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma.
Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation.
The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2.
The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas.
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas.
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth.
UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of Glioma via Regulating STAT3 Signaling Pathway.
Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme.
Glioma, Subependymal
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
Glomerulonephritis
Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B.
Expression of B cell receptor-associated signaling molecules in human lupus.
Glomerular epithelial-mesenchymal transdifferentiation in pauci-immune crescentic glomerulonephritis.
Oxidative stress-inducible protein tyrosine phosphatase in glomerulonephritis.
Proliferating and migrating mesangial cells responding to injury express a novel receptor protein-tyrosine phosphatase in experimental mesangial proliferative glomerulonephritis.
PTPRQ is a novel phosphatidylinositol phosphatase that can be expressed as a cytoplasmic protein or as a subcellularly localized receptor-like protein.
Glomerulonephritis, IGA
Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy.
Glomerulosclerosis, Focal Segmental
Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis.
Podocyte proteins in Galloway-Mowat syndrome.
Glucagonoma
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment.
Profile and differential expression of protein tyrosine phosphatases in mouse pancreatic islet tumor cell lines.
Glucose Intolerance
A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree.
Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action.
Combined Neural Inactivation of SOCS-3 and PTP-1B Reveal Additive, Synergistic, and Factor-Specific Roles in the Regulation of Body Energy Balance.
Disruption of the transmembrane dense core vesicle proteins IA-2 and IA-2beta causes female infertility.
Effects of vitamin D and resveratrol on metabolic associated markers in liver and adipose tissue from SAMP8 mice.
Elevated expression and activity of protein-tyrosine phosphatase 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats.
Endocrine regulation of energy metabolism by the skeleton.
Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2 diabetes in Birmingham, United Kingdom.
Genetic variation in receptor protein tyrosine phosphatase {sigma} is associated with type 2 diabetes in Swedish Caucasians.
Insulin secretion in islets from mice with a double knockout for the dense core vesicle proteins islet antigen-2 (IA-2) and IA-2beta.
Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.
Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance.
p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans.
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus.
Protein tyrosine phosphatase 1B and insulin resistance: role of endoplasmic reticulum stress/reactive oxygen species/nuclear factor kappa B axis.
Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice.
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Targeted disruption of the IA-2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice.
To binge or not to binge: Binge drinking disrupts glucose homeostasis by impairing hypothalamic but not liver insulin signaling.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Red cell acid phosphatase activity in carriers of beta-thalassemia trait and glucose-6-phosphate dehydrogenase deficiency.
Glucosephosphate Dehydrogenase Deficiency
Red cell acid phosphatase activity in carriers of beta-thalassemia trait and glucose-6-phosphate dehydrogenase deficiency.
glutamate-5-semialdehyde dehydrogenase deficiency
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Glycogen Storage Disease
Centronuclear myopathy: histochemistry and electron microscopy. Report of two cases.
Glycogen Storage Disease Type II
Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology.
Goiter
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Moderating Role of TSHR and PTPN22 Gene Polymorphisms in Effects of Excessive Fluoride on Thyroid: a School-Based Cross-Sectional Study.
p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
[Changes in the lactate dehydrogenase and alkaline and acid phosphatase activity in the arterial and venous blood serum and thyroid tissue in different forms of goiter]
[Histochemical characteristics of some oxidation-reduction hydrolytic enzymes in different forms of goiter]
Graft vs Host Disease
Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies.
The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.
Gram-Negative Bacterial Infections
Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice.
Gram-Positive Bacterial Infections
Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria.
The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages.
Granular Cell Tumor
Granular cell tumor of the scrotum in a child with Noonan syndrome.
Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11.
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Granuloma
A novel anti-mycobacterial function of mitogen-activated protein kinase phosphatase-1.
T-cell subsets in cutaneous sarcoidosis.
Granulomatosis with Polyangiitis
PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
Graves Disease
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
Analysis of chosen polymorphisms rs2476601 a/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 a/G - TSHR in pathogenesis of autoimmune thyroid diseases in children.
Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population.
Association of PTPN22 haplotypes with Graves' disease.
Association of PTPN22 polymorphism and its correlation with Graves' disease susceptibility in Polish adult population-A preliminary study.
Association of the protein tyrosine phosphatase nonreceptor 22 haplotypes with autoimmune thyroid disease in the Japanese population.
Association Studies of the GPR103 and BCL2L15 Genes in Autoimmune Thyroid Disease in the Japanese Population.
Associations of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms with susceptibility to Graves' disease in a Japanese population.
Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease.
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Genetic developments in autoimmune thyroid disease: an evolutionary process.
Genetic heterogeneity of susceptibility gene in different ethnic populations: refining association study of PTPN22 for Graves' disease in a Chinese Han population.
Genetics of Thyroid Disorders.
Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
Polymorphisms of the genes CTLA4, PTPN22, CD40, and PPARG and their roles in Graves' disease: susceptibility and clinical features.
Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy.
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Protein tyrosine phosphatase PTPN22 in human autoimmunity.
PTPN22 1858 C/T Exon Polymorphism is not Associated with Graves' Disease in Kashmiri population.
PTPN22 and CTLA-4 Polymorphisms are Associated with Polyglandular Autoimmunity.
PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes.
RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease.
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease.
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.
The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis.
Use of Tag single nucleotide polymorphisms (SNPs) to screen PTPN21: no association with Graves' disease.
Hamartoma
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Pathogenic variants of DYNC2H1, KIAA0556, and PTPN11 associated with hypothalamic hamartoma.
Systemic lupus erythematosus in a patient with PTEN hamartoma tumour syndrome.
Hamartoma Syndrome, Multiple
Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas.
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas.
Systemic lupus erythematosus in a patient with PTEN hamartoma tumour syndrome.
The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary re: M. A. Davies, et al., Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res., 8: 1904-1914, 2002.
Hashimoto Disease
Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
Head and Neck Neoplasms
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Intratumor microvessel density in biopsy specimens predicts local response of hypopharyngeal cancer to radiotherapy.
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Overexpression of CDC25A and CDC25B in head and neck cancers.
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
S-Nitrosylation of mitogen activated protein kinase phosphatase-1 suppresses radiation-induced apoptosis.
Hearing Loss
A C-terminal nonsense mutation links PTPRQ with autosomal-dominant hearing loss, DFNA73.
Autosomal Recessive Congenital Sensorineural Hearing Loss due to a Novel Compound Heterozygous PTPRQ Mutation in a Chinese Family.
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Deficit of mitogen-activated protein kinase phosphatase 1 (DUSP1) accelerates progressive hearing loss.
Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability.
Expression of ERK signaling inhibitors Dusp6, Dusp7, and Dusp9 during mouse ear development.
External ear anomalies and hearing impairment in Noonan Syndrome.
First confirmatory study on PTPRQ as an autosomal dominant non-syndromic hearing loss gene.
Hair Bundle Defects and Loss of Function in the Vestibular End Organs of Mice Lacking the Receptor-Like Inositol Lipid Phosphatase PTPRQ.
Identification of a novel compound heterozygous mutation in PTPRQ in a DFNB84 family with prelingual sensorineural hearing impairment.
Identification of Novel PTPRQ and MYO1A Mutations in An Iranian Pedigree with Autosomal Recessive Hearing Loss.
Identification of Two Novel Compound Heterozygous PTPRQ Mutations Associated with Autosomal Recessive Hearing Loss in a Chinese Family.
LEOPARD Syndrome Without Hearing Loss or Pulmonary Stenosis: A Report of 2 Cases.
Molecular and phenotypic spectrum of Noonan syndrome in Chinese patients.
Mutations in PTPRQ are a cause of autosomal-recessive nonsyndromic hearing impairment DFNB84 and associated with vestibular dysfunction.
Nonsense mutation of the stereociliar membrane protein gene PTPRQ in human hearing loss DFNB84.
Novel PTPRQ mutations identified in three congenital hearing loss patients with various types of hearing loss.
Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder.
Rosiglitazone Improves Glucocorticoid Resistance in a Sudden Sensorineural Hearing Loss by Promoting MAP Kinase Phosphatase-1 Expression.
Spectrum and frequencies of non GJB2 gene mutations in Czech patients with early non-syndromic hearing loss detected by gene panel NGS and whole-exome sequencing.
When transcripts matter: delineating between non-syndromic hearing loss DFNB32 and hearing impairment infertile male syndrome (HIIMS).
Whole-exome sequencing identified a novel heterozygous mutation of SALL1 and a new homozygous mutation of PTPRQ in a Chinese family with Townes-Brocks syndrome and hearing loss.
[Case report and diagnosis of Noonan syndrome with multiple lentigines with deafness as its main clinical feature].
Hearing Loss, Sensorineural
A Genome-First Approach to Rare Variants in Dominant Postlingual Hearing Loss Genes in a Large Adult Population.
Autosomal Recessive Congenital Sensorineural Hearing Loss due to a Novel Compound Heterozygous PTPRQ Mutation in a Chinese Family.
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Identification of Two Novel Compound Heterozygous PTPRQ Mutations Associated with Autosomal Recessive Hearing Loss in a Chinese Family.
IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function.
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
Novel PTPRQ mutations identified in three congenital hearing loss patients with various types of hearing loss.
Heart Arrest
Early glycogen synthase kinase-3? and protein phosphatase 2A independent tau dephosphorylation during global brain ischaemia and reperfusion following cardiac arrest and the role of the adenosine monophosphate kinase pathway.
Heart Defects, Congenital
A novel heterozygous MAP2K1 mutation in a patient with Noonan syndrome with multiple lentigines.
Atrioventricular canal defect in patients with RASopathies.
Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes.
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
Germ-line and somatic PTPN11 mutations in human disease.
Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
Noonan syndrome, the SOS1 gene and embryonal rhabdomyosarcoma.
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome.
PTPN11 mutations play a minor role in isolated congenital heart disease.
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Search for Rare Copy-Number Variants in Congenital Heart Defects Identifies Novel Candidate Genes and a Potential Role for FOXC1 in Patients With Coarctation of the Aorta.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
SHP-2 regulates growth factor dependent vascular signalling and function.
The genetics of congenital heart disease: a review of recent developments.
The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Heart Diseases
Association study of PTPN22 C1858T polymorphism in Trypanosoma cruzi infection.
Deletion of low molecular weight protein tyrosine phosphatase (Acp1) protects against stress-induced cardiomyopathy.
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.
Pyrrolo[1,2-a]quinoxal-5-inium salts and 4,5-dihydropyrrolo[1,2-a]quinoxalines: Synthesis, activity and computational docking for protein tyrosine phosphatase 1B.
Heart Failure
Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.
Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene.
Diabetic cardiomyopathy: a "cardiac stem cell disease" involving p66Shc, an attractive novel molecular target for heart failure therapy.
Differential gene expression in skeletal muscle after induction of heart failure: impact of cytokines on protein phosphatase 2A expression.
Distinct signaling functions for Shc isoforms in the heart.
Endothelial deletion of protein tyrosine phosphatase-1B protects against pressure overload-induced heart failure in mice.
Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice.
Exploration the Mechanism of Doxorubicin-Induced Heart Failure in Rats by Integration of Proteomics and Metabolomics Data.
Gene Deletion of Protein Tyrosine Phosphatase 1B Protects Against Sepsis-Induced Cardiovascular Dysfunction and Mortality.
Histone deacetylase 3 suppresses the expression of SHP-1 via deacetylation of DNMT1 to promote heart failure.
Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His.
Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure.
Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.
P66Shc deletion ameliorates oxidative stress and cardiac dysfunction in pressure overload-induced heart failure.
p66Shc links alpha1-adrenergic receptors to a reactive oxygen species-dependent AKT-FOXO3A phosphorylation pathway in cardiomyocytes.
Protein tyrosine phosphatase 1B regulates endothelial endoplasmic reticulum stress; role in endothelial dysfunction.
Protein Tyrosine Phosphatase-1B inactivation limits aging-associated heart failure in mice.
Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
Role of protein tyrosine phosphatase 1B in cardiovascular diseases.
The metabolic behaviour of the lymphocytes from serous effusions in various benign internal diseases.
The NF-kB regulates the SHP-1 expression in monocytes in congestive heart failure.
[New pharmacological approaches in heart failure: should we treat the endothelium?]
Heart Septal Defects, Atrial
A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy.
Case report: Noonan syndrome with multiple giant cell lesions and review of the literature.
The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome.
Heart Septal Defects, Ventricular
Mosaic partial deletion of PTPN12 in a child with interrupted aortic arch type A.
Hemangioblastoma
Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis.
Hemangioma
Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.
Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.
Hemangioma, Cavernous, Central Nervous System
Association of Variants in FCGR2A, PTPN2 and GM-CSF with Cerebral Cavernous Malformation: Potential Biomarkers for Symptomatic Disease.
Protein phosphatase 2a (PP2A) binds within the oligomerization domain of striatin and regulates the phosphorylation and activation of the mammalian Ste20-Like kinase Mst3.
Hemangiosarcoma
A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).
Angiogenesis-related gene mutations drive a subset of angiosarcomas.
Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma.
Recurrent PTPRB and PLCG1 mutations in angiosarcoma.
Hematologic Neoplasms
A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
Aberrant DNA methylation of key genes and Acute Lymphoblastic Leukemia.
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Deficiency in hematopoietic phosphatase ptpn6/Shp1 hyperactivates the innate immune system and impairs control of bacterial infections in zebrafish embryos.
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling.
High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma.
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.
Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation.
Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.
Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells.
Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Noonan Syndrome and Related Disorders: Genetics and Pathogenesis.
Noonan syndrome and related disorders: genetics and pathogenesis.
Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis.
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b.
Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies.
SHP-1 Protein Tyrosine Phosphatase Associates with the Adaptor Protein CrkL.
SHP-2 and myeloid malignancies.
Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2.
Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Structure of the complex of an iminopyridinedione PTP4A3 phosphatase inhibitor with human serum albumin.
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis.
The Fetal Phenotype of Noonan Syndrome Caused by Severe, Cancer-Related PTPN11 Variants.
The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/?-catenin signaling pathway.
The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP.
The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells.
The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
[Expression and Significance of PTPL1 in Hematological Malignan-cies].
[The Biological Function of SHP2 in Human Disease].
Hemochromatosis
Genetic colocalization atlas points to common regulatory sites and genes for hematopoietic traits and hematopoietic contributions to disease phenotypes.
Iron content and acid phosphatase activity in hepatic parenchymal lysosomes of patients with hemochromatosis before and after phlebotomy treatment.
Hemorrhagic Fever, Ebola
Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection.
Hemorrhagic Stroke
[Blood serum enzymatic spectrum in vascular diseases of the brain]
Hemorrhoids
miR-412-5p targets Xpo1 to regulate angiogenesis in hemorrhoid tissue.
Hepatitis
Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A.
Salvianolic acid A preconditioning confers protection against concanavalin A-induced liver injury through SIRT1-mediated repression of p66shc in mice.
[The morphologic basis for the mechanism of increased serum acid phosphatase activity in patients with viral hepatitis]
Hepatitis B
Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma.
Hepatitis B virus X protein impairs ?-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
Hepatitis B virus X protein mutant HBx?127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT.
Molecular basis of the interaction of the human tyrosine phosphatase PTPN3 with the hepatitis B virus core protein.
Protein phosphatase 2A impairs IFN?-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation.
Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
Suppression of hepatitis B viral gene expression by protein-tyrosine phosphatase PTPN3.
[Effect of PTPRD rs2279776 gene and interaction with hepatitis B virus mutations on the risk of hepatocellular carcinoma].
[Functional-metabolic activity of the mononuclear phagocyte system of the blood, liver, spleen and skin in children with hepatitis B]
Hepatitis B, Chronic
Association of PTPN22 gene polymorphisms with chronic hepatitis B virus infection in Chinese Han population.
Hepatitis C
Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.
Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line.
Hepatitis C Virus Induced miR200c Down Modulates FAP-1, a Negative Regulator of Src Signaling and Promotes Hepatic Fibrosis.
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A.
Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-{gamma} production.
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.
Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.
Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase.
Protein phosphatase 2A impairs IFN?-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation.
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients.
PTPN22 C1858T polymorphism and the outcome of hepatitis C virus infection.
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein.
Hepatitis C, Chronic
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A.
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.
Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.
PTPN22 C1858T polymorphism and the outcome of hepatitis C virus infection.
Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C.
Hepatitis, Alcoholic
Hepatic protein-tyrosine phosphatase 1B disruption and pharmacological inhibition attenuate ethanol-induced oxidative stress and ameliorate alcoholic liver disease in mice.
Hepatitis, Autoimmune
77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link.
Association of STAT4, TGF?1, SH2B3 and PTPN22 polymorphisms with autoimmune hepatitis.
C77G mutation in protein tyrosine phosphatase CD45 gene and autoimmune hepatitis.
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Hepatoblastoma
Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation.
In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas.
The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
Hepatolenticular Degeneration
Electron probe microanalysis of liver in Wilson's disease. Simultaneous assay for copper and for lead deposited by acid phosphatase activity in lysosomes.
LIVER CELL LYSOSOMES IN WILSON'S DISEASE: ACID PHOSPHATASE ACTIVITY BY LIGHT AND ELECTRON MICROSCOPY.
Studies on the pathogenesis of hepatolenticular degeneration. I. Acid phosphatase activity in copper-loaded rat livers.
Hepatomegaly
Biological action of lantadene C, a new hepatotoxicant from Lantana camara var. aculeata.
Effect of polymorphic crystal forms of lantana toxins on icterogenic action in guinea pigs.
Molecular structure, polymorphism, and toxicity of lantadene A, the pentacyclic triterpenoid from the hepatotoxic plant Lantana camara.
Hernias, Diaphragmatic, Congenital
Exome sequencing of fetuses with congenital diaphragmatic hernia supports a causal role for NR2F2, PTPN11, and WT1 variants.
Herpes Simplex
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Role of Cellular Phosphatase cdc25C in Herpes Simplex Virus 1 Replication.
Search for varicella zoster virus and herpes simplex virus-1 in normal human cerebral arteries.
The ESCRT-II Subunit EAP20/VPS25 and the Bro1 Domain Proteins HD-PTP and BROX Are Individually Dispensable for Herpes Simplex Virus 1 Replication.
The Interaction of Herpes Simplex Virus 1 Regulatory Protein ICP22 with the cdc25C Phosphatase Is Enabled In Vitro by Viral Protein Kinases US3 and UL13.
Herpes Zoster
ACTH Modulates PTP-PEST Activity and Promotes Its Interaction With Paxillin.
The localisation of acid phosphatase activity changes in lysosomes in the adrenal zona fasciculata of intact and hypophysectomized rats following ACTH administration.
Hirschsprung Disease
Downregulation of Protein Tyrosine Phosphatase Receptor Type R Accounts for the Progression of Hirschsprung Disease.
Histiocytic Sarcoma
Activating Mutations in PTPN11 and KRAS in Canine Histiocytic Sarcomas.
Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
PTPN11 mutations in canine and human disseminated histiocytic sarcoma.
Histiocytosis
an aggressive multifocal primary CNS histiocytosis with PTPN11 (Shp2) mutation.
Response to trametinib of histiocytosis with an activating PTPN11 mutation.
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Histiocytosis, Langerhans-Cell
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
histone deacetylase deficiency
Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis.
Hodgkin Disease
A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells.
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Acid phosphatase activity in monocytes and sera of patients with Hodgkin's disease.
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.
Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.
PTPN1 Is Recurrently Mutated in Lymphoid Cancers.
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
The PTP1B mutant PTP1B?2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
[Granulocyte acid phosphatase activity during the course of chronic myeloid leukemia and Hodgkin's disease]
[Granulocyte acid phosphatase activity in patients with Hodgkin's disease]
HTLV-I Infections
Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells.
Huntington Disease
Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
Calpain and STriatal-Enriched protein tyrosine Phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model.
MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.
Mitogen-Activated Protein Kinase Phosphatase (MKP)-1 in Nervous System Development and Disease.
Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
Hydrocephalus
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
External hydrocephalus as a prenatal feature of noonan syndrome.
Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus.
PTPRQ as a potential biomarker for idiopathic normal pressure hydrocephalus.
Hydrocephalus, Normal Pressure
PTPRQ as a potential biomarker for idiopathic normal pressure hydrocephalus.
Hydrops Fetalis
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.
PTPN11 gene mutation associated with abnormal gonadal determination.
Hydrothorax
Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.
Hyperalgesia
BDNF contributes to the development of neuropathic pain by induction of spinal long-term potentiation via SHP2 associated GluN2B-containing NMDA receptors activation in rats with spinal nerve ligation.
CSF-CN contributes to cancer-induced bone pain via the MKP-1-mediated MAPK pathway.
Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn of rats attenuated diabetic neuropathic pain.
Mitogen-activated protein kinase phosphatase-3 (MKP-3) in the surgical wound is necessary for the resolution of postoperative pain in mice.
Prooxidant-induced c-Src/nuclear factor kappa B-coupled signalling in sensory ganglia mediates cutaneous hyperalgesia.
Propentofylline reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatase-1: An experimental study in a rat model of acute incisional pain.
Shp-1 dephosphorylates TRPV1 in dorsal root ganglion neurons and alleviates CFA-induced inflammatory pain in rats.
Spinal mitogen-activated protein kinase phosphatase-3 (MKP-3) is necessary for the normal resolution of mechanical allodynia in a mouse model of acute postoperative pain.
Spinal SHP2 Contributes to Exaggerated Incisional Pain in Adult Rats Subjected to Neonatal and Adult Incisions via PI3K.
Hypercholesterolemia
Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction.
Epigenetic upregulation of p66shc mediates low-density lipoprotein cholesterol-induced endothelial cell dysfunction.
Mechanism of attenuation of diabetes mellitus and hypercholesterolemia induced vascular endothelial dysfunction by protein tyrosine phosphatase inhibition.
P66Shc mediates increased platelet activation and aggregation in hypercholesterolemia.
Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models.
[Prescription of Jingdan Yimin for treatment of metabolic syndrome].
Hyperglycemia
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy.
Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivity.
Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice.
Cardiac mitochondrial dysfunction during hyperglycemia-The role of oxidative stress and p66Shc signaling.
Diterpenes from seeds of Phalaris canariensis and their PTP1B inhibitory activity and hypoglycemic effects in streptozotocin-induced diabetic mice.
Effects of PPAR-gamma knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats.
Expression of SHP-1 Induced by Hyperglycemia Prevents Insulin Actions in Podocytes.
Glomerular VEGF resistance induced by PKC?/SHP-1 activation and contribution to diabetic nephropathy.
Growth Factor Deregulation and Emerging Role of Phosphatases in Diabetic Peripheral Artery Disease.
High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation.
Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2',3,3'-Tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS db Mice.
Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction.
Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.
Hypomethylation of the promoter of the catalytic subunit of protein phosphatase 2A in response to hyperglycemia.
Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition.
Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling.
Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice.
Integrin-associated protein association with SRC homology 2 domain containing tyrosine phosphatase substrate 1 regulates igf-I signaling in vivo.
IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function.
Leptin Signaling in the Arcuate Nucleus Reduces Insulin's Capacity to Suppress Hepatic Glucose Production in Obese Mice.
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
MAP Kinase Phosphatase 3 (MKP-3) Deficient Mice Are Resistant to Diet Induced-Obesity.
MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
Obesity Increases Mitogen-Activated Protein Kinase Phosphatase-3 Levels in the Hypothalamus of Mice.
P66Shc-Induced MicroRNA-34a Causes Diabetic Endothelial Dysfunction by Downregulating Sirtuin1.
Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes.
Protective effects of Salvia miltiorrhiza injection against learning and memory impairments in streptozotocin-induced diabetic rats.
Protein tyrosine phosphatase 1B is impaired in skeletal muscle of diabetic Psammomys obesus.
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance.
PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat.
Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice.
Regulation of malonyl-CoA-acyl carrier protein transacylase network in umbilical cord blood affected by intrauterine hyperglycemia.
Somatostatin protects photoreceptor cells against high glucose-induced apoptosis.
Hyperhomocysteinemia
Attenuation of hyperhomocysteinemia induced vascular dementia by sodium orthovanadate perhaps via PTP1B: Pertinent downstream outcomes.
Hyperinsulinism
Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice.
Chronic insulin treatment suppresses PTP1B function, induces increased PDGF signaling, and amplifies neointima formation in the balloon-injured rat artery.
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation.
Hyperinsulinemia induces insulin resistance and immune suppression via Ptpn6/Shp1 in zebrafish.
Insulin-inducible changes in the relative ratio of PTP1B splice variants.
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis.
Type 1 diabetes-related antibodies in the fetal circulation: prevalence and influence on cord insulin and birth weight in offspring of mothers with type 1 diabetes.
Hyperlipidemias
P66Shc and vascular endothelial function.
Hyperostosis
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved?
Hyperparathyroidism
[Blood serum alkaline and acid phosphatase activity in different forms of hyperparathyroidism]
Hypersensitivity
A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development.
A putative P-type ATPase, Apt1, is involved in stress tolerance and virulence in Cryptococcus neoformans.
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Arabidopsis MAP kinase phosphatase 1 and its target MAP kinases 3 and 6 antagonistically determine UV-B stress tolerance, independent of the UVR8 photoreceptor pathway.
Atf1 is a target of the mitogen-activated protein kinase Pmk1 and regulates cell integrity in fission yeast.
Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation.
Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling.
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76K.
Human Leukocyte Antigen (DR1)-DQB1*0501 and (DR15)-DQB1*0602 Haplotypes Are Associated with Humoral Responses to Early Food Allergens in Children.
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn of rats attenuated diabetic neuropathic pain.
Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.
Loss of STEP61 couples disinhibition to N-methyl-d-aspartate receptor potentiation in rodent and human spinal pain processing.
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms.
MiR-101 promotes pain hypersensitivity in rats with chronic constriction injury via the MKP-1 mediated MAPK pathway.
Mitogen activated protein kinase phosphatase-1 prevents the development of tactile sensitivity in a rodent model of neuropathic pain.
Mitogen-activated protein kinase phosphatase-3 (MKP-3) in the surgical wound is necessary for the resolution of postoperative pain in mice.
Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4.
Positive regulation of c-Jun N-terminal kinase and TNF-alpha production but not histamine release by SHP-1 in RBL-2H3 mast cells.
SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis.
Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway.
Spontaneous eosinophilic nasal inflammation in a genetically-mutant mouse: comparative study with an allergic inflammation model.
Striatal-enriched phosphatase 61 inhibited the nociceptive plasticity in spinal cord dorsal horn of rats.
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Ventromedial hypothalamus-specific Ptpn1 deletion exacerbates diet-induced obesity in female mice.
[Acid phosphatase activity in peripheral blood cells in streptococcal allergy of the immediate type]
[Classification and etiology of hyperthyroidism].
Hypertelorism
B56?-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Giant Cell Lesions in Noonan Syndrome: Case Report and Review of The Literature.
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Hypertension
Activity of two enzymes associated with apoptosis and cell aging in arterial hypertension.
Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate.
Aortic cholesterol esterase and other lysosomal enzyme activities in DOCA-salt, renal and spontaneous hypertension in the rat.
Association of genetic variants with chronic kidney disease in Japanese individuals with or without hypertension or diabetes mellitus.
Berberine attenuates pulmonary arterial hypertension via protein phosphatase 2A signaling pathway both in vivo and in vitro.
Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin neurons reduces neurogenic control of blood pressure and protects mice from leptin- and sympatho-mediated hypertension.
Differences in Oxidative Stress Status and Expression of MKP-1 in Dorsal Medulla of Transgenic Rats with Altered Brain Renin-Angiotensin System.
Distribution of the number of false discoveries in large-scale family-based association testing with application to the association between PTPN1 and hypertension and obesity.
Extracellular signal-regulated kinase 1/2 activation, via downregulation of mitogen-activated protein kinase phosphatase 1, mediates sex differences in desoxycorticosterone acetate-salt hypertension vascular reactivity.
Hypertension: Role of p66Shc in renal vascular dysfunction.
In vivo vascular rarefaction and hypertension induced by dexamethasone are related to phosphatase PTP1B activation not endothelial metabolic changes.
Induction of mitogen-activated protein kinase phosphatase-1 during acute hypertension.
MKP-1 is a target of miR-210 and mediate the negative regulation of miR-210 inhibitor on hypoxic hPASMC proliferation.
Molecular pathways of aging and hypertension.
Naringenin prevents pregnancy-induced hypertension via suppression of JAK/STAT3 signalling pathway in mice.
p53 impairs endothelium-dependent vasomotor function through transcriptional upregulation of p66shc.
p66Shc-mediated hydrogen peroxide production impairs nephrogenesis causing reduction of number of glomeruli.
Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population.
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells. Evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension.
Renal Mechanisms of Association between Fibroblast Growth Factor 1 and Blood Pressure.
Renal protein phosphatase 2A activity and spontaneous hypertension in rats.
Replication of Genome-Wide Association Signals of Type 2 Diabetes in Han Chinese in a Prospective Cohort.
The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension.
Trichostatin A Modulates Angiotensin II-induced Vasoconstriction and Blood Pressure Via Inhibition of p66shc Activation.
Tyrosine phosphatase 1B and leptin receptor genes and their interaction in type 2 diabetes.
VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetes.
VE-PTP inhibition: a novel therapeutic target for hypertension in diabetic patients.
[Determination of dehydrogenase and acid phosphatase activity in the lymphocytes in hypertension and vasorenal hypertension]
Hypertension, Portal
Defective mitogen-activated protein kinase (ERK2) signaling in gastric mucosa of portal hypertensive rats: potential therapeutic implications.
Hypertension, Pulmonary
Dual-specificity phosphatase (DUSP) genetic variants predict pulmonary hypertension in patients with bronchopulmonary dysplasia.
Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.
MKP-1 is a target of miR-210 and mediate the negative regulation of miR-210 inhibitor on hypoxic hPASMC proliferation.
The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension.
Hyperthyroidism
Genotypes in relation to phenotypic appearance and exposure to environmental factors in Graves hyperthyroidism.
RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease.
Specific activities of seminal vesicular phosphomonoesterases and Mg2+-,Ca2+- and Na+/K(+)-adenosine triphosphatases in hypo- and hyperthyroid albino rats.
[Cytochemical properties of peripheral blood neutrophils in patients with hyperthyroidism]
Hypertriglyceridemia
Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats.
Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression.
Hypocalcemia
Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.
Hypoglycemia
Acute induction of gene expression in brain and liver by insulin-induced hypoglycemia.
Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: a three-dimensional quantitative structure-activity relationship study using self-organizing molecular field analysis approach.
Hypogonadism
Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3?-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.
Hypoparathyroidism
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Hypophosphatasia
Normal circulating acid phosphatase activity in hypophosphatasia.
Persistently raised serum acid phosphatase activity in a patient with hypophosphatasia: electrophoretic and molecular weight characterisation as type 5.
Hypopigmentation
PP2A and DUSP6 are involved in sphingosylphosphorylcholine-induced hypopigmentation.
Hypoproteinemia
A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy.
Hypospadias
[Clinical and genetic analysis of Noonan syndrome in 20 children].
Hypotension
Deficiency of mitogen-activated protein kinase phosphatase-1 results in iNOS-mediated hypotension in response to low-dose endotoxin.
Differences in Oxidative Stress Status and Expression of MKP-1 in Dorsal Medulla of Transgenic Rats with Altered Brain Renin-Angiotensin System.
MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock.
MAP Kinase Phosphatase-1 and Septic Shock.
MAP kinase phosphatase-1, a critical negative regulator of the innate immune response.
Hypothyroidism
A phenome-wide association study of 26 mendelian genes reveals phenotypic expressivity of common and rare variants within the general population.
Familial autoimmune thyroid disease and PTPN-22.
Novel associations for hypothyroidism include known autoimmune risk loci.
Hypoxia, Brain
Effect of hypoxia on the expression and activity of mitogen-activated protein (MAP) kinase-phosphatase-1 (MKP-1) and MKP-3 in neuronal nuclei of newborn piglets: the role of nitric oxide.
Effects of Src Kinase Inhibition on Expression of Protein Tyrosine Phosphatase 1B after Brain Hypoxia in a Piglet Animal Model.
Mitogen-Activated Protein Kinase Phosphatase (MKP)-1 in Nervous System Development and Disease.
Hypoxia-Ischemia, Brain
The cytochemistry of anoxic and anoxic-ischemic encephalopathy in rats. I. Alterations in neuronal lysosomes identified by acid phosphatase activity.
Idiopathic Pulmonary Fibrosis
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
Role of Mitogen activated-kinase (MAPK)-phosphatase (MKP)-5 in pulmonary fibrosis.
IgA Deficiency
A functional PTPN22 polymorphism associated with several autoimmune diseases is not associated with IgA deficiency in the Spanish population.
IgA Vasculitis
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Immune System Diseases
CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry.
Genetic determinants of diabetes are similarly associated with other immune-mediated diseases.
Massively parallel sequencing of the mouse exome to accurately identify rare, induced mutations: an immediate source for thousands of new mouse models.
Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Infarction, Middle Cerebral Artery
Brevican and phosphacan expression and localization following transient middle cerebral artery occlusion in the rat.
Motheaten (me/me) mice deficient in SHP-1 are less susceptible to focal cerebral ischemia.
Infections
'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection.
A focused library of protein tyrosine phosphatase inhibitors.
A haplotype at intron 8 of PTPRT gene is associated with resistance to Brucella infection in Argentinian creole goats.
A novel anti-mycobacterial function of mitogen-activated protein kinase phosphatase-1.
A translocated protein tyrosine phosphatase of Pseudomonas syringae pv. tomato DC3000 modulates plant defence response to infection.
Abnormal IFN-gamma-dependent immunoproteasome modulation by Trypanosoma cruzi-infected macrophages.
Acid phosphatase activity in hemolymph of the migratory grasshopper, Melanoplus sanguinipes, during Beauveria bassiana infection.
Adenovirus sequesters phosphorylated STAT1 at viral replication centers and inhibits STAT dephosphorylation.
An ecto-protein tyrosine phosphatase of Entamoeba histolytica induces cellular detachment by disruption of actin filaments in HeLa cells.
Anaplasma phagocytophilum AnkA is tyrosine-phosphorylated at EPIYA motifs and recruits SHP-1 during early infection.
Anti-tumor necrosis factor ? treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.
Association between diversity in the Src homology 2 domain--containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer.
Association of PTPN22 gene polymorphisms with chronic hepatitis B virus infection in Chinese Han population.
Association study of PTPN22 C1858T polymorphism in Trypanosoma cruzi infection.
Associations of a PTPN11 G/A polymorphism at intron 3 with Helicobactor pylori seropositivity, gastric atrophy and gastric cancer in Japanese.
Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence.
Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective?
B Cell-Intrinsic Expression of Interferon Regulatory Factor 1 Supports Chronic Murine Gammaherpesvirus 68 Infection.
CD40-Modulated Dual-Specificity Phosphatases MAPK Phosphatase (MKP)-1 and MKP-3 Reciprocally Regulate Leishmania major Infection.
Cdc25A phosphatase suppresses apoptosis induced by serum deprivation.
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Celiac disease as an autoimmune condition.
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
Change in the isoenzyme composition of acid phosphatase in murine peritoneal macrophages exposed to or infected with Trypanosoma cruzi.
Characterization and kinetic analysis of protein tyrosine phosphatase-H2 from Microplitis demolitor bracovirus.
Characterization of a protein tyrosine phosphatase as a host factor promoting baculovirus replication in silkworm, Bombyx mori.
Characterization of myeloid-specific peroxidase, keratin 8, and dual specificity phosphatase 1 as innate immune genes involved in the resistance of crucian carp (Carassius auratus gibelio) to Cyprinid herpesvirus 2 infection.
Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth.
Cis-2 and trans-2-eisocenoic fatty acids are novel inhibitors for Mycobacterium tuberculosis Protein tyrosine phosphatase A.
Classical Examples of the Concept of the ASIA Syndrome.
Comparative Study of the Ability of Leishmania mexicana Promastigotes and Amastigotes to Alter Macrophage Signalling and Functions.
Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
Crystallization and preliminary crystallographic characterization of LmACR2, an arsenate/antimonate reductase from Leishmania major.
Decrease of acid phosphatase activity in murine peritoneal macrophages infected with Leishmania donovani.
Deficiency in hematopoietic phosphatase ptpn6/Shp1 hyperactivates the innate immune system and impairs control of bacterial infections in zebrafish embryos.
Deletion of the Dual Specific Phosphatase-4 (DUSP-4) Gene Reveals an Essential Non-redundant Role for MAP Kinase Phosphatase-2 (MKP-2) in Proliferation and Cell Survival.
Differential gene expression of ASUN, NEMF, PTPRC and DHX29: Candidate biomarkers for diagnosis of active and latent tuberculosis.
Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.
Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs.
Downmodulation of Effector Functions in NK Cells upon Toxoplasma gondii Infection.
Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells.
Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways.
Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Effect of virulent and less virulent strains of Nocardia asteroides on acid-phosphatase activity in alveolar and peritoneal macrophages maintained in vitro.
Endophyte-mediated effects on the growth and physiology of Achnatherum sibiricum are conditional on both N and P availability.
Environmental factors related to the induction of beta-cell autoantibodies in 1-yr-old healthy children.
Enzymatic changes in serum and tissues in fowl infected with a neurotropic-mesogenic strain of Newcastle disease virus.
Escherichia coli cyclomodulin Cif induces G2 arrest of the host cell cycle without activation of the DNA-damage checkpoint-signalling pathway.
Evidence for inhibition of fusion of lysosomal and prelysosomal compartments with phagosomes in macrophages infected with pathogenic Mycobacterium avium.
Exploitation of host cell signaling machinery: activation of macrophage phosphotyrosine phosphatases as a novel mechanism of molecular microbial pathogenesis.
Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.
Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disorders.
Expression of the A subunit of protein phosphatase 2A and characterization of its interactions with the catalytic and regulatory subunits.
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
First genome-wide association study of non-severe malaria in two birth cohorts in Benin.
Gene expression profiling identifies candidate biomarkers for active and latent tuberculosis.
Genetic predisposition to Helicobacter pylori-induced gastric precancerous conditions.
Genome-wide survey for baculoviral host homologs using the Bombyx genome sequence.
Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy.
Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma.
Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation.
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.
Histochemical differentiation of filarial larvae found in Simulium damnosum s.l. in West Africa.
Homophilic binding of PTP mu, a receptor-type protein tyrosine phosphatase, can mediate cell-cell aggregation.
Host cell responses to Listeria monocytogenes infection include differential transcription of host stress genes involved in signal transduction.
Human Cytomegalovirus miR-UL148D Facilitates Latent Viral Infection by Targeting Host Cell Immediate Early Response Gene 5.
Human genes in TB infection: their role in immune response.
Hydrolytic enzyme activity in rhesus monkey placenta during early gestational malaria: histochemical studies.
Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway.
Identification of a PP2A gene in Bombyx mori with antiviral function against B. mori nucleopolyhedrovirus.
Identification of leishmania fructose-1,6-bisphosphate aldolase as a novel activator of host macrophage Src homology 2 domain containing protein tyrosine phosphatase SHP-1.
Identification of lncRNA-155 encoded by MIR155HG as a novel regulator of innate immunity against influenza A virus infection.
Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics.
IFN-alpha beta secreted during infection is necessary but not sufficient for negative feedback regulation of IFN-alpha beta signaling by Mycobacterium tuberculosis.
Immunologic response to vaccine challenge in pregnant PTPN22 R620W carriers and non-carriers.
Immunological consequences of intestinal helminth infections: antigen presentation and immunosuppression by peritoneal cells.
Impaired CD45-associated tyrosine phosphatase activity during HIV-1 infection: implications for CD3 and CD4 receptor signalling.
Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
Insulin gene profile cycles with season of birth of future diabetic children and their relatives.
Insulin inhibits PDGF-directed VSMC migration via NO/ cGMP increase of MKP-1 and its inactivation of MAPKs.
Intracellular acid phosphatase content and ability of different macrophage populations to kill Nocardia asteroides.
Involvement of MAP-kinases and -phosphatases in uptake and intracellular replication of Listeria monocytogenes in J774 macrophage cells.
Involvement of protein tyrosine kinases and phosphatases in uptake and intracellular replication of virulent and avirulent Leishmania donovani promastigotes in mouse macrophage cells.
Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.
Isolation of two Locust protein targets of a protein tyrosine phosphatase from Metarhizium anisopliae strain CQMa102.
Knockout of MAPK Phosphatase-1 Exaggerates Type I IFN Response during Systemic Escherichia coli Infection.
Legionella pneumophila major acid phosphatase and its role in intracellular infection.
Leishmania major intracellular survival is not altered in SHP-1 deficient mev or CD45-/- mice.
Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation.
Leishmania-Induced IRAK-1 Inactivation Is Mediated by SHP-1 Interacting with an Evolutionarily Conserved KTIM Motif.
Malabsorption syndrome observed in the common octopus Octopus vulgaris infected with Aggregata octopiana (Protista: Apicomplexa).
MAP Kinase Phosphatase-1 and Septic Shock.
MAP kinase phosphatase-1, a critical negative regulator of the innate immune response.
MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response.
MAP kinase phosphatase-2 plays a critical role in response to infection by Leishmania mexicana.
MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages.
MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a.
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
MKP-2: out of the DUSP-bin and back into the limelight.
Molecular basis of the interaction of the human tyrosine phosphatase PTPN3 with the hepatitis B virus core protein.
MptpB Promotes Mycobacteria Survival by Inhibiting the Expression of Inflammatory Mediators and Cell Apoptosis in Macrophages.
Mycobacterium avium subsp. paratuberculosis PtpA is an endogenous tyrosine phosphatase secreted during infection.
Mycobacterium avium Subspecies paratuberculosis Infects and Replicates within Human Monocyte-Derived Dendritic Cells.
Natural Killer Cell Licensing During Viral Infection.
New strategies in fighting TB: targeting Mycobacterium tuberculosis-secreted phosphatases MptpA & MptpB.
Nonreceptor protein tyrosine phosphatases (NRPTPs) gene family associates with the risk of hepatocellular carcinoma in a Chinese hepatitis B virus-related subjects.
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Parvovirus-induced depletion of cyclin B1 prevents mitotic entry of infected cells.
Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis.
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain.
Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway.
Phosphorylation control of protein tyrosine phosphatase A activity in Mycobacterium tuberculosis.
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Poliovirus entry into human brain microvascular cells requires receptor-induced activation of SHP-2.
PP2A-dependent control of transcriptionally active FOXO3a in CD8(+) central memory lymphocyte survival requires p47(phox).
Prediction of the risk for gastric cancer using candidate methylation markers in the non-neoplastic gastric mucosae.
Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia.
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Protein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations.
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Protein tyrosine phosphatase PTPN22 has dual roles in promoting pathogen versus homeostatic-driven CD8 T-cell responses.
Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Protein Tyrosine Phosphatase-1B Negatively Impacts Host Defense against Pseudomonas aeruginosa Infection.
Proteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection.
PTP1B negatively regulates STAT1-independent Pseudomonas aeruginosa killing by macrophages.
PtpA, a secreted tyrosine phosphatase from Staphylococcus aureus, contributes to virulence and interacts with coronin-1A during infection.
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
Reactive oxygen species mediate virus-induced STAT activation: role of tyrosine phosphatases.
Receptor-like tyrosine phosphatases CD45 and CD148 have distinct functions in chemoattractant-mediated neutrophil migration and response to S. aureus.
Recombinant adenovirus of human p66Shc inhibits MCF-7 cell proliferation.
Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection.
Reduced pathogenicity of a Candida albicans MAP kinase phosphatase (CPP1) mutant in the murine mastitis model.
Regulation of innate immune response by MAP kinase phosphatase-1.
Relationship between the diversity of the cagA gene of Helicobacter pylori and gastric cancer in Okinawa, Japan.
Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production.
Role of SHP2 Protein Tyrosine Phosphatase in SERT Inhibition by Enteropathogenic E. coli (EPEC).
Runx proteins mediate protective immunity against Leishmania donovani infection by promoting CD40 expression on dendritic cells.
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.
SHP-1 As a Critical Regulator of Mycoplasma pneumoniae-Induced Inflammation in Human Asthmatic Airway Epithelial Cells.
SHP-1 plays a crucial role in CD40 signaling reciprocity.
SHP-1-Dependent Macrophage Differentiation Exacerbates Virus-Induced Myositis.
Shp-2 contributes to anti-RSV activity in human pulmonary alveolar epithelial cells by interfering with the IFN-?-induced Jak/Stat1 pathway.
SHP-2 Mediates Cryptosporidium parvum Infectivity in Human Intestinal Epithelial Cells.
SHP1 tyrosine phosphatase gets involved in host defense against Streptococcus agalactiae infection and BCR signaling pathway in Nile tilapia (Oreochromis niloticus).
Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma acuminatum and Cervical Cancer.
SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis.
Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Suppression of inflammatory and infection responses in lung macrophages by eucalyptus oil and its constituent 1,8-cineole: Role of pattern recognition receptors TREM-1 and NLRP3, the MAP kinase regulator MKP-1, and NF?B.
Susceptibility of naïve and differentiated PC12 cells to Japanese encephalitis virus infection.
T Cell Hypo-Responsiveness against Leishmania major in MAP Kinase Phosphatase (MKP) 2 Deficient C57BL/6 Mice Does Not Alter the Healer Disease Phenotype.
TGF-?(1) re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20.
The apo-structure of the low-molecular-weight protein tyrosine phosphatase A (MptpA) from Mycobacterium tuberculosis allows for better target-specific drug development.
The Aspergillus flavus Phosphatase CDC14 Regulates Development, Aflatoxin Biosynthesis and Pathogenicity.
The effect of intracellular Chlamydia psittaci on lysosomal enzyme activities in mouse peritoneal macrophages.
The effects of cure of Helicobacter pylori infection on the signal transduction of gastric epithelial cells.
The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance.
The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation.
The modulation of phosphatase expression impacts the proliferation efficiency of HSV-1 in infected astrocytes.
The p66Shc protein controls redox signaling and oxidation-dependent DNA damage in human liver cells.
The tyrosine phosphatase SHP-2 dephosphorylated by ALV-J via its Env efficiently promotes ALV-J replication.
Theoretical studies on the interaction of biphenyl inhibitors with Mycobacterium tuberculosis protein tyrosine phosphatase MptpB.
Therapeutic Targeting of Protein Tyrosine Phosphatases from Mycobacterium tuberculosis.
Thyroid autoimmunity.
TLR9 expression is required for the development of cigarette smoke-induced emphysema in mice.
Transformation of mouse peritoneal macrophages and bone marrow cells by simian virus 40.
Tyrosine phosphatase MptpA of Mycobacterium tuberculosis inhibits phagocytosis and increases actin polymerization in macrophages.
Tyrosine Phosphatase PTPN22: Multifunctional Regulator of Immune Signaling, Development, and Disease.
Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses.
Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant.
Tyrosine Phosphorylation and Dephosphorylation in Burkholderia cenocepacia Affect Biofilm Formation, Growth under Nutritional Deprivation, and Pathogenicity.
Weighted gene co-expression network analysis and drug-gene interaction bioinformatics uncover key genes associated with various presentations of malaria infection in African children and major drug candidates.
Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor-Mediated T-Cell Function by an RNA-Based Mechanism.
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Infertility
Acid phosphatase activity in human uterine fluid in relation to infertility.
Deletion of the tyrosine phosphatase Shp2 in Sertoli cells causes infertility in mice.
Lack of the protein tyrosine phosphatase SHP-1 results in decreased numbers of glia within the motheaten (me/me) mouse brain.
P66SHC deletion improves fertility and progeric phenotype of late-generation TERC-deficient mice but not their short lifespan.
Seminal acid phosphatase in relation to fertility.
Sustained High Protein-tyrosine Phosphatase 1B Activity in the Sperm of Obese Males Impairs the Sperm Acrosome Reaction.
When transcripts matter: delineating between non-syndromic hearing loss DFNB32 and hearing impairment infertile male syndrome (HIIMS).
[Clinical and experimental studies on male infertility. 2. Experimental studies. Histochemical demonstration of acid phosphatase activity in the testes of mice and their responce to the drugs for the male infertility (author's transl)]
[Expression levels of Cdc2 and Cdc25A mRNA in cattle, yak, and cattle-yak testis]
Infertility, Female
Disruption of the transmembrane dense core vesicle proteins IA-2 and IA-2beta causes female infertility.
Infertility, Male
Inhibition of CDC2/Cyclin B1 in response to selenium-induced oxidative stress during spermatogenesis: potential role of Cdc25c and p21.
Integrated Analysis of DNA Methylation and mRNA Expression Profiles to Identify Key Genes in Severe Oligozoospermia.
Post-transcriptional regulation of CDC25A by BOLL is a conserved fertility mechanism essential for human spermatogenesis.
Sustained High Protein-tyrosine Phosphatase 1B Activity in the Sperm of Obese Males Impairs the Sperm Acrosome Reaction.
The regulation of male fertility by the PTPN11 tyrosine phosphatase.
[Clinical and experimental studies on male infertility. 2. Experimental studies. Histochemical demonstration of acid phosphatase activity in the testes of mice and their responce to the drugs for the male infertility (author's transl)]
Inflammatory Bowel Diseases
A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.
Activation of Protein Tyrosine Phosphatase Non-Receptor Type 2 by Spermidine Exerts Anti-Inflammatory Effects in Human THP-1 Monocytes and in a Mouse Model of Acute Colitis.
An integrated in silico approach to understand protein-protein interactions: human meprin-? with fetuin-A.
Association of the protein-tyrosine phosphatase nonreceptor type substrate 1 (PTPNS1) gene with inflammatory bowel disease.
Association of ZAP70 and PTPN6, but Not BANK1 or CLEC2D, with Inflammatory Bowel Disease in the Tunisian Population.
Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.
Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis.
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
Inflammatory bowel disease: Are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase.
Knockout of Mkp-1 exacerbates colitis in Il-10-deficient mice.
Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon-?-Induced Signaling in Human Monocytes.
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia.
Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis.
Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort.
Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese population.
Presence of PTPN2 SNP rs1893217 Enhances the Anti-inflammatory Effect of Spermidine.
Protein tyrosine phosphatase ? targets apical junction complex proteins in the intestine and regulates epithelial permeability.
Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease.
Protein Tyrosine Phosphatase Non-Receptor Type 22 Modulates NOD2-Induced Cytokine Release and Autophagy.
PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.
PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis.
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
Regulation of epithelial barrier function by the inflammatory bowel disease candidate gene, PTPN2.
rs2476601 polymorphism in PTPN22 is associated with Crohn's disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls.
Spermidine stimulates T-cell protein tyrosine phosphatase-mediated protection of intestinal epithelial barrier function.
T cell protein tyrosine phosphatase prevents STAT1 induction of claudin-2 expression in intestinal epithelial cells.
T cells are influenced by a long non-coding RNA in the autoimmune associated PTPN2 locus.
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.
The functional genetic variation in the PTPN22 gene has a negligible effect on the susceptibility to develop inflammatory bowel disease.
The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions.
The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis.
The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation.
VSL#3 Probiotic Stimulates T-cell Protein Tyrosine Phosphatase-mediated Recovery of IFN-?-induced Intestinal Epithelial Barrier Defects.
Influenza, Human
A role for protein phosphatase 2A in regulating p38 mitogen activated protein kinase activation and tumor necrosis factor-alpha expression during influenza virus infection.
Autoimmune variant PTPN22 C1858T is associated with impaired responses to influenza virus vaccination.
CDC25B promotes influenza A virus replication by regulating the phosphorylation of nucleoprotein.
Immunologic response to vaccine challenge in pregnant PTPN22 R620W carriers and non-carriers.
Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Targeting cell division cycle 25 homolog B to regulate influenza virus replication.
Vaccinations may induce diabetes-related autoantibodies in one-year-old children.
[Biological properties of live and inactivated influenza vaccines under experimental conditions]
[Change in the acid phosphatase activity of susceptible cells at the early stages of their interaction with Sendai and influenza A2 (Hong Kong) 68 viruses]
Insulin Resistance
(-)-Epicatechin improves insulin sensitivity in high fat diet-fed mice.
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population.
2,4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018).
A comprehensive review on the antidiabetic activity of flavonoids targeting PTP1B and DPP-4: a structure-activity relationship analysis.
A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes.
A Novel Protein Tyrosine Phosphatase 1B inhibitor with Therapeutic Potential for Insulin Resistance.
A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway.
A phosphotyrosyl mimetic peptide reverses impairment of insulin-stimulated translocation of GLUT4 caused by overexpression of PTP1B in rat adipose cells.
A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree.
A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance.
Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans.
Accumulation of ceramide in slow-twitch muscle contributes to the development of insulin resistance in the obese JCR:LA-cp rat.
Acute exercise decreases PTP-1B protein level and improves insulin signaling in the liver of old rats.
Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and Is a Minor Regulator of Glucose Homeostasis.
Adipogenic action of vanadium: a new dimension in treating diabetes.
Alteration of phosphotyrosine phosphatase activity in tissues from diabetic and pregnant rats.
Alterations in specific protein-tyrosine phosphatases accompany insulin resistance of streptozotocin diabetes.
Alternative translation initiation of Caveolin-2 desensitizes insulin signaling through dephosphorylation of insulin receptor by PTP1B and causes insulin resistance.
Amorphastilbol exerts beneficial effects on glucose and lipid metabolism in mice consuming a high-fat-diet.
An evolving integrative physiology: skeleton and energy metabolism.
An extract of Urtica dioica L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A).
Angiotensin II-induced insulin resistance and protein tyrosine phosphatases.
Ankaflavin: a natural novel PPAR? agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo.
Anti-Diabetic Activity of 2,3,6-Tribromo-4,5-Dihydroxybenzyl Derivatives from Symphyocladia latiuscula through PTP1B Downregulation and ?-Glucosidase Inhibition.
Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms.
Anti-obesity and hypolipidemic effects of Rheum undulatum in high-fat diet-fed C57BL/6 mice through protein tyrosine phosphatase 1B inhibition.
Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice.
Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice.
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Association Between First Episode Schizophrenia, Metabolic Syndrome and Insulin Resistance-Related Proteins in Female Balb/C Mice.
Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study.
Association of the PTPN1 gene with type 2 diabetes and insulin resistance.
Association testing of the protein tyrosine phosphatase 1B gene (PTPN1) with type 2 diabetes in 7,883 people.
Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells.
Astragalus polysaccharide improves palmitate-induced insulin resistance by inhibiting PTP1B and NF-?B in C2C12 myotubes.
Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes.
Bardoxolone methyl prevents insulin resistance and the development of hepatic steatosis in mice fed a high-fat diet.
Basal activation of p70S6K results in adipose-specific insulin resistance in protein-tyrosine phosphatase 1B -/- mice.
Beneficial effects of Ginkgo biloba extract on insulin signaling cascade, dyslipidemia, and body adiposity of diet-induced obese rats.
BH3 mimetics derived from Bim-BH3 domain core region show PTP1B inhibitory activity.
Binding properties of marine bromophenols with human protein tyrosine phosphatase 1B: Molecular docking, surface plasmon resonance and cellular insulin resistance study.
Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action.
Bis(ethylmaltolato)oxidovanadium(iv) inhibited the pathogenesis of Alzheimer's disease in triple transgenic model mice.
Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo.
BPN, a marine-derived PTP1B inhibitor, activates insulin signaling and improves insulin resistance in C2C12 myotubes.
Characterization of the inhibitory activity of natural tanshinones from Salvia miltiorrhiza roots on protein tyrosine phosphatase 1B.
Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors.
Combination of the anthocyanidins malvidin and peonidin attenuates lipopolysaccharide-mediated inflammatory gene expression in primary human adipocytes.
Cyanidin and delphinidin modulate inflammation and altered redox signaling improving insulin resistance in high fat-fed mice.
CYC31, A Natural Bromophenol PTP1B Inhibitor, Activates Insulin Signaling and Improves Long Chain-Fatty Acid Oxidation in C2C12 Myotubes.
Cyclosporine A enhances gluconeogenesis while sirolimus impairs insulin signaling in peripheral tissues after 3 weeks of treatment.
Cysteine string protein 1 (CSP1) modulates insulin sensitivity by attenuating glucose transporter 4 (GLUT4) vesicle docking with the plasma membrane.
Data in support of fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice.
Decrease of miR-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid.
Deletion of Protein Tyrosine Phosphatase 1b Improves Peripheral Insulin Resistance and Vascular Function in Obese, Leptin-Resistant Mice via Reduced Oxidant Tone.
Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.
Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity.
Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy.
Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes.
Developmental switch from prolonged insulin action to increased insulin sensitivity in protein tyrosine phosphatase 1B-deficient hepatocytes.
Differential regulation of multiple hepatic protein tyrosine phosphatases in alloxan diabetic rats.
Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.
Double-Stranded RNA-Activated Protein Kinase Is a Key Modulator of Insulin Sensitivity in Physiological Conditions and in Obesity in Mice.
Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle.
Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells.
Dual specificity mitogen-activated protein (MAP) kinase phosphatase-4 plays a potential role in insulin resistance.
Early growth response-1 negative feedback regulates skeletal muscle postprandial insulin sensitivity via activating Ptp1b transcription.
Early obesity and age-related mimicry of metabolic syndrome in female mice with sex hormonal imbalances.
Early overnutrition impairs insulin signaling in the heart of adult Swiss mice.
Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice.
Effect of vanadium on insulin sensitivity in patients with impaired glucose tolerance.
Effects of adenovirus-mediated liver-selective overexpression of protein tyrosine phosphatase-1b on insulin sensitivity in vivo.
Effects of hepatic protein tyrosine phosphatase 1B and methionine restriction on hepatic and whole-body glucose and lipid metabolism in mice.
EGCG evokes Nrf2 nuclear translocation and dampens PTP1B expression to ameliorate metabolic misalignment under insulin resistance condition.
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Electroacupuncture Improves Insulin Resistance by Reducing Neuroprotein Y/Agouti-Related Protein Levels and Inhibiting Expression of Protein Tyrosine Phosphatase 1B in Diet-induced Obese Rats.
Elevated expression and activity of protein-tyrosine phosphatase 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats.
Endocrine regulation of energy metabolism by the skeleton.
Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.
Establishment of a cell-based drug screening model for identifying down-regulators of Protein Tyrosine Phosphatase 1B expression.
Estradiol Protects Neuropeptide Y/Agouti-related Peptide Neurons against Insulin Resistance in Females.
Evaluation of the hypoglycaemic and antioxidant effects of submerged Ganoderma lucidum cultures in type 2 diabetic rats.
Exercise training decreases mitogen-activated protein kinase phosphatase-3 expression and suppresses hepatic gluconeogenesis in obese mice.
Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance.
Expression of SHP-1 Induced by Hyperglycemia Prevents Insulin Actions in Podocytes.
Fanconi anemia links reactive oxygen species to insulin resistance and obesity.
Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: a new insight into its antidiabetic mechanism.
Flavonoids from Sophora alopecuroides L. improve palmitate-induced insulin resistance by inhibiting PTP1B activity in vitro.
FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice.
Fructose and hepatic insulin resistance.
Fucosterol activates the insulin signaling pathway in insulin resistant HepG2 cells via inhibiting PTP1B.
Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice.
Functional properties of Claramine: A novel PTP1B inhibitor and insulin-mimetic compound.
Gene Expression of Protein Tyrosine Phosphatase 1B and Endoplasmic Reticulum Stress During Septic Shock.
Genomic characterization of the human and mouse protein tyrosine phosphatase-1B genes.
Gestational Protein Restriction impairs Glucose Disposal in the Gastrocnemius muscles of Female Rats.
Grape powder extract attenuates tumor necrosis factor alpha-mediated inflammation and insulin resistance in primary cultures of human adipocytes.
Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis.
Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance.
Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies.
Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome?
Hepatic PTP1B Expression Involvement in the Effects of Chinese Medicine Formula Xiao-Gao-Jiang-Zhuo Using an Obese Rat Model.
Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance.
Hepatocyte-specific ptpn6 deletion protects from obesity-linked hepatic insulin resistance.
High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation.
High-Resolution Inhibition Profiling Combined with HPLC-HRMS-SPE-NMR for Identification of PTP1B Inhibitors from Vietnamese Plants.
High-Resolution PTP1B Inhibition Profiling Combined with HPLC-HRMS-SPE-NMR for Identification of PTP1B Inhibitors from Miconia albicans.
Hypoglycemic effect and mechanism of honokiol on type 2 diabetic mice.
Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B.
Hypoglycemic effects of Grifola frondosa (Maitake) polysaccharides F2 and F3 through improvement of insulin resistance in diabetic rats.
Hypoglycemic mechanism of a novel proteoglycan, extracted from Ganoderma lucidum, in hepatocytes.
Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.
Identification of Cyanidin-3-arabinoside Extracted from Blueberry as a Selective Protein Tyrosine Phosphatase 1B Inhibitor.
Identification of protein tyrosine phosphatase 1B (PTP1B) inhibitors through De Novo Evoluton, synthesis, biological evaluation and molecular dynamics simulation.
Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.
Improved adipose tissue function with initiation of protease inhibitor-only ART.
Improved Glucose Homeostasis in Mice with Muscle-Specific Deletion of Protein-Tyrosine Phosphatase 1B.
Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue.
Improving Obesity and Insulin Resistance by Targeting Skeletal Muscle MKP-1.
In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides.
In vivo vascular rarefaction and hypertension induced by dexamethasone are related to phosphatase PTP1B activation not endothelial metabolic changes.
Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects.
Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice.
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor.
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.
Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.
Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity.
Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice.
Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro.
Inhibiting protein tyrosine phosphatase 1B to improve regenerative functions of endothelial cells.
Inhibition of C1-Ten PTPase activity reduces insulin resistance through IRS-1 and AMPK pathways.
Inhibition of protein tyrosine phosphatase 1B by flavonoids: A structure - activity relationship study.
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice.
Inhibition of Src homology 2 domain containing protein tyrosine phosphatase as the possible mechanism of metformin-assisted amelioration of obesity induced insulin resistance in high fat diet fed C57BL/6J mice.
Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
Insulin receptor dephosphorylation by phosphotyrosine phosphatases obtained from insulin-resistant obese mice.
Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression.
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Insulin resistance associated to obesity: the link TNF-alpha.
Insulin resistance does not diminish eNOS expression, phosphorylation, or binding to HSP-90.
Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes.
Insulin signaling meets mitochondria in metabolism.
Interplay between gut microbiota and p66Shc affects obesity-associated insulin resistance.
Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine.
Intranasal Targeting of Hypothalamic PTP1B and TCPTP Reinstates Leptin and Insulin Sensitivity and Promotes Weight Loss in Obesity.
Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity.
Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer.
Kinetics and molecular docking studies of pimarane-type diterpenes as protein tyrosine phosphatase (PTP1B) inhibitors from Aralia continentalis roots.
Knock-down of LAR protein tyrosine phosphatase induces insulin resistance.
Knocking down amygdalar PTP1B in diet-induced obese rats improves insulin signaling/action, decreases adiposity and may alter anxiety behavior.
Leptin increases hepatic insulin sensitivity and protein tyrosine phosphatase 1B expression.
Leukocyte antigen-related inhibition attenuates palmitate-induced insulin resistance in muscle cells.
Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression.
Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress.
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice.
Looking at Marine-Derived Bioactive Molecules as Upcoming Anti-Diabetic Agents: A Special Emphasis on PTP1B Inhibitors.
Loss of protein tyrosine phosphatase 1B increases IGF-I receptor tyrosine phosphorylation but does not rescue retinal defects in IRS2-deficient mice.
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Mammalian life-span determinant p66shcA mediates obesity-induced insulin resistance.
Marine Bromophenol Derivative 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-isopropoxymethyl benzyl)benzene-1,2-diol Protects Hepatocytes from Lipid-Induced Cell Damage and Insulin Resistance via PTP1B Inhibition.
Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus.
Maternal insulin resistance multigenerationally impairs synaptic plasticity and memory via gametic mechanisms.
Membrane localization of protein-tyrosine phosphatase 1B is essential for its activation of sterol regulatory element-binding protein-1 gene expression and consequent hypertriglyceridaemia.
Metabolic diseases drug discovery world summit. July 28-29, 2003, San Diego, CA, USA.
Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis.
Metabolic Regulation of Methionine Restriction in Diabetes.
Modulation of cellular insulin signaling and PTP1B effects by lipid metabolites in skeletal muscle cells.
Modulation of Obesity and Insulin Resistance by the Redox Enzyme and Adaptor Protein p66Shc.
Molecular and cellular mechanisms linking inflammation to insulin resistance and ?-cell dysfunction.
Molecular mechanism of angiotensin II-induced insulin resistance in aortic vascular smooth muscle cells: roles of Protein Tyrosine Phosphatase-1B.
Molecular network analysis of phosphotyrosine and lipid metabolism in hepatic PTP1b deletion mice.
Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions.
MSI-1436 improves EMS adipose derived progenitor stem cells in the course of adipogenic differentiation through modulation of ER stress, apoptosis, and oxidative stress.
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
Natural Alkaloids and Diabetes Mellitus: A Review.
Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-?B-mediated PTP1B expression.
New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting ?-glucosidase and the PTP-1B signaling pathway.
Norathyriol reverses obesity- and high-fat-diet-induced insulin resistance in mice through inhibition of PTP1B.
Novel idebenone analogs block Shc's access to insulin receptor to improve insulin sensitivity.
Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking.
Novel Mixed-Type Inhibitors of Protein Tyrosine Phosphatase 1B. Kinetic and Computational Studies.
Novel Protein Tyrosine Phosphatase 1B Inhibitor-Geranylated Flavonoid from Mulberry Leaves Ameliorates Insulin Resistance.
NOX4 Pathway as a Source of Selective Insulin Resistance and Responsiveness.
Obesity Increases Mitogen-Activated Protein Kinase Phosphatase-3 Levels in the Hypothalamus of Mice.
Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.
Osmotic regulation of insulin-induced mitogen-activated protein kinase phosphatase (MKP-1) expression in H4IIE rat hepatoma cells.
Overexpression of protein-tyrosine phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinositide 3-kinase activity without altering glucose transport or Akt/Protein kinase B activation.
Overexpression of PTPN2 in Visceral Adipose Tissue Ameliorated Atherosclerosis via T Cells Polarization Shift in Diabetic Apoe-/- Mice.
Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance.
Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance.
p66(ShcA): linking mammalian longevity with obesity-induced insulin resistance.
P66SHC and ageing: ROS and TOR?
p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans.
Palmitate and inflammatory state additively induce the expression of PTP1B in muscle cells.
Peroxiredoxin 2 mediates insulin sensitivity of skeletal muscles through regulation of protein tyrosine phosphatase oxidation.
Peroxisome proliferator-activated receptor-gamma agonist improves skeletal muscle insulin signaling in the pregestational intrauterine growth-restricted rat offspring.
Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes.
Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus.
Phloridzin Acts as an Inhibitor of Protein-Tyrosine Phosphatase MEG2 Relevant to Insulin Resistance.
Phosphatase activity in rat adipocytes: effects of insulin and insulin resistance.
Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate the insulin receptor.
Pimarane Diterpenoids from the Seeds of Caesalpinia minax as PTP1B Inhibitors and Insulin Sensitizers.
Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge.
Possible Integrative Actions of Leptin and Insulin Signaling in the Hypothalamus Targeting Energy Homeostasis.
PP2A inhibition results in hepatic insulin resistance despite Akt2 activation.
Probing the relationship between insulin sensitivity and longevity using genetically modified mice.
Protein phosphatases and podocyte function.
Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).
Protein tyrosine phosphatase 1B and insulin resistance: role of endoplasmic reticulum stress/reactive oxygen species/nuclear factor kappa B axis.
Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Protein tyrosine phosphatase 1B inhibition: opportunities and challenges.
Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus.
Protein Tyrosine Phosphatase 1B inhibitors: a novel therapeutic strategy for the management of type 2 diabetes mellitus.
Protein tyrosine phosphatase 1B inhibitory activities of ursane- and lupane-type triterpenes from Sorbus pohuashanensis.
Protein tyrosine phosphatase 1B is impaired in skeletal muscle of diabetic Psammomys obesus.
Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis.
Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism.
Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities.
Protein tyrosine phosphatase activity in insulin-resistant rodent Psammomys obesus.
Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders.
Protein tyrosine phosphatase regulation in fibroblasts from patients with an insulin receptor gene mutation.
Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells.
Protein tyrosine phosphatase-1B gene PTPN1: selection of tagging single nucleotide polymorphisms and association with body fat, insulin sensitivity, and the metabolic syndrome in a normal female population.
Protein tyrosine phosphatase-1B in diabetes.
Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants.
Protein Tyrosine Phosphatases: Potential Role in beta-Cell Insulin Signal Transduction.
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure.
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance.
Protein-Tyrosine Phosphatase-1B Mediates Sleep Fragmentation-Induced Insulin Resistance and Visceral Adipose Tissue Inflammation in Mice.
Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells.
Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.
Protein-tyrosine-phosphatase 1B activation is regulated developmentally in muscle of neonatal pigs.
PTP1B and TCPTP: Non-redundant phosphatases in insulin signaling and glucose homeostasis.
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice.
PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat.
PTP1B deficiency improves hypothalamic insulin sensitivity resulting in the attenuation of AgRP mRNA expression under high-fat diet conditions.
PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro.
PTPIP51 interaction with PTP1B and 14-3-3? in adipose tissue of insulin-resistant mice.
PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol.
PTPN2 improved renal injury and fibrosis by suppressing STAT-induced inflammation in early diabetic nephropathy.
PTPRT regulates high-fat diet-induced obesity and insulin resistance.
Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice.
QSAR Studies of PTP1B Inhibitors: Recent Advances and Perspectives.
Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media.
Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats.
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.
Ratanhiaphenol III from Ratanhiae Radix is a PTP1B Inhibitor.
Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes.
Reduced Insulin Resistance Contributes to the Beneficial Effect of Protein Tyrosine Phosphatase-1B Deletion in a Mouse Model of Sepsis.
Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice.
Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice.
Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells.
Reduction of PTP1B induces differential expression of PI3-kinase (p85alpha) isoforms.
Replication of Genome-Wide Association Signals of Type 2 Diabetes in Han Chinese in a Prospective Cohort.
Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1-independent manner.
Reversal of diet-induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS-1 serine phosphorylation.
RNA sequencing of the human milk fat layer transcriptome reveals distinct gene expression profiles at three stages of lactation.
Role of protein tyrosine phosphatase 1B in cardiovascular diseases.
Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits.
Rosiglitazone attenuates tumor necrosis factor-?-induced protein tyrosine phosphatase-1B production in HepG2 cells.
Safranal, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves glucose tolerance in diabetic KK-A(y) mice.
Scopoletin Protects against Methylglyoxal-Induced Hyperglycemia and Insulin Resistance Mediated by Suppression of Advanced Glycation Endproducts (AGEs) Generation and Anti-Glycation.
SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits.
Selective hepatic insulin resistance in mice heterozygous for a mitochondrial trifunctional protein defect.
Selective inhibition of PTP1B by Vitalboside A from Syzygium cumini enhances insulin sensitivity and attenuates lipid accumulation via partial agonism to PPAR?: In Vitro and In Silico investigation.
Serum Ceramide Reduction by Blueberry Anthocyanin-Rich Extract Alleviates Insulin Resistance in Hyperlipidemia Mice.
Serum protein signature of coronary artery disease in type 2 diabetes mellitus.
Short-Term Strength Exercise Reduces Hepatic Insulin Resistance in Obese Mice by Reducing PTP1B Content, Regardless of Changes in Body Weight.
SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes.
SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.
Silencing insulin resistance through SIRT1.
SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B.
Skeletal muscle protein tyrosine phosphatase 1B regulates insulin sensitivity in African Americans.
Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance.
Skeletal Muscle-Specific Deletion of MKP-1 Reveals a p38 MAPK/JNK/Akt Signaling Node That Regulates Obesity-Induced Insulin Resistance.
Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action.
Statement of Retraction. Iria Nieto-Vázquez, Sonia Fernández-Veledo, Cristina de Alvaro, Cristina M. Rondinone, Angela M. Valverde, and Margarita Lorenzo. Protein-Tyrosine Phosphatase 1B-Deficient Myocytes Show Increased Insulin Sensitivity and Protection Against Tumor Necrosis Factor-?-Induced Insulin Resistance. Diabetes 2007;56:404-413. https://doi.org/10.2337/db06-0989.
Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet.
Structure determination of T cell protein-tyrosine phosphatase.
Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics.
Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B.
Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: a three-dimensional quantitative structure-activity relationship study using self-organizing molecular field analysis approach.
Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B.
Synthesis and biological evaluation of novel N-aryl-?-(benzoazol-2-yl)-sulfanylalkanamides as dual inhibitors of ?-glucosidase and protein tyrosine phosphatase 1B.
Synthesis of benzofuran scaffold-based potential PTP-1B inhibitors.
Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors.
Synthesis, biological activity and structure-activity relationships of new benzoic acid-based protein tyrosine phosphatase inhibitors endowed with insulinomimetic effects in mouse C2C12 skeletal muscle cells.
Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors.
Synthesis, molecular docking and PTP1B inhibitory activity of functionalized 4,5-dihydronaphthofurans and dibenzofurans.
T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice.
T-Cell Protein Tyrosine Phosphatase Regulates Bone Resorption and Whole-Body Insulin Sensitivity through Its Expression in Osteoblasts.
Targeted SHP-1 Silencing Modulates the Macrophage Phenotype, Leading to Metabolic Improvement in Dietary Obese Mice.
Targeting density-enhanced phosphatase-1 (DEP-1) with antisense oligonucleotides improves the metabolic phenotype in high-fat diet-fed mice.
Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes.
TCPTP Regulates Insulin Signaling in AgRP Neurons to Coordinate Glucose Metabolism With Feeding.
The allelic variant of LAR gene promoter -127 bp T-->A is associated with reduced risk of obesity and other features related to insulin resistance.
The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity.
The dual-specificity phosphatase 2 (DUSP2) does not regulate obesity-associated inflammation or insulin resistance in mice.
The Effects of Total Flavonoids from Buckwheat Flowers and Leaves on Renal Damage and PTP1B Expression in Type 2 Diabetic Rats.
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
The Role of Inflammation in Diabetic Retinopathy.
The Role of MKP-1 in Insulin-Induced Cardioprotection.
The Role of MKP-5 in Adipocyte-Macrophage Interactions during Obesity.
The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance.
The Role of PTP1B O-GlcNAcylation in Hepatic Insulin Resistance.
The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding.
The Shc locus regulates insulin signaling and adiposity in mammals.
The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities.
TISSUE-SPECIFICITY ON INSULIN ACTION AND RESISTANCE. PAST TO RECENT MECHANISMS.
TNF? increases hypothalamic PTP1B activity via the NF?B pathway in rat hypothalamic organotypic cultures.
To binge or not to binge: Binge drinking disrupts glucose homeostasis by impairing hypothalamic but not liver insulin signaling.
Toward a treatment of diabesity: Rational design, synthesis and biological evaluation of benzene-sulfonamide derivatives as a new class of PTP-1B inhibitors.
Transcriptional response of porcine skeletal muscle to feeding a linseed-enriched diet to growing pigs.
Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action.
Treatment of type 2 diabetes mellitus via reversing insulin resistance and regulating lipid homeostasis in vitro and in vivo using cajanonic acid A.
Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Vanadate enhances but does not normalize glucose transport and insulin receptor phosphorylation in skeletal muscle from obese women with gestational diabetes mellitus.
Vitamin A improves insulin sensitivity by increasing insulin receptor phosphorylation through protein tyrosine phosphatase1B regulation at early age in obese rats of WNIN/Ob strain.
Water Extract of Mungbean (Vigna radiata L.) Inhibits Protein Tyrosine Phosphatase-1B in Insulin-Resistant HepG2 Cells.
Zinc Supplementation and Strength Exercise in Rats with Type 2 Diabetes: Akt and PTP1B Phosphorylation in Nonalcoholic Fatty Liver.
[Effects of candesartan on expressions of JAK2 and PTP-1B in adipose tissue of high-fat diet-fed rats].
[Effects of flavones of buckwheat flower and leaf on insulin resistance and liver PTP1B in type 2 diabetic rats]
[Free fatty acids promoting PTP1B expression in rat skeletal muscle and hepatic cells]
[Impairments of insulin receptor function in insulin resistant states]
[Investigating the effects of compound WS090152 on non-alcoholic fatty liver in mice].
[Investigation of a compound, compatibility of Rhodiola crenulata, Cordyceps militaris, and Rheum palmatum, on metabolic syndrome treatment I--improving insulin resistance].
[Molecular mechanism and clinical impact of insulin resistance in type 2 diabetes mellitus]
[Prescription of Jingdan Yimin for treatment of metabolic syndrome].
[Study on the mechanism of action of total flavonoids of Litsea coreana for reducing blood glucose level in rat with type 2 diabetes mellitus]
[The effect of different types of bariatric surgery on the metabolic and hormonal parameters in rats with decompensed form of type 2 diabetes mellitus.]
[The protein expression of insulin receptor substrate-1 and protein tyrosine phosphatase with two src-homology II in the adipose tissue from type II diabetic patients]
[The role of protein tyrosine phosphatase (PTP-1B) in insulin resistance]
Insulinoma
Autoantibodies to protein tyrosine phosphatase-like proteins in type I diabetes. Overlapping specificities to phogrin and ICA512/IA-2.
Carboxypeptidase-H autoantibodies differentiate a more latent subset of autoimmune diabetes from phenotypic type 2 diabetes among Chinese adults.
Differential Regulation of Endoplasmic Reticulum Stress by Protein Tyrosine Phosphatase 1B and T Cell Protein Tyrosine Phosphatase.
Evaluating the Prognostic Value of Islet Autoantibody Monitoring in Islet Transplant Recipients with Long-Standing Type 1 Diabetes Mellitus.
IA-2, a transmembrane protein tyrosine phosphatase, is expressed in human lung cancer cell lines with neuroendocrine phenotype.
IA-2beta, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion.
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment.
Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2.
Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma.
Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes.
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application.
Profile and differential expression of protein tyrosine phosphatases in mouse pancreatic islet tumor cell lines.
Role of immune system in type 1 diabetes mellitus pathogenesis.
Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients.
Secretory-granule dynamics visualized in vivo with a phogrin-green fluorescent protein chimaera.
Splice variant 3, but not 2 of receptor protein-tyrosine phosphatase sigma can mediate stimulation of insulin-secretion by alpha-latrotoxin.
Intellectual Disability
B56?-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Clinical and Molecular Analysis of Patients with RASopathies in Turkish Patients.
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome.
Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability.
Hyperactivated PTP1B phosphatase in parvalbumin neurons alters anterior cingulate inhibitory circuits and induces autism-like behaviors.
IL-1 receptor accessory protein-like 1 associated with mental retardation and autism mediates synapse formation by trans-synaptic interaction with protein tyrosine phosphatase ?.
Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase, and homer 1, in autism: a postmortem study in cerebellar vermis and superior frontal cortex.
PTPN4 germline variants result in aberrant neurodevelopment and growth.
The tyrosine phosphatase Shp2 in development and cancer.
[Clinical and genetic analysis of Noonan syndrome in 20 children].
Intestinal Neoplasms
Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells.
Intestinal Volvulus
Acid phosphatase activity in the larval stages of Onchocerca volvulus developing in the vector Simulium damnosum.
Some observations on onchocerciasis including sowda in the Yemen Arab Republic.
Invasive Fungal Infections
Expression of SHP-1 and SOCS6 in patients with acute leukemia and their clinical implication.
Iron Overload
Iron content and acid phosphatase activity in hepatic parenchymal lysosomes of patients with hemochromatosis before and after phlebotomy treatment.
Iron overload threatens the growth of osteoblast cells via inhibiting the PI3K/AKT/FOXO3a/DUSP14 signaling pathway.
Ischemic Attack, Transient
Prevention of JNK phosphorylation as a mechanism for rosiglitazone in neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase.
Ischemic Stroke
A peptide mimetic of tyrosine phosphatase STEP as a potential therapeutic agent for treatment of cerebral ischemic stroke.
Motheaten (me/me) mice deficient in SHP-1 are less susceptible to focal cerebral ischemia.
Neuronal protein-tyrosine phosphatase 1B hinders sensory-motor functional recovery and causes affective disorders in two different focal ischemic stroke models.
PTP1B inhibitor alleviates deleterious microglial activation and neuronal injury after ischemic stroke by modulating the ER stress-autophagy axis via PERK signaling in microglia.
PTPN21 protects PC12 cell against oxygen-glucose deprivation by activating cdk5 through ERK1/2 signaling pathway.
Regulation of post-ischemic inflammatory response: A novel function of the neuronal tyrosine phosphatase STEP.
S-nitrosylated SHP-2 contributes to NMDA receptor-mediated excitotoxicity in acute ischemic stroke.
Upregulation of protein phosphatase 2A and NR3A-pleiotropic effect of simvastatin on ischemic stroke rats.
Joint Diseases
Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Kallmann Syndrome
Renal agenesis in Kallmann syndrome: a network approach.
Keloid
Alpha-naphthyl acid phosphatase activity in normal human skin and keloids.
Multifaceted array-based keloidal gene expression profiling reveals specific MDFI upregulation in keloid lesions.
Pleiotrophin is downregulated in human keloids.
Protein tyrosine phosphatase 1B regulates fibroblasts proliferation, motility and extracellular matrix synthesis via the MAPK/ERK signalling pathway in keloid.
Keratitis, Herpetic
[Alkaline and acid phosphatase activity and localization in the eye tissues and fluids in herpetic keratitis]
Keratoacanthoma
An ultrastructural study of the localization of acid phosphatase activity in the untreated and vitamin A acid treated keratoacanthoma.
Keratoconjunctivitis
[Polymorphic markers of certain genes in the development of dry keratoconjunctivitis in patients with rheumatoid arthritis and Sjogren's syndrome].
Keratoconus
Enhanced expression of a transmembrane phosphotyrosine phosphatase (LAR) in keratoconus cultures and corneas.
Ocular findings in Noonan syndrome: a retrospective cohort study of 105 patients.
[Study on enhanced leukocyte antigen-related tyrosine phosphatase in keratoconus]
Keratosis
Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation.
RASopathies: Clinical Diagnosis in the First Year of Life.
Ketosis
Preserved Proinsulin Production in Homozygous PTPN 22 C1858T Variant Type 1 Diabetes: A Possible Explanation for Absence of Overt Ketoacidosis Despite Omission of Exogenous Insulin.
[Subclassification of seronegative type 1 diabetic subjects with HLA-DQ genotypes]
Kidney Cortex Necrosis
Key genes of renal tubular necrosis: a bioinformatics analysis.
Kidney Diseases
Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.
Hippocampal mitogen-activated protein kinase phosphatase-1 regulates behavioral and systemic effects of chronic corticosterone administration.
Oxidative stress, a common molecular pathway for kidney disease: role of the redox enzyme p66Shc.
p66Shc-mediated hydrogen peroxide production impairs nephrogenesis causing reduction of number of glomeruli.
Role of protein phosphatase 2A in kidney disease (Review).
Kidney Diseases, Cystic
Altered regulation of SHP-2 and PTP 1B tyrosine phosphatases in cystic kidneys from bcl-2 -/- mice.
Kidney Failure, Chronic
Decreased p66Shc promoter methylation in patients with end-stage renal disease.
Lower p66Shc promoter methylation in subjects with chronic renal failure.
Kidney Neoplasms
Antitumor activity of irradiated riboflavin on human renal carcinoma cell line 786-O.
Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.
Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells.
microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells.
Modulation of bcl-2 family proteins in MAPK independent apoptosis induced by a cdc25 phosphatase inhibitor Cpd 5 in renal cancer cells.
Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Klatskin Tumor
Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells.
PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Kwashiorkor
Infantile jejunal mucosa in infection and malnutrition.
Lafora Disease
A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).
Abnormal metabolism of glycogen phosphate as a cause for Lafora disease.
Advances in the genetics of progressive myoclonus epilepsy.
Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329.
Expression, purification and characterization of soluble red rooster laforin as a fusion protein in Escherichia coli.
Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase.
Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.
Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity.
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease.
Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.
The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2.
Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex.
Lambert-Eaton Myasthenic Syndrome
Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.
Laryngeal Neoplasms
DIAPH2, PTPRD and HIC1 Gene Polymorphisms and Laryngeal Cancer Risk.
Functions of Shp2 in cancer.
Latent Autoimmune Diabetes in Adults
Association of common type 1 and type 2 diabetes gene variants with latent autoimmune diabetes in adults: A meta-analysis.
Low Frequencies of Autoimmunity-Associated PTPN22 Polymorphisms in MODY Patients, Including Those Transiently Expressing Islet Cell Autoantibodies.
The association of PTPN22 rs2476601 polymorphism and CTLA-4 rs231775 polymorphism with LADA risks: a systematic review and meta-analysis.
The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.
Latent Tuberculosis
Cis-2 and trans-2-eisocenoic fatty acids are novel inhibitors for Mycobacterium tuberculosis Protein tyrosine phosphatase A.
Differential gene expression of ASUN, NEMF, PTPRC and DHX29: Candidate biomarkers for diagnosis of active and latent tuberculosis.
Learning Disabilities
Connecting the dots between SHP2 and glutamate receptors.
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome.
Legionnaires' Disease
Identification of putative cytoskeletal protein homologues in the protozoan host Hartmannella vermiformis as substrates for induced tyrosine phosphatase activity upon attachment to the Legionnaires' disease bacterium, Legionella pneumophila.
Leigh Disease
Modulation of mitochondrial dysfunction-related oxidative stress in fibroblasts of patients with Leigh syndrome by inhibition of prooxidative p66Shc pathway.
Leiomyoma
PTPN22 and uterine leiomyomas.
Significant relationship of combined ACP1/PTPN22 genotype variants with the growth of uterine leiomyomas.
Leiomyomatosis
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
Leiomyosarcoma
Leiomyosarcoma of the heart and its pulmonary metastasis, both with prominent osteoclast-like multinucleated giant cells expressing tartrate-resistant acid phosphatase activity.
Leishmaniasis
Crystallization and preliminary crystallographic characterization of LmACR2, an arsenate/antimonate reductase from Leishmania major.
Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases.
Leishmania major intracellular survival is not altered in SHP-1 deficient mev or CD45-/- mice.
Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation.
Peroxovanadium-mediated protection against murine leishmaniasis: role of the modulation of nitric oxide.
Proteases and phosphatases during Leishmania-macrophage interaction: paving the road for pathogenesis.
Role of host phosphotyrosine phosphatase SHP-1 in the development of murine leishmaniasis.
Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production.
Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines.
Leishmaniasis, Visceral
Immunomodulation of dual specificity phosphatase 4 during visceral leishmaniasis.
Leishmania infantum-chagasi activates SHP-1 and reduces NFAT5/TonEBP activity in the mouse kidney inner medulla.
Lentigo
Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions.
Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Cochlear implantation and clinical features in patients with Noonan syndrome and Noonan syndrome with multiple lentigines caused by a mutation in PTPN11.
Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation.
Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.
Extensive abdominal lipomatosis in a patient with Noonan/LEOPARD syndrome (Noonan syndrome-Multiple Lentigines).
Familial LEOPARD Syndrome With Hypertrophic Cardiomyopathy.
Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.
Hypertrophic neuropathy in Noonan syndrome with multiple lentigines.
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
Leopard syndrome: a report of five cases from one family in two generations.
Leopard syndrome: the potential cardiac defect underlying skin phenotypes.
Noonan Syndrome with Multiple Lentigines and PTPN11 Mutation: A Case with Intracerebral Hemorrhage.
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Noonan syndrome: clinical aspects and molecular pathogenesis.
Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation.
Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.
PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype".
PTPN11 mutations in LEOPARD syndrome.
SHP2 sails from physiology to pathology.
Sporadic case of eruptive lentiginosis caused by Thr468Met missense mutation in the PTPN11 gene in a Han Chinese patient: first report and systematic literature review.
Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2.
The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
[Molecular genetic mutation analysis of the PTPN11 gene in the multiple lentigines (LEOPARD) syndrome]
LEOPARD Syndrome
A Novel A461S Mutation of PTPN11 in a Female with LEOPARD Syndrome.
A novel PTPN11 gene mutation in a patient with LEOPARD Syndrome.
A novel PTPN11 missense mutation in a patient with LEOPARD syndrome.
A novel PTPN11 mutation in LEOPARD syndrome.
Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive).
Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Cochlear implantation and clinical features in patients with Noonan syndrome and Noonan syndrome with multiple lentigines caused by a mutation in PTPN11.
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes.
Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations.
Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Distinct and overlapping functions of ptpn11 genes in Zebrafish development.
Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human Disease.
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Familial aggregation of genetically heterogeneous hypertrophic cardiomyopathy: a boy with LEOPARD syndrome due to PTPN11 mutation and his nonsyndromic father lacking PTPN11 mutations.
Familial cases of atypical clinical features genetically diagnosed as LEOPARD syndrome (multiple lentigines syndrome).
Familial LEOPARD Syndrome With Hypertrophic Cardiomyopathy.
Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling.
Functions of Shp2 in cancer.
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.
Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11.
Germline PTPN11 and somatic PIK3CA variant in a boy with megalencephaly-capillary malformation syndrome (MCAP) - pure coincidence?
Hypertrophic neuropathy in Noonan syndrome with multiple lentigines.
Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome.
IMAGE CARDIO MED. A patient with LEOPARD syndrome and PTPN11 mutation.
Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His.
Is sudden cardiac death predictable in LEOPARD syndrome?
Leopard syndrome caused by heterozygous missense mutation of Tyr 279 Cys in the PTPN11 gene in a sporadic case of Chinese Han.
LEOPARD Syndrome Caused by Tyr279Cys Mutation in the PTPN11 Gene.
LEOPARD syndrome in an infant with severe hypertrophic cardiomyopathy and PTPN11 mutation.
LEOPARD Syndrome with PTPN11 Gene Mutation in Three Family Members Presenting with Different Phenotypes.
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
LEOPARD syndrome with recurrent PTPN11 mutation Y279C and different cutaneous manifestations: two case reports and a review of the literature.
LEOPARD Syndrome Without Hearing Loss or Pulmonary Stenosis: A Report of 2 Cases.
LEOPARD Syndrome: A Variant of Noonan Syndrome Strongly Associated With Hypertrophic Cardiomyopathy.
Leopard syndrome: the potential cardiac defect underlying skin phenotypes.
Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation.
mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?
Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome.
Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11.
New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
Noonan Syndrome and Related Disorders: Genetics and Pathogenesis.
Noonan syndrome and related disorders: genetics and pathogenesis.
Noonan Syndrome with Multiple Lentigines and PTPN11 Mutation: A Case with Intracerebral Hemorrhage.
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Noonan syndrome: clinical aspects and molecular pathogenesis.
P0-Related Protein Accelerates Human Mesenchymal Stromal Cell Migration by Modulating VLA-5 Interactions with Fibronectin.
Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation.
Patient with confirmed LEOPARD syndrome developing multiple melanoma.
Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.
Phenotype-genotype correlation in a patient with co-occurrence of Marfan and LEOPARD syndromes.
Phenotypical diversity of patients with LEOPARD syndrome carrying the worldwide recurrent p.Tyr279Cys PTPN11 mutation.
Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development.
Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.
Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype.
PTPN11 gene mutation associated with abnormal gonadal determination.
PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain.
PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
PTPN11 mutations in LEOPARD syndrome.
PTPN11 Mutations in LEOPARD Syndrome: Report of Four Cases in Taiwan.
PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience.
PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.
Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
Scalp melanoma in a woman with LEOPARD syndrome: Possible implication of PTPN11 signaling in melanoma pathogenesis.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
SHP-2 regulates growth factor dependent vascular signalling and function.
Shp2 in myocytes is essential for cardiovascular and neointima development.
Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2-Induced Gastrulation Defects.
SHP2 sails from physiology to pathology.
Spectrum of Mutations in Noonan Syndrome and Their Correlation with Phenotypes.
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis.
Syndromic Hearing Loss in Association with PTPN11-Related Disorder: The Experience of Cochlear Implantation in a Child with LEOPARD Syndrome.
Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2.
The case of 17-year-old male with LEOPARD syndrome.
The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
The regulation of male fertility by the PTPN11 tyrosine phosphatase.
The tyrosine phosphatase Shp2 (PTPN11) in cancer.
The tyrosine phosphatase Shp2 in development and cancer.
Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome.
Visual function in Noonan and LEOPARD syndrome.
[Molecular genetic mutation analysis of the PTPN11 gene in the multiple lentigines (LEOPARD) syndrome]
[Noonan syndrome and Leopard syndrome linked to mutation of the gene PTPN11]
[PTPN11 gene mutation in LEOPARD syndrome]
[The Biological Function of SHP2 in Human Disease].
Leprosy
Analysis of the rs2476601 polymorphism of PTPN22 in Mexican mestizo patients with leprosy.
Macrophage function in leprosy.
Protein tyrosine phosphatase non-receptor type 22 gene polymorphism C1858T is not associated with leprosy in Azerbaijan, Northwest Iran.
Semen biochemistry of leprosy patients.
The role of polymorphic protein tyrosine phosphatase non-receptor type 22 in leprosy.
Leprosy, Lepromatous
Semen biochemistry of leprosy patients.
Leprosy, Paucibacillary
Semen biochemistry of leprosy patients.
Leukemia
(1)H, (15)N and (13)C sequence specific backbone assignment of the vanadate inhibited hematopoietic tyrosine phosphatase.
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
A definitive role of Shp-2 tyrosine phosphatase in mediating embryonic stem cell differentiation and hematopoiesis.
A gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival.
A toxicogenomic approach for identifying biomarkers for myelosuppressive anemia in rats.
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Aggregation of IgE receptors in rat basophilic leukemia 2H3 cells induces tyrosine phosphorylation of the cytosolic protein-tyrosine phosphatase HePTP.
Alterations in tyrosine phosphorylation during the granulocytic maturation of HL-60 leukemia cells.
An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
Apoptosis and mitotic arrest are two independent effects of the protein phosphatases inhibitor okadaic acid in K562 leukemia cells.
Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase.
Association of the protein-tyrosine phosphatase DEP-1 with its substrate FLT3 visualized by in situ proximity ligation assay.
BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Biochemical characterization of tyrosine kinase and phosphotyrosine phosphatase activities of HL-60 leukemia cells.
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
CD14/16 monocyte profiling in juvenile myelomonocytic leukemia.
Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation.
Characterization of SET/I2PP2A Isoforms in Dogs.
Childhood and adolescent lymphoid and myeloid leukemia.
Clinical and molecular epidemiology of neonatal leukemia in brazil.
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Complete Resolution of Lymphoid Interstitial Pneumonia in a Patient With Juvenile Myelomonocytic Leukemia Treated With Allogeneic Bone Marrow Transplant: Killing 2 Birds With 1 Stone.
Computational identification of microRNAs and their targets in liver cirrhosis.
Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model.
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Critical role of Shp2 in tumor growth involving regulation of c-Myc.
Cross talk between p38MAPK and ERK is mediated through MAPK-mediated protein phosphatase 2A catalytic subunit ? and MAPK phosphatase-1 expression in human leukemia U937 cells.
Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2.
De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation.
Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia.
Design of a comprehensive fluorescence in situ hybridization assay for genetic classification of T-cell acute lymphoblastic leukemia.
Different outcomes of allogeneic hematopoietic stem cell transplant in a pair of twins affected by juvenile myelomonocytic leukemia.
Differential expression of protein tyrosine phosphatase genes during phorbol ester-induced differentiation of human leukemia U937 cells.
Differential regulation of leukemia inhibitory factor-stimulated neuronal gene expression by protein phosphatases SHP-1 and SHP-2 through mitogen-activated protein kinase-dependent and -independent pathways.
Differentiation-induced changes in protein-tyrosine phosphatase activity and commensurate expression of CD45 in human leukemia cell lines.
Distinct promoters control transmembrane and cytosolic protein tyrosine phosphatase epsilon expression during macrophage differentiation.
Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human Disease.
DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia.
Down-regulation of c-Myc and Max genes is associated to inhibition of protein phosphatase 2A in K562 human leukemia cells.
Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle.
Down-regulation of telomerase activity via protein phosphatase 2A activation in salvicine-induced human leukemia HL-60 cell apoptosis.
DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118.
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling.
Effects of extremely low frequency magnetic fields on NGF induced neuronal differentiation of PC12 cells.
Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro.
Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells.
Enlargement of secretory vesicles by protein tyrosine phosphatase PTP-MEG2 in rat basophilic leukemia mast cells and Jurkat T cells.
Erythroblast transformation by the friend spleen focus-forming virus is associated with a block in erythropoietin-induced STAT1 phosphorylation and DNA binding and correlates with high expression of the hematopoietic phosphatase SHP-1.
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play.
Evaluation of protein tyrosine phosphatase activity in patients with acute leukemia.
Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
Expanding the SHOC2 mutation associated phenotype of noonan syndrome with loose anagen hair: Structural brain anomalies and myelofibrosis.
Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2E69K.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression changes of ERK1/2, STAT3 and SHP-2 in bone marrow cells from gamma-ray induced leukemia mice.
Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
Expression of SHP-1 and SOCS6 in patients with acute leukemia and their clinical implication.
Factors affecting acid phosphatase activity in exponential and synchronized L5178Y mouse leukemia cells.
Four-year remission despite umbilical cord graft rejection in juvenile myelomonocytic leukemia with PTPN11 mutations.
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
Functional involvement of PTP-U2L in apoptosis subsequent to terminal differentiation of monoblastoid leukemia cells.
Functional variation of SHP-2 promoter is associated with preterm birth and delayed myelination and motor development in preterm infants.
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas.
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Genetic alterations of protein tyrosine phosphatases in human cancers.
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Germline PTPN11 mutation affecting exon 8 in a case of syndromic juvenile myelomonocytic leukemia.
Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association.
HOXA11 plays critical roles in disease progression and response to cytarabine in AML.
Hypophosphorylation of pRB and repression of cyclin D3 and cdc25A during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells.
Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11).
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
Increased prostate-type acid phosphatase activity in serum and typical bone lesions simulating the presence of prostatic carcinoma.
Independent roles of SOCS-3 and SHP-2 in the regulation of neuronal gene expression by leukemia inhibitory factor.
Induction of a Tumor-associated Activating Mutation in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhances Mitochondrial Metabolism, Leading to Oxidative Stress and Senescence.
Inhibition of ATRA-induced myeloid differentiation in acute promyelocytic leukemia by a new protein tyrosine phosphatase inhibitor, 3,4-dephostatin.
Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.
Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B.
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.
Involvement of SHP-1, a phosphotyrosine phosphatase, during myeloid cell differentiation in acute promyelocytic leukemia cell lines.
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.
Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation.
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Malignant fibrous histiocytoma-pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.
Malignant lymphoma of pre-T-cell type terminating in acute myelocytic leukemia. A case report with enzymic and immunologic marker studies.
Mangiferin induces cell cycle arrest at G2/M phase through ATR-Chk1 pathway in HL-60 leukemia cells.
Mechanistic insights explain the transforming potential of the T507K substitution in the protein tyrosine phosphatase SHP2.
Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate.
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4.
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor.
Mutational analysis of PTPRT phosphatase domains in common human cancers.
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations.
Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.
Myricetin prevents thapsigargin-induced CDK5-P66Shc signalosome mediated pancreatic ?-cell dysfunction.
Negative autoregulation of Src homology region 2-domain-containing phosphatase-1 in rat basophilic leukemia-2H3 cells.
Negative regulation of immunoreceptor signaling by protein adapters: Shc proteins join the club.
Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl.
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis.
Novel PROTACs for degradation of SHP2 protein.
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Oncophosphosignaling Favors a Glycolytic Phenotype in Human Drug Resistant Leukemia.
Osteopetrosis mimicking juvenile myelomonocytic leukemia.
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia.
Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome.
Phorbol ester stimulates the activity of a protein tyrosine phosphatase containing SH2 domains (PTP1C) in HL-60 leukemia cells by increasing gene expression.
Phorbol ester-induced expression, phosphorylation, and translocation of protein-tyrosine-phosphatase 1C in HL-60 cells.
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
Positive regulation of c-Jun N-terminal kinase and TNF-alpha production but not histamine release by SHP-1 in RBL-2H3 mast cells.
Potent activation of phospholipase D by phenylarsine oxide in rat basophilic leukemia (RBL-2H3) cells.
Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice.
Preferential requirement for protein tyrosine phosphatase activity in the 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of human colon cancer cells.
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.
Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia.
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo.
Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin- 10-induced JAK-STAT signaling.
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Protein tyrosine phosphatase-PEST (PTP-PEST) regulates mast cell-activating signals in PTP activity-dependent and -independent manners.
Protein-tyrosine phosphatase activity maintains the viability of hairy cells and modulates their response to interferon-alpha.
Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells.
Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells.
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.
PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis.
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias.
RAS diseases in children.
Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTPepsilon C.
Regulation of CD45 expression in human leukemia cells.
Regulation of protein phosphotyrosine content by changes in tyrosine kinase and protein phosphotyrosine phosphatase activities during induced granulocytic and monocytic differentiation of HL-60 leukemia cells.
Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3.
Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome.
Reversible phosphorylation in haematological malignancies: Potential role for protein tyrosine phosphatases in treatment?
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.
Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Role of protein phosphatases in the cancer microenvironment.
Serial investigation of PTPN11 mutation in nonhematopoietic tissues in a patient with juvenile myelomonocytic leukemia who was treated with unrelated cord blood transplantation.
SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis.
SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal.
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.
Shp2 function in hematopoietic stem cell biology and leukemogenesis.
Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia.
Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia.
Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants.
Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP.
Suppression of protein tyrosine phosphatase PTPN22 gene induces apoptosis in T-cell leukemia cell line (Jurkat) through the AKT and ERK pathways.
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies.
Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
TCR-induced downregulation of protein tyrosine phosphatase PEST augments secondary T cell responses.
TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells.
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
The function of the protein tyrosine phosphatase SHP-1 in cancer.
The molecular basis of leukemia.
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
The oncoprotein I-2PP2A/SET negatively regulates the MEK/ERK pathway and cell proliferation.
The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.
The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models.
The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Therapeutic potential of targeting the oncogenic SHP2 phosphatase.
Thymoquinone Suppresses Cell Proliferation and Enhances Apoptosis of HL60 Leukemia Cells through Re-Expression of JAK/STAT Negative Regulators.
Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations.
Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
Two bcr/abl fusion gene products, P210bcr/abl and P190bcr/abl, are equally sensitive to the protein tyrosine phosphatase of mature granulocytes.
Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft.
Tyrosine kinase and phosphotyrosine phosphatase activity in human promyelocytic leukemia cells and human polymorphonuclear leukocytes.
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Tyrosine phosphatase SHP-2 is a regulator of p27(Kip1) tyrosine phosphorylation.
[Analysis of PTPN11 Mutation in Children Leukemia and Its Clinical Significance].
[Beta-glucuronidase and acid phosphatase activity in the blast cells of acute lymphoblastic and undifferentiated leukemia patients]
[Characteristics of the diagnosis and treatment of secondary pneumonia in acute leukemia]
[Demethylation effect of inhibitor As2O3 on expression of SHP-1 and C-kit genes in leukemia HL-60 cells].
[Effect of 5-aza-CdR Demethylation on Expression of SHP-1 and C-kit Genes in Leukemia HL-60 Cells].
[Effect of A Methylation Inhibitor 5-aza-2'-deoxycytidine on SHP-1 Gene Expression, Proliferation and Apoptosis in K562 Cells.]
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
[Effects of protein tyrosine kinase, protein tyrosine phosphatase and protein kinase C on the apoptosis of arsenic trioxide treated NB4 cells and human cortex neurons]
[Expression and clinical value of SHP-1 and c-kit in acute leukemia]
[Immunophenotype analysis of leukemic mantle cell lymphoma].
[Involvement of PTP-U2 in terminal differentiation and apoptosis of leukemia cells]
[Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]
[Recent progress in the protein-tyrosine phosphatase SHP1 gene: the significant correlation of the SHP1 gene silencing with the onset of lymphomas/leukemias]
[Research progress of protein tyrosine phosphatase SHP-2].
[The expression and clinical significance of hematopoietic cell phosphatase and cysteinyl aspartate-specific proteinase in leukemia]
Leukemia, Erythroblastic, Acute
Characterization of a protein tyrosine phosphatase (RIP) expressed at a very early stage of differentiation in both mouse erythroleukemia and embryonal carcinoma cells.
Chromosomal location of murine protein tyrosine phosphatase (Ptprj and Ptpre) genes.
Evidence for a novel antioxidant function and isoform-specific regulation of the human p66Shc gene.
Expression of the protein tyrosine phosphatase beta2 gene in mouse erythroleukemia cells induces terminal erythroid differentiation.
Induction of IW32 erythroleukemia cell differentiation by p53 is dependent on protein tyrosine phosphatase.
Induction of specific protein tyrosine phosphatase transcripts during differentiation of mouse embryonal carcinoma (F9) cells.
Induction of specific protein tyrosine phosphatase transcripts during differentiation of mouse erythroleukemia cells.
Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation.
Leukemia, Hairy Cell
The cytochemistry of tartrate-resistant acid phosphatase. Technical considerations.
Leukemia, Lymphocytic, Chronic, B-Cell
Activation of Protein Tyrosine Phosphatase Receptor Type ? Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia.
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.
LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy.
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells.
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.
p66Shc deficiency in the E?-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.
P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia.
PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
PRL-2 increases Epo and IL-3 responses in hematopoietic cells.
Regulation of Selective B Cell Autophagy by the Pro-oxidant Adaptor p66SHC.
SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts.
The cytokine midkine and its receptor RPTP? regulate B cell survival in a pathway induced by CD74.
The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia.
The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia.
Quantification of the leukocyte common antigen (CD45) in mature B-cell malignancies.
[Blood immunoglobulin level and acid phosphatase activity in the lymphocytes in different stages of lymphocytic leukemia according to the Rai classification]
[Lymphocyte acid phosphatase activity in lymphocytic leukemia studied in tissue culture with the use of diffusion chambers]
Leukemia, Monocytic, Acute
Association of the protein-tyrosine phosphatase DEP-1 with its substrate FLT3 visualized by in situ proximity ligation assay.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type ? in chronic myeloid leukemia patients.
Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.
Characterization of a membrane-associated phosphotyrosyl protein phosphatase from the A431 human epidermoid carcinoma cell line.
Differential expression of SHP-1 in chronic myeloid leukemia.
Differentiation-induced changes in protein-tyrosine phosphatase activity and commensurate expression of CD45 in human leukemia cell lines.
DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
Eupolyphaga sinensis Walker inhibits human chronic myeloid leukemia cell K562 growth by inducing G2-M phase cell cycle arrest and targeting EGFR signaling pathway and in S180 tumor-bearing mice.
Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia.
Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.
Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
LMWPTP modulates the antioxidant response and autophagy process in human chronic myeloid leukemia cells.
Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Phosphotyrosine phosphatase activity prevents the detection of P210bcr/abl protein in mature cells in chronic myelogenous leukemia even by an immunoblotting technique.
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Protein tyrosine phosphatase 1B negatively regulates macrophage development through CSF-1 signaling.
Protein Tyrosine Phosphatase Receptor Type {gamma} Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia.
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Redirecting traffic using the XPO1 police.
Regulative Loop between ?-catenin and Protein Tyrosine Receptor Type ? in Chronic Myeloid Leukemia.
Resveratrol inhibits STAT5 activation through the induction of SHP-1 and SHP-2 tyrosine phosphatases in chronic myelogenous leukemia cells.
Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation.
SHP1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
[Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance].
[Granulocyte acid phosphatase activity during the course of chronic myeloid leukemia and Hodgkin's disease]
[Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]
[SHP-1 gene in the disease progression of chronic myeloid leukemia].
[The expression and clinical significance of hematopoietic cell phosphatase and cysteinyl aspartate-specific proteinase in leukemia]
Leukemia, Myeloid
Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells.
Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro.
Involvement of SHP-1, a phosphotyrosine phosphatase, during myeloid cell differentiation in acute promyelocytic leukemia cell lines.
Phorbol ester-resistant monoblastoid leukemia cells with a functional mitogen-activated protein kinase cascade but without responsive protein tyrosine phosphatases.
Presence of "prostatic" acid phosphatase in human neutrophils.
PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling.
The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP.
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Triphenyltin enhances the neutrophilic differentiation of promyelocytic HL-60 cells.
Up-regulation of I-2(PP2A)/SET gene expression in rat primary hepatomas and regenerating livers.
[Expression and Significance of PTPL1 in Hematological Malignan-cies].
[Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance].
Leukemia, Myeloid, Acute
A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Acute myeloid leukemia in an adult Noonan syndrome patient with PTPN11 mutation.
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia.
Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.
Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD.
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature.
Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia.
Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
Dual-specificity phosphatase 10 is fused to MDS1/EVI1-like gene 1 in a case of acute myelogenous leukemia with der1t1;1(p36.3;q21).
Dynamics of clonal evolution in myelodysplastic syndromes.
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients.
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation.
Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.
KIAA1524: A novel MLL translocation partner in acute myeloid leukemia.
LEO1 is regulated by PRL-3 and mediates its oncogenic properties in Acute Myeloid Leukemia.
LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.
Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.
Low frequency of exon 3 PTPN11 mutations in adult de novo acute myeloid leukemia. Analysis of a consecutive series of 173 patients.
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.
Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations.
Myelodysplastic syndrome with multilineage dysplasia evolving to acute myeloid leukemia: Noonan syndrome with c.218C>T mutation in PTPN11 gene.
Non-canonical activation of ?-catenin by PRL-3 phosphatase in acute myeloid leukemia.
Noonan Syndrome and Related Disorders: Genetics and Pathogenesis.
Noonan syndrome and related disorders: genetics and pathogenesis.
Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.
PRL-2 increases Epo and IL-3 responses in hematopoietic cells.
PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling.
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.
PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia.
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia.
SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP.
The protein phosphatase 2A regulatory subunit B55? is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia.
Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.
Transcriptional repression of Cdc25B by IER5 inhibits the proliferation of leukemic progenitor cells through NF-YB and p300 in acute myeloid leukemia.
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
[Effects of PTPN11 on the Biological Characteristics of AML Cells].
[Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance].
Leukemia, Myelomonocytic, Chronic
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
A gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
CD14/16 monocyte profiling in juvenile myelomonocytic leukemia.
Childhood and adolescent lymphoid and myeloid leukemia.
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Complete Resolution of Lymphoid Interstitial Pneumonia in a Patient With Juvenile Myelomonocytic Leukemia Treated With Allogeneic Bone Marrow Transplant: Killing 2 Birds With 1 Stone.
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Different outcomes of allogeneic hematopoietic stem cell transplant in a pair of twins affected by juvenile myelomonocytic leukemia.
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling.
Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
Expanding the SHOC2 mutation associated phenotype of noonan syndrome with loose anagen hair: Structural brain anomalies and myelofibrosis.
Four-year remission despite umbilical cord graft rejection in juvenile myelomonocytic leukemia with PTPN11 mutations.
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Germline PTPN11 mutation affecting exon 8 in a case of syndromic juvenile myelomonocytic leukemia.
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation.
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations.
Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.
Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl.
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Osteopetrosis mimicking juvenile myelomonocytic leukemia.
Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome.
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
RAS diseases in children.
Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome.
Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Role of protein phosphatases in the cancer microenvironment.
Serial investigation of PTPN11 mutation in nonhematopoietic tissues in a patient with juvenile myelomonocytic leukemia who was treated with unrelated cord blood transplantation.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia.
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
The molecular basis of leukemia.
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
Leukemia, Prolymphocytic
Alkaline phosphatase and tartrate resistant acid phosphatase activity in cells of prolymphocytic leukemia.
Leukemia, Prolymphocytic, T-Cell
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
Leukemia, Promyelocytic, Acute
Inhibition of ATRA-induced myeloid differentiation in acute promyelocytic leukemia by a new protein tyrosine phosphatase inhibitor, 3,4-dephostatin.
Involvement of SHP-1, a phosphotyrosine phosphatase, during myeloid cell differentiation in acute promyelocytic leukemia cell lines.
Leukemia, T-Cell
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate.
Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia.
Suppression of protein tyrosine phosphatase PTPN22 gene induces apoptosis in T-cell leukemia cell line (Jurkat) through the AKT and ERK pathways.
Leukemia-Lymphoma, Adult T-Cell
Comprehensive high-throughput meta-analysis of differentially expressed microRNAs in transcriptomic datasets reveals significant disruption of MAPK/JNK signal transduction pathway in Adult T-cell leukemia/lymphoma.
Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
KU70 Inhibition Impairs Both Non-Homologous End Joining and Homologous Recombination DNA Damage Repair Through SHP-1 Induced Dephosphorylation of SIRT1 in Adult T-Cell Leukemia-Lymphoma Cells.
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Leukocytosis
Increased expression of tyrosine phosphatase SHP2 in experimental pneumococcal meningitis: correlation with tumor necrosis factor-alpha and cerebrospinal fluid pleocytosis.
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
[Changes in the functional state of the lysosomal apparatus of the peripheral blood neutrophilic leukocytes in rabbits under the action of immobilization with thyroid hormone deficiency]
[Effect of beta receptor blockaders on the status of the lysosomal system of peripheral blood neutrophils in rabbits with immobilization stress]
Leukomalacia, Periventricular
Accelerated Axonal Loss Following Acute CNS Demyelination in Mice Lacking Protein Tyrosine Phosphatase Receptor Type Z.
Li-Fraumeni Syndrome
Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
Lichen Planus, Oral
Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients.
Lipoma
PP2A binds the LIM-domains of Lipoma Preferred Partner via its PR130/B" subunit to regulate cell adhesion and migration.
Liposarcoma
Characterization of a human cell line stably over-expressing the candidate oncogene, dual specificity phosphatase 12.
Liver Abscess, Amebic
Characterization of the protein tyrosine phosphatase PRL from Entamoeba histolytica.
Liver Cirrhosis
Computational identification of microRNAs and their targets in liver cirrhosis.
Inhibition of p66Shc Oxidative Signaling via CA-Induced Upregulation of miR-203a-3p Alleviates Liver Fibrosis Progression.
Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone.
LncRNA Mical2/miR-203a-3p sponge participates in epithelial-mesenchymal transition by targeting p66Shc in liver fibrosis.
p66Shc Contributes to Liver Fibrosis through the Regulation of Mitochondrial Reactive Oxygen Species.
Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases.
PTP1B confers liver fibrosis by regulating the activation of hepatic stellate cells.
PTP1B promotes macrophage activation by regulating the NF-?B pathway in alcoholic liver injury.
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
The metabolic behaviour of the lymphocytes from serous effusions in various benign internal diseases.
[Methods of hemostasis and hepatectomy in injuries of the liver]
Liver Cirrhosis, Biliary
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
The PTPN22 1858T variant is not associated with primary biliary cirrhosis.
Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22.
Liver Diseases
Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
Dual-specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice through TAK1 Suppression.
Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1.
Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression.
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Increased hepatic FAT/CD36, PTP1B and decreased HNF4A expression contributes to dyslipidemia associated with ethanol-induced liver dysfunction: Rescue effect of ginger extract.
Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease.
Interrogating Endogenous Protein Phosphatase Activity with Rationally Designed Chemosensors.
Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.
Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
Polymorphism of Receptor-Type Tyrosine-Protein Phosphatase Delta gene in the development of non-alcoholic fatty liver disease.
Protein tyrosine Phosphatase (PTP1B): A promising Drug Target against life threatening ailments.
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients.
Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling.
PTPROt aggravates inflammation by enhancing NF-?B activation in liver macrophages during nonalcoholic steatohepatitis.
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
[Changes in tissue acid phosphatase activity in serveral liver disease]
Liver Diseases, Alcoholic
Activated protein phosphatase 2A disrupts nutrient sensing balance between mTORC1 and AMPK causing sarcopenia in alcoholic liver disease.
Hepatic protein-tyrosine phosphatase 1B disruption and pharmacological inhibition attenuate ethanol-induced oxidative stress and ameliorate alcoholic liver disease in mice.
Reduced methylation of PP2Ac promotes ethanol-induced lipid accumulation through FOXO1 phosphorylation in vitro and in vivo.
Liver Failure
Protein tyrosine phosphatase 1B modulates GSK3?/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity.
Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure.
Signalling pathways involved in paracetamol-induced hepatotoxicity: new insights on the role of protein tyrosine phosphatase 1B.
Liver Failure, Acute
Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo.
PTPN14 aggravates inflammation through promoting proteasomal degradation of SOCS7 in acute liver failure.
Liver Neoplasms
Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.
Epidermal Growth Factor Activates the Rho GTPase-activating Protein (GAP) Deleted in Liver Cancer 1 via Focal Adhesion Kinase and Protein Phosphatase 2A.
Functions of Shp2 in cancer.
miR-186 Inhibits Liver Cancer Stem Cells Expansion via Targeting PTPN11.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Oncogenic potential of CK2? and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.
Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic ?-Catenin, PIK3CA and MET.
Silencing CDC25A inhibits the proliferation of liver cancer cells by downregulating IL?6 in vitro and in vivo.
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
[Inhibiting effects of RNA interference PRL-3 on the invasion of human hepatocellular cancer cells.]
Lung Diseases
Circulating levels of tartrate-resistant acid phosphatase in macrophage-activated lung disease.
Protein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Suppression of cytokine production by glucocorticoids is mediated by MKP-1 in human lung epithelial cells.
The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38.
[Comparative data of a study of the alkaline and acid phosphatase activity of blood serum and of neutrophils in patients with nonspecific inflammatory lung diseases]
[Determination of alveolar macrophage function in nonspecific lung diseases by the simultaneous estimation of phagocytosis and acid phosphatase activity]
Lung Injury
Loss of myeloid-specific protein phosphatase 2A enhances lung injury and fibrosis and results in IL-10-dependent sensitization of epithelial cell apoptosis.
Phosphotyrosine phosphatase and tyrosine kinase inhibition modulate airway pressure-induced lung injury.
Protection against reperfusion lung injury via aborgating multiple signaling cascades by trichostatin A.
Role of mitogen-activated protein kinase phosphatase-1 in corticosteroid insensitivity of chronic oxidant lung injury.
Suppression of the p66shc adapter protein by protocatechuic acid prevents the development of lung injury induced by intestinal ischemia reperfusion in mice.
YAP expression in endothelial cells prevents ventilator-induced lung injury.
Lung Neoplasms
A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A.
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
A superoxide-mediated MKP-1 Degradation and JNK Activation Pathway for Luteolin-induced Lung Cancer Cytotoxicity.
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
Anti-proliferative effect of (19Z)-halichondramide, a novel marine macrolide isolated from the sponge Chondrosia corticata, is associated with G2/M cell cycle arrest and suppression of mTOR signaling in human lung cancer cells.
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
CDC25B induces cellular senescence and correlates with tumor suppression in a p53-dependent manner.
CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture.
Coexisting amplifications of the chromosome 1p32 genes (PTPRF and MYCL1) encoding protein tyrosine phosphatase LAR and L-myc in a small cell lung cancer line.
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells.
Copy number variations of chromosome 17p13.1 might be linked to high risk of lung cancer in heavy smokers.
DDIAS promotes STAT3 activation by preventing STAT3 recruitment to PTPRM in lung cancer cells.
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Downregulating PRL-3 inhibit migration and invasion of lung cancer cell via RhoA and mDia1.
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells.
Effect of protein-tyrosine phosphatase 4A3 by small interfering RNA on the proliferation of lung cancer.
Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Erratum to: The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.
Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7.
Functions of Shp2 in cancer.
Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium.
Genome Wide Methylome Alterations in Lung Cancer.
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.
High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis.
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines.
Human Cancer-Associated Mutations in the A{alpha} Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in A{alpha} Knock-In and Knockout Mice.
IA-2, a transmembrane protein tyrosine phosphatase, is expressed in human lung cancer cell lines with neuroendocrine phenotype.
Implication of a protein-tyrosine-phosphatase in human lung cancer.
In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
Inhibitors of Protein Tyrosine Phosphatase PTP1B With Anticancer Potential.
Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Involvement of cdc25c in cell cycle alteration of a radioresistant lung cancer cell line established with fractionated ionizing radiation.
Involvement of MAPK phosphatase-1 in dexamethasone-induced chemoresistance in lung cancer.
Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4.
Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP ?/? signaling by menin.
Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate.
Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU.
MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK.
miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.
miR-339-5p Increases Radiosensitivity of Lung Cancer Cells by Targeting Phosphatases of Regenerating Liver-1 (PRL-1).
MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A.
Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
Mitogen-Activated Protein Kinase Phosphatase-1 Is Required for Cisplatin Resistance.
Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.
Molecular Nodal Restaging Based on CEACAM5, FGFR2b and PTPN11 Expression Adds No Relevant Clinical Information in Resected Non-Small Cell Lung Cancer.
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Mutational analysis of PTPRT phosphatase domains in common human cancers.
N160 of Aiolos Determines its DNA-Binding Activity.
Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells.
Novel PROTACs for degradation of SHP2 protein.
NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide in human lung cancer cells.
Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics.
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.
PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting I?B?.
Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation.
Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC.
Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.
Protein tyrosine phosphatase receptor-type O targeted by methylation in lung cancer.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization.
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression.
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Regulation and deregulation of G2 checkpoint proteins with cisplatin.
Regulation of lung cancer cell growth and invasiveness by beta-TRCP.
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells.
Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients.
Statistical completion of a partially identified graph with applications for the estimation of gene regulatory networks.
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Tangeretin derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells in vitro and in vivo.
The carcinogen (7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene induces Cdc25B expression in human bronchial and lung cancer cells.
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.
The Lysyl Oxidase Propeptide Interacts with the Receptor-Type Protein Tyrosine Phosphatase Kappa and Inhibits {beta}-Catenin Transcriptional Activity in Lung Cancer Cells.
The Nonreceptor-Type Tyrosine Phosphatase PTPN13 Is a Tumor Suppressor Gene in Non-Small Cell Lung Cancer.
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells.
The red wine component ellagic acid induces autophagy and exhibits anti-lung cancer activity in vitro and in vivo.
The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.
Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway.
Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells.
YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
[Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer]
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
[Expression of protein-tyrosine-phosphatase 1B in non-small-cell lung cancer and its prognostic significance].
[Expressions and significances of PRL-3 and RhoC in A549 cell].
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Lupus Erythematosus, Systemic
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus.
Altered expression of protein tyrosine phosphatase, non-receptor type 22 isoforms in systemic lupus erythematosus.
Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus.
Association analysis of the PTPN22 gene in childhood-onset systemic lupus erythematosus in Mexican population.
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease.
Association between PPP2CA polymorphisms and clinical features in southwest Chinese systemic lupus erythematosus patients.
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Association of PTPN22 gene polymorphism and systemic lupus erythematosus in a cohort of Egyptian patients: impact on clinical and laboratory results.
Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations.
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes.
Associations between PTPN22 and TLR9 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis.
Autoimmunity-associated protein tyrosine phosphatase PEP negatively regulates IFN-? receptor signaling.
Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression.
Contribution of the R620W polymorphism of protein tyrosine phosphatase non-receptor 22 to systemic lupus erythematosus in Poland.
CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Expression of the sialosyl-Tn epitope on CD45 derived from activated peripheral blood T cells.
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes.
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
High prevalence of protein tyrosine phosphatase non-receptor N22 gene functional variant R620W in systemic lupus erythematosus patients from Kuwait: implications for disease susceptibility.
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
JAK2 and PTPRC mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
Meta-Analysis of the Correlation Between PTPN22 Gene Polymorphisms and Susceptibility to Systemic Lupus Erythematosus.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Multiplex family-based study in systemic lupus erythematosus: association between the R620W polymorphism of PTPN22 and the FcgammaRIIa (CD32A) R131 allele.
No association of PTPN22 R620 W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus.
Pathogenesis and treatment of autoimmune rheumatic diseases.
Promoter Hypomethylation Results in Increased Expression of Protein Phosphatase 2A in T Cells from Patients with Systemic Lupus Erythematosus.
Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus.
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.
Protein tyrosine phosphatase PTPN22 in human autoimmunity.
PTPN22 1858C>T gene polymorphism in patients with SLE: association with serological and clinical results.
PTPN22 1858C?>?T polymorphism and susceptibility to systemic lupus erythematosus: a meta-analysis update.
PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes.
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
PTPN22 gene polymorphism in Behçet's disease.
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
PTPN22 Gene Polymorphisms in Pediatric Systemic Lupus Erythematosus.
PTPN22 polymorphisms, but not R620W, were associated with the genetic susceptibility of systemic lupus erythematosus and rheumatoid arthritis in a Chinese Han population.
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
PTPN22 Variant R620W Is Associated With Reduced Toll-like Receptor 7-Induced Type I Interferon in Systemic Lupus Erythematosus.
PTPN22: its role in SLE and autoimmunity.
PTPN22: the archetypal non-HLA autoimmunity gene.
R620W polymorphism of protein tyrosine phosphatase PTPN22 in Egyptian children and adolescents with systemic lupus erythematosus: relation to thyroid autoimmunity.
Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE).
Regulation of autoimmune and anti-tumour T cell responses by PTPN22.
Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors.
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
The association between the PTPN22 C1858T polymorphism and systemic lupus erythematosus: a meta-analysis update.
The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients.
The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus.
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility.
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.
The PTPN22 C1858T variant as a risk factor for rheumatoid arthritis and systemic lupus erythematosus but not for systemic sclerosis in the Colombian population.
The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in caucasian case-control samples.
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples.
The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.
TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey.
Tumor necrosis factor receptor II and PTPN22 genes polymorphisms and the risk of systemic lupus erythematosus in Egyptian children.
[Correlation between PTPN22 gene polymorphism and systemic lupus erythematosus in Chinese Han patients.]
[Genetic polymorphisms of low molecular weight protein tyrosine phosphatase (LMW-PTP): relationship with erythrocyte enzymatic phenotype in patients with Systemic Lupus Erythematosus]
Lupus Nephritis
Association of polymorphic variants of PTPN22, TNF and VDR genes in children with lupus nephritis: A study in Colombian family triads.
IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice.
Lymphadenopathy
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Lymphangioma, Cystic
How necessary is to analyze PTPN11 gene in fetuses with first trimester cystic hygroma and normal karyotype?
Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.
Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites.
PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings.
Lymphatic Metastasis
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer.
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Clinical significance of sCIP2A levels in breast cancer.
Clinicopathological significance of PTPN12 expression in human breast cancer.
Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer.
Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation.
Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro.
Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma.
Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer.
High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer.
IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer.
Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer.
Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
Phosphatase of Regenerating Liver-3 Induces Angiogenesis by Increasing Extracellular Signal-Regulated Kinase Phosphorylation in Endometrial Adenocarcinoma.
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.
Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy.
Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.
PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.
PTP4A3 expression increases strongly in lymph node metastases from colorectal carcinoma.
Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma.
Role of silencing phosphatase of regenerationg liver-3 expression by microRNA interference in the growth of gastric cancer.
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance.
Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer.
Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway.
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
[Methylation of PTPRG gene and its regulation in gastric cancer]
Lymphedema
Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema.
Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans.
Lymphocytic Choriomeningitis
CD8+ T cell responses to a viral escape mutant epitope: active suppression via altered SHP-1 activity.
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection.
PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
Lymphohistiocytosis, Hemophagocytic
Reduced Tyk2/SHP-1 interaction and lack of SHP-1 mutation in a kindred of familial hemophagocytic lymphohistiocytosis.
Lymphoma
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Acid phosphatase activity of the lymphocytes during polychemotherapy of lymphoproliferative diseases.
Activating Mutations in PTPN11 and KRAS in Canine Histiocytic Sarcomas.
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor.
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation.
Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma.
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas.
Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation.
cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas.
Comparative quantitative analysis of cluster of differentiation 45 antigen expression on lymphocyte subsets.
Correction: The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration.
Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.
Differential induction of glioblastoma migration and growth by two forms of pleiotrophin.
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia.
Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes.
Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.
Effects of pleiotrophin, a heparin-binding growth factor, on human primary and immortalized chondrocytes.
Elevation of lymphocyte CD45 protein tyrosine phosphatase activity during mitosis.
Enzyme polymorphism in the classification of human malignant lymphoma.
Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation.
Expression of pleiotrophin and its receptors in human placenta suggests roles in trophoblast life cycle and angiogenesis.
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma.
Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas.
Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Genetic analysis of Raf1, Mdm2, c-Myc, Cdc25a and Cdc25b proto-oncogenes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice.
Haploinsufficiency of the ESCRT Component HD-PTP Predisposes to Cancer.
Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
High expression of PTPN21 in B-cell non-Hodgkin's gastric lymphoma, a positive mediator of STAT5 activity.
High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.
Identification of pleiotrophin in conditioned medium secreted from neural stem cells by SELDI-TOF and SELDI-tandem mass spectrometry.
Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.
Inhibition of Receptor Protein Tyrosine Phosphatase ?/? reduces alcohol intake in rats.
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.
Lck-dependent tyrosyl phosphorylation of the phosphotyrosine phosphatase SH-PTP1 in murine T cells.
Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway.
Molecular cloning and characterization of a novel human receptor protein tyrosine phosphatase gene, hPTP-J: down-regulation of gene expression by PMA and calcium ionophore in Jurkat T lymphoma cells.
Molecular Pathogenesis of Peripheral T Cell Lymphoma.
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
No evidence for involvement of mouse protein-tyrosine phosphatase-BAS-like Fas-associated phosphatase-1 in Fas-mediated apoptosis.
Oxidative stress induces B lymphocyte DNA damage and apoptosis by upregulating p66shc.
Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins.
Pleiotrophin increases neurite length and number of spiral ganglion neurons in vitro.
Pleiotrophin induces neurite outgrowth and up-regulates growth-associated protein (GAP-43) mRNA through the ALK/GSK3beta/beta-catenin signaling in developing mouse neurons.
Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Potential biomarkers screening to predict side effects of dexamethasone in different cancers.
PRL-2 increases Epo and IL-3 responses in hematopoietic cells.
Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.
Protein tyrosine phosphatase receptor type C (PTPRC or CD45).
Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.
Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis.
Proteomic Analysis of Malignant B-Cell Derived Microparticles Reveals CD148 as a Potentially Useful Antigenic Biomarker for Mantle Cell Lymphoma Diagnosis.
PTN-PTPRZ signalling is involved in deer antler stem cell regulation during tissue regeneration.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene.
Receptor-type tyrosine-protein phosphatase ? directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.
Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas.
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias : combination analysis with cDNA expression array and tissue microarray.
Regulation of BCR- and PKC/Ca(2+)-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and -tyrosine phosphatase activities.
SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts.
SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis.
SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases.
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes.
Structure and function of midkine as the basis of its pharmacological effects.
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2.
The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2.
The function of the protein tyrosine phosphatase SHP-1 in cancer.
The genetics of nodal marginal zone lymphoma.
The heparin-binding growth factor midkine: the biological activities and candidate receptors.
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells.
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
The tyrosine343 residue of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Transcriptional regulation of a receptor protein tyrosine phosphatase gene hPTP-J by PKC-mediated signaling pathways in Jurkat and Molt-4 T lymphoma cells.
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Tumor-associated macrophages increase the proportion of cancer stem cells in lymphoma by secreting pleiotrophin.
Tyrosine kinase and CD45 tyrosine phosphatase activity mediate p21ras activation in B cells stimulated through the antigen receptor.
Tyrosine phosphatase activity of lymphoma CD45 (GP180) is regulated by a direct interaction with the cytoskeleton.
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies.
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells]
[Construction and expression of recombinant adenovirus carrying human SHP-1 gene]
[Effect of As2O3 on demethylation of SHP-1 gene in human lymphoma cell line T2.]
[Effect of Bortezomib on Proliferation, Apoptosis and SHP-2 Gene Expression of Lymphoma Cells].
[Effects of sodium orthovanadate on proliferation and apoptosis in raji cells and its mechanism]
[Evaluation of tartrate-resistant acid phosphatase activity in lymphoma cells of the bone marrow]
[Expression and Significance of PTPL1 in Hematological Malignan-cies].
[Methylation Status of PTPL1 Gene in Non-Hodgkin's Lymphoma Cells].
[Polar acid phosphatase as T lymphoma marker (author's transl)]
[Recent progress in the protein-tyrosine phosphatase SHP1 gene: the significant correlation of the SHP1 gene silencing with the onset of lymphomas/leukemias]
[SHP-1 gene's methylation status of Daudi lymphoma cell and the demethylation effect of 5-aza-2'-deoxycytidine]
Lymphoma, B-Cell
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
BCL6 regulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia.
Effect of Huaier on the proliferation and apoptosis of human gastric cancer cells through modulation of the PI3K/AKT signaling pathway.
Effect of Jianpi Bushen prescription on the expression of SHP-1 and apoptosis-related genes in chemically damaged model mice.
Epigenetic deregulation in pediatric acute lymphoblastic leukemia.
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.
Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation.
Haploinsufficiency of the ESCRT Component HD-PTP Predisposes to Cancer.
Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls.
In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).
Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway.
PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis.
Protective effect of zinc on N-methyl-N-nitrosourea and testosterone-induced prostatic intraepithelial neoplasia in the dorsolateral prostate of Sprague Dawley rats.
PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.
PTPN1 Is Recurrently Mutated in Lymphoid Cancers.
PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest.
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts.
SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts.
T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
Lymphoma, B-Cell, Marginal Zone
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Lymphoma, Follicular
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Histochemical and immunohistochemical study of diffuse large-cell lymphomas.
Lymphoma, Large B-Cell, Diffuse
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.
Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
Lymphoma, Large-Cell, Anaplastic
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Lymphoma, Mantle-Cell
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis.
Proteomic Analysis of Malignant B-Cell Derived Microparticles Reveals CD148 as a Potentially Useful Antigenic Biomarker for Mantle Cell Lymphoma Diagnosis.
SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts.
Lymphoma, Non-Hodgkin
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma.
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma.
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas.
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin's lymphoma: a predictor of aggressive disease and new treatment target.
[Methylation Status of PTPL1 Gene in Non-Hodgkin's Lymphoma Cells].
Lymphoma, Primary Effusion
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
Lymphoma, T-Cell
Genetic screening for synthetic lethal partners of polynucleotide kinase/phosphatase: potential for targeting SHP-1 depleted cancers.
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.
Molecular Pathogenesis of Peripheral T Cell Lymphoma.
Lymphoma, T-Cell, Cutaneous
Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.
Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides.
Lymphoma, T-Cell, Peripheral
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Lymphopenia
PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion.
The tyrosine phosphatase PTPN22 discriminates weak self peptides from strong agonist TCR signals.
Lymphoproliferative Disorders
CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A.
Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disorders.
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Isoenzymatic study of leucocytic acid phosphatase in haematologic diagnosis.
Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7.
Lysosomal Storage Diseases
[Decrease in the rats of intraliposomal proteolysis and labilization of rat liver lysosomes following suramin administration]
Macular Degeneration
Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina.
Macular Edema
Exploring the effect of inhibitor AKB-9778 on VE-PTP by molecular docking and molecular dynamics simulation.
Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates tie2.
Malabsorption Syndromes
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
Malaria
A Bacterial Phosphatase-Like Enzyme of the Malaria Parasite Plasmodium falciparum Possesses Tyrosine Phosphatase Activity and Is Implicated in the Regulation of Band 3 Dynamics during Parasite Invasion.
Characterization of a unique aspartate-rich protein of the SET/TAF-family in the human malaria parasite, Plasmodium falciparum, which inhibits protein phosphatase 2A.
First genome-wide association study of non-severe malaria in two birth cohorts in Benin.
[Acid phosphatase activity of circulating leukocytes in mice in experimental malaria]
Malaria, Cerebral
Protein Tyrosine Phosphatase Inhibition Prevents Experimental Cerebral Malaria by Precluding CXCR3 Expression on T Cells.
Malnutrition
Maternal food restriction enhances insulin-induced GLUT-4 translocation and insulin signaling pathway in skeletal muscle from suckling rats.
Massive Hepatic Necrosis
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
Mastitis
GWAS and gene networks for milk-related traits from test-day multiple lactations in Portuguese Holstein cattle.
Reduced pathogenicity of a Candida albicans MAP kinase phosphatase (CPP1) mutant in the murine mastitis model.
Mastocytoma
The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells.
Mastocytosis
Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently.
SLAM family member 8 is involved in oncogenic KIT-mediated signaling in human mastocytosis.
Medulloblastoma
Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation.
Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
p53 Function is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Megalencephaly
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Melanoma
67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance.
A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis.
A receptor-type protein tyrosine phosphatase PTP zeta is expressed in human cutaneous melanomas.
Activated lymphocyte killer cells derived from melanoma tissue or peripheral blood.
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
An Anticancer Effect of Curcumin Mediated by Down-regulating PRL-3 Expression on Highly Metastatic Melanoma Cells.
Antagonism of p66shc by melanoma inhibitory activity.
Cantharidin induces G2/M phase arrest by inhibition of Cdc25c and Cyclin A and triggers apoptosis through reactive oxygen species and the mitochondria?dependent pathways of A375.S2 human melanoma cells.
CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation.
Cinerols, Nitrogenous Meroterpenoids from the Marine Sponge Dysidea cinerea.
Comparative proteomic analysis of mouse melanoma cell line B16, a metastatic descendant B16F10, and B16 overexpressing the metastasis-associated tyrosine phosphatase PRL-3.
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Endothelial Phosphatase VE-PTP Participates in Vasculogenic Mimicry by Preventing Autophagic Degradation of VE-Cadherin.
Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.
Expression and prognostic significance of CIP2A in cutaneous malignant melanoma.
Expression of cell cycle regulators in human cutaneous malignant melanoma.
FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface.
Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
HDAC6 interacts with PTPN1 to enhance melanoma cells progression.
Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.
Inhibition mechanism of naphthylphenylamine derivatives acting on the CDC25B dual phosphatase and analysis of the molecular processes involved in the high cytotoxicity exerted by one selected derivative in melanoma cells.
Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome.
Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.
LMW-PTP modulates glucose metabolism in cancer cells.
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation.
MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells.
Melanoma exosomes deliver a complex biological payload that upregulates PTPN11 to suppress T lymphocyte function.
Microarray analysis of differentially expressed genes regulating lipid metabolism during melanoma progression.
miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGF?R1, GNAQ, WASL, and RAC1.
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis.
Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation.
Patient with confirmed LEOPARD syndrome developing multiple melanoma.
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo.
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1.
PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.
PRL-3/PTP4A3 phosphatase regulates integrin ?1 in adhesion structures during migration of human ocular melanoma cells.
Protein tyrosine phosphatase 4A3 (PTP4A3) is required for Xenopus laevis cranial neural crest migration in vivo.
Protein Tyrosine Phosphatase 4A3 (PTP4A3) Promotes Human Uveal Melanoma Aggressiveness Through Membrane Accumulation of Matrix Metalloproteinase 14 (MMP14).
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2.
Protein tyrosine phosphatase genes downregulated in melanoma.
Proteomic analysis and the antimetastatic effect of N-(4-methyl)phenyl-O-(4-methoxy) phenyl-thionocarbamate-induced apoptosis in human melanoma SK-MEL-28 cells.
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells.
RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.
Scalp melanoma in a woman with LEOPARD syndrome: Possible implication of PTPN11 signaling in melanoma pathogenesis.
Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Targeted chemotherapy overcomes drug resistance in melanoma.
Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy.
The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
The phosphatase Shp1 interacts with and dephosphorylates cortactin to inhibit invadopodia function.
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.
The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization.
Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrial-dependent signaling pathways in A375.S2 human melanoma cells.
Tubeimoside I Inhibits Cell Proliferation and Induces a Partly Disrupted and Cytoprotective Autophagy Through Rapidly Hyperactivation of MEK1/2-ERK1/2 Cascade via Promoting PTP1B in Melanoma.
Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.
Melanoma, Experimental
Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity.
Melioidosis
Demonstration of acid phosphatase activity in antigenic glycoprotein fractions obtained from the culture filtrate of Pseudomonas pseudomallei.
Memory Disorders
A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease.
Alzheimer's Disease Drug Discovery--11th international conference--Promising new therapeutic approaches. 27-28 September 2010, Jersey City, NJ, USA.
Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid ?-Associated Alzheimer's Disease in Mice.
Phenotypically distinct subtypes of psychosis accompany novel or rare variants in four different signaling genes.
Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits.
Se-Methylselenocysteine Ameliorates Neuropathology and Cognitive Deficits by Attenuating Oxidative Stress and Metal Dyshomeostasis in Alzheimer Model Mice.
Trillium tschonoskii maxim extract attenuates abnormal Tau phosphorylation.
Meniere Disease
Association of a functional polymorphism of PTPN22 encoding a lymphoid protein phosphatase in bilateral Meniere's disease.
Meningioma
Deficiency of the protein-tyrosine phosphatase DEP-1/PTPRJ promotes matrix metalloproteinase-9 expression in meningioma cells.
Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies.
LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.
Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
Loss of the Protein-Tyrosine Phosphatase DEP-1/PTPRJ Drives Meningioma Cell Motility.
MKP-3 regulates PDGF-BB effects and MAPK activation in meningioma cells.
Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma.
Meningitis
Acid phosphatase activity of cerebrospinal fluid cells in bacterial and abacterial meningitis.
[Acid phosphatase activity of the cerebrospinal fluid in various types of meningitis.]
[Change in acid phosphatase activity in meningitis and brain abscess.]
Meningitis, Pneumococcal
Increased expression of tyrosine phosphatase SHP2 in experimental pneumococcal meningitis: correlation with tumor necrosis factor-alpha and cerebrospinal fluid pleocytosis.
Menkes Kinky Hair Syndrome
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
MERRF Syndrome
Advances in the genetics of progressive myoclonus epilepsy.
Mesothelioma
Data mining analysis of the PP2A cell cycle axis in mesothelioma patients.
Mesothelioma, Malignant
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
Metabolic Diseases
Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population.
Anti-obesity and hypolipidemic effects of Rheum undulatum in high-fat diet-fed C57BL/6 mice through protein tyrosine phosphatase 1B inhibition.
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Important roles of protein tyrosine phosphatase PTPN12 in tumor progression.
Improving Obesity and Insulin Resistance by Targeting Skeletal Muscle MKP-1.
Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice.
MAP kinase phosphatase-1--a new player at the nexus between sarcopenia and metabolic disease.
Metabolic Disease: Protein tyrosine phosphatase inhibitor reverses diabetes.
Mitogen-activated protein kinase phosphatase-1 - a potential therapeutic target in metabolic disease.
Prenatal Growth Patterns and Birthweight Are Associated With Differential DNA Methylation and Gene Expression of Cardiometabolic Risk Genes in Human Placentas: A Discovery-Based Approach.
Protein-tyrosine phosphatase 1B substrates and metabolic regulation.
PTP1B: A simple enzyme for a complex world.
Role of protein tyrosine phosphatase 1B in cardiovascular diseases.
Role of Receptor Protein Tyrosine Phosphatases (RPTPs) in Insulin Signaling and Secretion.
The association of genetically controlled CpG methylation (cg158269415) of protein tyrosine phosphatase, receptor type N2 (PTPRN2) with childhood obesity.
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
Metabolic Syndrome
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population.
At the Crossroads of Longevity and Metabolism: The Metabolic Syndrome and Life-Span Determinant Pathways.
Cellular effects of small molecule PTP1B inhibitors on insulin signaling.
Docking of oxalyl aryl amino benzoic acid derivatives into PTP1B.
DUSP1 Gene Polymorphisms Are Associated with Obesity-Related Metabolic Complications among Severely Obese Patients and Impact on Gene Methylation and Expression.
Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome?
Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.
Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress.
MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice.
MSI-1436 improves EMS adipose derived progenitor stem cells in the course of adipogenic differentiation through modulation of ER stress, apoptosis, and oxidative stress.
New aspects of p66Shc in ischemia reperfusion injury and cardiovascular diseases.
No association of reported functional protein tyrosine phosphatase 1B 3' UTR gene polymorphism with features of the metabolic syndrome in a Swedish population.
p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans.
Penostatin derivatives, a novel kind of protein phosphatase 1b inhibitors isolated from solid cultures of the entomogenous fungus Isaria tenuipes.
Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.
Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders.
Protein tyrosine phosphatase-1B gene PTPN1: selection of tagging single nucleotide polymorphisms and association with body fat, insulin sensitivity, and the metabolic syndrome in a normal female population.
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
PTP1B Inhibitors from the Entomogenous Fungi Isaria fumosorosea.
PTP1B: A simple enzyme for a complex world.
Reply to Dahlman et al. No association of reported functional protein tyrosine phosphatase 1B 3'UTR gene polymorphism with features of the metabolic syndrome in a Swedish population. J Int Med 2004; 255: 694-5.
Single nucleotide polymorphisms of protein tyrosine phosphatase 1B gene are associated with obesity in morbidly obese French subjects.
Structure and biosynthesis of fumosorinone, a new protein tyrosine phosphatase 1B inhibitor firstly isolated from the entomogenous fungus Isaria fumosorosea.
The low molecular weight protein tyrosine phosphatase promotes adipogenesis and subcutaneous adipocyte hypertrophy.
The Role of Inflammation in Diabetic Retinopathy.
The role of protein-tyrosine phosphatase 1B in integrin signaling.
The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
Upregulation of lipogenesis and protein tyrosine phosphatase-1B expression in the liver of Wistar rats with metabolic syndrome chronically induced by drinking sucrose water.
[Prescription of Jingdan Yimin for treatment of metabolic syndrome].
methylenetetrahydrofolate dehydrogenase (nad+) deficiency
Altered protein phosphatase 2A methylation and Tau phosphorylation in the young and aged brain of methylenetetrahydrofolate reductase (MTHFR) deficient mice.
Metrorrhagia
Automated MALDI Target Preparation Concept: Providing Ultra-High-Throughput Mass Spectrometry-Based Screening for Drug Discovery.
Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1.
Microcephaly
Final Exon Frameshift Biallelic PTPN23 Variants Are Associated with Microcephalic Complex Hereditary Spastic Paraplegia.
Micrognathism
Inactivation of LAR family phosphatase genes Ptprs and Ptprf causes craniofacial malformations resembling Pierre-Robin sequence.
Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.
Microphthalmos
Rapamycin prevents spontaneous abortion by triggering decidual stromal cell autophagy-mediated NK cell residence.
Microscopic Polyangiitis
PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
Migraine Disorders
Susceptible genes of restless legs syndrome in migraine.
Mitochondrial Diseases
Oxidative stress-dependent p66Shc phosphorylation in skin fibroblasts of children with mitochondrial disorders.
Monoclonal Gammopathy of Undetermined Significance
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Mouth Neoplasms
Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.
CIP2A overexpression in Taiwanese oral cancer patients.
Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo.
Functions of Shp2 in cancer.
Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer.
Increased Expression of the PRL-3 Gene in Human Oral Squamous Cell Carcinoma and Dysplasia Tissues.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression.
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Role of Salivary Biomarkers in Oral Cancer Detection.
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.
Movement Disorders
PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
Moyamoya Disease
Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
Mucocutaneous Lymph Node Syndrome
Atypical coronary artery aneurysms due to Kawasaki disease in Noonan syndrome with a novel PTPN11 mutation.
Mucopolysaccharidoses
[Changes in acid phosphatase activity induced by vitamin A in cultures of fibroblasts from a patient with mucopolysaccharidosis]
Multiple Endocrine Neoplasia
Mapping of the gene encoding the B56 beta subunit of protein phosphatase 2A (PPP2R5B) to a 0.5-Mb region of chromosome 11q13 and its exclusion as a candidate gene for multiple endocrine neoplasia type 1 (MEN1).
The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
Multiple Endocrine Neoplasia Type 1
Mapping of the gene encoding the B56 beta subunit of protein phosphatase 2A (PPP2R5B) to a 0.5-Mb region of chromosome 11q13 and its exclusion as a candidate gene for multiple endocrine neoplasia type 1 (MEN1).
Multiple Endocrine Neoplasia Type 2a
PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.
Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
Multiple Endocrine Neoplasia Type 2b
PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
Multiple Myeloma
Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1.
Differential regulation of FGFR3 by PTPN1 and PTPN2.
Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN.
Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission.
Histochemical and immunohistochemical techniques on acrylate embedded bone biopsies.
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Phosphatase of regenerating liver-3 regulates cancer cell metabolism in multiple myeloma.
Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.
PRL-3 promotes a positive feedback loop between STAT1/2-induced gene expression and glycolysis in multiple myeloma.
Protein phosphatase 2A modulates the proliferation of human multiple myeloma cells via regulation of the production of reactive oxygen intermediates and anti-apoptotic factors.
Retraction: Boswellic Acid Blocks Signal Transducers and Activators of Transcription 3 Signaling, Proliferation, and Survival of Multiple Myeloma via the Protein Tyrosine Phosphatase SHP-1.
Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3.
The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling.
Triptolide blocks the STAT3 signaling pathway through induction of protein tyrosine phosphatase SHP-1 in multiple myeloma cells.
Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.
[Plasma cell acid phosphatase in the differential diagnosis of monoclonal gammopathies]
[Usefulness of plasma cell acid phosphatase in the differential diagnosis of monoclonal gammopathies]
Multiple Sclerosis
A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.
A point mutation in PTPRC is associated with the development of multiple sclerosis.
Accelerated Axonal Loss Following Acute CNS Demyelination in Mice Lacking Protein Tyrosine Phosphatase Receptor Type Z.
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
CD45 (PTPRC) as a candidate gene in multiple sclerosis.
Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study.
Could ?-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson's Disease and Diabetes as Well as Potential Therapies?
CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
Does 77C-->G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?
Enhanced frequency of a PTPRC (CD45) exon A mutation (77C-->G) in systemic sclerosis.
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.
Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.
Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
MicroRNA-448 promotes multiple sclerosis development through induction of Th17 response through targeting protein tyrosine phosphatase non-receptor type 2 (PTPN2).
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Mitogen-Activated Protein Kinase Phosphatase (MKP)-1 in Nervous System Development and Disease.
Protein tyrosine phosphatase gene (PTPN22) polymorphism in multiple sclerosis.
Protein tyrosine phosphatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population.
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients.
PTPRC (CD45) is not associated with multiple sclerosis in a large cohort of German patients.
PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients.
Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes.
RXR? Blocks Nerve Regeneration after Spinal Cord Injury by Targeting p66shc.
SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.
Synthesis and Biological Evaluation of FTY720 (Fingolimod) Derivatives with Aromatic Head Group as Anticancer Agents.
The control of reactive oxygen species production by SHP-1 in oligodendrocytes.
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis.
The role of the PTPRC (CD45) mutation in the development of multiple sclerosis in the North West region of the United Kingdom.
Muscle Hypotonia
B56?-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Neurodevelopmental phenotype caused by a de novo PTPN4 single nucleotide variant disrupting protein localization in neuronal dendritic spines.
Muscle Spasticity
Activity of smooth muscle phosphatases 1 and 2A in rabbit basilar artery in vasospasm.
Morphological and functional effects of altered cysteine string protein at the Drosophila larval neuromuscular junction.
Recombinant osteopontin attenuates experimental cerebral vasospasm following subarachnoid hemorrhage in rats through an anti-apoptotic mechanism.
Recombinant osteopontin in cerebral vasospasm after subarachnoid hemorrhage.
Muscle Weakness
Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome.
Muscular Atrophy
C1-Ten Is a Protein Tyrosine Phosphatase of Insulin Receptor Substrate 1 (IRS-1), Regulating IRS-1 Stability and Muscle Atrophy.
Dietary supplementation with ketoacids protects against CKD-induced oxidative damage and mitochondrial dysfunction in skeletal muscle of 5/6 nephrectomised rats.
Dual-specificity phosphatase 29 is induced during neurogenic skeletal muscle atrophy and attenuates glucocorticoid receptor activity in muscle cell culture.
Dual-Specificity Phosphatase 4 (Dusp4) is Upregulated During Skeletal Muscle Atrophy and Modulates Extracellular Signal-Regulated Kinase (ERK) Activity.
Effects of various drugs on denervation changes in rat muscles.
Inhibition of C1-Ten PTPase activity reduces insulin resistance through IRS-1 and AMPK pathways.
The lysosomal enzymes acid phosphatase and cathepsin D in rats intoxicated with Senna occidentalis seeds.
Muscular Diseases
Germanium myopathy: clinical and experimental pathological studies.
Growth stimulation of primary B cell precursors by the anti-phosphatase Sbf1.
Selective screening of late-onset Pompe disease (LOPD) in patients with non-diagnostic muscle biopsies.
SHP-1-Dependent Macrophage Differentiation Exacerbates Virus-Induced Myositis.
Muscular Dystrophies
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
Muscular Dystrophy, Duchenne
Concomitance of basophilia, ribonucleic acid and acid phosphatase activity in regenerating muscle fibres.
Musculoskeletal Abnormalities
P0-Related Protein Accelerates Human Mesenchymal Stromal Cell Migration by Modulating VLA-5 Interactions with Fibronectin.
Myasthenia Gravis
Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis.
Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis.
Expression and clinical significance of protein tyrosine phosphatase nonreceptor 22 in resected thymoma.
Lack of association of the CIITA -168A?G promoter SNP with myasthenia gravis and its role in autoimmunity.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
PTPN22 and CTLA-4 gene polymorphisms in resected thymomas and thymus for myasthenia gravis.
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data.
PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-Analysis.
PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis.
The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.
The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis.
Mycobacterium Infections
Systematic Analysis of Mycobacterial Acylation Reveals First Example of Acylation-mediated Regulation of Enzyme Activity of a Bacterial Phosphatase.
Mycoses
The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.
Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses.
Myelodysplastic Syndromes
A case of Behcet's disease associated with myelodysplastic syndrome involving trisomy 8 and a gain-of-function mutation in SHP-2.
A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1.
Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.
Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes.
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome.
Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis.
Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.
Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia.
Myelodysplastic syndrome with multilineage dysplasia evolving to acute myeloid leukemia: Noonan syndrome with c.218C>T mutation in PTPN11 gene.
Novel oncogenic PTPN11 mutations in myelodysplastic syndrome in Korean patients.
PTK2 and PTPN11 expression in myelodysplastic syndromes.
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
[Experimental study of SHP-1 promoter methylation in myelodysplastic syndromes and its related mechanism].
[Relationship between SHP-1 gene methylation and STAT3 phosphorylation and prognosis in patients with myelodysplastic syndrome].
Myeloproliferative Disorders
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Functional variation of SHP-2 promoter is associated with preterm birth and delayed myelination and motor development in preterm infants.
Genetic landscape of RASopathies in Chinese: Three decades' experience in Hong Kong.
Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation.
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Malignant diseases in Noonan syndrome and related disorders.
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal.
The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling.
Transient myeloproliferative disorder in an infant with PTPN11 mutation.
Myocardial Infarction
Cardiac alkaline and acid phosphatase activity and potassium concentration in dogs with acute myocardial infarction.
Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICE-inhibitory protein.
Crucial lncRNAs associated with adipocyte differentiation from human adipose-derived stem cells based on co-expression and ceRNA network analyses.
Disrupting protein tyrosine phosphatase ? does not prevent sympathetic axonal dieback following myocardial infarction.
Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice.
Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating ?-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting ?-Catenin.
Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia.
Overexpression of protein phosphatase 2A in a murine model of chronic myocardial infarction leads to increased adverse remodeling but restores the regulation of ?-catenin by glycogen synthase kinase 3?
PTPRG is an ischemia risk locus essential for HCO3--dependent regulation of endothelial function and tissue perfusion.
RNA interference targeting SHP-1 attenuates myocardial infarction in rats.
Selective Vascular Endothelial Protection Reduces Cardiac Dysfunction in Chronic Heart Failure.
SH2 domain-containing protein tyrosine phosphatase-2 (SHP-2) prevents cardiac remodeling after myocardial infarction through ERK/SMAD signaling pathway.
Simultaneous regulation of apoptotic gene silencing and angiogenic gene expression for myocardial infarction therapy: Single-carrier delivery of SHP-1 siRNA and VEGF-expressing pDNA.
Survival pathways in hypertrophy and heart failure: the gp130-STAT axis.
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis.
Targeting protein tyrosine phosphatase ? after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias.
Targeting Protein Tyrosine Phosphatase PTP-PEST for Therapeutic Intervention in Acute Myocardial Infarction.
Up-regulating microRNA-203 alleviates myocardial remodeling and cell apoptosis through down-regulating PTP1B in rats with myocardial infarction.
Upregulating MicroRNA-203 Alleviates Myocardial Remodeling and Cell Apoptosis Through Downregulating Protein Tyrosine Phosphatase 1B in Rats With Myocardial Infarction.
[Acid phosphatase activity of the leukocytes of patients with myocardial infarct]
[Leukocyte acid phosphatase activity in myocardial infarct]
Myocardial Ischemia
Coronary artery dilatation in LEOPARD syndrome. A child case and literature review.
Electron microscopic cytochemical studies on acid phosphatase activity in acute myocardial ischemia.
Overexpression of miR-210 promotes the potential of cardiac stem cells against hypoxia.
Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis.
Myocardial Reperfusion Injury
The tyrosine phosphatase inhibitor bis(maltolato)oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels.
Myocarditis
Induction of autoimmunity in the absence of CD28 costimulation.
Myoclonic Epilepsies, Progressive
A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).
Alternative splicing modulates subcellular localization of laforin.
Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase.
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.
Regional and developmental expression of Epm2a gene and its evolutionary conservation.
Myoclonus
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Myoma
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-? production.
Myopathies, Structural, Congenital
A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast.
Centronuclear myopathy: histochemistry and electron microscopy. Report of two cases.
ICAAR, a novel member of a new family of transmembrane, tyrosine phosphatase-like proteins.
Inaugural article: myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate.
MTM1 gene mutations in Japanese patients with the severe infantile form of myotubular myopathy.
Rat testicular myotubularin, a protein tyrosine phosphatase expressed by Sertoli and germ cells, is a potential marker for studying cell-cell interactions in the rat testis.
Myopia
Association Mapping of the High-Grade Myopia MYP3 Locus Reveals Novel Candidates UHRF1BP1L, PTPRR, and PPFIA2.
Association of Extracellular Signal-Regulated Kinase Genes With Myopia: A Longitudinal Study of Chinese Children.
Novel Myopia Genes and Pathways Identified From Syndromic Forms of Myopia.
Myositis
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Regulation of the chikungunya-virus-induced innate inflammatory response by protein tyrosine phosphatase non-receptor 6 in muscle cells.
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
The PTPN22 gene is associated with idiopathic inflammatory myositis.
Myotoxicity
The lysosomal enzymes acid phosphatase and cathepsin D in rats intoxicated with Senna occidentalis seeds.
Myxoma
Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.
Nasal Polyps
The expression of cancerous inhibitor protein phosphatase 2A in chronic rhinosinusitis with nasal polyps.
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
Nasopharyngeal Carcinoma
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma.
Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma.
Increased SHP-1 expression results in radioresistance, inhibition of cellular senescence, and cell cycle redistribution in nasopharyngeal carcinoma cells.
Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
MicroRNA-378g enhanced radiosensitivity of NPC cells partially by targeting protein tyrosine phosphatase SHP-1.
MicroRNA-4649-3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells.
Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Over-expression of protein tyrosine phosphatase 4A2 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma.
PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.
PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.
Quinalizarin enhances radiosensitivity of nasopharyngeal carcinoma cells partially by suppressing SHP-1 expression.
SHP-1 overexpression increases the radioresistance of NPC cells by enhancing DSB repair, increasing S phase arrest and decreasing cell apoptosis.
The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma.
Neoplasm Metastasis
1H, 15N, 13C resonance assignments of the reduced and active form of human Protein Tyrosine Phosphatase, PRL-1.
1HN, 13C, and 15N backbone resonance assignments of the SET/TAF-1?/I2PP2A oncoprotein (residues 23-225).
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets.
A novel binding factor of 14-3-3beta functions as a transcriptional repressor and promotes anchorage-independent growth, tumorigenicity, and metastasis.
A phosphatase associated with metastasis of colorectal cancer.
A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
Aberrant activation of the CD45-Wnt signaling axis promotes stemness and therapy resistance in colorectal cancer cells.
Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge Chondrosia corticata, on human prostate cancer cells via modulation of epithelial-to-mesenchymal transition.
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells.
Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis.
Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver.
Can dehydroepiandrostenedione (DHEA) target PRL-3 to prevent colon cancer metastasis?
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels.
CCL26 Participates in the PRL-3-Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration.
CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma.
CDC25A functions as a novel Ar corepressor in prostate cancer cells.
Cdc25A Regulates Matrix Metalloprotease 1 through Foxo1 and Mediates Metastasis of Breast Cancer Cells.
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer.
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Clinical significance of sCIP2A levels in breast cancer.
Clinicopathological significance of PTPN12 expression in human breast cancer.
Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer.
Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Correlation between Liver Metastases and the Level of PRL-3 mRNA Expression in Patients with Primary Colorectal Cancer.
Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer.
Detection of the GD2+/CD56+/CD45- immunophenotype by flow cytometry in cerebrospinal fluids from a patient with retinoblastoma.
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
DNA copy number changes at 8q11-24 in metastasized colorectal cancer.
Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression.
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation.
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Effect of VTCN1 on progression and metastasis of ovarian carcinoma in vitro and vivo.
Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.
Elevation of serum acid phosphatase in cancers with bone metastasis.
Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer.
Epithelial-Mesenchymal Transition in Colorectal Carcinoma: Comparison Between Primary Tumor, Lymph Node and Liver Metastases.
Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro.
Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo.
Expression of receptor protein tyrosine phosphatase ? is a risk factor for triple negative breast cancer relapse.
Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma.
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Gene expression profiles in cells transformed by overexpression of the IGF-I receptor.
Gene heterogeneity in metastasis of colorectal cancer to the lung.
Generation of conditional knockout alleles for PRL-3.
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.
Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis.
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/?-catenin signaling.
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer.
High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis.
High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients.
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis.
Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.
Identification of genes that may play critical roles in phenobarbital (PB)-induced liver tumorigenesis due to altered DNA methylation.
Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3.
Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta?analysis and cross?species comparison.
Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer.
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Immunohistochemical assessment of PRL-3 (PTP4A3) expression in tumor buds, invasion front, central region of tumor and metastases of colorectal cancer.
Increase in CIP2A expression is associated with doxorubicin resistance.
Increased metastasis with loss of E2F2 in Myc-driven tumors.
Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B.
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Integrated Analysis of Global mRNA and Protein Expression Data in HEK293 Cells Overexpressing PRL-1.
KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer.
Leiomyosarcoma of the heart and its pulmonary metastasis, both with prominent osteoclast-like multinucleated giant cells expressing tartrate-resistant acid phosphatase activity.
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Loss of receptor protein tyrosine phosphatase ?/? (RPTP?/?) promotes prostate cancer metastasis.
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer.
Low molecular weight protein tyrosine phosphatase as signaling hub of cancer hallmarks.
Mapping nucleolar localization sequences of 1A6/DRIM.
Mass spectrometry study of PRL-3 phosphatase inactivation by disulfide bond formation and cysteine into glycine conversion.
Measuring p66Shc Signaling Pathway Activation and Mitochondrial Translocation in Cultured Cells.
MenaINV mediates synergistic crosstalk between signaling pathways driving chemotaxis and haptotaxis.
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3.
MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling.
MicroRNA-217 suppressed epithelial-to-mesenchymal transition in gastric cancer metastasis through targeting PTPN14.
microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer.
MicroRNA-378g enhanced radiosensitivity of NPC cells partially by targeting protein tyrosine phosphatase SHP-1.
MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU.
MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta.
miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1.
miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE.
miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB.
miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Molecular Profiles and Metastasis Markers in Chinese Patients with Gastric Carcinoma.
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
N160 of Aiolos Determines its DNA-Binding Activity.
Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells.
New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53.
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.
Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.
Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
Overexpression of PTPRN Promotes Metastasis of Lung Adenocarcinoma and Suppresses NK Cell Cytotoxicity.
Overexpression of the Protein Tyrosine Phosphatase PRL-2 Correlates with Breast Tumor Formation and Progression.
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma.
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
Phosphatase of regenerating liver-3 directly interacts with integrin ?1 and regulates its phosphorylation at tyrosine 783.
Phosphatase of Regenerating Liver-3 Induces Angiogenesis by Increasing Extracellular Signal-Regulated Kinase Phosphorylation in Endometrial Adenocarcinoma.
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo.
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis.
Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis.
Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis.
Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration.
Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.
Presence of creatine kinase BB isoenzyme in some patients with prostatic carcinoma.
Primary pineal tumors - Unraveling histological challenges and certain clinical myths.
PRL phosphatases as potential molecular targets in cancer.
PRL PTPs: mediators and markers of cancer progression.
PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
PRL-3 and PRL-1 promote cell migration, invasion, and metastasis.
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
PRL-3 expression in metastatic cancers.
PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.
PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism.
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.
PRL-3 phosphatase and cancer metastasis.
PRL-3 phosphatase is implicated in ovarian cancer growth.
PRL-3 promotes breast cancer progression by downregulating p14
PRL-3 promotes cell adhesion by interacting with JAM2 in colon cancer.
PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly.
PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo.
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.
PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN.
PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels.
PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.
PRL-3 suppresses c-Fos and integrin alpha2 expression in ovarian cancer cells.
PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
PRL-3/PTP4A3 phosphatase regulates integrin ?1 in adhesion structures during migration of human ocular melanoma cells.
PRL-3: a metastasis-associated phosphatase in search of a function.
PRL-3: a phosphatase for metastasis?
Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy.
Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer.
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Protein phosphatase 2A C? regulates proliferation, migration, and metastasis of osteosarcoma cells.
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.
Protein tyrosine phosphatase 4A3 (PTP4A3) is required for Xenopus laevis cranial neural crest migration in vivo.
Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.
Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.
Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling.
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling.
Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R?2-Promoted Invasion and Metastasis in Cancer Cells.
Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion.
Proteomic analysis identifies translationally controlled tumor protein as a mediator of phosphatase of regenerating liver-3-promoted proliferation, migration and invasion in human colon cancer cells.
Proteomic maps of human gastrointestinal stromal tumor subgroups.
PTP-PEST phosphatase variations in human cancer.
PTP1B Contributes to Calreticulin-Induced Metastatic Phenotypes in Esophageal Squamous Cell Carcinoma.
PTP1B expression contributes to gastric cancer progression.
PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
PTP1B up-regulates EGFR expression by dephosphorylating MYH9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma.
PTP4A3 (PRL-3) expression correlate with lymphatic metastases in gastric cancer.
PTP4A3 expression increases strongly in lymph node metastases from colorectal carcinoma.
PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization.
PTPH1 promotes tumor growth and metastasis in human glioma.
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
PTPN11 hypomethylation is associated with gastric cancer progression.
PTPN2 negatively regulates macrophage inflammation in atherosclerosis.
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization.
PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.
PTPR? Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF-? Receptor 1.
PTPRA facilitates cancer growth and migration via the TNF-?-mediated PTPRA-NF-?B pathway in MCF-7 breast cancer cells.
PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition.
PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin.
PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.
PTPRM, a candidate tumor suppressor gene in small intestinal neuroendocrine tumors.
Pyrophosphatase overexpression is associated with cell migration, invasion, and poor prognosis in gastric cancer.
Ras-induced and ERK1/2 Phosphorylation-Dependent Isomerization of PTP-PEST by PIN1 Promotes FAK Dephosphorylation by PTP-PEST.
Regulation of the Src Kinase-associated Phosphoprotein 55 Homologue by the Protein Tyrosine Phosphatase PTP-PEST in the Control of Cell Motility.
Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.
Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma.
Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and stemness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-independent mechanisms.
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.
Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.
Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
RNA Sequencing Analysis Reveals Interactions between Breast Cancer or Melanoma Cells and the Tissue Microenvironment during Brain Metastasis.
Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti- Cancer Drug Target.
Role of silencing phosphatase of regenerationg liver-3 expression by microRNA interference in the growth of gastric cancer.
Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis.
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.
SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.
SHP-2 Interacts with CD81 and Regulates the Malignant Evolution of Colorectal Cancer by Inhibiting Epithelial-Mesenchymal Transition.
SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro.
Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells.
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Snail as a key regulator of PRL-3 gene in colorectal cancer.
Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.
Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.
Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer.
Structural insights into molecular function of the metastasis-associated phosphatase PRL-3.
Structure and backbone dynamics of vanadate-bound PRL-3: comparison of 15N nuclear magnetic resonance relaxation profiles of free and vanadate-bound PRL-3.
Structure of human PRL-3, the phosphatase associated with cancer metastasis.
Structure of the complex of an iminopyridinedione PTP4A3 phosphatase inhibitor with human serum albumin.
TAFs contributes the function of PTPN2 in colorectal carcinogenesis through activating JAK/STAT signaling pathway.
Targeting PTPs with small molecule inhibitors in cancer treatment.
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.
The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer.
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability.
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
The Expression of the Phosphatase Regenerating Liver 3 Gene is Associated with Outcome in Patients with Colorectal Cancer.
The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone.
The interplay between p66Shc, reactive oxygen species and cancer cell metabolism.
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
The mechanisms of colorectal cancer cell mesenchymal-epithelial transition induced by hepatocyte exosome-derived miR-203a-3p.
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation.
The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
The Phosphatase PRL-3 Is Involved in Key Steps of Cancer Metastasis.
The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma.
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.
The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
The SIX1-EYA transcriptional complex as a therapeutic target in cancer.
The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance.
The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.
The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas.
Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer.
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.
Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression.
Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway.
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.
Vemurafenib downmodulates aggressiveness mediators of colorectal cancer (CRC): Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP), Protein Tyrosine Phosphatase 1B (PTP1B) and Transforming Growth Factor ? (TGF?).
Whole-exome sequencing identifies prognostic mutational signatures in gastric cancer.
YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
[Construction of a lentiviral vector for RNA interference of PRL-3 gene and its stable expression in SW480 cells]
[Construction of the life cycle of Angiostrongylus cantonensis in laboratory]
[Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer]
[Establishment of a colorectal cancer cell line with PRL-3 and CDH22 gene knock-down by lentivirus-mediated RNA interference.]
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
[Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance].
[Histochemical study of the immune response of the regional lymph nodes in breast and stomach cancer]
[Methylation of PTPRG gene and its regulation in gastric cancer]
[Phosphatase of regenerating liver-3 (PRL-3) and tumor metastasis]
[Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
Neoplasm Micrometastasis
Erratum to: The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Neoplasm, Residual
Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer.
Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia.
Neoplasms
(-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.
17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.
1alpha,25-dihydroxyvitamin D3 activates T cells of tumor bearers through protein phosphatase 2A.
1H, 13C and 15N NMR chemical shift assignments of cAMP-regulated phosphoprotein-19 and -16 (ARPP-19 and ARPP-16).
1H, 15N, 13C resonance assignments of the reduced and active form of human Protein Tyrosine Phosphatase, PRL-1.
1HN, 13C, and 15N backbone resonance assignments of the SET/TAF-1?/I2PP2A oncoprotein (residues 23-225).
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets.
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization.
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors.
?-Caryophyllene attenuates lipopolysaccharide-induced acute lung injury via inhibition of the MAPK signalling pathway.
?-Tocotrienol but not ?-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
A 100-kb physical and transcriptional map around the EDH17B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase.
A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells.
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
A Conserved Amino Acid in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and Repression of Epithelial Differentiation.
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.
A dimeric urea of the bisabolene sesquiterpene from the Okinawan marine sponge Axinyssa sp. inhibits protein tyrosine phosphatase 1B activity in Huh-7 human hepatoma cells.
A FERM domain governs apical confinement of PTP-BL in epithelial cells.
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
A functional role for Smad7 in sustaining colon cancer cell growth and survival.
A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1.
A high-molecular weight complex with acid phosphatase activity in human breast cancer.
A highly conserved processed PTEN pseudogene is located on chromosome band 9p21.
A Highly Sensitive Electrochemiluminescence Biosensor for Pyrophosphatase Detection Based on Click Chemistry-Triggered Hybridization Chain Reaction in Homogeneous Solution.
A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.
A molecular link between E2F-1 and the MAPK cascade.
A monoclonal antibody against the catalytic domain of PTP1B.
A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
A new abietane diterpenoid from Ajuga ovalifolia var. calantha induces human lung epithelial A549 cell apoptosis by inhibiting SHP2.
A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type ? in chronic myeloid leukemia patients.
A nonhomologous end-joining pathway is required for protein phosphatase 2A promotion of DNA double-strand break repair.
A Nonsynonymous/Synonymous Substitution Analysis of the B56 Gene Family Aids in Understanding B56 Isoform Diversity.
A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.
A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer.
A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
A novel PTPRZ1-ETV1 fusion in gliomas.
A novel splice variant of the protein tyrosine phosphatase PTPRJ that encodes for a soluble protein involved in angiogenesis.
A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis.
A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).
A polar extract of the Maya healing plant Anthurium schlechtendalii (Aracea) exhibits strong in vitro anticancer activity.
A polybromodiphenyl ether from an Indonesian marine sponge Lamellodysidea herbacea and its chemical derivatives inhibit protein tyrosine phosphatase 1B, an important target for diabetes treatment.
A Potential Therapeutic Application of SET/I2PP2A Inhibitor OP449 for Canine T-Cell Lymphoma.
A preliminary study of elevated alkaline phosphatase and cathepsin in bronchial aspirates of patients with lung cancer and bronchitis.
A retrospective cohort study of clinical value of PRL-3 in stage III human colorectal cancer.
A role for protein phosphatase 2A in regulating p38 mitogen activated protein kinase activation and tumor necrosis factor-alpha expression during influenza virus infection.
A role for receptor tyrosine phosphatase zeta in glioma cell migration.
A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2).
A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites.
A SMAP in the face for cancer.
A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55.
A squalamine derivative, NV669, as a novel PTP1B inhibitor: in vitro and in vivo effects on pancreatic and hepatic tumor growth.
A synthetic biotinylated peptide, BP21, inhibits the induction of mRNA expression of inflammatory substances by oxidized- and lyso-phosphatidylcholine.
A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma.
A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles.
A transgenic Drosophila model demonstrates that the Helicobacter pylori CagA protein functions as a eukaryotic Gab adaptor.
A truncated isoform of the protein phosphatase 2A B56gamma regulatory subunit may promote genetic instability and cause tumor progression.
A tyrosine phosphatase is associated with the somatostatin receptor.
A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
A unique and rapid approach toward the efficient development of novel protein tyrosine phosphatase (PTP) inhibitors based on 'clicked' pseudo-glycopeptides.
Aberrant activation of the CD45-Wnt signaling axis promotes stemness and therapy resistance in colorectal cancer cells.
Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.
Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas.
Abnormal splicing of SHP-1 protein tyrosine phosphatase in human T cells. Implications for lymphomagenesis.
Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.
Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA damage but is not sufficient to produce tumors.
Absence of PTEN/MMAC1 germ-line mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome.
Absolute configuration and protein tyrosine phosphatase 1B inhibitory activity of xanthoepocin, a dimeric naphtopyrone from Penicillium sp. IQ-429.
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin.
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Acetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer.
Acid Phosphatase Activity of Normal and Tumor Tissue of Tobacco Grown in Vitro and in Vivo.
Acid phosphatase and non-specific alpha-naphthol acetate esterase activities of monocytes in patients with cancer of the digestive tract during surgical treatment.
Acid phosphatase in prostatic tissue homogenates from patients with benign prostatic hyperplasia and prostatic carcinoma.
Acid phosphatase response in murine rhabdomyosarcoma for various tumour volumes and after different doses of neutron irradiation, alone or combined with exogenous ATP.
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.
Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure.
Actinomycetes for marine drug discovery isolated from mangrove soils and plants in China.
Activated lymphocyte killer cells derived from melanoma tissue or peripheral blood.
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Activating Mutations in PTPN11 and KRAS in Canine Histiocytic Sarcomas.
Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients.
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase.
Activation of oncogenic tyrosine kinase signaling promotes insulin receptor-mediated cone photoreceptor survival.
Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
Activation of protein kinases and the inactivation of protein phosphatase 2A in tumour necrosis factor and interleukin-1 signal-transduction pathways.
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.
Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction.
Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells.
Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma.
Acute lymphoblastic leukemia in the context of RASopathies.
Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity.
Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B.
Adrenocorticotropin induces mitogen-activated protein kinase phosphatase 1 in Y1 mouse adrenocortical tumor cells.
Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells.
Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity.
ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers.
Alkaline phosphatase and phosphoamino acid phosphatases in normal and cancerous tissues of the human larynx.
Alkaloids from the nearly ripe fruits of Evodia rutaecarpa and their bioactivities.
Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer.
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Allelic loss of the PTEN gene and mutation of the TP53 gene in choriocarcinoma arising from gastric adenocarcinoma: analysis of loss of heterozygosity in two male patients with extragonadal choriocarcinoma.
AlloDriver: a method for the identification and analysis of cancer driver targets.
Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo.
Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.
Altered distribution and expression of protein tyrosine phosphatases in normal human skin as compared to squamous cell carcinomas.
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
Altered genome-wide methylation in endometriosis.
Altered response of a human squamous cell carcinoma cell line to 1, 25-dihydroxyvitamin D(3) after transfer of a normal chromosome 11.
An acid phosphatase in the plasma membranes of human astrocytoma showing marked specificity toward phosphotyrosine protein.
An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.
An Adamantyl-Substituted Retinoid-Derived Molecule That Inhibits Cancer Cell Growth and Angiogenesis by Inducing Apoptosis and Binds to Small Heterodimer Partner Nuclear Receptor: Effects of Modifying Its Carboxylate Group on Apoptosis, Proliferation, and Protein-Tyrosine Phosphatase Activity.
An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo.
An Anticancer Effect of Curcumin Mediated by Down-regulating PRL-3 Expression on Highly Metastatic Melanoma Cells.
An integrated in silico approach to understand protein-protein interactions: human meprin-? with fetuin-A.
An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis.
An unexpected new role of mutant Ras: perturbation of human embryonic development.
An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond.
Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer.
Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas.
Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol.
Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways.
Angiogenic Endothelial Cell Signaling in Cardiac Hypertrophy and Heart Failure.
Anti-Alzheimer's Disease Molecular Mechanism of Acori Tatarinowii Rhizoma Based on Network Pharmacology.
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss.
Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Anti-proliferative effect of (19Z)-halichondramide, a novel marine macrolide isolated from the sponge Chondrosia corticata, is associated with G2/M cell cycle arrest and suppression of mTOR signaling in human lung cancer cells.
Anti-tumor effects of perphenazine on canine lymphoma.
Anticancer activity of sodium stibogluconate in synergy with IFNs.
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge Chondrosia corticata, on human prostate cancer cells via modulation of epithelial-to-mesenchymal transition.
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase.
Apigetrin induces extrinsic apoptosis, autophagy and G2/M phase cell cycle arrest through PI3K/AKT/mTOR pathway in AGS human gastric cancer cell.
Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.
Approaches to Investigating the Protein Interactome of PTEN.
Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia.
Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas.
Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells.
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Assessment of biochemical parameters and characterization of TNF? -308G/A and PTPN22 +1858C/T gene polymorphisms in the risk of obesity in adolescents.
Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Association between diversity in the Src homology 2 domain--containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer.
Association between serum pepsinogens and polymorphismof PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese.
Association of 3BP2 with SHP-1 regulates SHP-1-mediated production of TNF-? in RBL-2H3 cells.
Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation.
Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer.
Association of polyomavirus middle tumor antigen with 14-3-3 proteins.
Association of protein phosphatase 2A with polyoma virus medium tumor antigen.
Association of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. Phosphatidic acid activates receptor dephosphorylation by PTP1C.
Association of the protein-tyrosine phosphatase DEP-1 with its substrate FLT3 visualized by in situ proximity ligation assay.
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells.
Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation.
Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer.
Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression.
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy.
Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset.
Azide-alkyne cycloaddition-mediated cyclization of phosphonopeptides and their evaluation as PTP1B binders and enrichment tools.
B Cell-Intrinsic SHP1 Expression Promotes the Gammaherpesvirus-Driven Germinal Center Response and the Establishment of Chronic Infection.
B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.
B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A.
Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Beyond the metabolic function of PTP1B.
Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine.
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.
Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver.
Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors.
Biological function of protein tyrosine phosphatase H-type receptor and its progress in tumor.
Biology of the gonadotropin-releasing hormone system in gynecological cancers.
Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy.
Blastic transformation of hairy cell leukemia.
Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels.
Body mass and glucocorticoid response in asthma.
Both HPV and carcinogen contribute to the development of resistance to apoptosis during oral carcinogenesis.
BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.
c-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer.
c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas.
Caged xanthones displaying protein tyrosine phosphatase 1B (PTP1B) inhibition from Cratoxylum cochinchinense.
Calpain 2 regulates Akt-FoxO-p27(Kip1) protein signaling pathway in mammary carcinoma.
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
Cancer reversal: regulation of phosphotyrosine phosphatase.
Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.
Cancer-associated fibroblasts promote bone invasion in oral squamous cell carcinoma.
Cancer-derived mutations in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.
Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma.
Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Carcinoma of the prostate in childhood and adolescence: report of a case and review of the literature.
Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels.
Catalytically inactive protein phosphatase 2A can bind to polyomavirus middle tumor antigen and support complex formation with pp60(c-src).
CCL26 Participates in the PRL-3-Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration.
CD148 Serves as a Prognostic Marker of Gastric Cancer and Hinders Tumor Progression by Dephosphorylating EGFR.
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.
CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma.
CDC20 maintains tumor initiating cells.
cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas.
CDC25 phosphatases as potential human oncogenes.
cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas.
CDC25A functions as a novel Ar corepressor in prostate cancer cells.
CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells.
Cdc25A Is a Critical Mediator of Ischemic Neuronal Death In Vitro and In Vivo.
CDC25A levels determine the balance of proliferation and checkpoint response.
Cdc25A promotes cell survival by stimulating NF-?B activity through I?B-? phosphorylation and destabilization.
Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.
Cdc25A Regulates Matrix Metalloprotease 1 through Foxo1 and Mediates Metastasis of Breast Cancer Cells.
CDC25A: a rebel within the CDC25 phosphatases family?
CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death.
Cdc25B as a steroid receptor coactivator.
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
CDC25B induces cellular senescence and correlates with tumor suppression in a p53-dependent manner.
CDC25B involvement in the centrosome duplication cycle and in microtubule nucleation.
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors.
CDC25B mediates rapamycin-induced oncogenic responses in cancer cells.
CDC25B overexpression stabilises centrin 2 and promotes the formation of excess centriolar foci.
CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.
Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Cdc6 knockdown inhibits human neuroblastoma cell proliferation.
CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual specificity phosphatase 1.
cDNA microarray analysis of differential gene expression in gastric cancer cells sensitive and resistant to 5-Fluorouracil and Cisplatin.
Cell cycle control by the CDC25 phosphatases.
Cell cycle dysregulation influences survival in high risk breast cancer patients.
Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.
Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors.
Cell Type-Specific and Inducible PTEN Gene Silencing by a Tetracycline Transcriptional Activator-Regulated Short Hairpin RNA.
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.
Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr307 on PP2Ac.
Changes of expressions of phosphotyrosine phosphatases in rat hepatocellular carcinoma induced by 3'-methyl-4-dimethylamino-azobenzene.
Characterization of gene rearrangements resulted from genomic structural aberrations in human esophageal squamous cell carcinoma KYSE150 cells.
Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array.
Characterization of SHP-1 protein tyrosine phosphatase transcripts, protein isoforms and phosphatase activity in epithelial cancer cells.
Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha.
Characterization of the interactions between PDZ domains of the protein-tyrosine phosphatase PTPL1 and the carboxyl-terminal tail of Fas.
Characterization of the submicroscopic deletion in the small-cell lung carcinoma (SCLC) cell line U2020.
Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-?B pathway in breast cancer cells.
Childhood Myeloid Neoplasms With PTPN11 Mutations in Brazil.
Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases.
Chlorin e6 and CRISPR-Cas9 dual-loading system with deep penetration for a synergistic tumoral photodynamic-immunotherapy.
Chondroitin Sulfate Proteoglycans Potently Inhibit Invasion and Serve as a Central Organizer of the Brain Tumor Microenvironment.
Chrodrimanins O-S from the fungus Penicillium sp. SCS-KFD09 isolated from a marine worm, Sipunculusnudus.
Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells.
Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A.
CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling.
CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
CIP2A expression is associated with synovial hyperplasia and invasive function of fibroblast-like synoviocytes in rheumatoid arthritis.
CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
CIP2A Is Highly Expressed in Hepatocellular Carcinoma and Predicts Poor Prognosis.
CIP2A is overexpressed in esophageal squamous cell carcinoma.
CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing ?-catenin.
CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Cip2A modulates osteogenic differentiation via the ERK-Runx2 pathway in MG63 cells.
CIP2A overexpression in Taiwanese oral cancer patients.
Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection.
CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer.
CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy.
CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis.
CIP2A, an oncoprotein, is associated with cell proliferation, invasion and migration in laryngeal carcinoma cells.
Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer.
Circumventing Cellular Control of PP2A by Methylation Promotes Transformation in an Akt-Dependent Manner.
Cisplatin-induced inhibition of p34cdc2 is abolished by 5-fluorouracil.
Clinical Analysis of PTEN, p53 and Her-2/neu Expressions in Thyroid Cancers.
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer.
Clinical relevance of protein-tyrosine (de-)phosphorylation in head and neck cancer.
Clinical significance of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in human cancers.
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma.
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Clinicopathological significance of PTPN12 expression in human breast cancer.
Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.
Clonal architectures and driver mutations in metastatic melanomas.
Cluster of differentiation 45 activation is crucial in interleukin-10-dependent tumor-associated dendritic cell differentiation.
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.
Colorectal carcinomas and PTEN/MMAC1 gene mutations.
Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer.
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Comments on: "Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk".
Common molecular cytogenetic pathway in papillary tumors of the pineal region (PTPR).
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Comparative effects of nodularin and microcystin-LR in zebrafish: 2. Uptake and molecular effects in eleuthero-embryos and adult liver with focus on endoplasmic reticulum stress.
Comparative evaluation of serum acid phosphatase, urinary cholesterol, and androgens in diagnosis of prostatic cancer.
Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia.
Comparative proteomic analysis uncovers potential biomarkers involved in the anticancer effect of Scutellarein in human gastric cancer cells.
Competitive protein tyrosine phosphatase 1B (PTP1B) inhibitors, prenylated caged xanthones from Garcinia hanburyi and their inhibitory mechanism.
Comprehensive analysis of vascular endothelial growth factor-C related factors in stomach cancer.
Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach.
Conformational Rigidity and Protein Dynamics at Distinct Timescales Regulate PTP1B Activity and Allostery.
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells.
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair.
Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites.
Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer.
Correlation between High Field MR Images and Histopathological Findings of Rat Transplanted Cancer Immediately after Partial Microwave Coagulation.
Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.
Critical role of Shp2 in tumor growth involving regulation of c-Myc.
Cross Talk between Wnt/?-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Crystal Structure and Substrate Specificity of PTPN12.
Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme.
Crystal structures of the apo form and a complex of human LMW-PTP with a phosphonic acid provide new evidence of a secondary site potentially related to the anchorage of natural substrates.
Crystallization and preliminary X-ray diffraction analysis of rat protein tyrosine phosphatase eta.
CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages.
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential.
Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7.
Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity.
Cytogenetical assignment and physical mapping of the human R-PTP-kappa gene (PTPRK) to the putative tumor suppressor gene region 6q22.2-q22.3.
Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.
Cytotoxicity of new alkylamino- and phenylamino-containing polyfluorinated derivatives of 1,4-naphthoquinone.
Cytotoxicity of new polyfluorinated 1,4-naphtoquinones with diverse substituents in the quinone moiety.
D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta.
DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study.
Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach.
Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients.
Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer.
Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma.
Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma.
Decreased Glucocorticoid Signaling Potentiates Lipid-Induced Inflammation and Contributes to Insulin Resistance in the Skeletal Muscle of Fructose-Fed Male Rats Exposed to Stress.
Decreased total MKP-1 protein levels predict poor prognosis in breast cancer.
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
Deletion of inositol polyphosphate 4-phosphatase type-II B affects spermatogenesis in mice.
Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23.
Deletion of Ptpn1 induces myeloproliferative neoplasm.
Deletion of PTPN22 improves effector and memory CD8+ T cell responses to tumors.
Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Demonstrating the effect of SHP2 inhibitor on cervical squamous cell carcinoma from the perspective of ZAP70.
DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients.
Dephosphorylation of Bcl-2 by protein phosphatase 2A results in apoptosis resistance.
Dephosphorylation of the adaptor LAT and phospholipase C-? by SHP-1 inhibits natural killer cell cytotoxicity.
Dephosphorylation-directed tricyclic DNA amplification cascades for sensitive detection of protein tyrosine phosphatase.
Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.
Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Design and functional activity of phosphopeptides with potential immunomodulating capacity, based on the sequence of Grb2-associated binder 1.
Design novel inhibitors for treating cancer by targeting Cdc25B catalytic domain with de novo design.
Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.
Design, synthesis, and functional evaluation of triazine-based bivalent agents that simultaneously target the active site and hot spot of phosphatase Cdc25B.
Design, Synthesis, Biological Activity, and Structural Analysis of Lactam-Constrained PTPRJ Agonist Peptides.
Detection of phosphotyrosine-containing proteins in polyomavirus middle tumor antigen-transformed cells after treatment with a phosphotyrosine phosphatase inhibitor.
Determination of acid phosphatase activity in cells of prostatic tumours.
Development and application of a PCR-HRM molecular diagnostic method of SNPs linked with TNF inhibitor efficacy.
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.
Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity.
Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the ?-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study.
Development of Accessible Peptidic Tool Compounds To Study the Phosphatase PTP1B in Intact Cells.
Development of artificial chimerical gene regulatory elements specific for cancer gene therapy.
Development of novel thiazolopyrimidines as CDC25B phosphatase inhibitors.
Dexamethasone Decreases Xenograft Response to Paclitaxel Through Inhibition of Tumor Cell Apoptosis.
Diallyl trisulfide is more cytotoxic to prostate cancer cells PC-3 than to noncancerous epithelial cell line PNT1A: a possible role of p66Shc signaling axis.
DIAPH2, PTPRD and HIC1 Gene Polymorphisms and Laryngeal Cancer Risk.
Different p53 genotypes regulating different phosphorylation sites and subcellular location of CDC25C associated with the formation of polyploid giant cancer cells.
Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells.
Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor.
Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma.
Differential expression of SHP2, a protein-tyrosine phosphatase with SRC homology-2 domains, in various types of renal tumour.
Differential gene expression in pristane-induced arthritis susceptible DA versus resistant E3 rats.
Differential induction of glioblastoma migration and growth by two forms of pleiotrophin.
Differential regulation of JNK activation and MKP-1 expression by peroxovanadium complexes.
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Digoxin enhances radiation response in radioresistant A549 cells by reducing protein phosphatase 2A.
Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites carcinoma cells.
Diosmin induces cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and blocks tumour growth in xenografted nude mice
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein.
Discovering Genotype Variants in an Infant with VACTERL through Clinical Exome Sequencing: A Support for Personalized Risk Assessment and Disease Prevention.
Discovery and characterization of a novel inhibitor of CDC25B, LGH00045.
Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1.
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
Discovery of Cdc25A Lead Inhibitors with a Novel Chemotype by Virtual Screening: Application of Pharmacophore Modeling Based on a Training Set with a Limited Number of Unique Components.
Discovery of novel inhibitor of human leukocyte common antigen-related phosphatase.
Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.
Discovery of PTPRJ Agonist Peptides That Effectively Inhibit in Vitro Cancer Cell Proliferation and Tube Formation.
Disrupting the transmembrane domain-mediated oligomerization of protein tyrosine phosphatase receptor J inhibits EGFR-driven cancer cell phenotypes.
Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells.
Dissecting molecular events in thyroid neoplasia provides evidence for distinct evolution of follicular thyroid adenoma and carcinoma.
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells.
DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1.
DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter.
Dnacin A1 and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity.
Do phosphatase of regenerating liver-3, matrix metalloproteinases-2, matrix metalloproteinases-9, and epidermal growth factor receptor-1 predict response to therapy and survival in glioblastoma multiforme?
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Does the dual-specificity MAPK phosphatase Pyst2-L lead a monogamous relationship with the Erk2 protein?
Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression.
Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma.
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.
Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Downregulated genes by silencing MYC pathway identified with RNA-SEQ analysis as potential prognostic biomarkers in gastric adenocarcinoma.
Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.
Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells.
Downregulation of PTPRH (Sap-1) in colorectal tumors.
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation.
Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter.
Druggable cancer phosphatases.
Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis.
Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor.
Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
Dual Role of the PTPN13 Tyrosine Phosphatase in Cancer.
Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors.
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment.
Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.
Duplication of ALK F1245 missense mutation due to acquired uniparental disomy associated with aggressive progression in a patient with relapsed neuroblastoma.
DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype.
DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system.
DUSP12 regulates the tumorigenesis and prognosis of hepatocellular carcinoma.
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner.
DUSP4 is involved in the enhanced proliferation and survival of DUSP4-overexpressing cancer cells.
DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.
DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.
Dynamic recruitment of protein tyrosine phosphatase PTPD1 to EGF stimulation sites potentiates EGFR activation.
Dynamin 2 mediates PDGFR?-SHP-2-promoted glioblastoma growth and invasion.
Dysidavarones A-D, new sesquiterpene quinones from the marine sponge Dysidea avara.
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer.
Effect of leuprolide on growth of rat prostatic tumor (R 3327) and weight of male accessory sex organs.
Effect of nonsense mutations on PTEN mRNA stability.
Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs).
Effects of alkaloids from Sophora flavescens on osteoblasts infected with Staphylococcus aureus and osteoclasts.
Effects of cytokines on potassium channels in renal tubular epithelia.
Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression.
Efficacy of an anti-cancer strategy targeting SET in canine osteosarcoma.
Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo.
EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing.
EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.
ELECTRON-MICROSCOPIC STUDIES OF ACID PHOSPHATASE ACTIVITY IN THE LIVER OF PATIENTS WITH CANCER OF THE ALIMENTARY TRACT.
Elevated expression of the cdc25A protein phosphatase in colon cancer.
Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors.
Elevated phosphatase of regenerating liver 3 (PRL-3) promotes cytoskeleton reorganization, cell migration and invasion in endometrial stromal cells from endometrioma.
Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.
Elevated protein-tyrosine-phosphatase activity in human colon-carcinoma.
Elevation of serum acid phosphatase in cancers with bone metastasis.
Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain dependent manner.
Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis.
Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers.
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
Endogenous tumor suppression mediated by PTEN involves survivin gene silencing.
Endotoxin conditioning induces VCP/p97-mediated and inducible nitric-oxide synthase-dependent Tyr284 nitration in protein phosphatase 2A.
Endurance training prevents inflammation and apoptosis in hypothalamic neurons of obese mice.
Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice.
Enhanced cell growth inhibition following PTEN nonviral gene transfer using polyethylenimine and photochemical internalization in endometrial cancer cells.
Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature.
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome.
Enhancement of doxorubicin-induced cytotoxicity by hyperthermia in Ehrlich ascites cells.
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Enhancing Therapeutic Efficacy of Cisplatin by Blocking DNA Damage Repair.
Enumeration of the simian virus 40 early region elements necessary for human cell transformation.
EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.
Epigenetic modifiers 5-aza-2'-deoxycytidine and valproic acid differentially change viability, DNA damage and gene expression in metastatic and non-metastatic colon cancer cell lines.
Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.
Epigenetic reprogramming in atherosclerosis.
Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer.
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
Epithelial Protein-Tyrosine Phosphatase 1B (PTP1B) Contributes to the Induction of Mammary Tumors by HER2/Neu but is not Essential for Tumor Maintenance.
Epithelial Src homology region 2 domain-containing phosphatase-1 restrains intestinal growth, secretory cell differentiation, and tumorigenesis.
Epitope-specific engagement of the protein tyrosine phosphatase CD45 induces tumor necrosis factor-alpha gene expression via transcriptional mechanisms.
ER stress-related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer.
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Erratum to: Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Escape from p21-mediated Oncogene-induced Senescence Leads to Cell Dedifferentiation and Dependence on Anti-apoptotic Bcl-xL and MCL1 Proteins.
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
Estrogen sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells.
Evaluating the biological functions of the prognostic genes identified by the Pathology Atlas in bladder cancer.
Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1.
Evaluation of licorice flavonoids as protein tyrosine phosphatase 1B inhibitors.
Evaluation of PHA-P reactivity of lymphocytes in tumor development by acid phosphatase activity.
Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Evaluation of protein tyrosine phosphatase activity in patients with acute leukemia.
Evidence for regulation of the tumor necrosis factor alpha-convertase (TACE) by protein-tyrosine phosphatase PTPH1.
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Evolutionary Analysis of the B56 Gene Family of PP2A Regulatory Subunits.
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome.
Exploring CIP2A modulators using multiple molecular modeling approaches.
Exploring the effect of aplidin on low molecular weight protein tyrosine phosphatase by molecular docking and molecular dynamic simulation study.
Expression analysis and essential role of the putative tyrosine phosphatase His-domain-containing protein tyrosine phosphatase (HD-PTP).
Expression analysis and modulation by HIV-Tat of the tyrosine phosphatase HD-PTP.
Expression and chromosomal assignment of PTPH1 gene encoding a cytosolic protein tyrosine phosphatase homologous to cytoskeletal-associated proteins.
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma.
Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors.
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.
Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.
Expression of a receptor protein tyrosine phosphatase in human glial tumors.
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line.
Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.
Expression of CDC25 phosphatases in human gastric cancer.
Expression of cell regulatory proteins in ovarian borderline tumors.
Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer.
Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro.
Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Expression of phosphatase of regenerating liver-3 is associated with prognosis of Wilms' tumor.
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro.
Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo.
Expression of protein tyrosine phosphatases and its significance in esophageal cancer.
Expression of receptor protein tyrosine phosphatase ? is a risk factor for triple negative breast cancer relapse.
Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.
Expression of the cdc25B mRNA correlated with that of N-myc in neuroblastoma.
Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73.
Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
Expression of the membrane protein tyrosine phosphatase CD148 in human tissues.
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Expression of the transmembrane protein tyrosine phosphatase RPTPalpha in human oral squamous cell carcinoma.
Expression of TMEFF2 in Human Pancreatic Cancer Tissue and the Effects of TMEFF2 Knockdown on Cell, Proliferation, and Apoptosis in Human Pancreatic Cell Lines.
Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues.
Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Expression Profiling during Mammary Epithelial Cell Three-Dimensional Morphogenesis Identifies PTPRO as a Novel Regulator of Morphogenesis and ErbB2-Mediated Transformation.
Expression, generation, and purification of unphosphorylated and phospho-Ser-380/Thr-382/Thr-383 form of recombinant PTEN phosphatase.
Extracellular Vesicle Analysis Allows for Identification of Invasive IPMN.
Extraskeletal osteoclastomas responsive to dexamethasone treatment in Paget bone disease.
Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3.
FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface.
FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis.
FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.
Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2.
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Fetal cell microchimerism in papillary thyroid cancer: a possible role in tumor damage and tissue repair.
Fish oil positively regulates anabolic signalling alongside an increase in whole-body gluconeogenesis in ageing skeletal muscle.
Fish oil suppresses cell growth and metastatic potential by regulating PTEN and NF-?B signaling in colorectal cancer.
Flavonoids as potent allosteric inhibitors of protein tyrosine phosphatase 1B: molecular dynamics simulation and free energy calculation.
Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK.
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis.
From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase.
Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms.
Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7.
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma.
Functional analysis of the putative tumor suppressor PTPRD in neuroblastoma cells.
Functional comparison of long and short splice forms of RPTPbeta: implications for glioblastoma treatment.
Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.
Functional short tandem repeat polymorphism of PTPN11 and susceptibility to hepatocellular carcinoma in Chinese populations.
Functional STR within PTPN11: a novel potential risk factor for colorectal cancer.
Functions of Shp2 in cancer.
Fusaresters A-E, new ?-pyrone-containing polyketides from fungus Fusarium sp. Hungcl and structure revision of fusariumin D.
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv.
Gab2 is phosphorylated on tyrosine upon interleukin-2/interleukin-15 stimulation in mycosis-fungoides-derived tumor T cells and associates inducibly with SHP-2 and Stat5a.
Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis.
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Gene expression in poorly differentiated papillary thyroid carcinomas.
Gene expression profiles in cells transformed by overexpression of the IGF-I receptor.
Gene expression profiling after LINC00472 overexpression in an NSCLC cell line.
Gene expression profiling in cells with enhanced gamma-secretase activity.
Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
Generation of conditional knockout alleles for PRL-3.
Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability.
Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
Genetic alterations in endometrial cancer by targeted next-generation sequencing.
Genetic alterations of protein tyrosine phosphatases in human cancers.
Genetic approaches to the study of the molecular basis of human cancer.
Genetic determinants at the interface of cancer and neurodegenerative disease.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Genetic landscape of RASopathies in Chinese: Three decades' experience in Hong Kong.
Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.
Genetic profile of PTEN gene in Indian oral squamous cell carcinoma primary tumors.
Genetic screening for synthetic lethal partners of polynucleotide kinase/phosphatase: potential for targeting SHP-1 depleted cancers.
Genetic variants in PPP2CA are associated with gastric cancer risk in a Chinese population.
Genome wide analysis of pathogenic SH2 domain mutations.
Genome-scale screening of deubiquitinase subfamily identifies USP3 as a stabilizer of Cdc25A regulating cell cycle in cancer.
Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis.
Genome-wide disease association study in chewing tobacco associated oral cancers.
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva.
Genomic Alteration in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Inferred from Karyotyping, Molecular Cytogenetics, and Array Comparative Genomic Hybridization.
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis.
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Genomic structure, chromosomal location, and mutation analysis of the human CDC14A gene.
Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression.
Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis.
Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer.
Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.
Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.
Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
Giant Cell Tumor of Bonelike Lesion in a Trp53 Mutant Mouse.
Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin C.
Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell.
Global phosphotyrosine proteomics identifies PKC? as a marker of responsiveness to Src inhibition in colorectal cancer.
Glycybridins A-K, Bioactive Phenolic Compounds from Glycyrrhiza glabra.
GnRH antagonists in the treatment of gynecological and breast cancers.
Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
Good Guy in Bad Company: How STRNs Convert PP2A into an Oncoprotein.
Granular cell tumor of the scrotum in a child with Noonan syndrome.
Grb2 binding induces phosphorylation-independent activation of Shp2.
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.
Haploinsufficiency of the ESCRT Component HD-PTP Predisposes to Cancer.
HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain.
HDAC1 controls CIP2A transcription in human colorectal cancer cells.
Heat shock inhibition of lipopolysaccharide-mediated tumor necrosis factor expression is associated with nuclear induction of MKP-1 and inhibition of mitogen-activated protein kinase activation.
Helicobacter pylori and gastric carcinogenesis.
Helicobacter pylori CagA -- a bacterial intruder conspiring gastric carcinogenesis.
Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis.
Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice.
Heparin Decreases in Tumor Necrosis Factor ? (TNF?)-induced Endothelial Stress Responses Require Transmembrane Protein 184A and Induction of Dual Specificity Phosphatase 1.
Hepatic inflammation facilitates transcription-associated mutagenesis via AID activity and enhances liver tumorigenesis.
Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1.
Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
Heptad repeats regulate protein phosphatase 2a recruitment to I-kappaB kinase gamma/NF-kappaB essential modulator and are targeted by human T-lymphotropic virus type 1 tax.
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/?-catenin signaling.
Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies.
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.
High expression of Cdc25B and low expression of 14-3-3? is associated with the development and poor prognosis in urothelial carcinoma of bladder.
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer.
High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.
High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes.
High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
High-dose folic acid supplementation alters the human sperm methylome and is influenced by the MTHFR C677T polymorphism.
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
High-resolution dose-response screening using droplet-based microfluidics.
High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma.
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Highly parallel identification of essential genes in cancer cells.
Hinokitiol suppresses growth of B16 melanoma by activating ERK/MKP3/proteosome pathway to downregulate survivin expression.
Histiocytic Sarcoma Associated with Coombs Negative Acute Hemolytic Anemia: A Rare Presentation.
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Histochemical study of acid phosphatase activity in cerebral tumors.
Histochemically demonstrable protein tyrosine phosphatase in human breast and colorectal cancer: large decrease in its activity in colorectal cancer suggests a tumor suppressor role in colorectal mucosal cells.
Histone acetylation and activation of cAMP-response element-binding protein regulate transcriptional activation of MKP-M in lipopolysaccharide-stimulated macrophages.
Histopathologic and ultrastructural features and claudin expression in papillary tumors of the pineal region: a multicenter analysis.
Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution.
Homozygous losses detected by array comparative genomic hybridization in multiplex urothelial carcinomas of the bladder.
Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may target
Human Cancer-Associated Mutations in the A{alpha} Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in A{alpha} Knock-In and Knockout Mice.
Human Cdc25A phosphatase has a non-redundant function in G2 phase by activating Cyclin A-dependent kinases.
Human Cytomegalovirus-Encoded Human Interleukin-10 (IL-10) Homolog Amplifies Its Immunomodulatory Potential by Upregulating Human IL-10 in Monocytes.
Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis.
Human osteogenic sarcoma. Study of the ultrastructure, with special notes on the localization of alkaline and acid phosphatase.
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Human papillomavirus and prostate cancer: The role of viral expressed proteins in the inhibition of anoikis and induction of metastasis.
Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers.
Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.
Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis.
Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells.
Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21.
Hypoxic suppression of the cell cycle gene CDC25A in tumor cells.
ICDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy.
Identification and characterization of renal cell carcinoma gene markers.
Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14.
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T.
Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases.
Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer.
Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells.
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.
Identification of an Apis cerana cerana MAP kinase phosphatase 3 gene (AccMKP3) in response to environmental stress.
Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.
Identification of binding sites on the regulatory A subunit of protein phosphatase 2A for the catalytic C subunit and for tumor antigens of simian virus 40 and polyomavirus.
Identification of caffeoylquinic acid derivatives as natural protein tyrosine phosphatase 1B inhibitors from Artemisia princeps.
Identification of CDC25C as a Potential Biomarker in Hepatocellular Carcinoma Using Bioinformatics Analysis.
Identification of common microRNA-mRNA regulatory biomodules in human epithelial cancers.
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11).
Identification of demethylincisterol A3 as a selective inhibitor of protein tyrosine phosphatase Shp2.
Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC.
Identification of Differentially Expressed Genes Involved in the Formation of Multicellular Tumor Spheroids by HT-29 Colon Carcinoma Cells.
Identification of genes and signaling pathways associated with the pathogenesis of juvenile spondyloarthritis.
Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning.
Identification of IkappaBalpha as a substrate of Fas-associated phosphatase-1.
Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3.
Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta?analysis and cross?species comparison.
Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma.
Identification of new inhibitors for low molecular weight protein tyrosine phosphatase isoform B.
Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking.
Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients.
Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.
Identification of novel inhibitors of mitogen-activated protein kinase phosphatase-1 with structure-based virtual screening.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Identification of PTPN1 as a novel negative regulator of the JNK MAPK pathway using a synthetic screening for pathway-specific phosphatases.
Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'.
Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T.
Identification of structural elements involved in the interaction of simian virus 40 small tumor antigen with protein phosphatase 2A.
Identification of target proteins of N-acetylglucosaminyl transferase V in human colon cancer and implications of protein tyrosine phosphatase kappa in enhanced cancer cell migration.
Identification of the quinolinedione inhibitor binding site in Cdc25 phosphatase B through docking and molecular dynamics simulations.
Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells.
Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling.
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.
IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases.
IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition.
Immunohistochemical assessment of PRL-3 (PTP4A3) expression in tumor buds, invasion front, central region of tumor and metastases of colorectal cancer.
Immunohistochemical Detection of Hematopoietic Cell-specific Protein-Tyrosine Phosphatase (Tyrosine Phosphatase SHP-1) in a Series of Endometrioid and Serous Endometrial Carcinoma.
Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Immunohistochemical examination of anti-inflammatory and anti-apoptotic effects of hesperetin on trinitrobenzene sulfonic acid induced colitis in rats.
Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma.
Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues.
Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice.
Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen.
Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways.
Important roles of protein tyrosine phosphatase PTPN12 in tumor progression.
In Cell and In Vitro Assays to Measure PTEN Ubiquitination.
In Vitro and In Vivo Effects of Tumor Suppressor Gene PTEN on Endometriosis: An Experimental Study.
In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents.
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.
In-gel digestion coupled with mass spectrometry (GeLC-MS/MS)-based salivary proteomic profiling of canine oral tumors.
Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase.
Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma.
Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint.
Incidence and prognostic value of multiple gene promoter methylations in gliomas.
Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer.
Increase in CIP2A expression is associated with doxorubicin resistance.
Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma.
Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Increased expression of tyrosine phosphatase SHP2 in experimental pneumococcal meningitis: correlation with tumor necrosis factor-alpha and cerebrospinal fluid pleocytosis.
Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1.
Increased metastasis with loss of E2F2 in Myc-driven tumors.
Increased miR-155-5p expression in dermal mesenchymal stem cells of psoriatic patients: comparing the microRNA expression profile by microarray.
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Increased SHP-1 expression results in radioresistance, inhibition of cellular senescence, and cell cycle redistribution in nasopharyngeal carcinoma cells.
Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice.
Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice.
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer.
Induction of a Tumor-associated Activating Mutation in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhances Mitochondrial Metabolism, Leading to Oxidative Stress and Senescence.
Induction of Cdc25B expression by epidermal growth factor and transforming growth factor-alpha.
Induction of E-cadherin endocytosis by loss of protein phosphatase 2A expression in human breast cancers.
Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B.
Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B.
Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro.
Influence of CO2 pneumoperitoneum on intracellular pH and signal transduction in cancer cells.
Influence of molecular genetics in Vogt-Koyanagi-Harada disease.
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Inhibiting the inhibitor: targeting vascular endothelial protein tyrosine phosphatase to promote tumor vascular maturation.
Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones.
Inhibition of cell growth and spreading by stomach cancer-associated protein-tyrosine phosphatase-1 (SAP-1) through dephosphorylation of p130cas.
Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma.
Inhibition of conjugated linoleic acid on mouse forestomach neoplasia induced by benzo (a) pyrene and chemopreventive mechanisms.
Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor.
Inhibition of growth and stimulation of apoptosis by beta-sitosterol treatment of MDA-MB-231 human breast cancer cells in culture.
Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation.
Inhibition of KIF22 suppresses cancer cell proliferation by delaying mitotic exit through upregulating CDC25C expression.
Inhibition of MAP kinase by sphingosine and its methylated derivative, N,N-dimethylsphingosine.
Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells.
Inhibition of p38 by Vitamin D Reduces Interleukin-6 Production in Normal Prostate Cells via Mitogen-Activated Protein Kinase Phosphatase 5: Implications for Prostate Cancer Prevention by Vitamin D.
Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation.
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer.
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells.
Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase.
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer.
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Inhibition of tumor necrosis factor-[alpha]-induced SHP-2 phosphatase activity by shear stress: a mechanism to reduce endothelial inflammation.
Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase.
Inhibitor binding sites in the protein tyrosine phosphatase SHP-2.
Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.
Inhibitors of Protein Tyrosine Phosphatase PTP1B With Anticancer Potential.
Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells.
Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway.
Integrated analyses of murine breast cancer models reveal critical parallels with human disease.
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Integrating omics data and protein interaction networks to prioritize driver genes in cancer.
Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer.
Integrative epigenomic and genomic analysis of malignant pheochromocytoma.
Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer.
Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma.
Interaction of the protein tyrosine phosphatase PTPL1 with the PtdIns(3,4)P2-binding adaptor protein TAPP1.
Interdependence between EGFR and Phosphatases Spatially Established by Vesicular Dynamics Generates a Growth Factor Sensing and Responding Network.
Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue.
Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Interpretations on the Interaction between Protein Tyrosine Phosphatase and E7 Oncoproteins of High and Low-Risk HPV: A Computational Perception.
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Intracellular ethanol-mediated oxidation and apoptosis in HepG2/CYP2E1 cells impaired by two active peptides from seahorse (Hippocampus kuda bleeler) protein hydrolysates via the Nrf2/HO-1 and akt pathways.
Intratumor microvessel density in biopsy specimens predicts local response of hypopharyngeal cancer to radiotherapy.
Investigation of circRNA-miRNA-mRNA network in colorectal cancer using an integrative bioinformatics approach.
Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth.
Investigation of the component of Propionibacterium acnes (Corynebacterium parvum) responsible for macrophage activation.
Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: A report from the children's oncology group.
Involvement of a putative protein-tyrosine phosphatase and I kappa B-alpha serine phosphorylation in nuclear factor kappa B activation by tumor necrosis factor.
Involvement of Akt in mitochondria-dependent apoptosis induced by a cdc25 phosphatase inhibitor naphthoquinone analog.
Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
Involvement of reactive oxygen species/c-Jun NH(2)-terminal kinase pathway in kotomolide A induces apoptosis in human breast cancer cells.
Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer.
Isolation and Functional Characterization of Peptide Agonists of PTPRJ, a Tyrosine Phosphatase Receptor Endowed with Tumor Suppressor Activity.
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Isorhapontigenin (ISO) inhibited cell transformation by inducing G0/G1 phase arrest via increasing MKP-1 mRNA Stability.
JAK/STAT signal transduction: Regulators and implication in hematological malignancies.
JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells.
KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer.
Key insights into the protein tyrosine phosphatase PTPN11/SHP2 associated with noonan syndrome and cancer.
Kinetic studies on a murine sarcoma and an analysis of apoptosis.
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B.
Knockdown of PRL-3 increases mitochondrial superoxide anion production through transcriptional regulation of RAP1.
Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells.
Knocking Down Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) Reverts Chemoresistance through Inactivation of Src and Bcr-Abl Proteins.
Koelreuteria Formosana Extract Induces Growth Inhibition and Cell Death in Human Colon Carcinoma Cells via G2/M Arrest and LC3-II Activation-Dependent Autophagy.
LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells.
Large granular lymphocyte leukemia/lymphoma in six cats.
Leukemogenic Ptpn11 allele causes defective erythropoiesis in mice.
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation.
Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress.
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
Lineage-negative lymphoma with a helper innate lymphoid cell phenotype.
Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA.
Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
LITAF, HHEX, and DUSP1 expression in mesenchymal stem cells from patients with psoriasis.
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
LMW-PTP is a positive regulator of tumor onset and growth.
LMW-PTP modulates glucose metabolism in cancer cells.
LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy.
LMWPTP modulates the antioxidant response and autophagy process in human chronic myeloid leukemia cells.
lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway.
Localization of acid phosphatase activity in a giant cell tumor of bone.
Localization of gallium in tumor cells. Electron microscopy, electron probe microanalysis and analytical ion microscopy.
LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.
Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression.
Long non-coding RNA UCA1 promotes breast cancer by upregulating PTP1B expression via inhibiting miR-206.
Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4.
Loss of DUSP2 predicts a poor prognosis in patients with bladder cancer.
Loss of DUSP3 activity radiosensitizes human tumor cell lines via attenuation of DNA repair pathways.
Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex.
Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer.
Loss of protein phosphatase 2A expression correlates with phosphorylation of DP-1 and reversal of dysplasia through differentiation in a conditional mouse model of cancer progression.
Loss of protein phosphatase 2A regulatory subunit B56? promotes spontaneous tumorigenesis in vivo.
Loss of Protein Tyrosine Phosphatase Receptor J Expression Predicts an Aggressive Clinical Course in Patients with Esophageal Squamous Cell Carcinoma.
Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells.
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer.
Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Loss of SHP-1 phosphatase alters cytokine expression in the mouse hindbrain following cochlear ablation.
Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Loss of TAK1 increases cell traction force in a ROS-dependent manner to drive epithelial-mesenchymal transition of cancer cells.
Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.
Loss of the Protein-Tyrosine Phosphatase DEP-1/PTPRJ Drives Meningioma Cell Motility.
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Loss-of-Function Variants in the Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk.
Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c.
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer.
Low molecular weight protein tyrosine phosphatase as signaling hub of cancer hallmarks.
Low molecular weight protein tyrosine phosphatase genetic polymorphism and susceptibility to cancer development.
Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism.
Low Molecular Weight Protein Tyrosine Phosphatase Slow Isoform Knockdown in MDA-MB-435 Cells Decreases RAW 264.7 Osteoclastic Differentiation.
Low molecular weight protein tyrosine phosphatase: Multifaceted functions of an evolutionarily conserved enzyme.
Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma.
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
Luteolin sensitizes the antiproliferative effect of interferon ?/? by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
Macrophage migration inhibitory factor in the pathogenesis of leukemia (Review).
Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling.
MAP Kinase Regulation of the Candida albicans Pheromone Pathway.
MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation.
MAPK-specific tyrosine phosphatases: new targets for drug discovery?
MAPKAPK2 plays a crucial role in the progression of head and neck squamous cell carcinoma by regulating transcript stability.
Mapping of the gene encoding the B56 beta subunit of protein phosphatase 2A (PPP2R5B) to a 0.5-Mb region of chromosome 11q13 and its exclusion as a candidate gene for multiple endocrine neoplasia type 1 (MEN1).
Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor.
Mass spectrometry study of PRL-3 phosphatase inactivation by disulfide bond formation and cysteine into glycine conversion.
Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer.
MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
MASTL: A novel therapeutic target for Cancer Malignancy.
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
Measuring p66Shc Signaling Pathway Activation and Mitochondrial Translocation in Cultured Cells.
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
Mechanisms of antineoplastic action of somatostatin analogs.
Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells.
Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation.
Melanoma exosomes deliver a complex biological payload that upregulates PTPN11 to suppress T lymphocyte function.
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Merkel Cell Polyomavirus Small T Antigen Is Oncogenic in Transgenic Mice.
Meroterpenoids with Protein Tyrosine Phosphatase 1B Inhibitory Activity from a Hyrtios sp. Marine Sponge.
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase.
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk.
Metalloproteinase- and gamma-secretase-mediated cleavage of protein-tyrosine phosphatase receptor type Z.
Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion.
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer.
Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions - a Taiwanese Gynecologic Oncology Group (TGOG) study.
Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Methylation and expression of PTPN22 in esophageal squamous cell carcinoma.
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate.
Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen.
MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.
Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias.
Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
Microbially Guided Discovery and Biosynthesis of Biologically Active Natural Products.
Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling.
MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.
microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells.
MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.
MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A.
MicroRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma.
MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review.
Microtubule disruption and tumor suppression by mitogen-activated protein kinase phosphatase 4.
MiR-101 promotes pain hypersensitivity in rats with chronic constriction injury via the MKP-1 mediated MAPK pathway.
miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25?CDC25A?.
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
miR-142-3p inhibits cancer cell proliferation by targeting CDC25C.
miR-146b Regulates Cell Proliferation and Apoptosis in Gastric Cancer by Targeting PTP1B.
miR-152 inhibits proliferation of human endometrial cancer cells via inducing G2/M phase arrest by suppressing CDC25B expression.
miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.
MiR-19b suppresses PTPRG to promote breast tumorigenesis.
miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1.
MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.
miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B.
MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1.
miR-34c inhibits proliferation of glioma by targeting PTP1B.
miR-383 Down-Regulates the Oncogene CIP2A to Influence Glioma Proliferation and Invasion.
MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A.
miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma.
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB.
MiR-6803-5p Promotes Cancer Cell Proliferation and Invasion via PTPRO/NF-?B Axis in Colorectal Cancer.
miR?122?5p suppresses the oncogenesis of PTC by inhibiting DUSP4 expression.
miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression.
miRNA-497 Negatively Regulates the Growth and Motility of Chondrosarcoma Cells by Targeting Cdc25A.
miRNA-7a-2-3p Inhibits Neuronal Apoptosis in Oxygen-Glucose Deprivation (OGD) Model.
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.
Mitochondrial-associated nitric oxide synthase activity inhibits cytochrome c oxidase: Implications for breast Cancer.
Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer.
Mitogen-activated protein kinase (MAPK) phosphatase-3 (MKP-3) displays a p-JNK-MAPK substrate preference in astrocytes in vitro.
Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis.
Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity.
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin.
Mitogen-Activated Protein Kinase Phosphatase-1 Is Required for Cisplatin Resistance.
Mitogen-activated protein kinase phosphatase-1 prevents lipopolysaccharide-induced apoptosis in immature rat intestinal epithelial cells.
Mitogen-activated protein kinase phosphatase-1 represses c-Jun NH2-terminal kinase-mediated apoptosis via NF-kappaB regulation.
Mitogen-Activated Protein Kinase Phosphatase-2 Deletion Impairs Synaptic Plasticity and Hippocampal-Dependent Memory.
Mitogen-activated protein kinases and apoptosis in PIN.
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
MKP-4 suppresses hepatocarcinogenesis by targeting ERK1/2 pathway.
MKP1 mediates resistance to therapy in HER2-positive breast tumors.
Modelling the p53/p66Shc Aging Pathway in the Shortest Living Vertebrate Nothobranchius Furzeri.
Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents.
Modification of the effects of hyperthermia and neutron radiation on the activity of acid phosphatase in CaNT tumors.
Modulation of the cytotoxic activity of tumor necrosis factor by protein tyrosine kinase and protein tyrosine phosphatase inhibitors.
Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor.
Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism.
Molecular analysis of Aedes aegypti classical protein tyrosine phosphatases uncovers an ortholog of mammalian PTP-1B implicated in the control of egg production in mosquitoes.
Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes.
Molecular Analysis of the Interaction between Human PTPN21 and the Oncoprotein E7 from Human Papillomavirus Genotype 18.
Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.
Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Molecular and phenotypic spectrum of Noonan syndrome in Chinese patients.
Molecular crosstalk between cancer and neurodegenerative diseases.
Molecular docking and virtual screening for novel protein tyrosine phosphatase 1B (PTP1B) inhibitors.
Molecular dynamics simulation of the interaction between protein tyrosine phosphatase 1B and aryl diketoacid derivatives.
Molecular Magnetic Resonance Imaging of Tumors with a PTPµ Targeted Contrast Agent.
Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity.
Molecular mechanism of T-cell protein tyrosine phosphatase (TCPTP) activation by mitoxantrone.
Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors.
Molecular mechanisms supporting a pathogenic role for human polyomavirus 6 small T antigen: protein phosphatase 2A targeting and MAPK cascade activation.
Molecular model of the A subunit of protein phosphatase 2A: interaction with other subunits and tumor antigens.
Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis.
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Mononuclear phagocyte function in head and neck cancer. Chemotactic responsiveness of blood monocytes in correlation between histologic grade of the tumor and infiltration of these cells into the tumor area.
Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.
Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1.
Morin-dependent inhibition of low molecular weight protein tyrosine phosphatase (LMW-PTP) restores sensitivity to apoptosis during colon carcinogenesis: Studies in vitro and in vivo, in an Apc-driven model of colon cancer.
Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.
mRNA expression of Fas receptor (CD95)-associated proteins (Fas-associated phosphatase-1/FAP-1, Fas-associating protein with death domain/FADD, and receptor-interacting protein/RIP) in human leukaemia/lymphoma cell lines.
mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells.
Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.
Multimodal control of Cdc25A by nitrosative stress.
Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11.
Multiple unexpected lesions of metachondromatosis detected by technetium-99m methylene diphosphonate SPECT/CT: A case report.
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia.
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas.
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Mutation of the PTEN gene in a human hepatic angiosarcoma.
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.
Mutational analysis of FLASH and PTPN13 genes in colorectal carcinomas.
Mutational analysis of mononucleotide repeats in dual specificity tyrosine phosphatase genes in gastric and colon carcinomas with microsatellite instability.
Mutational analysis of PTPRT phosphatase domains in common human cancers.
Mutational analysis of the tyrosine phosphatome in colorectal cancers.
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Mutational dynamics between primary and relapse neuroblastomas.
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
Mutations of PTPN11 are rare in adult myeloid malignancies.
Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary.
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity.
Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-? production in tumor microenvironment.
Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis.
N160 of Aiolos Determines its DNA-Binding Activity.
Nanocatalyst Complex Can Dephosphorylate Key Proteins in MAPK Pathway for Cancer Therapy.
Naphthoquinone analogs as inactivators of cdc25 phosphatase.
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
Negative Feed-forward Control of Tumor Necrosis Factor (TNF) by Tristetraprolin (ZFP36) Is Limited by the Mitogen-activated Protein Kinase Phosphatase, Dual-specificity Phosphatase 1 (DUSP1): IMPLICATIONS FOR REGULATION BY GLUCOCORTICOIDS.
Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells.
Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells.
Network-Based Predictors of Progression in Head and Neck Squamous Cell Carcinoma.
Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells.
Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling.
Neutrophil acid phosphatase activity in patients with gastric or rectum carcinoma during surgical treatment.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
New model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone.
New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53.
NF?B and TGF? contribute to the expression of PTPN3 in activated human lymphocytes.
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
Nitric oxide down-regulates MKP-3 mRNA levels: involvement in endothelial cell protection from apoptosis.
Non-canonical activation of ?-catenin by PRL-3 phosphatase in acute myeloid leukemia.
Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.
Non-HLA associations with autoimmune diseases.
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases.
Notable roles of EZH2 and DNMT1 in epigenetic dormancy of the SHP1 gene during the progression of chronic myeloid leukaemia.
Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.
Novel acyclic enediynes inhibit Cyclin A and Cdc25C expression and induce apoptosis phenomenon to show potent antitumor proliferation.
Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1.
Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells.
Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.
Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Novel PROTACs for degradation of SHP2 protein.
Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents.
Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects.
Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas.
Nox4 redox regulation of PTP1B contributes to the proliferation and migration of glioblastoma cells by modulating tyrosine phosphorylation of coronin-1C.
NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A.
NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.
NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.
NSAIDs activate PTEN and other phosphatases in human colon cancer cells: novel mechanism for chemopreventive action of NSAIDs.
Nuclear binding of androgens and acid phosphatase activity in prostatic tumors of Nb rats.
Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer.
Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death.
Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells.
On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives.
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.
Oncogenic PTPN11 Mutations are Rare in Solid Tumors.
Oncogenic role of ALX3 in cervical cancer cells through KDM2B-mediated histone demethylation of CDC25A.
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.
Oncoprotein CIP2A promotes the disassembly of primary cilia and inhibits glycolytic metabolism.
Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis.
Organic Synthesis Toward Small-Molecule Probes and Drugs Special Feature: Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors.
Osteoglycin-induced VEGF Inhibition Enhances T Lymphocytes Infiltrating in Colorectal Cancer.
Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma.
Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Over-expression of protein tyrosine phosphatase 4A2 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Overexpression of CDC25A and CDC25B in head and neck cancers.
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas.
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.
Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells.
Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery.
Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Overexpression of CIP2A is associated with poor prognosis in multiple myeloma.
Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas.
Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
Overexpression of long noncoding RNA PTPRG-AS1 is associated with poor prognosis in epithelial ovarian cancer.
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.
Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas.
Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
Overexpression of PTPRN Promotes Metastasis of Lung Adenocarcinoma and Suppresses NK Cell Cytotoxicity.
Overexpression of TC-PTP in murine epidermis attenuates skin tumor formation.
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.
Overexpression of the dual specificity phosphatase, Cdc25C, confers sensitivity on tumor cells to doxorubicin-induced cell death.
Overexpression of the Protein Tyrosine Phosphatase PRL-2 Correlates with Breast Tumor Formation and Progression.
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.
Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
Oxidation and inactivation of low molecular weight protein tyrosine phosphatase by the anticancer drug Aplidin.
Oxidative stress induces B lymphocyte DNA damage and apoptosis by upregulating p66shc.
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.
p14(ARF) Triggers G(2) Arrest Through ERK-Mediated Cdc25C Phosphorylation, Ubiquitination and Proteasomal Degradation.
p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/{beta}-Catenin Signaling.
p38 MAP kinase's emerging role as a tumor suppressor.
p53 downregulates expression of the G1/S cell cycle phosphatase Cdc25A.
p63 regulates cell proliferation and cell cycle progression?associated genes in stromal cells of giant cell tumor of the bone.
p66Shc activation promotes increased oxidative phosphorylation and renders CNS cells more vulnerable to amyloid beta toxicity.
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
p66Shc as a switch in bringing about contrasting responses in cell growth: implications on cell proliferation and apoptosis.
p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling.
p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas.
p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.
Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.
Papillary tumor of the pineal region in pediatric populations: An additional case and systematic review of a rare tumor entity.
Papillary Tumor of the Pineal Region: A Distinct Molecular Entity.
Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder.
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
Pathophysiological significance of N-myc downstream-regulated gene 2 in cancer development through protein phosphatase 2A phosphorylation regulation.
Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase.
PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.
Peptide-templated gold nanoparticle nanosensor for simultaneous detection of multiple posttranslational modification enzymes.
Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors.
Perphenazine exerts antitumor effects on HUT78 cells through Akt dephosphorylation by protein phosphatase 2A.
Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma.
PHAP1 promotes glioma cell proliferation by regulating the Akt/p27/stathmin pathway.
Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.
Phelligridimer A, a highly oxygenated and unsaturated 26-membered macrocyclic metabolite with antioxidant activity from the fungus Phellinus igniarius.
Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression.
Phosphatase 2A associated with polyomavirus small-T or middle-T antigen is an okadaic acid-sensitive tyrosyl phosphatase.
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics.
Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma.
Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
Phosphatase of regenerating liver-3 directly interacts with integrin ?1 and regulates its phosphorylation at tyrosine 783.
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo.
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Phosphatase of regenerating liver-3 regulates cancer cell metabolism in multiple myeloma.
Phosphatases and tumorigenesis.
Phosphatases: the new brakes for cancer development?
Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells.
Phosphoamino acid phosphatases in normal and cancerous tissues of the human uterus, cervix and ovary.
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer.
Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1.
Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.
Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.
Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration.
Phosphorylation of a C-SRC-related protein in macrophages activated in vitro with lymphokine.
Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: A potential novel prognostic marker for breast cancer.
Phosphorylation-Specific Peptidyl-Prolyl Isomerization of Neuronal Cytoskeletal Proteins by Pin1: Implications for Therapeutics in Neurodegeneration.
Phosphorylation-specific peptidyl-prolyl isomerization of neuronal cytoskeletal proteins by Pin1: implications for therapeutics in neurodegeneration.
Phosphotyrosine phosphatase activity in the macrophage is enhanced by lipopolysaccharide, tumor necrosis factor alpha, and granulocyte/macrophage-colony stimulating factor: correlation with priming of the respiratory burst.
Photoaffinity labeling of protein phosphatase 2A, the receptor for a tumor promoter okadaic acid, by [27-3H]methyl 7-O-(4-azidobenzoyl)okadaate.
Piceamycin and its N-acetylcysteine adduct is produced by Streptomyces sp. GB 4-2.
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis.
Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer.
Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2).
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo.
PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells.
Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis.
Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis.
Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma.
Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration.
Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer.
Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies.
PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
PP2A fulfills its promises as tumor suppressor: which subunits are important?
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential.
PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells.
PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway.
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
PP2AC Phospho-Tyr307 Antibodies Are Not Specific for this Modification but Are Sensitive to Other PP2AC Modifications Including Leu309 Methylation.
PP2AC? of Alveolar Macrophages Is a Novel Protective Factor for LPS-Induced Acute Respiratory Distress Syndrome.
PPAR? inhibits breast cancer progression by upregulating PTPRF expression.
Ppm1b negatively regulates necroptosis through dephosphorylating Rip3.
PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers.
PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
PR55?-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.
Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer.
Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.
Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.
PRL phosphatases as potential molecular targets in cancer.
PRL PTPs: mediators and markers of cancer progression.
PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.
PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth.
PRL-3 activates mTORC1 in Cancer Progression.
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
PRL-3 disrupts epithelial architecture by altering the post-mitotic midbody position.
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
PRL-3 expression in metastatic cancers.
PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK.
PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism.
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.
PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts.
PRL-3 phosphatase and cancer metastasis.
PRL-3 phosphatase is implicated in ovarian cancer growth.
PRL-3 promotes breast cancer progression by downregulating p14
PRL-3 promotes cell adhesion by interacting with JAM2 in colon cancer.
PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly.
PRL-3 promotes gastric cancer migration and invasion through a NF-?B-HIF-1?-miR-210 axis.
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
PRL-3 promotes telomere deprotection and chromosomal instability.
PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1.
PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.
PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels.
PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1.
PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.
PRL-3 suppresses c-Fos and integrin alpha2 expression in ovarian cancer cells.
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
PRL-3: a metastasis-associated phosphatase in search of a function.
PRL-3: a phosphatase for metastasis?
PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity.
Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
Production of DUSP1 protein using the baculovirus insect cell expression system and its in vitro effects on cancer cells.
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Prognosis of patients with multifocal glioblastoma: a case-control study.
Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.
Prognostic role of CIP2A expression in serous ovarian cancer.
Prognostic significance of CDC25B expression in gliomas.
Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data.
Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis.
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy.
Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer.
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Programmable Unlocking Nano-Matryoshka-CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response.
Progress in the correlation between PTPN12 gene expression and human tumors.
Proinflammatory genotype is associated with the frailty phenotype in the English Longitudinal Study of Ageing.
Protective effect of zinc on N-methyl-N-nitrosourea and testosterone-induced prostatic intraepithelial neoplasia in the dorsolateral prostate of Sprague Dawley rats.
Protein dynamics analysis reveals that missense mutations in cancer-related genes appear frequently on hinge-neighboring residues.
Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells.
Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
Protein phosphatase 1B dephosphorylates Rho guanine nucleotide dissociation inhibitor 1 and suppresses cancer cell migration and invasion.
Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.
Protein Phosphatase 2A (PP2A) Regulation of Markers of Extracellular Matrix Remodelling in HCC Cells: Functional Consequences for Tumour Invasion.
Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.
Protein phosphatase 2A A? regulates A? protein expression and stability.
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Protein phosphatase 2A and phosphatidylinositol 3-kinase regulate the activity of Sp1-responsive promoters.
Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Protein Phosphatase 2A as a Potential Target for Anticancer Therapy.
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation.
Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer.
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
Protein Phosphatase 2A Is Essential for B-cell Tumor Redox Homeostasis.
Protein phosphatase 2A is essential to maintain active Wnt signaling and its A? tumor suppressor subunit is not expressed in colon cancer cells.
Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia.
Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
Protein phosphatase 2A promotes endothelial survival via stabilization of translational inhibitor 4E-BP1 following exposure to tumor necrosis factor-?.
Protein phosphatase 2A regulatory subunits and cancer.
Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen.
Protein Phosphatase Methyl-Esterase PME-1 Protects Protein Phosphatase 2A from Ubiquitin/Proteasome Degradation.
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Protein tyrosine (de-)phosphorylation in head and neck squamous cell carcinoma.
Protein tyrosine Phosphatase (PTP1B): A promising Drug Target against life threatening ailments.
Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.
Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.
Protein Tyrosine Phosphatase 1B Inhibitors from the Stems of Akebia quinata.
Protein tyrosine phosphatase 1B regulates fibroblasts proliferation, motility and extracellular matrix synthesis via the MAPK/ERK signalling pathway in keloid.
Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation.
Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities.
Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide.
Protein tyrosine phosphatase epsilon activates Yes and Fyn in Neu-induced mammary tumor cells.
Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis.
Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice.
Protein tyrosine phosphatase epsilon inhibits signaling by mitogen-activated protein kinases.
Protein tyrosine phosphatase genes downregulated in melanoma.
Protein tyrosine phosphatase H1 is a target of the E6 oncoprotein of high-risk genital human papillomaviruses.
Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting I?B?.
Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer.
Protein tyrosine phosphatase N2 regulates TNF?-induced signalling and cytokine secretion in human intestinal epithelial cells.
Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.
Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells.
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.
Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling.
Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation.
Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC.
Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328.
Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene.
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating ?-catenin.
Protein Tyrosine Phosphatase Receptor Type {gamma} Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia.
Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility.
Protein tyrosine phosphatase receptor-like genes are frequently hypermethylated in sporadic colorectal cancer.
Protein tyrosine phosphatase receptor-type ? acts as a negative regulator suppressing breast cancer.
Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.
Protein tyrosine phosphatase receptor-type O (PTPRO) is co-regulated by E2F1 and miR-17-92.
Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling.
Protein tyrosine phosphatase µ (PTP µ or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis.
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R?2-Promoted Invasion and Metastasis in Cancer Cells.
Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
Protein tyrosine phosphatases in glioma biology.
Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling.
Protein tyrosine phosphatases receptor type D is a potential tumour suppressor gene inactivated by deoxyribonucleic acid methylation in paediatric acute myeloid leukaemia.
Protein tyrosine phosphatases.
Protein tyrosine phosphatome metabolic screen identifies TC-PTP as a positive regulator of cancer cell bioenergetics and mitochondrial dynamics.
Protein-tyrosine Phosphatase 1B Antagonized Signaling by Insulin-like Growth Factor-1 Receptor and Kinase BRK/PTK6 in Ovarian Cancer Cells.
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance.
Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility.
Protein-tyrosine Phosphatase DEP-1 Controls Receptor Tyrosine Kinase FLT3 Signaling.
Protein-tyrosine phosphatase epsilon regulates Shc signaling in a kinase-specific manner: increasing coherence in tyrosine phosphatase signaling.
Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras OR neu.
Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-kappa B.
Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion.
Proteogenomic and metabolomic characterization of human glioblastoma.
Proteomic analysis identifies translationally controlled tumor protein as a mediator of phosphatase of regenerating liver-3-promoted proliferation, migration and invasion in human colon cancer cells.
Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel digestion coupled with mass spectrometry (GeLC MS/MS) approaches.
Proteomic analysis reveals plasma haptoglobin, interferon-?, and interleukin-1? as potential biomarkers of pediatric refractory epilepsy.
Proteomic Profiling of Signaling Proteins in Ten Different Tumor Cell Lines.
Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma.
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.
PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1.
PTEN gene and integrin signaling in cancer.
PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model.
Pten is essential for embryonic development and tumour suppression.
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.
PTEN mutations are common in sporadic microsatellite stable colorectal cancer.
PTEN, a unique tumor suppressor gene.
PTEN-L promotes type I interferon responses and antiviral immunity.
PTEN-PDZ domain interactions: Binding of PTEN to PDZ domains of PTPN13.
PTN signaling: Components and mechanistic insights in human ovarian cancer.
PTP-PEST phosphatase variations in human cancer.
PTP1B and TC-PTP: regulators of transformation and tumorigenesis.
PTP1B Contributes to Calreticulin-Induced Metastatic Phenotypes in Esophageal Squamous Cell Carcinoma.
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation.
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of PTEN-deficient prostate cancers.
PTP1B expression contributes to gastric cancer progression.
PTP1B expression is an independent positive prognostic factor in human breast cancer.
PTP1B Inhibitors from the Entomogenous Fungi Isaria fumosorosea.
PTP1B Is an Androgen Receptor-Regulated Phosphatase That Promotes the Progression of Prostate Cancer.
PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
PTP1B regulates cortactin tyrosine phosphorylation by targeting Tyr446.
PTP1B targets the endosomal sorting machinery: dephosphorylation of regulatory sites on the endosomal sorting complex required for transport component STAM2.
PTP1B: A simple enzyme for a complex world.
PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells.
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
PTPH1 promotes tumor growth and metastasis in human glioma.
PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.
PTPIP51 regulates mouse cardiac ischemia/reperfusion through mediating the mitochondria-SR junction.
PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3? and PTP1B in situ.
PTPL1 and PKC? contribute to proapoptotic signalling in prostate cancer cells.
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
PTPL1: a large phosphatase with a split personality.
PTPN1 Is Recurrently Mutated in Lymphoid Cancers.
PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
PTPN11 gene mutation associated with abnormal gonadal determination.
PTPN11 hypomethylation is associated with gastric cancer progression.
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.
PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein.
PTPN11 mutations are associated with poor outcomes across myeloid malignancies.
PTPN11 mutations in canine and human disseminated histiocytic sarcoma.
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.
PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker.
PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
PTPN12/PTP-PEST Regulates Phosphorylation-Dependent Ubiquitination and Stability of Focal Adhesion Substrates in Invasive Glioblastoma Cells.
PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.
PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.
PTPN13/PTPL1: An Important Regulator of Tumor Aggressiveness.
PTPN14 acts as a candidate tumor suppressor in prostate cancer and inhibits cell proliferation and invasion through modulating LATS1/YAP signaling.
PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis.
PTPN14 is required for the density-dependent control of YAP1.
PTPN14 phosphatase and YAP promote TGF? signalling in rheumatoid synoviocytes.
PTPN14, a target gene of miR-4295, restricts the growth and invasion of osteosarcoma cells through inactivation of YAP1 signaling.
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
PTPN2 induced by inflammatory response and oxidative stress contributed to glioma progression.
PTPN2 Loss Sensitizes Tumor Cells to Immunotherapy.
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
PTPN21 Overexpression Promotes Osteogenic and Adipogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells but Inhibits the Immunosuppressive Function.
PTPN22 and CTLA-4 Polymorphisms are Associated with Polyglandular Autoimmunity.
PTPN2: a tumor suppressor you want deleted?
PTPN3 acts as a tumor suppressor and boosts TGF-? signaling independent of its phosphatase activity.
PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma.
PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor.
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation.
PTPN9 induces cell apoptosis by mitigating the activation of Stat3 and acts as a tumor suppressor in colorectal cancer.
PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.
PTPRA facilitates cancer growth and migration via the TNF-?-mediated PTPRA-NF-?B pathway in MCF-7 breast cancer cells.
PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.
PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition.
PTPRD copy number variants and Ewing's sarcoma: Strengthening the association and therapeutic implications.
PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas.
PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin.
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.
PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.
PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.
PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells.
PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133.
PTPRM, a candidate tumor suppressor gene in small intestinal neuroendocrine tumors.
PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.
PTPRO-Associated Hepatic Stellate Cell Activation Plays a Critical Role in Liver Fibrosis.
PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis.
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.
PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer.
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
PTPRU, As A Tumor Suppressor, Inhibits Cancer Stemness By Attenuating Hippo/YAP Signaling Pathway.
PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma.
pTyr(421) Cortactin Is Overexpressed in Colon Cancer and Is Dephosphorylated by Curcumin: Involvement of Non-Receptor Type 1 Protein Tyrosine Phosphatase (PTPN1).
Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene.
Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.
Pyrophosphatase overexpression is associated with cell migration, invasion, and poor prognosis in gastric cancer.
Pyrrolo[1,2-a]quinoxal-5-inium salts and 4,5-dihydropyrrolo[1,2-a]quinoxalines: Synthesis, activity and computational docking for protein tyrosine phosphatase 1B.
Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias.
Quantification of the leukocyte common antigen (CD45) in mature B-cell malignancies.
R3327 prostate adenocarcinoma clonogenic cells: epithelial properties and hormone response.
Racial Disparities in the Molecular Landscape of Cancer.
Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression.
Rapid destruction of human Cdc25A in response to DNA damage.
RAS diseases in children.
RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.
Ras, TrkB, and ShcA Protein Expression Patterns in Pediatric Brain Tumors.
Ras-induced and ERK1/2 Phosphorylation-Dependent Isomerization of PTP-PEST by PIN1 Promotes FAK Dephosphorylation by PTP-PEST.
Rational Design of Selective Organoruthenium Inhibitors of Protein Tyrosine Phosphatase 1B.
Rational Design, Synthesis and Biological Evaluation of Modular Fluorogenic Substrates with High Affinity and Selectivity for PTP1B.
Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Recent advance on PTP1B inhibitors and their biomedical applications.
Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.
Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B.
Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival.
Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21.
Receptor-type protein tyrosine phosphatases in cancer.
Receptor-type tyrosine-protein phosphatase ? directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.
Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas.
Recombinant adenovirus of human p66Shc inhibits MCF-7 cell proliferation.
Recovery of anoikis in Src-transformed cells and human breast carcinoma cells by restoration of the SIRP ?1/SHP-2 signaling system.
Recurrent CDC25C mutations drive malignant transformation in FPD/AML.
Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
Recurrent ganglioneuroma in PTPN11-associated Noonan syndrome: A case report and literature review.
Recurrent PTPRB and PLCG1 mutations in angiosarcoma.
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
Redox Regulation of a Gain-of-Function Mutation (N308D) in SHP2 Noonan Syndrome.
Redox regulation of the protein tyrosine phosphatase PTP1B in cancer cells.
Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors.
Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma.
Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives.
Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTPepsilon C.
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Regulated expression of PTPRJ/CD148 and an antisense long noncoding RNA in macrophages by proinflammatory stimuli.
Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
Regulation of cancer stem cell properties by SIX1, a member of the PAX-SIX-EYA-DACH network.
Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity.
Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1 mediated pathways.
Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.
Regulation of LC3-Dependent Protective Autophagy in Ovarian Cancer Cells by Protein Phosphatase 2A.
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1.
Regulation of RPTP?-c-Src signalling pathway by miR-218.
Regulation of RPTPbeta/phosphacan expression and glycosaminoglycan epitopes in injured brain and cytokine-treated glia.
Regulation of tumor cell migration by protein tyrosine phosphatase (PTP)-proline-, glutamate-, serine-,and threonine-rich sequence (PEST).
Regulative Loop between ?-catenin and Protein Tyrosine Receptor Type ? in Chronic Myeloid Leukemia.
Relationship between CD45 antigen expression and putative stages of differentiation in B-cell malignancies.
Relationship between HPV typing and the status of G2 cell cycle regulators in cervical neoplasia.
Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells.
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.
Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.
Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
Resistance to TNF-alpha cytotoxicity can be achieved through different signaling pathways in rat mesangial cells.
Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and stemness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-independent mechanisms.
Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion.
Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo.
Reversible oxidation of phosphatase and tensin homolog (PTEN) alters its interactions with signaling and regulatory proteins.
Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.
Rheumatoid arthritis susceptibility genes: An overview.
Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation.
Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti- Cancer Drug Target.
Role of PTEN in neutrophil extracellular trap formation.
Role of PTPRJ genotype in papillary thyroid carcinoma risk.
Role of silencing phosphatase of regenerationg liver-3 expression by microRNA interference in the growth of gastric cancer.
Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs).
Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
Rosette forming glioneuronal tumor in the optico-chiasmatic region-a novel entity in a new location.
Rosiglitazone attenuates tumor necrosis factor-?-induced protein tyrosine phosphatase-1B production in HepG2 cells.
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis.
S-Nitrosylation of mitogen activated protein kinase phosphatase-1 suppresses radiation-induced apoptosis.
Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors.
Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.
SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells.
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis.
Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase.
Select Stabilization of a Tumor-Suppressive PP2A Heterotrimer.
Selective binding modes and allosteric inhibitory effects of lupane triterpenes on protein tyrosine phosphatase 1B.
Selective Covalent Inhibition of "Allosteric Cys121" Distort the Binding of PTP1B Enzyme: A Novel Therapeutic Approach for Cancer Treatment.
Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated -7 (mda-7)/interleukin-24 (IL-24) gene.
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in?vitro and in?vivo.
Selective Pressures on Human Cancer Genes along the Evolution of Mammals.
Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase.
Sensing invasion: Cell surface receptors driving spreading of glioblastoma.
Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7.
Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin's lymphoma: a predictor of aggressive disease and new treatment target.
SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.
SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling.
SHP-1 in Cell-Cycle Regulation.
SHP-1 is a target of regorafenib in colorectal cancer.
SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis).
SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases.
SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells.
SHP-1: the next checkpoint target for cancer immunotherapy?
SHP-2 and myeloid malignancies.
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
SHP-2 can suppress transformation induced by platelet-derived growth factor.
SHP-2 expression negatively regulates NK cell function.
SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling.
SHP-2 Interacts with CD81 and Regulates the Malignant Evolution of Colorectal Cancer by Inhibiting Epithelial-Mesenchymal Transition.
SHP-2 is a novel target of Abl kinases during cell proliferation.
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-? production.
SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively.
SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro.
SHP-2, SH2-containing protein tyrosine phosphatase-2.
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade.
SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
SHP2 positively regulates TGF?1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.
SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3? signaling pathway.
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.
SHP2 sails from physiology to pathology.
Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice.
SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.
SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56gamma knockdown.
Significance of "high" acid phosphatase activity in the serum of normal children.
Significance of PTPRZ1 and CIN85 expression in cervical carcinoma.
Significant relationship of combined ACP1/PTPN22 genotype variants with the growth of uterine leiomyomas.
Silencing CDC25A inhibits the proliferation of liver cancer cells by downregulating IL?6 in vitro and in vivo.
Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Silencing of the PP2A catalytic subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis.
Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor.
Simian virus 40 small tumor antigen inhibits dephosphorylation of protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation.
Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs.
Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
SIRPalpha1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration.
Small amplicons high resolution melting analysis (SA-HRMA) allows successful genotyping of acid phosphatase 1 (ACP1) polymorphisms in the Italian population.
Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2.
Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo.
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Small molecule 1'-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway.
Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma.
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration.
SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways.
Solid-phase synthesis of dysidiolide-derived protein phosphatase inhibitors.
Solution NMR studies reveal no global flexibility in the catalytic domain of CDC25B.
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas.
Somatic mutations affect key pathways in lung adenocarcinoma.
Somatic PTPN11 Mutation in a Child With Neuroblastoma and Protein Losing Enteropathy.
Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis.
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
Spatially interacting phosphorylation sites and mutations in cancer.
SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.
Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Specificity of HCPTP variants toward EphA2 tyrosines by quantitative selected reaction monitoring.
Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
Spermatogonia-dependent expression of testicular genes in mice.
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Spirulina phycocyanin induces differential protein expression and apoptosis in SKOV-3 cells.
Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.
Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3.
SRC signaling is crucial in the growth of synovial sarcoma cells.
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.
Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.
STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5.
STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes.
Statement of Retraction. Iria Nieto-Vázquez, Sonia Fernández-Veledo, Cristina de Alvaro, Cristina M. Rondinone, Angela M. Valverde, and Margarita Lorenzo. Protein-Tyrosine Phosphatase 1B-Deficient Myocytes Show Increased Insulin Sensitivity and Protection Against Tumor Necrosis Factor-?-Induced Insulin Resistance. Diabetes 2007;56:404-413. https://doi.org/10.2337/db06-0989.
Statistical completion of a partially identified graph with applications for the estimation of gene regulatory networks.
Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
Steroids up-regulate p66Shc longevity protein in growth regulation by inhibiting its ubiquitination.
Stimulation of Suicidal Erythrocyte Death by the CDC25 Inhibitor NSC-95397.
Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding sites.
Structural analysis of the PTEN:P-Rex2 signaling complex reveals how cancer-associated mutations coordinate to hyperactivate Rac1.
Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40.
Structural and functional characterization of the PDZ domain of the human phosphatase PTPN3 and its interaction with the human papillomavirus E6 oncoprotein.
Structural basis for recognition of the tumor suppressor protein PTPN14 by the oncoprotein E7 of human papillomavirus.
Structural Basis for Selective Interaction between the ESCRT Regulator HD-PTP and UBAP1.
Structural Basis for Specific Interaction of TGF? Signaling Regulators SARA/Endofin with HD-PTP.
Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Structural Insight into the Critical Role of the N-Terminal Region in the Catalytic Activity of Dual-Specificity Phosphatase 26.
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
Structural Stability of Human Protein Tyrosine Phosphatase ? Catalytic Domain: Effect of Point Mutations.
Structure and backbone dynamics of vanadate-bound PRL-3: comparison of 15N nuclear magnetic resonance relaxation profiles of free and vanadate-bound PRL-3.
Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion.
Structure and functions of His domain protein tyrosine phosphatase in receptor trafficking and cancer.
Structure of human dual-specificity phosphatase 7, a potential cancer drug target.
Structure of human PRL-3, the phosphatase associated with cancer metastasis.
Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins.
Structure of the complex of an iminopyridinedione PTP4A3 phosphatase inhibitor with human serum albumin.
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis.
Structure-functional implications of longevity protein p66Shc in health and disease.
Structures, biogenesis, and biological activities of pyrano[4,3-c]isochromen-4-one derivatives from the Fungus Phellinus igniarius.
Studies of the molecular mechanisms in the regulation of telomerase activity.
Studies on alkaline phosphatase activity cultured cells from a patient with fibrodysplasia ossificans progressiva.
Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines.
Subcellular localisation of Cdc25A determines cell fate.
Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility.
Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma.
Suppression of B-Raf(V600E) cancers by MAPK hyper-activation.
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains.
Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.
Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome-wide expression profile, and inhibits gastric cancer cell growth.
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.
Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases.
Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases.
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways.
Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal.
Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B.
Synthesis and Biological Evaluation of FTY720 (Fingolimod) Derivatives with Aromatic Head Group as Anticancer Agents.
Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway.
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Synthetic peptides containing ITIM-like domains block expression of inflammatory mediators and migration/invasion of cancer cells through activation of SHP-1 and PI3K.
Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.
Systemic inhibition of PTPN22 augments anticancer immunity.
Systemic lupus erythematosus in a patient with PTEN hamartoma tumour syndrome.
T Cell Protein Tyrosine Phosphatase in Glucose Metabolism.
T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice.
T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
TAFs contributes the function of PTPN2 in colorectal carcinogenesis through activating JAK/STAT signaling pathway.
Take your "M" time.
Tangeretin derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells in vitro and in vivo.
Targeted Degradation of the Oncogenic Phosphatase SHP2.
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.
Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back.
Targeting 14-3-3?-CDC25A interactions to trigger apoptotic cell death in skin cancer.
Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis.
Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.
Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer.
Targeting intracellular oncoproteins with antibody therapy or vaccination.
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy.
Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators.
Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.
Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor.
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies.
Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
Targeting PTPs with small molecule inhibitors in cancer treatment.
Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?
Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma.
Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth.
Targeting the Yin and the Yang: Combined Inhibition of the Tyrosine Kinase c-Src and the Tyrosine Phosphatase SHP-2 Disrupts Pancreatic Cancer Signaling and Biology In Vitro and Tumor Formation In Vivo.
Tartrate-resistant acid phosphatase in serum of cancer patients.
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.
Terpenoids from the Soft Coral Sinularia sp. Collected in Yongxing Island.
TGF-?1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death.
The 3D structure of protein phosphatase 2A: new insights into a ubiquitous regulator of cell signaling.
The ?-catenin destruction complex.
The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA.
The Anti-Inflammatory Effects of Vitamin D in Tumorigenesis.
The Anti-Tumor Agent Sodium Selenate Decreases Methylated PP2A, Increases GSK3?Y216 Phosphorylation, Including Tau Disease Epitopes and Reduces Neuronal Excitability in SHSY-5Y Neurons.
The antiproliferative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway.
The association of genetically controlled CpG methylation (cg158269415) of protein tyrosine phosphatase, receptor type N2 (PTPRN2) with childhood obesity.
The B56?3 regulatory subunit-containing protein phosphatase 2A outcompetes Akt to regulate p27KIP1 subcellular localization by selectively dephosphorylating phospho-Thr157 of p27KIP1.
The Basic Biology of PP2A in Hematologic Cells and Malignancies.
The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1.
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
The binding affinity of PTPN13's tandem PDZ2/3 domain is allosterically modulated.
The C. elegans homolog of the mammalian tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to regulate binary cell fate decisions.
The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1.
The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer.
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.
The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms.
The dual specificity phosphatase Cdc25B, but not the closely related Cdc25C, is capable of inhibiting cellular proliferation in a manner dependent upon its catalytic activity.
The Dual Specificity Phosphatase Cdc25C is a Direct Target for Transcriptional Repression by the Tumor Suppressor p53.
The Dual-Specificity Phosphatase 10 (DUSP10): Its Role in Cancer, Inflammation, and Immunity.
The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor- and interleukin-1-induced nuclear factor-?B activation by dephosphorylating the protein kinase TAK1.
The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling.
The E3 ubiquitin ligase MID1 catalyzes ubiquitination and cleavage of Fu.
The effect of YAP expression in tumor cells and tumor stroma on the prognosis of patients with squamous cell carcinoma of the oral cavity floor and oral surface of the tongue.
The effects of ACTH on acid phosphatase activity in endosomes, GERL and lysosomes of cultured adrenal tumor cells.
The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability.
The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary re: M. A. Davies, et al., Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res., 8: 1904-1914, 2002.
The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats.
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
The Expression of the Phosphatase Regenerating Liver 3 Gene is Associated with Outcome in Patients with Colorectal Cancer.
The Expression, Functions, Interactions and Prognostic Values of PTPRZ1: A Review and Bioinformatic Analysis.
The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone.
The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells.
The Fetal Phenotype of Noonan Syndrome Caused by Severe, Cancer-Related PTPN11 Variants.
The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages.
The function of the protein tyrosine phosphatase SHP-1 in cancer.
The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application.
The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/?-catenin signaling pathway.
The gene for leukocyte antigen-related tyrosine phosphatase (LAR) is localized to human chromosome 1p32, a region frequently deleted in tumors of neuroectodermal origin.
The genetics of nodal marginal zone lymphoma.
The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.
The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
The histochemical behaviour, electrophoretic mobility and distribution in cell fractions of acid phosphatase isozymes in prostatic cancer and benign prostate hyperplasia.
The HNF1?-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1.
The homophilic receptor PTPRK selectively dephosphorylates multiple junctional regulators to promote cell-cell adhesion.
The impact of hepatocyte nuclear factor-1? on liver malignancies and cell stemness with metabolic consequences.
The interaction of SET and protein phosphatase 2A as target for cancer therapy.
The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation.
The interplay between p66Shc, reactive oxygen species and cancer cell metabolism.
The Interplay between PP2A and microRNAs in Leukemia.
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
The Involvement of the Mammalian Target of Rapamycin, Protein Tyrosine Phosphatase 1b and Dipeptidase 4 Signaling Pathways in Cancer and Diabetes: A Narrative Review.
The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
The lipid phosphatase activity of PTEN is critical for its tumor supressor function.
The mechanism of binding of the second PDZ domain from the Protein Tyrosine Phosphatase-BL to the Adenomatous Polyposis Coli tumor suppressor.
The metal face of protein tyrosine phosphatase 1B.
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation.
The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer.
The molecular basis of leukemia.
The murine orthologue of the Golgi-localized TPTE protein provides clues to the evolutionary history of the human TPTE gene family.
The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints.
The natural course of low grade, non-metastatic prostatic carcinoma.
The natural tumorcide Manumycin-A targets protein phosphatase 1? and reduces hydrogen peroxide to induce lymphoma apoptosis.
The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
The Nonreceptor-Type Tyrosine Phosphatase PTPN13 Is a Tumor Suppressor Gene in Non-Small Cell Lung Cancer.
The open architecture of HD-PTP phosphatase provides new insights into the mechanism of regulation of ESCRT function.
The overexpression of TDP-43 in astrocytes causes neurodegeneration via a PTP1B-mediated inflammatory response.
The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
The p52 isoform of SHC1 is a key driver of breast cancer initiation.
The p53-p66Shc apoptotic pathway is dispensable for tumor suppression whereas the p66Shc-generated oxidative stress initiates tumorigenesis.
The p53-p66shc-Manganese Superoxide Dismutase (MnSOD) network: a mitochondrial intrigue to generate reactive oxygen species.
The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth.
The phosphatase of regenerating liver 3 (PRL-3) promotes cell migration via Arf-activity dependent stimulation of integrin alpha5 recycling.
The phosphatase PRL-3 affects intestinal homeostasis by altering the crypt cell composition.
The Phosphatase PRL-3 Is Involved in Key Steps of Cancer Metastasis.
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
The phosphatase Shp1 interacts with and dephosphorylates cortactin to inhibit invadopodia function.
The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.
The Potential Role of Sildenafil in Cancer Management through EPR Augmentation.
The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma.
The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer.
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.
The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth.
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.
The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function.
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis.
The Protein Tyrosine Phosphatase SHP-1 Modulates the Suppressive Activity of Regulatory T Cells.
The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion.
The PTP1B mutant PTP1B?2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7.
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.
The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.
The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas.
The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation.
The Pyst2-L phosphatase is involved in cell-crowding.
The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue.
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells.
The receptor protein-tyrosine phosphatase, Dep1, acts in arterial/venous cell fate decisions in zebrafish development.
The receptor-like protein-tyrosine phosphatase DEP-1 is constitutively associated with a 64-kDa protein serine/threonine kinase.
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
The Regulatory Role of KIBRA and PTPN14 in Hippo Signaling and Beyond.
The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study.
The role of Cdc25A in the regulation of cell proliferation and apoptosis.
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review.
The role of CIP2A in cancer: A review and update.
The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis.
The role of Helicobacter pylori CagA in gastric carcinogenesis.
The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis.
The role of Merkel cell polyomavirus and other human polyomaviruses in emerging hallmarks of cancer.
The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38.
The role of protein phosphatase 2A in inflammation and cancer.
The role of PTEN in the progression and survival of prostate cancer.
The role of PTEN, a phosphatase gene, in inherited and sporadic nonmedullary thyroid tumors.
The role of SET/I2PP2A in canine mammary tumors.
The serologically defined colon cancer antigen-3 interacts with the protein tyrosine phosphatase PTPN13 and is involved in the regulation of cytokinesis.
The significance of creatine kinase (CKBB) in metastatic cancer of the prostate.
The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells.
The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter.
The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance.
The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA.
The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
The TNF-?-induced expression of miR-130b protects cervical cancer cells from the cytotoxicity of TNF-?.
The transmembranal and cytoplasmic forms of protein tyrosine phosphatase epsilon physically associate with the adaptor molecule Grb2.
The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn).
The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
The tumor suppressor PTPRK promotes ZNRF3 internalization and is required for Wnt inhibition in the Spemann organizer.
The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
The tumor-selective somatostatin analog, TT2-32 induces a biphasic activation of phosphotyrosine phosphatase activity in human colon tumor cell line, SW620.
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
The two faces of PTP1B in cancer.
The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
The tyrosine phosphatase DEP-1 induces cytoskeletal rearrangements, aberrant cell-substratum interactions and a reduction in cell proliferation.
The tyrosine phosphatase HD-PTP (PTPN23) is degraded by calpains in a calcium-dependent manner.
The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis.
The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
The tyrosine phosphatase Shp2 (PTPN11) in cancer.
The tyrosine phosphatase Shp2 in development and cancer.
The tyrosine343 residue of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration.
The vitamin-like dietary supplement para-aminobenzoic acid enhances the antitumor activity of ionizing radiation.
The wind god promotes lung cancer.
Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer.
Therapeutic potential of targeting the oncogenic SHP2 phosphatase.
Therapeutic relevance of the protein phosphatase 2A in cancer.
Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.
Thyroid hormone antagonizes tumor necrosis factor-alpha signaling in pituitary cells through the induction of dual specificity phosphatase 1.
Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling.
Timing is everything: regulation of Cdk1 and aneuploidy.
Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.
Tobacco habituated and non-habituated subjects exhibit different mutational spectrums in head and neck squamous cell carcinoma.
Toll-like receptor-mediated IRE1? activation as a therapeutic target for inflammatory arthritis.
Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway.
Toxoplasma GRA16 Inhibits NF-?B Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells.
TRAIL and ceramide.
TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis.
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Transcriptome profiling analysis on whole bodies of microbial challenged Eriocheir sinensis larvae for immune gene identification and SNP development.
Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma.
Transduction motif analysis of gastric cancer based on a human signaling network.
Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.
Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.
Treatment with DHA Modifies the Response of MDA-MB-231 Breast Cancer Cells and Tumors from nu/nu Mice to Doxorubicin through Apoptosis and Cell Cycle Arrest.
Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.
TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression.
Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA.
TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer.
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers.
Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation.
Tumor necrosis factor receptor II and PTPN22 genes polymorphisms and the risk of systemic lupus erythematosus in Egyptian children.
Tumor necrosis factor-?-mediated suppression of dual-specificity phosphatase 4: crosstalk between NF?B and MAPK regulates endothelial cell survival.
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells.
Tumor Suppression by p53: Bring in the Hippo!
Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases.
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties.
Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas.
Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.
Tumor vessel up-regulation of INSR revealed by single-cell expression analysis of the tyrosine kinome and phosphatome in human cancers.
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.
Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion.
Tumor-Suppression Mechanisms of Protein Tyrosine Phosphatase O and Clinical Applications.
Tumor-suppressive Function of Protein-tyrosine Phosphatase Non-receptor Type 23 in Testicular Germ Cell Tumors Is Lost upon Overexpression of miR142-3p microRNA.
Tumoral Prostate Shows Different Expression Pattern of Somatostatin Receptor 2 (SSTR2) and Phosphotyrosine Phosphatase SHP-1 (PTPN6) According to Tumor Progression.
Tumour suppressor function of protein tyrosine phosphatase receptor-T.
Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth.
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.
Tuning the Protein Phosphorylation by Receptor Type Protein Tyrosine Phosphatase Epsilon (PTPRE) in Normal and Cancer Cells.
Two-photon imaging of multicellular tumor spheroids: A novel method for evaluating the efficacy of CDC25 phosphatase inhibitors.
Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells.
Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
Tyrosine phosphatase PTP? contributes to HER2-evoked breast tumor initiation and maintenance.
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.
Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression.
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells.
Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer.
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A.
Ubiquitin-Specific Protease 29 Regulates Cdc25A-Mediated Tumorigenesis.
Ultrasound-Based Molecular Imaging of Tumors with PTPmu Biomarker-Targeted Nanobubble Contrast Agents.
Ultrastructural changes in human prepubertal prostatic epithelium grown in vitro.
Ultrastructural localization of acid phosphatase in human laryngeal carcinoma.
Ultrastructure of tumor cell interaction with alveolar macrophages stimulated by vitamin A.
Uncovering a tumor suppressor for triple-negative breast cancers.
Understanding the effect of alternative splicing in the folding and function of the second PDZ from protein tyrosine phosphatase-BL.
Unknown primary adenocarcinoma: incidence of overinvestigation and natural history.
Unnatural amino acid mutagenesis reveals dimerization as a negative regulatory mechanism of VHR's phosphatase activity.
Unscheduled expression of CDC25B in S-phase leads to replicative stress and DNA damage.
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression.
Upregulated miR-665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion.
Upregulation of CIP2A in estrogen depletion-resistant breast cancer cells treated with low-dose everolimus.
Upregulation of metastasis-associated PRL-3 initiates chordoma in zebrafish.
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.
Upregulation of PTP1B After Rat Spinal Cord Injury.
Using the MCoTI-II Cyclotide Scaffold To Design a Stable Cyclic Peptide Antagonist of SET, a Protein Overexpressed in Human Cancer.
USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status.
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.
Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.
VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis.
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.
VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C.
Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation.
Virtual Screening of Novel and Selective Inhibitors of Protein Tyrosine Phosphatase 1B over T-Cell Protein Tyrosine Phosphatase Using a Bidentate Inhibition Strategy.
Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells.
Visualizing the origins of selfish de novo mutations in individual seminiferous tubules of human testes.
Vitamin C transiently arrests cancer cell cycle progression in S phase and G2/M boundary by modulating the kinetics of activation and the subcellular localization of Cdc25C phosphatase.
Vitamin K3 induces cell cycle arrest and cell death by inhibiting Cdc25 phosphatase.
When Overgrowth Bumps Into Cancer: The PTEN-Opathies.
When overgrowth bumps into cancer: the PTEN-opathies.
Whole exome sequencing in Dandy-Walker variant with intellectual disability reveals an activating CIP2A mutation as novel genetic cause.
Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.
Wnt signalling in mammalian development and cancer.
Woodylides A-C, New Cytotoxic Linear Polyketides from the South China Sea Sponge Plakortis simplex.
YAP and TAZ, Hippo Signaling Targets, Act as a Rheostat for Nuclear SHP2 Function.
YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.
YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
Zanthoxylum avicennae extracts induce cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and block tumor growth in xenografted nude mice.
[A case of giant prostate cancer]
[A new styrene dimer derivative from Litsea greenmaniana].
[Acid phosphatase activity and non-specific esterase D of alpha-naphthyl acetate in the lymphocytes of patients with digestive system neoplasms after surgical treatment]
[Acid phosphatase activity and phagocytic capabilities of reticuloendothelial system cells of mice with experimental tumors]
[Acid phosphatase activity in cultures of glial tumors]
[Acid phosphatase activity in uterine cervix in cases of planoepithelial cancer]
[Advanced prostate cancer--an analysis of 17 cases]
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells]
[Association between diversity in the Src homology 2 domain-containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer. J Infect Dis 2004;189:820-827]
[Change in brain alkaline and acid phosphatase activity under the action of adrenocorticotrophic hormone and hydrocortisone in experimental transplanted cancer of the rat mammary gland]
[Changes of phenotypes associated with activated Src by overexpressed PTPalpha in NIH3T3 cells]
[Chemical constituents of stems and branches of Adina polycephala]
[Construction and expression of PRL-3 plasmid with C104S point mutation and CAAX deletion.]
[Cutaneous histiocytosarcoma: clinical, immunohistochemical and ultrastructural aspects; difficulties of study and problems of nosology (author's transl)]
[Cytologic study of giant cell tumors. Electron microscopy. Cyto-enzymology]
[Down regulation of mitogen activated protein kinase phosphatase-1 mediate acquired multidrug resistance in pancreatic adenocarcinoma cell line SW1990/Fu]
[Effects of a novel gene NOR(1) on the protein expression of HepG2 cell line.]
[Enzyme cytochemical and immunocytological differentiation of infiltrative cells in the skin in mycosis fungoides]
[Enzymological study of prostatic cancer. II. Serum lactic dehydrogenase, alkaline phosphatase, leucine aminopeptidase, total acid phosphatase, prostatic acid phosphatase activity and lactic dehydrogenase isoenzymes in prostatic cancer, with special reference to relation with stage and histological malignancy]
[Expression and clinical value of SHP-1 and c-kit in acute leukemia]
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
[Expression and Significance of PTPL1 in Hematological Malignan-cies].
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
[Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance].
[Expressions and significances of PRL-3 and RhoC in A549 cell].
[Gene expression profiles in squamous esophageal cancer tissues and adjacent almost normal tissues]
[Growth phenomena of jaw ameloblastomas]
[Impairments of insulin receptor function in insulin resistant states]
[Inhibition of pinocytosis and of acid phosphatase activity caused by lack of serum in the culture medium of Ehrlich ascites tumor cells (author's transl)]
[Methylation of PTPRG gene and its regulation in gastric cancer]
[Molecular mechanism and clinical impact of insulin resistance in type 2 diabetes mellitus]
[Non-anthraquinones constituents from the roots of Knoxia valerianoides].
[Oncogenic mechanism of Helicobacter pylori]
[Phosphatase of regenerating liver-3 (PRL-3) and tumor metastasis]
[Prognostic value of CDC25 phosphatases expression in laryngeal cancer]
[Prostate and menadiol sodium diphosphate - menadiol sodium diphosphate as a new substrate for measuring acid phosphatase activity and a discussion on prostatic tumor model ]
[PTPL1, a proapoptotic protein tyrosine phosphatase in breast cancers]
[Research progress of protein tyrosine phosphatase SHP-2].
[Research progress on MKP-1 in tumor drug resistance].
[Role of silencing PRL-3 expression by miRNA interference in the growth of gastric cancer]
[Screening and identification of tumor related genes in early stages of transformed NIH3T3 cells associated with overexpressed PTPalpha]
[Some findings on acid phosphatase activity in cerebral tumors]
[Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]
[The Biological Function of SHP2 in Human Disease].
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
[The effects of PTEN gene on migration and FAK phosphorylation of SMMC-7721 human hepatocarcinoma cell line]
[The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues]
[The significance of acid phosphatase activity in the cytologic diagnosis of thyroid malignancy (author's transl)]
{Gamma}-tocotrienol but not {gamma}-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
Neoplasms, Germ Cell and Embryonal
Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Tumor-suppressive Function of Protein-tyrosine Phosphatase Non-receptor Type 23 in Testicular Germ Cell Tumors Is Lost upon Overexpression of miR142-3p microRNA.
Neoplasms, Glandular and Epithelial
Association of PTP4A3 expression and tumour size in functioning pituitary adenoma: a descriptive study.
Neoplasms, Neuroepithelial
CP6 Anopthalmia and dysembryoplastic neuroepithelial tumours in a family with Noonan syndrome and a novel PTPN11 mutation.
Neoplastic Cells, Circulating
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Nephritis
A receptor-like inositol lipid phosphatase is required for the maturation of developing cochlear hair bundles.
Acid phosphatase activity of normal and Masugi nephritis in mice.
Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B.
Glomerular epithelial protein 1 and podocalyxin-like protein 1 in inflammatory glomerular disease (crescentic nephritis) in rabbit and man.
Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation.
Nephritis, Hereditary
A rare association of pathological variant of Alport's syndrome caused by hemizygous 5' splice mutation in intron 10 of COL4A5 gene with metachondromatosis due to heterozygous missense variation in protein tyrosine phosphatase nonreceptor type 11 gene.
Nephritis, Interstitial
Oxidative stress-inducible protein tyrosine phosphatase in glomerulonephritis.
Nephrosis
Early changes in gene expression that influence the course of primary glomerular disease.
GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis. A marker of acute podocyte injury.
Nephrosis, Lipoid
Podocyte proteins in Galloway-Mowat syndrome.
Nephrotic Syndrome
Disruption of PTPRO Causes Childhood-Onset Nephrotic Syndrome.
Mutational landscape of TRPC6, WT1, LMX1B, APOL1, PTPRO, PMM2, LAMB2 and WT1 genes associated with Steroid resistant nephrotic syndrome.
Podocyte phenotypes as defined by expression and distribution of GLEPP1 in the developing glomerulus and in nephrotic glomeruli from MCD, CNF, and FSGS. A dedifferentiation hypothesis for the nephrotic syndrome.
Podocyte proteins in Galloway-Mowat syndrome.
Nervous System Diseases
Aging is associated with dimerization and inactivation of the brain-enriched tyrosine phosphatase STEP.
Down-regulation of BDNF in cell and animal models increases striatal-enriched protein tyrosine phosphatase 61 (STEP61 ) levels.
Extreme enrichment of VNTR-associated polymorphicity in human subtelomeres: genes with most VNTRs are predominantly expressed in the brain.
Mechanisms and Disease Associations of Haplotype-Dependent Allele-Specific DNA Methylation.
Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease.
Neural Tube Defects
Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.
Neuralgia
BDNF contributes to the development of neuropathic pain by induction of spinal long-term potentiation via SHP2 associated GluN2B-containing NMDA receptors activation in rats with spinal nerve ligation.
Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1.
Carnosic acid attenuates neuropathic pain in rat through the activation of spinal sirtuin1 and down-regulation of p66shc expression.
Hypertrophic neuropathy in Noonan syndrome with multiple lentigines.
Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn of rats attenuated diabetic neuropathic pain.
MiR-101 promotes pain hypersensitivity in rats with chronic constriction injury via the MKP-1 mediated MAPK pathway.
p66shc siRNA-Encapsulated PLGA Nanoparticles Ameliorate Neuropathic Pain Following Spinal Nerve Ligation.
PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain.
Spinal SIRP?1-SHP2 interaction regulates spinal nerve ligation-induced neuropathic pain via PSD-95-dependent NR2B activation in rats.
Neurilemmoma
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Neuroblastoma
Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas.
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma.
Atomic structure of dual-specificity phosphatase 26, a novel p53 phosphatase.
Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2.
Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.
Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.
Elevated protein-tyrosine-phosphatase activity in human colon-carcinoma.
Expression of the cdc25B mRNA correlated with that of N-myc in neuroblastoma.
Functional analysis of the putative tumor suppressor PTPRD in neuroblastoma cells.
Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
Initiation and maintenance of CNTF-Jak/STAT signaling in neurons is blocked by protein tyrosine phosphatase inhibitors.
Interactions Between Glycogen Synthase Kinase 3beta, Protein Kinase B, and Protein Phosphatase 2A in Tau Phosphorylation in Mouse N2a Neuroblastoma Cells.
Leucine Carboxyl Methyltransferase 1 (LCMT1)-dependent Methylation Regulates the Association of Protein Phosphatase 2A and Tau Protein with Plasma Membrane Microdomains in Neuroblastoma Cells.
Liprin alfa 2 gene expression is increased by cannabis use and associated with neuropsychological function.
MKP-1 contributes to oxidative stress-induced apoptosis via inactivation of ERK1/2 in SH-SY5Y cells.
Molecular Basis of the Interaction of the Human Protein Tyrosine Phosphatase Non-receptor Type 4 (PTPN4) with the Mitogen-activated Protein Kinase p38?.
Mutational dynamics between primary and relapse neuroblastomas.
Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Neuroblastoma PTPome analysis unveils association of DUSP5 and PTPN1 expression with poor prognosis.
Neuroprotective Effects of Protein Tyrosine Phosphatase 1B Inhibition against ER Stress-Induced Toxicity.
Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation.
Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation.
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.
Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene.
Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP.
Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling.
Proteomic investigation of Cbl and Cbl-b in neuroblastoma cell differentiation highlights roles for SHP-2 and CDK16.
Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A.
PTPN11 induces endoplasmic stress and apoptosis in SH-SY5Y cells.
Receptor protein tyrosine phosphatase alpha activates pp60c-src and is involved in neuronal differentiation.
Receptor tyrosine phosphatase beta (RPTPbeta) activity and signaling are attenuated by glycosylation and subsequent cell surface galectin-1 binding.
Regulation of protein phosphatase 2A methylation by LCMT1 and PME-1 plays a critical role in differentiation of neuroblastoma cells.
Somatic PTPN11 Mutation in a Child With Neuroblastoma and Protein Losing Enteropathy.
Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration.
Subcellular Localization and Differentiation-Induced Redistribution of the Protein Tyrosine Phosphatase PTP-BL in Neuroblastoma Cells.
TC-PTP Dephosphorylates the Guanine Nucleotide Exchange Factor C3G (RapGEF1) and Negatively Regulates Differentiation of Human Neuroblastoma Cells.
The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
The testosterone metabolite 3?-androstanediol inhibits oxidative stress-induced ERK phosphorylation and neurotoxicity in SH-SY5Y cells through an MKP3/DUSP6-dependent mechanism.
Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.
Transcriptional response to muscarinic acetylcholine receptor stimulation: regulation of Egr-1 biosynthesis by ERK, Elk-1, MKP-1, and calcineurin in carbachol-stimulated human neuroblastoma cells.
Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence.
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
Vanadate protects human neuroblastoma SH-SY5Y cells against peroxynitrite-induced cell death.
Neurodegenerative Diseases
A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation.
A STEP forward in neural function and degeneration.
Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.
Alterations of STEP46 and STEP61 Expression in the Rat Retina with Age and AMD-Like Retinopathy Development.
Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases.
CSP? reduces aggregates and rescues striatal dopamine release in ?-synuclein transgenic mice.
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Genetic determinants at the interface of cancer and neurodegenerative disease.
Heterozygous Meg2 Ablation Causes Intraocular Pressure Elevation and Progressive Glaucomatous Neurodegeneration.
Immunohistochemical Localization of Fas-associated phosphatase-1 (FAP-1) in Alzheimer disease hippocampus.
Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3?/PP2A pathway in Parkinson's disease.
Molecular crosstalk between cancer and neurodegenerative diseases.
Molecular underpinnings of neurodegenerative disorders: striatal-enriched protein tyrosine phosphatase signaling and synaptic plasticity.
Neuroprotective Effects of Protein Tyrosine Phosphatase 1B Inhibition against ER Stress-Induced Toxicity.
Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer's disease.
p66Shc Aging Protein in Control of Fibroblasts Cell Fate.
Phosphorylation-Specific Peptidyl-Prolyl Isomerization of Neuronal Cytoskeletal Proteins by Pin1: Implications for Therapeutics in Neurodegeneration.
Phosphorylation-specific peptidyl-prolyl isomerization of neuronal cytoskeletal proteins by Pin1: implications for therapeutics in neurodegeneration.
PP2AC? of Alveolar Macrophages Is a Novel Protective Factor for LPS-Induced Acute Respiratory Distress Syndrome.
Protein Phosphatase 2a (Pp2a) Regulates Innate Immune and Proteolytic Responses to Cigarette Smoke Exposure in the Lung.
Protein phosphatase 2A facilitates axonogenesis by dephosphorylating CRMP2.
Protein Phosphatase 2A: a Double-Faced Phosphatase of Cellular System and Its Role in Neurodegenerative Disorders.
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
PTPIP51 regulates mouse cardiac ischemia/reperfusion through mediating the mitochondria-SR junction.
PTPN11 induces endoplasmic stress and apoptosis in SH-SY5Y cells.
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding sites.
Synthesis of benzopentathiepin analogs and their evaluation as inhibitors of the phosphatase STEP.
The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.
The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2.
The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity.
The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival.
Neurodermatitis
[Neutrophil alkaline and acid phosphatase activity in the blood of children with neurodermatitis]
Neuroectodermal Tumors
LAR tyrosine phosphatase receptor: alternative splicing is preferential to the nervous system, coordinated with cell growth and generates novel isoforms containing extensive CAG repeats.
Leukocyte common antigen-related receptor-linked tyrosine phosphatase. Regulation of mRNA expression.
Neuroendocrine Tumors
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
PTPRM, a candidate tumor suppressor gene in small intestinal neuroendocrine tumors.
Neurofibroma
Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.
Neurofibromatoses
A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
LEOPARD syndrome: clinical diagnosis in the first year of life.
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Myelodysplastic and myeloproliferative disorders of childhood.
Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia.
Neurofibromatosis 1
A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Clinical variability of neurofibromatosis 1: A modifying role of cooccurring PTPN11 variants and atypical brain MRI findings.
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
LEOPARD syndrome: clinical diagnosis in the first year of life.
Myelodysplastic and myeloproliferative disorders of childhood.
Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia.
Neurofibrosarcoma
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Neuroinflammatory Diseases
A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation.
AGK2 Alleviates Lipopolysaccharide Induced Neuroinflammation through Regulation of Mitogen-Activated Protein Kinase Phosphatase-1.
Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1.
Comparative Analysis of Protein Tyrosine Phosphatases Regulating Microglial Activation.
Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia.
Distribution of different isoforms of receptor protein tyrosine phosphatase ? (Ptprg-RPTP ?) in adult mouse brain: upregulation during neuroinflammation.
Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy.
PTP1B inhibitor alleviates deleterious microglial activation and neuronal injury after ischemic stroke by modulating the ER stress-autophagy axis via PERK signaling in microglia.
Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits.
Neuromyelitis Optica
HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica.
Neuronal Ceroid-Lipofuscinoses
A cluster of palmitoylated cysteines are essential for aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis.
Advances in the genetics of progressive myoclonus epilepsy.
Oligomerization of Cysteine String Protein alpha mutants causing adult neuronal ceroid lipofuscinosis.
Recurrent mutations in DNAJC5 cause autosomal dominant Kufs Disease.
Neutropenia
Clinical differential diagnosis of hairy-cell leukaemia.
SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 are dramatically increased at the protein level in neutrophils from patients with severe congenital neutropenia (Kostmann's syndrome).
Niemann-Pick Disease, Type C
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Niemann-Pick Diseases
Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Non-alcoholic Fatty Liver Disease
Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells.
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Dual-specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice through TAK1 Suppression.
Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1.
Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression.
Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21.
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.
Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: Potential role of PPAR?
Interrogating Endogenous Protein Phosphatase Activity with Rationally Designed Chemosensors.
Polymorphism of Receptor-Type Tyrosine-Protein Phosphatase Delta gene in the development of non-alcoholic fatty liver disease.
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
PTPROt aggravates inflammation by enhancing NF-?B activation in liver macrophages during nonalcoholic steatohepatitis.
SHP-1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production.
Targeting DUSP16/TAK1 signaling alleviates hepatic dyslipidemia and inflammation in high fat diet (HFD)-challenged mice through suppressing JNK MAPK.
Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-/- mice via p66shc/cytochrome C cascade.
The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
Utility of a new model to diagnose an alcohol basis for steatohepatitis.
Zinc Supplementation and Strength Exercise in Rats with Type 2 Diabetes: Akt and PTP1B Phosphorylation in Nonalcoholic Fatty Liver.
Non-ST Elevated Myocardial Infarction
Increased PTPN22 expression and defective CREB activation impair regulatory T-cell differentiation in non-ST-segment elevation acute coronary syndromes.
Noonan Syndrome
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
A de novo T73I Mutation in PTPN11 in a Neonate with Severe and Prolonged Congenital Thrombocytopenia and Noonan Syndrome.
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
A mother and son with Noonan syndrome resulting from a PTPN11 mutation.
A mother and son with Noonan syndrome resulting from a PTPN11 mutation: first report of molecularly proven cases from Turkey.
A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.
A new PTPN11 mutation in juvenile myelomonocytic leukaemia associated with Noonan syndrome.
A novel approach using long-read sequencing and ddPCR to investigate gonadal mosaicism and estimate recurrence risk in two families with developmental disorders.
A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.
A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome.
A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype.
A PTPN11 Gene Mutation (Y63C) Causing Noonan Syndrome is Not Associated with Short Stature in General Population.
A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy.
Absence of PTPN11 mutations in 28 cases of cardiofaciocutaneous (CFC) syndrome.
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Acute Lymphoblastic Leukemia Developing in a Patient With Noonan Syndrome Harboring a PTPN11 Germline Mutation.
Acute myeloid leukemia in an adult Noonan syndrome patient with PTPN11 mutation.
Analysis of giant cell tumour of bone cells for Noonan syndrome/Cherubism-related mutations.
Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients.
Aortic root dilatation is a rare complication of Noonan syndrome.
Atypical coronary artery aneurysms due to Kawasaki disease in Noonan syndrome with a novel PTPN11 mutation.
Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.
Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results.
Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions.
CD14/16 monocyte profiling in juvenile myelomonocytic leukemia.
Clinical and hematologic findings in Noonan syndrome patients with PTPN11 gene mutations.
Clinical and Molecular Analysis of Patients with RASopathies in Turkish Patients.
Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
CLINICAL REPORT OF A PATIENT WITH DE NOVO TRISOMY 12q23.1q24.33.
Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation.
Clonal duplication of a germline PTPN11 mutation due to acquired uniparental disomy in acute lymphoblastic leukemia blasts from a patient with Noonan syndrome.
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?
Cochlear implantation and clinical features in patients with Noonan syndrome and Noonan syndrome with multiple lentigines caused by a mutation in PTPN11.
Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy.
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment.
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Connecting the dots between SHP2 and glutamate receptors.
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome.
Coronary artery dilatation in LEOPARD syndrome. A child case and literature review.
Counteracting Effects Operating on Src Homology 2 Domain-containing Protein-tyrosine Phosphatase 2 (SHP2) Function Drive Selection of the Recurrent Y62D and Y63C Substitutions in Noonan Syndrome.
CP6 Anopthalmia and dysembryoplastic neuroepithelial tumours in a family with Noonan syndrome and a novel PTPN11 mutation.
Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.
Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations.
Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS).
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human Disease.
Does the rare A172G mutation of PTPN11 gene convey a mild Noonan syndrome phenotype?
Duplication of chromosome band 12q24.11q24.23 results in apparent Noonan syndrome.
Electrocardiography in Noonan syndrome PTPN11 gene mutation--phenotype characterization.
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum.
Evolutionary constraint and disease associations of post-translational modification sites in human genomes.
Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance.
Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.
Expanding the clinical spectrum of ocular anomalies in Noonan syndrome: Axenfeld-anomaly in a child with PTPN11 mutation.
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.
Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study.
External hydrocephalus as a prenatal feature of noonan syndrome.
First-year growth in children with Noonan syndrome: Associated with feeding problems?
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
Functions of Shp2 in cancer.
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.
Genetic evaluation and management of fetal chylothorax: review and insights from a case of Noonan syndrome.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Genetics and variation in phenotype in Noonan syndrome.
Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome.
Germ-line and somatic PTPN11 mutations in human disease.
Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
Germline gain-of-function mutations in SOS1 cause Noonan syndrome.
Germline KRAS mutations cause Noonan syndrome.
Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Giant cell lesion of the jaw as a presenting feature of Noonan syndrome.
Granular cell tumor of the scrotum in a child with Noonan syndrome.
Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation.
High resolution melting analysis for mutation detection for PTPN11 gene: applications of this method for diagnosis of Noonan syndrome.
Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Hotspots in PTPN11 Gene Among Indian Children With Noonan Syndrome.
Hypertrophic neuropathy in Noonan syndrome with multiple lentigines.
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11).
Identification of demethylincisterol A3 as a selective inhibitor of protein tyrosine phosphatase Shp2.
IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene.
Impact of Growth Hormone Therapy on Adult Height in Patients with PTPN11 Mutations Related to Noonan Syndrome.
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus.
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Key insights into the protein tyrosine phosphatase PTPN11/SHP2 associated with noonan syndrome and cancer.
KRAS Analysis in 34 Noonan Syndrome Patients without PTPN11 Mutation.
Lack of Catch-Up Growth with Growth Hormone Treatment in a Child Born Small for Gestational Age Leading to a Diagnosis of Noonan Syndrome with a Pathogenic PTPN11 Variant.
Lethal presentation of neurofibromatosis and Noonan syndrome.
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
Mild variable Noonan syndrome in a family with a novel PTPN11 mutation.
Mitochondrial DNA haplogroup 'R' is associated with Noonan syndrome of south India.
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.
Molecular characterization of a balanced rearrangement of chromosome 12 in two siblings with Noonan syndrome.
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Multifocal Pigmented Villonodular Synovitis in the Noonan Syndrome.
Mutation analysis of PTPN11 in Noonan syndrome by WAVE.
Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies.
Mutation Spectrum and Phenotypic Features in Noonan Syndrome with PTPN11 Mutations: Definition of Two Novel Mutations.
Mutational analysis of PTPN11 gene in Taiwanese children with Noonan syndrome.
Mutational analysis of the PTPN11 gene in Egyptian patients with Noonan syndrome.
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Myelodysplastic syndrome with multilineage dysplasia evolving to acute myeloid leukemia: Noonan syndrome with c.218C>T mutation in PTPN11 gene.
Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Neurons or Glia? Can SHP2 Know It All?
New Mutations Associated with Rasopathies in a Central European Population and Genotype-Phenotype Correlations.
No mutation in the gene for Noonan syndrome, PTPN11, in 18 patients with Costello syndrome.
Nonspecific phenotype of Noonan syndrome diagnosed by whole exome sequencing.
Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Noonan syndrome and related disorders: alterations in growth and puberty.
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
Noonan Syndrome and Related Disorders: Genetics and Pathogenesis.
Noonan syndrome and related disorders: genetics and pathogenesis.
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.
Noonan Syndrome Case Report: PTPN11 and Other Potential Genetic Factors Contributing to Lethal Hypertrophic Right Ventricular Cardiomyopathy.
Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.
Noonan Syndrome in Thai Children.
Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.
Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications.
Noonan Syndrome with Multiple Lentigines and PTPN11 Mutation: A Case with Intracerebral Hemorrhage.
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.
Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
Noonan syndrome, the SOS1 gene and embryonal rhabdomyosarcoma.
Noonan Syndrome-Associated SHP2 Dephosphorylates GluN2B to Regulate NMDA Receptor Function.
Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis.
Noonan Syndrome: Common Molecular Alterations and the Consequences.
Noonan syndrome: Prenatal diagnosis in a woman carrying a PTPN11 gene mutation.
Noonan syndrome: relationships between genotype, growth, and growth factors.
Noonan syndrome: Severe phenotype and PTPN11 mutations.
Novel mutations in PTPN11 gene in two girls with Noonan syndrome phenotype.
NRAS Mutations in Noonan Syndrome.
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Occurrence of high-grade glioma in Noonan syndrome: Report of two cases.
Ocular manifestations of Noonan syndrome.
Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants.
Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome.
Pathogenic gene screening in 91 Chinese patients with short stature of unknown etiology with a targeted next-generation sequencing panel.
Pathogenic PTPN11 variants involving the poly-glutamine Gln255 -Gln256 -Gln257 stretch highlight the relevance of helix B in SHP2's functional regulation.
Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.
Phenotype-genotype analysis of 242 individuals with RASopathies: 18-year experience of a tertiary center in Brazil.
Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.
Prenatal detection of Noonan syndrome by mutation analysis of the PTPN11 and the KRAS genes.
Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites.
Probable Noonan syndrome in a boy without PTPN11 mutation, manifesting unusual complications.
Prolonged thrombocytopenia in a neonate with Noonan syndrome: a case report.
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome.
Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome.
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings.
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype.
PTPN11 gene mutation associated with abnormal gonadal determination.
PTPN11 Mutation Associated with Aortic Dilation and Hypertrophic Cardiomyopathy in a Pediatric Patient with Noonan Syndrome.
PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning.
PTPN11 mutation in a young man with Noonan syndrome and retinitis pigmentosa.
PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome.
PTPN11 mutations in LEOPARD syndrome.
PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
PTPN11 mutations play a minor role in isolated congenital heart disease.
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Rapid detection by hydrops panel of Noonan syndrome with PTPN11 mutation (p.Thr73Ile) and persistent thrombocytopenia.
Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk.
Recurrent ganglioneuroma in PTPN11-associated Noonan syndrome: A case report and literature review.
Redox Regulation of a Gain-of-Function Mutation (N308D) in SHP2 Noonan Syndrome.
Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
Response to Growth Hormone Therapy in Children with Noonan Syndrome: Correlation with or without PTPN11 Gene Mutation.
Severe aortic valvar stenosis in familial Noonan syndrome with mutation of the PTPN11 gene.
Severe congenital thrombocytopaenia--first clinical manifestation of Noonan syndrome.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
SHP-2 and myeloid malignancies.
SHP-2 regulates growth factor dependent vascular signalling and function.
SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.
Shp2 function in hematopoietic stem cell biology and leukemogenesis.
Shp2 in myocytes is essential for cardiovascular and neointima development.
SHP2 mutations induce precocious gliogenesis of Noonan syndrome-derived iPSCs during neural development in vitro.
SHP2 sails from physiology to pathology.
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
SOS1 mutations in Noonan syndrome: Cardiomyopathies and not only congenital heart defects! Report of six patients including two novel variants and literature review.
Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome.
Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2.
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis.
Targeted next-generation sequencing in the diagnosis of neurodevelopmental disorders.
Targeted Ptpn11 deletion in mice reveals the essential role of SHP2 in osteoblast differentiation and skeletal homeostasis.
Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2.
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies.
The cardiofaciocutaneous syndrome.
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
The Fetal Phenotype of Noonan Syndrome Caused by Severe, Cancer-Related PTPN11 Variants.
The first Noonan syndrome gene: PTPN11, which encodes the protein tyrosine phosphatase SHP-2.
The first PTPN1 1 mutations in hotspot exons reported in Moroccan children with Noonan syndrome and comparison of mutation rate to previous studies.
The genetics of congenital heart disease: a review of recent developments.
The History of Noonan Syndrome.
The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
The molecular genetics of congenital heart disease: a review of recent developments.
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
The role of somatropin therapy in children with Noonan syndrome.
The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.
Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations.
Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.
Twin infant with lymphatic dysplasia diagnosed with Noonan syndrome by molecular genetic testing.
Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft.
Visual function in Noonan and LEOPARD syndrome.
[Clinical and genetic analysis of Noonan syndrome in 20 children].
[Clinical and molecular study of the Noonan syndrome].
[Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway]
[Molecular genetic mutation analysis of the PTPN11 gene in the multiple lentigines (LEOPARD) syndrome]
[Multiple granular cell tumours in a patient with Noonan's syndrome and juvenile myelomonocytic leukaemia].
[Mutation analysis of PTPN11 gene in Noonan syndrome.]
[Noonan syndrome and Leopard syndrome linked to mutation of the gene PTPN11]
[Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation]
[SOS1 mutation: a new cause of Noonan syndrome]
[The Biological Function of SHP2 in Human Disease].
[Variability in clinical expression of Noonan syndrome--the report of two familial cases]
Obesity
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population.
4-Quinolone-3-carboxylic acids as cell-permeable inhibitors of protein tyrosine phosphatase 1B.
A brake becomes an accelerator: PTP1B--a new therapeutic target for breast cancer.
A focused library of protein tyrosine phosphatase inhibitors.
A Hypothalamic Phosphatase Switch Coordinates Energy Expenditure with Feeding.
A microfluidics-based mobility shift assay to discover new tyrosine phosphatase inhibitors.
A molecular dynamics study of WPD-loop flexibility in PTP1B.
A new bioactive steroidal ketone from the South China Sea sponge Xestospongia testudinaria.
A novel screening model for the molecular drug for diabetes and obesity based on tyrosine phosphatase Shp2.
A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models.
A re-examination of the difluoromethylenesulfonic acid group as a phosphotyrosine mimic for PTP1B inhibition.
A simple and visible colorimetric method through Zr(4+)-phosphate coordination for the assay of protein tyrosine phosphatase 1B and screening of its inhibitors.
A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree.
Absolute configuration and protein tyrosine phosphatase 1B inhibitory activity of xanthoepocin, a dimeric naphtopyrone from Penicillium sp. IQ-429.
Absolute structures and bioactivities of euryspongins and eurydiene obtained from the marine sponge Euryspongia sp. collected at Iriomote Island.
ACP1 genotype, glutathione reductase activity, and riboflavin uptake affect cardiovascular risk in the obese.
Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and Is a Minor Regulator of Glucose Homeostasis.
Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes.
An extract of Urtica dioica L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A).
An investigation of obesity susceptibility genes in Northern Han Chinese by targeted resequencing.
An Isoform-Selective PTP1B Inhibitor Derived from Nitrogen-Atom Augmentation of Radicicol.
An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro.
Analyses of shared genetic factors between asthma and obesity in children.
Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population.
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Antiobesity and Antidiabetes Effects of a Cudrania tricuspidata Hydrophilic Extract Presenting PTP1B Inhibitory Potential.
Apparent lack of effect of obesity on the soluble phosphatidic acid phosphatase activity in human adipose tissue.
Assessment of biochemical parameters and characterization of TNF? -308G/A and PTPN22 +1858C/T gene polymorphisms in the risk of obesity in adolescents.
Association of PTP1B gene polymorphism with obesity in Chinese children.
Association of PTPN1 polymorphisms with breast cancer risk: A case-control study in Chinese females.
Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B.
Azide-alkyne cycloaddition-mediated cyclization of phosphonopeptides and their evaluation as PTP1B binders and enrichment tools.
Beneficial effects of PTP1B deficiency on brown adipocyte differentiation and protection against apoptosis induced by pro- and anti-inflammatory stimuli.
Beyond the metabolic function of PTP1B.
Binding properties of marine bromophenols with human protein tyrosine phosphatase 1B: Molecular docking, surface plasmon resonance and cellular insulin resistance study.
Brominated polyunsaturated lipids with protein tyrosine phosphatase-1B inhibitory activity from Chinese marine sponge Xestospongia testudinaria.
Caged xanthones displaying protein tyrosine phosphatase 1B (PTP1B) inhibition from Cratoxylum cochinchinense.
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
Cembrane diterpenoids from the soft coral Sarcophyton trocheliophorum Marenzeller as a new class of PTP1B inhibitors.
Characterization of Protein Tyrosine Phosphatase 1B Inhibition by Chlorogenic Acid and Cichoric Acid.
Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors.
Combined Ligand- and Receptor-Based Virtual Screening Methodology to Identify Structurally Diverse Protein Tyrosine Phosphatase 1B Inhibitors.
Combined Neural Inactivation of SOCS-3 and PTP-1B Reveal Additive, Synergistic, and Factor-Specific Roles in the Regulation of Body Energy Balance.
CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors.
Competitive protein tyrosine phosphatase 1B (PTP1B) inhibitors, prenylated caged xanthones from Garcinia hanburyi and their inhibitory mechanism.
Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach.
Computational revelation of binding mechanisms of inhibitors to endocellular protein tyrosine phosphatase 1B using molecular dynamics simulations.
Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.
Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity.
Correlation Between Nasal Epithelial Injury and In Vitro Cytotoxicity Using a Series of Small Molecule Protein Tyrosine Phosphatase 1B Inhibitors Investigated for Reversal of Leptin Resistance in Obesity.
Dammaranes from Gynostemma pentaphyllum and synthesis of their derivatives as inhibitors of protein tyrosine phosphatase 1B.
Dehydroepiandrosterone-enhanced dual specificity protein phosphatase (DDSP) prevents diet-induced and genetic obesity.
Deletion of Protein Tyrosine Phosphatase 1b Improves Peripheral Insulin Resistance and Vascular Function in Obese, Leptin-Resistant Mice via Reduced Oxidant Tone.
Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin neurons reduces neurogenic control of blood pressure and protects mice from leptin- and sympatho-mediated hypertension.
Deletion of protein tyrosine phosphatase 1B rescues against myocardial anomalies in high fat diet-induced obesity: Role of AMPK-dependent autophagy.
Dephosphorylation of CCAAT/enhancer-binding protein ? by protein phosphatase 2A containing B56? is required at the early time of adipogenesis.
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Design and Synthesis of Imidazolidine-2,4-Dione Derivatives as Selective Inhibitors by Targeting Protein Tyrosine Phosphatase-1B Over T-Cell Protein Tyrosine Phosphatase.
Design, synthesis, and biological evaluation of novel 2-ethyl-5-phenylthiazole-4-carboxamide derivatives as protein tyrosine phosphatase 1B inhibitors with improved cellular efficacy.
Design, Synthesis, Biological Activity and Molecular Dynamics Studies of Specific Protein Tyrosine Phosphatase 1B Inhibitors over SHP-2.
Development of Accessible Peptidic Tool Compounds To Study the Phosphatase PTP1B in Intact Cells.
Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening.
Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B.
Discovery of 2-ethoxy-4-(methoxymethyl)benzamide derivatives as potent and selective PTP1B inhibitors.
Discovery of Bisindole as a Novel Scaffold for Protein Tyrosine Phosphatase 1B Inhibitors.
Discovery of core-structurally novel PTP1B inhibitors with specific selectivity containing oxindole-fused spirotetrahydrofurochroman by one-pot reaction.
Discovery of novel high potent and cellular active ADC type PTP1B inhibitors with selectivity over TC-PTP via modification interacting with C site.
Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity.
Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.
Distribution of the number of false discoveries in large-scale family-based association testing with application to the association between PTPN1 and hypertension and obesity.
Double-Stranded RNA-Activated Protein Kinase Is a Key Modulator of Insulin Sensitivity in Physiological Conditions and in Obesity in Mice.
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma.
Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice.
Early overnutrition impairs insulin signaling in the heart of adult Swiss mice.
Effects of adenovirus-mediated liver-selective overexpression of protein tyrosine phosphatase-1b on insulin sensitivity in vivo.
Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance.
Endocrine regulation of energy metabolism by the skeleton.
Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models.
Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.
Evaluation of licorice flavonoids as protein tyrosine phosphatase 1B inhibitors.
Exercise training decreases mitogen-activated protein kinase phosphatase-3 expression and suppresses hepatic gluconeogenesis in obese mice.
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Flavonoids as potent allosteric inhibitors of protein tyrosine phosphatase 1B: molecular dynamics simulation and free energy calculation.
Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency.
Four phragmalin orthoesters from the Chinese mangrove Xylocarpus granatum.
Functional properties of Claramine: A novel PTP1B inhibitor and insulin-mimetic compound.
Furanoterpenes, new types of protein tyrosine phosphatase 1B inhibitors, from two Indonesian marine sponges, Ircinia and Spongia spp.
Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Genomic characterization of the human and mouse protein tyrosine phosphatase-1B genes.
Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development.
Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis.
Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2.
Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: Potential role of PPAR?
HF diets increase hypothalamic PTP1B and induce leptin resistance through both leptin-dependent and -independent mechanisms.
High-fat diet alters PP2A, TC10, and CIP4 expression in visceral adipose tissue of rats.
High-resolution dose-response screening using droplet-based microfluidics.
High-throughput methods in identification of protein tyrosine phosphatase inhibitors and activators.
Human protein tyrosine phosphatase 1B inhibitors: QSAR by genetic function approximation.
Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGFbeta/Smad2 signaling.
Identification of Bidentate Salicylic Acid Inhibitors of PTP1B.
Identification of caffeoylquinic acid derivatives as natural protein tyrosine phosphatase 1B inhibitors from Artemisia princeps.
Identification of novel PTPRQ phosphatase inhibitors based on the virtual screening with docking simulations.
Improved metabolic phenotype of hypothalamic PTP1B-deficiency is dependent upon the leptin receptor.
Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue.
Improving Obesity and Insulin Resistance by Targeting Skeletal Muscle MKP-1.
In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
In silico modeling of protein tyrosine phosphatase 1B inhibitors with cellular activity.
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
In vitro effects of cinnamic acid derivatives on protein tyrosine phosphatase 1B.
In vitro enzymatic assays of protein tyrosine phosphatase 1B.
In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.
Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects.
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.
Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity.
Indole- and Pyrazole-Glycyrrhetinic Acid Derivatives as PTP1B Inhibitors: Synthesis, In Vitro and In Silico Studies.
Inducible Knockdown of Endothelial Protein Tyrosine Phosphatase-1B Promotes Neointima Formation in Obese Mice by Enhancing Endothelial Senescence.
Inhibition of protein tyrosine phosphatase (PTP1B) and ?-glucosidase by geranylated flavonoids from Paulownia tomentosa.
Inhibition of protein tyrosine phosphatase 1B (PTP1B) and ?-glucosidase by xanthones from Cratoxylum cochinchinense, and their kinetic characterization.
Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity.
Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum.
Inhibition of protein tyrosine phosphatase 1B by lignans from Myristica fragrans.
Inhibition of protein tyrosine phosphatase 1B by lupeol and lupenone isolated from Sorbus commixta.
Inhibition of Protein Tyrosine Phosphatase 1B by Prenylated Isoflavonoids Isolated from the Stem Bark of Erythrina addisoniae1.
Inhibition of Protein Tyrosine Phosphatase 1B by Ursane-Type Triterpenes Isolated from Symplocos paniculata.
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells.
Inhibition of Src homology 2 domain containing protein tyrosine phosphatase as the possible mechanism of metformin-assisted amelioration of obesity induced insulin resistance in high fat diet fed C57BL/6J mice.
Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice.
Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
Inhibitors of protein tyrosine phosphatase 1B (PTP1B).
Insulin regulates POMC neuronal plasticity to control glucose metabolism.
Inter-Tissue Gene Co-Expression Networks between Metabolically Healthy and Unhealthy Obese Individuals.
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Intranasal Targeting of Hypothalamic PTP1B and TCPTP Reinstates Leptin and Insulin Sensitivity and Promotes Weight Loss in Obesity.
Investigating mammalian tyrosine phosphatase inhibitors as potential 'piggyback' leads to target Trypanosoma brucei transmission.
Investigating the impact of Asp181 point mutations on interactions between PTP1B and phosphotyrosine substrate.
Investigation of selective binding of inhibitors to PTP1B and TCPTP by accelerated molecular dynamics simulations.
Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer.
Knocking down amygdalar PTP1B in diet-induced obese rats improves insulin signaling/action, decreases adiposity and may alter anxiety behavior.
Leptin and insulin act on POMC neurons to promote the browning of white fat.
Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.
Leptin resistance following over-expression of protein tyrosine phosphatase 1B in liver.
Leptin Signaling in the Arcuate Nucleus Reduces Insulin's Capacity to Suppress Hepatic Glucose Production in Obese Mice.
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice.
Looking at Marine-Derived Bioactive Molecules as Upcoming Anti-Diabetic Agents: A Special Emphasis on PTP1B Inhibitors.
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms.
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Mammalian life-span determinant p66shcA mediates obesity-induced insulin resistance.
MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice.
MAPK-specific tyrosine phosphatases: new targets for drug discovery?
Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus.
Massively parallel sequencing of the mouse exome to accurately identify rare, induced mutations: an immediate source for thousands of new mouse models.
Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling.
Methylenedisalicylic acid derivatives: new PTP1B inhibitors that confer resistance to diet-induced obesity.
Mice lacking DUSP6/8 have enhanced ERK1/2 activity and resistance to diet-induced obesity.
Minimally disruptive optical control of protein tyrosine phosphatase 1B.
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
MKP-5 Relieves Lipotoxicity-Induced Islet ?-Cell Dysfunction and Apoptosis via Regulation of Autophagy.
Modulation of Obesity and Insulin Resistance by the Redox Enzyme and Adaptor Protein p66Shc.
Molecular analysis of Aedes aegypti classical protein tyrosine phosphatases uncovers an ortholog of mammalian PTP-1B implicated in the control of egg production in mosquitoes.
Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B.
Molecular docking and virtual screening for novel protein tyrosine phosphatase 1B (PTP1B) inhibitors.
Molecular Dynamics Approach to Probe the Allosteric Inhibition of PTP1B by Chlorogenic and Cichoric Acid.
Molecular dynamics simulation of the interaction between protein tyrosine phosphatase 1B and aryl diketoacid derivatives.
Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling.
Molecular Dynamics Simulations of A27S and K120A Mutated PTP1B Reveals Selective Binding of the Bidentate Inhibitor.
MSI-1436 improves EMS adipose derived progenitor stem cells in the course of adipogenic differentiation through modulation of ER stress, apoptosis, and oxidative stress.
Multiple machine learning based descriptive and predictive workflow for the identification of potential PTP1B inhibitors.
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
Neuronal PTP1B regulates body weight, adiposity and leptin action.
New prenylated flavanones from Erythrina abyssinica with Protein tyrosine phosphatase 1B (PTP1B) inhibitory activity.
No Association of PTPN1 Polymorphisms With Macronutrient Intake and Measures of Adiposity.
Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1.
Novel chromenedione derivatives displaying inhibition of protein tyrosine phosphatase 1B (PTP1B) from Flemingia philippinensis.
Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking.
Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control.
Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methanesulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic.
Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Obesity Increases Mitogen-Activated Protein Kinase Phosphatase-3 Levels in the Hypothalamus of Mice.
Oleanane triterpenes as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Camellia japonica.
Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities.
Optimization of extraction parameters of PTP1? (protein tyrosine phosphatase 1?), inhibitory polyphenols, and anthocyanins from Zea mays L. using response surface methodology (RSM).
Osteoarthritis Is a Low-Grade Inflammatory Disease: Obesity's Involvement and Herbal Treatment.
Overexpression of Mitogen-activated protein kinase phosphatase-3 (MKP-3) reduces FoxO1 phosphorylation in mice hypothalamus.
Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B.
Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and protein kinase C.
p66(ShcA): linking mammalian longevity with obesity-induced insulin resistance.
p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans.
Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice.
Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus.
Pharmacophore modeling for protein tyrosine phosphatase 1B inhibitors.
Phenethyl isothiocyanate activates leptin signaling and decreases food intake.
Possible Integrative Actions of Leptin and Insulin Signaling in the Hypothalamus Targeting Energy Homeostasis.
Possible modulation of FAS and PTP-1B signaling in ameliorative potential of Bombax ceiba against high fat diet induced obesity.
Prediction of future rheumatoid arthritis.
Prodrug delivery of novel PTP1B inhibitors to enhance insulin signalling.
Protein tyrosine phosphatase 1B (PTP1B) and obesity.
Protein tyrosine phosphatase 1B (PTP1B) inhibitory constituents from the aerial parts of Tradescantia spathacea Sw.
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population.
Protein tyrosine phosphatase 1B inhibition: opportunities and challenges.
Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus.
Protein tyrosine phosphatase 1B inhibitory activity of amentoflavone and its cellular effect on tyrosine phosphorylation of insulin receptors.
Protein tyrosine phosphatase 1B inhibitory activity of Indonesian herbal medicines and constituents of Cinnamomum burmannii and Zingiber aromaticum.
Protein tyrosine phosphatase 1B inhibitory by dammaranes from Vietnamese Giao-Co-Lam tea.
Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.
Protein tyrosine phosphatase 1B inhibits adipocyte differentiation and mediates TNF? action in obesity.
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.
Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line.
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis.
Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation.
Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Protein tyrosine phosphatase 1B, a major regulator of leptin-mediated control of cardiovascular function.
Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities.
Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity.
Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity.
Protein tyrosine phosphatase alpha inhibits hypothalamic leptin receptor signaling and regulates body weight in vivo.
Protein Tyrosine Phosphatase, Receptor Type B (PTPRB) Inhibits Brown Adipocyte Differentiation through Regulation of VEGFR2 Phosphorylation.
Protein tyrosine phosphatase-1B in diabetes.
Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrina mildbraedii.
Protein tyrosine phosphatase-1B modulates pancreatic ?-cell mass.
Protein tyrosine phosphatases as drug targets: PTP1B and beyond.
Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
Protein tyrosine phosphatases as potential therapeutic targets.
Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling.
Protein tyrosine phosphatases: the quest for negative regulators of insulin action.
Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling.
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Protein-tyrosine phosphatase 1B as a potential drug target for obesity.
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.
Protein-tyrosine phosphatase 1B substrates and metabolic regulation.
PTP1B and TC-PTP: regulators of transformation and tumorigenesis.
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery.
PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity.
PTP1B inhibitory activity of kaurane diterpenes isolated from Siegesbeckia glabrescens.
PTP1B inhibitory effects of tridepside and related metabolites isolated from the Antarctic lichen Umbilicaria antarctica.
PTP1B Inhibitory Secondary Metabolites from Marine-Derived Fungal Strains Penicillium spp. and Eurotium sp.
PTP1B regulates cortactin tyrosine phosphorylation by targeting Tyr446.
PTP1B regulates leptin signal transduction in vivo.
PTP1B: a double agent in metabolism and oncogenesis.
PTPIP51 interaction with PTP1B and 14-3-3? in adipose tissue of insulin-resistant mice.
PTPRJ Inhibits Leptin Signaling, and Induction of PTPRJ in the Hypothalamus Is a Cause of the Development of Leptin Resistance.
PTPRS and PER3 methylation levels are associated with childhood obesity: results from a genome-wide methylation analysis.
PTPRT regulates high-fat diet-induced obesity and insulin resistance.
Pyrrolo[1,2-a]quinoxal-5-inium salts and 4,5-dihydropyrrolo[1,2-a]quinoxalines: Synthesis, activity and computational docking for protein tyrosine phosphatase 1B.
Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media.
Rational Design, Synthesis and Biological Evaluation of Modular Fluorogenic Substrates with High Affinity and Selectivity for PTP1B.
Recent advance on PTP1B inhibitors and their biomedical applications.
Recent advances in protein tyrosine phosphatase 1B inhibitors.
Recent Advances in Protein Tyrosine Phosphatase 1B Targeted Drug Discovery for Type II Diabetes and Obesity.
Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.
Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B.
Reduction of hypothalamic protein tyrosine phosphatase improves insulin and leptin resistance in diet-induced obese rats.
Regulation of the insulin antagonistic protein tyrosine phosphatase 1B by dietary Se studied in growing rats.
Regulation of the SNARE-interacting protein Munc18c tyrosine phosphorylation in adipocytes by protein-tyrosine phosphatase 1B.
Reversal of diet-induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS-1 serine phosphorylation.
Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy.
Role of p66shc in skeletal muscle function.
Role of protein tyrosine phosphatase-1B in diabetes and obesity.
Role of PTP1B in POMC neurons during chronic high-fat diet: sex differences in regulation of liver lipids and glucose tolerance.
Role of Receptor Protein Tyrosine Phosphatases (RPTPs) in Insulin Signaling and Secretion.
Rosiglitazone attenuates tumor necrosis factor-?-induced protein tyrosine phosphatase-1B production in HepG2 cells.
Sarcophytrols G - L, Novel Minor Metabolic Components from South China Sea Soft Coral Sarcophyton trocheliophorum Marenzeller.
Selecting protein tyrosine phosphatases as drug targets.
Selective binding modes and allosteric inhibitory effects of lupane triterpenes on protein tyrosine phosphatase 1B.
Selective inhibition of PTP1B by Vitalboside A from Syzygium cumini enhances insulin sensitivity and attenuates lipid accumulation via partial agonism to PPAR?: In Vitro and In Silico investigation.
Sesquiterpenoids with PTP1B Inhibitory Activity and Cytotoxicity from the Edible Mushroom Pleurotus citrinopileatus.
Short-term Cudrania tricuspidata fruit vinegar administration attenuates obesity in high-fat diet-fed mice by improving fat accumulation and metabolic parameters.
SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.
Shp2 suppresses the adipogenic differentiation of preadipocyte 3T3-L1 cells at an early stage.
Single nucleotide polymorphisms in protein tyrosine phosphatase 1beta (PTPN1) are associated with essential hypertension and obesity.
Single nucleotide polymorphisms of protein tyrosine phosphatase 1B gene are associated with obesity in morbidly obese French subjects.
Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance.
Spirobiflavonoid stereoisomers from the endangered conifer Glyptostrobus pensilis and their protein tyrosine phosphatase 1B inhibitory activity.
Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding sites.
Structural and stereochemical studies of five new pregnane steroids from the stem bark of Toona ciliata var. pubescens.
Structural Basis of Fullerene Derivatives as Novel Potent Inhibitors of Protein Tyrosine Phosphatase 1B: Insight into the Inhibitory Mechanism through Molecular Modeling Studies.
Structural flexibility and interactions of PTP1B's S-loop.
Structure determination of T cell protein-tyrosine phosphatase.
Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B.
Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta.
Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.
Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors.
Structure-functional implications of longevity protein p66Shc in health and disease.
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Sustained High Protein-tyrosine Phosphatase 1B Activity in the Sperm of Obese Males Impairs the Sperm Acrosome Reaction.
Synthesis and biological evaluation of 4,4-dimethyl lithocholic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B.
Synthesis and Biological Evaluation of Oleanolic Acid Derivatives As Inhibitors of Protein Tyrosine Phosphatase 1B.
Synthesis of benzofuran scaffold-based potential PTP-1B inhibitors.
Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors.
T Cell Protein Tyrosine Phosphatase in Glucose Metabolism.
Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.
Tea contains potent inhibitors of tyrosine phosphatase PTP1B.
Technology evaluation: ISIS-113715, Isis.
The adaptor protein p66Shc inhibits mTOR-dependent anabolic metabolism.
The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity.
The design strategy of selective PTP1B inhibitors over TCPTP.
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
The LIM domain only 4 protein is a metabolic responsive inhibitor of protein tyrosine phosphatase 1B that controls hypothalamic leptin signaling.
The low molecular weight protein tyrosine phosphatase promotes adipogenesis and subcutaneous adipocyte hypertrophy.
The mode of action of the Protein tyrosine phosphatase 1B inhibitor Ertiprotafib.
The Role of MKP-5 in Adipocyte-Macrophage Interactions during Obesity.
The role of protein-tyrosine phosphatase 1B in integrin signaling.
The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.
The two faces of PTP1B in cancer.
The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice.
Thunberol, a new sterol from the Chinese brown alga Sargassum thunbergii.
Toward a treatment of diabesity: Rational design, synthesis and biological evaluation of benzene-sulfonamide derivatives as a new class of PTP-1B inhibitors.
Unraveling the allosteric inhibition mechanism of PTP1B by free energy calculation based on umbrella sampling.
Upregulation of PTP1B After Rat Spinal Cord Injury.
Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake.
Using yeast to screen for inhibitors of protein tyrosine phosphatase 1B.
Varic acid analogues from fungus as PTP1B inhibitors: Biological evaluation and structure-activity relationships.
Ventromedial hypothalamus-specific Ptpn1 deletion exacerbates diet-induced obesity in female mice.
Virtual Screening of Novel and Selective Inhibitors of Protein Tyrosine Phosphatase 1B over T-Cell Protein Tyrosine Phosphatase Using a Bidentate Inhibition Strategy.
Water-molecule network and active-site flexibility of apo protein tyrosine phosphatase 1B.
X-ray Structure of PTP1B in-Complex With a new PTP1B Inhibitor.
[Design, synthesis and evaluation of malonic acid-based PTP1B inhibitors].
[Does inhibition of tyrosine phosphatase 1B protect from obesity and type 2 diabetes?]
[Impairments of insulin receptor function in insulin resistant states]
[PTP1B inhibitory activities of bromophenol derivatives from algae]
[Role of protein tyrosine phosphatase 1B in the type 2 diabetes and obesity]
[SAR of benzoyl sulfathiazole derivatives as PTP1B inhibitors].
[Search for Protein Tyrosine Phosphatase 1B Inhibitors from Marine Organisms and Induced Production of New Fungal Metabolites by Modulating Culture Methods].
Obesity, Maternal
Dynamic changes in p66Shc mRNA expression in peripheral blood mononuclear cells following resistance training intervention in old frail women born to obese mothers: a pilot study.
Obstetric Labor, Premature
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Odontogenic Cysts
Odontogenic keratocysts: a clinical and histological study with special reference to enzyme histochemistry.
Oligodendroglioma
Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes.
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Onchocerciasis
Histochemical differentiation of filarial larvae found in Simulium damnosum s.l. in West Africa.
Oncogene Addiction
Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer.
Opisthorchiasis
Protein tyrosine phosphatase, opisthorchiasis and dengue: A proteomics interrelationship.
Proteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection.
Optic Nerve Injuries
Myelin suppresses axon regeneration by PIR-B/SHP-mediated inhibition of Trk activity.
Oral Submucous Fibrosis
[Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance].
Osteitis
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved?
Osteoarthritis
Abnormal PTPN11 enhancer methylation promotes rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and joint inflammation.
Deletion of Dual Specificity Phosphatase 1 Does Not Predispose Mice to Increased Spontaneous Osteoarthritis.
Dual specificity phosphatase 1 has a protective role in osteoarthritis fibroblast?like synoviocytes via inhibition of the MAPK signaling pathway.
Expression of the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in the serum, cartilage and subchondral bone of patients with osteoarthritis.
Localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis.
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
p66shc siRNA Nanoparticles Ameliorate Chondrocytic Mitochondrial Dysfunction in Osteoarthritis.
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.
PTPN14 phosphatase and YAP promote TGF? signalling in rheumatoid synoviocytes.
Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase Promotes Inflammation and Accelerates Osteoarthritis by Activating ?-Catenin.
Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal.
The differentiation of prehypertrophic into hypertrophic chondrocytes drives an OA-remodeling program and IL-34 expression.
Osteoarthritis, Hip
Protein metabolism in the synovial membrane in the hip osteoarthritis.
Osteochondroma
A rare association of pathological variant of Alport's syndrome caused by hemizygous 5' splice mutation in intron 10 of COL4A5 gene with metachondromatosis due to heterozygous missense variation in protein tyrosine phosphatase nonreceptor type 11 gene.
Chondrosarcoma in Metachondromatosis: A Rare Case Report.
From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis.
Intraosseous atypical chondroid tumor or chondrosarcoma grade 1 in patients with multiple osteochondromas.
Metachondromatosis: more than just multiple osteochondromas.
Osteogenesis Imperfecta
Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta.
Osteolysis
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Inhibition of protein phosphatase 2A attenuates titanium-particle induced suppression of bone formation.
Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption.
Osteomyelitis
The receptor-type protein tyrosine phosphatase CD45 promotes onset and severity of IL-1?-mediated autoinflammatory osteomyelitis.
Osteoporosis
Effects of garlic oil on postmenopausal osteoporosis using ovariectomized rats: comparison with the effects of lovastatin and 17beta-estradiol.
Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate.
Identification of N-(5-(phenoxymethyl)-1,3,4-thiadiazol-2-yl)acetamide derivatives as novel protein tyrosine phosphatase epsilon inhibitors exhibiting anti-osteoclastic activity.
M1 macrophage-derived exosomes aggravate bone loss in postmenopausal osteoporosis via a microRNA-98/DUSP1/JNK axis.
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
Prevention of bone loss by oil extract of garlic (Allium sativum Linn.) in an ovariectomized rat model of osteoporosis.
Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Upregulation of PTP1B After Rat Spinal Cord Injury.
Osteosarcoma
Circular RNA circCCDC66 Contributes to Malignant Phenotype of Osteosarcoma by Sponging miR-338-3p to Upregulate the Expression of PTP1B.
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Effect of the traditional Chinese medicine Qi Teng Xiao Zhuo granules on chronic glomerulonephritis rats studied by using long noncoding RNAs expression profiling.
Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.
High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma.
Histochemical and electron-microscopic aspects of bone tumor diagnosis.
Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
Interrogating PP1 Activity in the MAPK Pathway with Optimized PP1-Disrupting Peptides.
Long non-coding RNA ASBEL promotes osteosarcoma cell proliferation, migration and invasion by regulating microRNA-21.
MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma.
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
MiRNA-98-5p inhibits the progression of osteosarcoma by regulating cell cycle via targeting CDC25A expression.
Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition.
Neuregulin-regulated gene expression in mammary carcinoma cells.
Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases.
Protein phosphatase 2A C? regulates proliferation, migration, and metastasis of osteosarcoma cells.
PTPN14, a target gene of miR-4295, restricts the growth and invasion of osteosarcoma cells through inactivation of YAP1 signaling.
Retraction of: DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Significance of "high" acid phosphatase activity in the serum of normal children.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
The phosphatase PTPRG controls FGFR1 activity and influences sensitivity to FGFR kinase inhibitors.
The Protein Tyrosine Phosphatase Rptp? Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice.
Triptolide induces mitochondrial apoptosis through modulating dual specificity phosphatase 1/mitogen-activated protein kinases cascade in osteosarcoma cells.
Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression.
Otitis Media
Bone resorption in chronic otitis media. A light-microscopical and histochemical investigation of acid phosphatase activity.
Curcumin Inhibits NTHi-Induced MUC5AC Mucin Overproduction in Otitis Media via Upregulation of MAPK Phosphatase MKP-1.
Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.
Ovarian Neoplasms
Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells.
Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.
Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Antiproliferative Signaling of Luteinizing Hormone-Releasing Hormone in Human Endometrial and Ovarian Cancer Cells through G Protein? I-Mediated Activation of Phosphotyrosine Phosphatase.
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer.
Autoantibody signature for the serologic detection of ovarian cancer.
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer.
CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular Spheroids by Promoting E-cadherin Expression and Arresting Cell Cycles.
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients.
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis.
DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells.
Dysregulation of the TGF-beta postreceptor signaling pathway in cell lines derived from primary or metastatic ovarian cancer.
ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.
Four diterpenoid inhibitors of Cdc25B phosphatase from a marine anemone.
Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells.
Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.
Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.
Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.
Lysophosphatidic acid modulates the association of PTP1B with N-cadherin/catenin complex in SKOV3 ovarian cancer cells.
Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations.
MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12.
MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
p21-Activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.
p66Shc longevity protein regulates the proliferation of human ovarian cancer cells.
PRL-3 phosphatase is implicated in ovarian cancer growth.
PRL-3 suppresses c-Fos and integrin alpha2 expression in ovarian cancer cells.
Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer.
Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells.
Protein tyrosine phosphatase inhibition induces anti-tumor activity: Evidence of Cdk2/p27(kip1) and Cdk2/SHP-1 complex formation in human ovarian cancer cells.
Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer.
Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating ?-catenin.
Protein-tyrosine Phosphatase 1B Antagonized Signaling by Insulin-like Growth Factor-1 Receptor and Kinase BRK/PTK6 in Ovarian Cancer Cells.
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
PTN signaling: Components and mechanistic insights in human ovarian cancer.
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
PTPN12 controls PTEN and the AKT signalling to FAK and HER2 in migrating ovarian cancer cells.
PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.
PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.
Regulation of LC3-Dependent Protective Autophagy in Ovarian Cancer Cells by Protein Phosphatase 2A.
Screening and prognostic value of potential biomarkers for ovarian cancer.
Spatial regulation of signaling by the coordinated action of the protein tyrosine kinases MET and FER.
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
The function of the protein tyrosine phosphatase SHP-1 in cancer.
The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways.
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression.
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK.
[Combinative effects of FAP-1 antisense oligonucleotide and carboplatin on apoptosis of ovarian cancer cell SKOV3]
Overnutrition
Early overnutrition impairs insulin signaling in the heart of adult Swiss mice.
MAP kinase phosphatase-1--a new player at the nexus between sarcopenia and metabolic disease.
Overweight
Anti-obesity effect of plant diterpenes and their derivatives: A review.
Pancreatic Neoplasms
A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.
An ITIM-like motif within the CCK2 receptor sequence required for interaction with SHP-2 and the activation of the AKT pathway.
Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A.
Blockade of dual-specificity phosphatase 28 decreases chemo-resistance and migration in human pancreatic cancer cells.
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.
DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.
Effects of cerulein on keratin 8 phosphorylation and perinuclear reorganization in pancreatic cancer cells: Involvement of downregulation of protein phosphatase 2A and alpha4.
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.
Expression of TMEFF2 in Human Pancreatic Cancer Tissue and the Effects of TMEFF2 Knockdown on Cell, Proliferation, and Apoptosis in Human Pancreatic Cell Lines.
FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis.
FoxM1 is a Novel Target of a Natural Agent in Pancreatic Cancer.
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer.
Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture.
Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway.
Haloperidol induces demethylation and expression of the dual specificity phosphatase 6 gene in MIA PaCa-2 human pancreatic cancer cells.
Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair.
Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1?-VEGF mediated angiogenesis.
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1.
Liprin-?4 as a Possible New Therapeutic Target for Pancreatic Cancer.
Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.
miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-?B Signaling Pathways.
Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers.
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation.
Phorbol ester reduces phosphorylation of epidermal growth factor receptor in pancreatic cancer cells by activation of a tyrosine phosphatase.
PR55? subunit of protein phosphatase 2A supports the tumorigenic and metastatic potential of pancreatic cancer cells by sustaining hyperactive oncogenic signaling.
PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression.
Receptor-type protein tyrosine phosphatase gamma (PTPgamma), a new identifier for myeloid dendritic cells and specialized macrophages.
Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.
Regulation of the src homology 2 domain-containing protein tyrosine phosphatase PTP1C by glucocorticoids in rat pancreatic AR42J cells.
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration.
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer.
Targeting the Yin and the Yang: Combined Inhibition of the Tyrosine Kinase c-Src and the Tyrosine Phosphatase SHP-2 Disrupts Pancreatic Cancer Signaling and Biology In Vitro and Tumor Formation In Vivo.
The use of protein phosphatase 2A activators in combination therapies for pancreas cancer.
Tumor Suppression by p53: Bring in the Hippo!
[Construction and primary application of oligonucleotide microarray specialized for pancreatic adenocarcinoma-associated genes]
[Down regulation of mitogen activated protein kinase phosphatase-1 mediate acquired multidrug resistance in pancreatic adenocarcinoma cell line SW1990/Fu]
[Down-regulated expression of PP2A catalytic subunit in pancreatic cancer cells promotes cell growth].
Pancreatitis
Acid phosphatase activity in different organs as a marker of acute pancreatitis.
Changes in the expression and dynamics of SHP-1 and SHP-2 during cerulein-induced acute pancreatitis in rats.
Modulation in the expression of SHP-1, SHP-2 and PTP1B due to the inhibition of MAPKs, cAMP and neutrophils early on in the development of cerulein-induced acute pancreatitis in rats.
Pancreatic Protein Tyrosine Phosphatase 1B Deficiency Exacerbates Acute Pancreatitis in Mice.
Pancreatic T cell protein-tyrosine phosphatase deficiency ameliorates cerulein-induced acute pancreatitis.
PAR2 exerts local protection against acute pancreatitis via modulation of MAP kinase and MAP kinase phosphatase signaling.
Rolipram and SP600125 Suppress the Early Increase in PTP1B Expression During Cerulein-Induced Pancreatitis in Rats.
Pancreatitis, Chronic
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.
Papilloma
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin.
G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv.
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
The p53-p66Shc apoptotic pathway is dispensable for tumor suppression whereas the p66Shc-generated oxidative stress initiates tumorigenesis.
Papillomavirus Infections
EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.
Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.
Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma acuminatum and Cervical Cancer.
Paralysis
Impaired embryonic motility in dusp27 mutants reveals a developmental defect in myofibril structure.
Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds.
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.
Morphological and functional effects of altered cysteine string protein at the Drosophila larval neuromuscular junction.
Paralysis and early death in cysteine string protein mutants of Drosophila.
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
The human cytomegalovirus UL11 protein interacts with the receptor tyrosine phosphatase CD45, resulting in functional paralysis of T cells.
Paraneoplastic Cerebellar Degeneration
Gene expression profile following stable expression of the cellular prion protein.
Paraparesis, Spastic
Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
Paraproteinemias
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
[Cytological study of acid phosphatase activity of plasma cells in monoclonal gammopathies]
[Plasma cell acid phosphatase in the differential diagnosis of monoclonal gammopathies]
Parasitemia
Direct exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) increases infectivity of human erythrocytes to a malarial parasite.
Parasitic Diseases
Expression on human eosinophils of CD148: a membrane tyrosine phosphatase. Implications in the effector function of eosinophils.
Paratuberculosis
Immunoreactivity of protein tyrosine phosphatase A (PtpA) in sera from sheep infected with Mycobacterium avium subspecies paratuberculosis.
Mycobacterium avium subsp. paratuberculosis PtpA is an endogenous tyrosine phosphatase secreted during infection.
Relationship of acid phosphatase activity to ultrastructural features in mice inoculated with Mycobacterium paratuberculosis.
Parkinson Disease
Autophagy inhibition rescues structural and functional defects caused by the loss of mitochondrial chaperone Hsc70-5 in Drosophila.
Blocking receptor protein tyrosine phosphatase beta/zeta: a potential therapeutic strategy for Parkinson's disease.
Connecting Parkinson's Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches.
Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).
Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.
Phosphorylation of ?-synuclein is crucial in compensating for proteasomal dysfunction.
Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy.
Protein tyrosine phosphatase inhibition reduces degeneration of dopaminergic substantia nigra neurons and projections in 6-OHDA treated adult rats.
Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus.
PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
Role of Receptor Protein Tyrosine Phosphatase ?/? in Neuron-Microglia Communication in a Cellular Model of Parkinson's Disease.
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.
The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity.
Therapeutic Role of Protein Tyrosine Phosphatase 1B in Parkinson's Disease via Antineuroinflammation and Neuroprotection In Vitro and In Vivo.
Parkinsonian Disorders
Overview of tyrosine hydroxylase in Parkinson's disease.
Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations.
Pediatric Obesity
Association of PTP1B gene polymorphism with obesity in Chinese children.
Effect of PTP1B inhibitors and taurine on blood lipid profiles in adolescent obesity.
Genome-wide copy number variation analysis identifies novel candidate loci associated with pediatric obesity.
PTPRS and PER3 methylation levels are associated with childhood obesity: results from a genome-wide methylation analysis.
The association of genetically controlled CpG methylation (cg158269415) of protein tyrosine phosphatase, receptor type N2 (PTPRN2) with childhood obesity.
Pemphigus
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
PTPN22 1858T is not a risk factor for North American Pemphigus vulgaris.
PTPN22 R620W polymorphism is not associated with pemphigus.
Region 1p13.2 including the RSBN1, PTPN22, AP4B1 and long non-coding RNA genes does not bear risk factors for endemic pemphigus foliaceus (fogo selvagem).
Pericarditis
A polymorphism upstream MIR1279 gene is associated with pericarditis development in Systemic Lupus Erythematosus and contributes to definition of a genetic risk profile for this complication.
Periodontal Diseases
Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss.
Functionalized nanoparticles containing MKP-1 agonists reduce periodontal bone loss.
[Alkaline and acid phosphatase activity in human saliva in parodontosis]
Periodontitis
25-Hydroxyvitamin D
Comparison of Experimental Diabetic Periodontitis Induced by Porphyromonas gingivalis in Mice.
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
MAP Kinase Phosphatase-1 Protects against Inflammatory Bone Loss.
Porphyromonas gingivalis Tyrosine Phosphatase Php1 Promotes Community Development and Pathogenicity.
Tyrosine-protein phosphatase non-receptor type 2 inhibits alveolar bone resorption in diabetic periodontitis via dephosphorylating CSF1 receptor.
Ultrastructural localization of acid phosphatase activity in plasma cells containing Russell's bodies in periodontitis.
[Affect of protein tyrosine phosphatase non-receptor type 2 and nuclear factor-kappaB on periodontal destruction with diabetes].
Peripheral Arterial Disease
Dual specificity phosphatase 5 regulates perfusion recovery in experimental peripheral artery disease.
Growth Factor Deregulation and Emerging Role of Phosphatases in Diabetic Peripheral Artery Disease.
Peripheral Nerve Injuries
Mitogen activated protein kinase phosphatase-1 prevents the development of tactile sensitivity in a rodent model of neuropathic pain.
Peripheral Vascular Diseases
Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease.
Peritoneal Neoplasms
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Peritonitis
Non-Lyn Src Family Kinases Activate SIRP?-SHP-1 to Inhibit PI3K-Akt2 and Dampen Proinflammatory Macrophage Polarization.
PTPN22 Is a Critical Regulator of Fc? Receptor-Mediated Neutrophil Activation.
TBK1 and IKK? act like an OFF switch to limit NLRP3 inflammasome pathway activation.
Persistent Infection
B Cell-Intrinsic SHP1 Expression Promotes the Gammaherpesvirus-Driven Germinal Center Response and the Establishment of Chronic Infection.
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
Peutz-Jeghers Syndrome
Gene for the human transmembrane-type protein tyrosine phosphatase H (PTPRH): genomic structure, fine-mapping and its exclusion as a candidate for Peutz-Jeghers syndrome.
Pheochromocytoma
Enhancement or induction of neurite formation by a protein tyrosine phosphatase inhibitor, 3,4-dephostatin, in growth factor-treated PC12h cells.
Leukocyte common-antigen-related tyrosine phosphatase receptor: altered expression of mRNA and protein in the New England Deaconess Hospital rat line exhibiting spontaneous pheochromocytoma.
Loss of heterozygosity on the short arm of chromosome 1 in pheochromocytoma and abdominal paraganglioma.
Overexpression of striatal enriched phosphatase (STEP) promotes the neurite outgrowth induced by a cAMP analogue in PC12 cells.
Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2.
Rapid deactivation of MAP kinase in PC12 cells occurs independently of induction of phosphatase MKP-1.
The I(1)-imidazoline receptor in PC12 pheochromocytoma cells reverses NGF-induced ERK activation and induces MKP-2 phosphatase.
The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
Vanadate stimulates differentiation and neurite outgrowth in rat pheochromocytoma PC12 cells and neurite extension in human neuroblastoma SH-SY5Y cells.
Pinealoma
Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
Papillary Tumor of the Pineal Region in Children: Presentation of a Case and Comprehensive Literature Review.
Recurrent pineocytoma-like papillary tumor of the pineal region - a case report and literature review.
Pituitary Neoplasms
Computational analysis identifies invasion-associated genes in pituitary adenomas.
Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity.
Placental Insufficiency
Dual specificity phosphatase 9 (DUSP9) expression is down-regulated in the severe pre-eclamptic placenta.
Plague
Characterization of new substrates targeted by Yersinia tyrosine phosphatase YopH.
Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 A and the complex with tungstate.
Dynamics of the WPD loop of the Yersinia protein tyrosine phosphatase.
High-resolution structure of the Yersinia pestis protein tyrosine phosphatase YopH in complex with a phosphotyrosyl mimetic-containing hexapeptide.
Investigations of linker structure on the potency of a series of bidentate protein tyrosine phosphatase inhibitors.
Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH.
Microbial pathogenesis and tyrosine dephosphorylation: surprising 'bedfellows'.
The Cys(X)5Arg catalytic motif in phosphoester hydrolysis.
Tripeptide inhibitors of Yersinia protein-tyrosine phosphatase.
Yersinia pestis and Approaches to Targeting its Outer Protein H Protein-Tyrosine Phosphatase (YopH).
Yersinia phosphatase induces mitochondrially dependent apoptosis of T cells.
Pleural Effusion
Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites.
Pneumonia
A critical role of SHP-1 in regulation of type 2 inflammation in the lung.
Manganese-dependent protein O-phosphatases in prokaryotes and their biological functions.
Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury.
Role of mitogen-activated protein kinase phosphatase-1 in corticosteroid insensitivity of chronic oxidant lung injury.
The metabolic behaviour of the lymphocytes from serous effusions in various benign internal diseases.
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
[Characteristics of the diagnosis and treatment of secondary pneumonia in acute leukemia]
[Cytochemical study of the leukocyte acid phosphatase activity in pneumonia]
[Features of the diagnosis and treatment of paracancerous pneumonia in bronchogenic pulmonary carcinoma]
[Immunological indices and the acid phosphatase activity of the blood serum in patients with suppurative and destructive complications of acute pneumonia during the treatment/process]
Pneumoperitoneum
Influence of CO2 pneumoperitoneum on intracellular pH and signal transduction in cancer cells.
Polycystic Kidney Diseases
Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease.
MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.
Polycystic Kidney, Autosomal Dominant
PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.
Polycythemia
Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly.
The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera.
Polycythemia Vera
Defective expression of the SHP-1 phosphatase in polycythemia vera.
Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells.
PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells.
Polyendocrinopathies, Autoimmune
PTPN22 and CTLA-4 Polymorphisms are Associated with Polyglandular Autoimmunity.
Polyhydramnios
Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.
Polymyalgia Rheumatica
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Polymyositis
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
Polyneuropathies
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
Prader-Willi Syndrome
Malignant fibrous histiocytoma-pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.
Pre-Eclampsia
Decreased nephrin and GLEPP-1, but increased VEGF, Flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia.
Evaluation of MicroRNA-210 and Protein tyrosine phosphatase, non-receptor type 2 in Pre-eclampsia.
MiRNA-548c-5p downregulates inflammatory response in preeclampsia via targeting PTPRO.
Protein Phosphatase 2A Activation Via ApoER2 in Trophoblasts Drives Preeclampsia in a Mouse Model of the Antiphospholipid Syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acid phosphatase activity of the lymphocytes during polychemotherapy of lymphoproliferative diseases.
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Acute Lymphoblastic Leukemia Developing in a Patient With Noonan Syndrome Harboring a PTPN11 Germline Mutation.
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Clinical and molecular epidemiology of neonatal leukemia in brazil.
Clonal duplication of a germline PTPN11 mutation due to acquired uniparental disomy in acute lymphoblastic leukemia blasts from a patient with Noonan syndrome.
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia.
Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Impact of mutations in FLT3, PTPN11, and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.
Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation.
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features.
Morphologic and ultrastructural characteristics of T-cell acute lymphoblastic leukemia.
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.
Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance.
Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia.
Prognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemia.
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo.
PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy.
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
PTPN21-CDSlong isoform inhibits the response of acute lymphoblastic leukemia cells to NK-mediated lysis via the KIR/HLA-I axis.
PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia.
Redirecting traffic using the XPO1 police.
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
The leukocyte common antigen (CD45) on human pre-B leukemia cells: variant glycoprotein form expression during the cell exposure to phorbol ester is blocked by a nonselective protein kinase inhibitor H7.
[Acute lymphoblastic leukemia with a mature B-lymphocyte phenotype and preferential centrosomal acid phosphatase activity]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Design of a comprehensive fluorescence in situ hybridization assay for genetic classification of T-cell acute lymphoblastic leukemia.
Differential diagnostic value of acid phosphatase and beta-glucuronidase in acute leukaemia.
Efficient and repetitive production of hematopoietic and endothelial cells from feeder-free monolayer culture system of primate embryonic stem cells.
Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.
Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis.
Mutant Idh2 cooperates with a NUP98-HOXD13 fusion to induce early immature thymocyte precursor ALL.
Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.
PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo.
PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b.
Suppression of protein tyrosine phosphatase PTPN22 gene induces apoptosis in T-cell leukemia cell line (Jurkat) through the AKT and ERK pathways.
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
Prediabetic State
An islet-cell protein tyrosine phosphatase is a likely precursor to the 37-kDa autoantigen in type 1 diabetes: human and macaque sequences, tissue distribution, unique and shared epitopes, and predictive autoantibodies.
HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2 beta) in human prediabetes.
HLA-DR4-associated T and B cell responses to specific determinants on the IA-2 autoantigen in type 1 diabetes.
Human SHC-transforming protein 1 and its isoforms p66shc: A novel marker for prediabetes.
Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials.
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus.
Pregnancy, Tubal
[Acid phosphatase activity in tubal pregnancy]
Premature Birth
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Functional variation of SHP-2 promoter is associated with preterm birth and delayed myelination and motor development in preterm infants.
Genome-wide association study identifies a novel maternal gene?×?stress interaction associated with spontaneous preterm birth.
Primary Immunodeficiency Diseases
Autoimmunity in primary antibody deficiency is associated with protein tyrosine phosphatase nonreceptor type 22 (PTPN22).
Primary Myelofibrosis
Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.
CDC25c expression in patients with myelofibrosis is associated with stronger myeloproliferation and shorter overall survival.
Prion Diseases
Reduced expression of the presynaptic co-chaperone cysteine string protein alpha (CSP?) does not exacerbate experimentally-induced ME7 prion disease.
Proctitis
Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis.
Progeria
P66SHC deletion improves fertility and progeric phenotype of late-generation TERC-deficient mice but not their short lifespan.
Prostatic Diseases
[Immunological colorimetric determination of serum prostatic acid phosphatase activity in patients with prostatic diseases comparing with RIA and Kind-King modified methods]
Prostatic Hyperplasia
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Prostatic Intraepithelial Neoplasia
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Mitogen-activated protein kinases and apoptosis in PIN.
Prostatic Neoplasms
Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis.
Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells.
Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells.
Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation.
Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways.
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.
CDC25A functions as a novel Ar corepressor in prostate cancer cells.
Cdc25B as a steroid receptor coactivator.
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture.
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.
Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.
Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells.
Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells.
Cross Talk between Wnt/?-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells.
Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate.
Diallyl trisulfide is more cytotoxic to prostate cancer cells PC-3 than to noncancerous epithelial cell line PNT1A: a possible role of p66Shc signaling axis.
Diallyl Trisulfide-Induced G2/M Phase Cell Cycle Arrest in DU145 Cells Is Associated with Delayed Nuclear Translocation of Cyclin-Dependent Kinase 1.
Diallyl trisulfide-induced prostate cancer cell death is associated with Akt/PKB dephosphorylation mediated by P-p66shc.
Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2.
Down-regulation of CK2 activity results in a decrease in the level of cdc25C phosphatase in different prostate cancer cell lines.
Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells.
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.
ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion.
Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines.
Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis.
Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.
Human prostatic Acid phosphatase: structure, function and regulation.
Identification of androgen-regulated genes in human prostate.
Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods
Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Immunoreactive prostatic acid phosphatase in prostatic cancer: diagnosis and followup of patients.
Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway.
Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer.
Inhibition of p38 by Vitamin D Reduces Interleukin-6 Production in Normal Prostate Cells via Mitogen-Activated Protein Kinase Phosphatase 5: Implications for Prostate Cancer Prevention by Vitamin D.
Integrative Analysis of MicroRNA and Gene Interactions for Revealing Candidate Signatures in Prostate Cancer.
Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer.
Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells.
Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.
Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery.
Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
Loss of receptor protein tyrosine phosphatase ?/? (RPTP?/?) promotes prostate cancer metastasis.
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer.
Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
miRNA-627 inhibits cell proliferation and cell migration, promotes cell apoptosis in prostate cancer cells through upregulating MAP3K1, PTPRK and SRA1.
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.
Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis.
Mitogen-activated protein kinases and apoptosis in PIN.
Modulation of protein phosphatase 2A (PP2A) activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Molecular events in the early phases of prostate carcinogenesis.
Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling.
Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase beta/zeta.
Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer.
p66Shc is indispensable for phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells.
p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
p66Shc regulates migration of castration-resistant prostate cancer cells.
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Physapubescin B Exhibits Potent Activity against Human Prostate Cancer In Vitro and In Vivo.
Potential biomarkers screening to predict side effects of dexamethasone in different cancers.
Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
Presence of "prostatic" acid phosphatase in human neutrophils.
Procyanidin B2 3,3?-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK.
Prostate cancer cell proliferation is suppressed by microRNA-3160-5p via targeting of F-box and WD repeat domain containing 8.
Prostate tumour markers and differentiation grade in prostatic cancer.
Prostate tumour markers as an aid in the staging of prostatic cancer.
Prostatic acid phosphatase in serum of patients with prostatic cancer is a specific phosphotyrosine acid phosphatase.
Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of PTEN-deficient prostate cancers.
PTP1B Is an Androgen Receptor-Regulated Phosphatase That Promotes the Progression of Prostate Cancer.
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
PTPL1 and PKC? contribute to proapoptotic signalling in prostate cancer cells.
PTPN14 acts as a candidate tumor suppressor in prostate cancer and inhibits cell proliferation and invasion through modulating LATS1/YAP signaling.
Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells.
Reactive-oxygen-species-mediated Cdc25C degradation results in differential antiproliferative activities of vanadate, tungstate, and molybdate in the PC-3 human prostate cancer cell line.
Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells.
Receptor-like protein tyrosine phosphatase ? negatively regulates the apoptosis of prostate cancer cells via the JNK pathway.
Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin.
Role of Reactive Oxygen Species in the Cytotoxicity of Arsenic Trioxide and Pamidronate for Human Prostate Cancer Cells.
Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells.
shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells.
Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.
Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
The function of the protein tyrosine phosphatase SHP-1 in cancer.
The histochemical behaviour, electrophoretic mobility and distribution in cell fractions of acid phosphatase isozymes in prostatic cancer and benign prostate hyperplasia.
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.
The role of PTEN in the progression and survival of prostate cancer.
Transcriptional activation of the human prostatic acid phosphatase gene by NF-kappaB via a novel hexanucleotide-binding site.
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer.
[Determination of acid phosphatase in prostatic carcinoma]
[Enzymological study of prostatic cancer. II. Serum lactic dehydrogenase, alkaline phosphatase, leucine aminopeptidase, total acid phosphatase, prostatic acid phosphatase activity and lactic dehydrogenase isoenzymes in prostatic cancer, with special reference to relation with stage and histological malignancy]
[ERK1/2 and p38 kinases are important regulators in P2Y receptor-mediated prostate cancer invasion]
[Phosphotyrosine phosphatase SHP-1, somatostatin and prostate cancer]
Prostatitis
Chronic prostatitis, chlamydia trachomatis and infertility.
Protein profiling of isolated leukocytes, myofibroblasts, epithelial, Basal, and endothelial cells from normal, hyperplastic, cancerous, and inflammatory human prostate tissues.
protein-long-chain fatty-acyl-lysine deacylase (nad+) deficiency
Sirtuin 6 is a negative regulator of Fc?RI signaling and anaphylactic responses.
Protein-Losing Enteropathies
A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy.
Somatic PTPN11 Mutation in a Child With Neuroblastoma and Protein Losing Enteropathy.
protein-serine/threonine phosphatase deficiency
pmp1+, a suppressor of calcineurin deficiency, encodes a novel MAP kinase phosphatase in fission yeast.
protein-tyrosine-phosphatase deficiency
A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.
A critical role for protein tyrosine phosphatase nonreceptor type 5 in determining individual susceptibility to develop stress-related cognitive and morphological changes.
A key role for PTP1B in dendritic cell maturation, migration, and T cell activation.
A new form of inherited thrombocytopenia caused by loss-of-function mutations in PTPRJ.
Altered MAP kinase phosphorylation and impaired motor coordination in PTPRR deficient mice.
Beneficial effects of PTP1B deficiency on brown adipocyte differentiation and protection against apoptosis induced by pro- and anti-inflammatory stimuli.
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
CD5-mediated inhibition of TCR signaling proceeds normally in the absence of SHP-1.
CDC25B promotes influenza A virus replication by regulating the phosphorylation of nucleoprotein.
CDRH3 length is the target of selection of disease-associated IgM autoantibodies.
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
circ-PRKCB acts as a ceRNA to regulate p66Shc-mediated oxidative stress in intestinal ischemia/reperfusion.
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B.
Control of dendritic cell migration, T cell-dependent immunity, and autoimmunity by protein tyrosine phosphatase PTPN12 expressed in dendritic cells.
Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice.
Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.
Deficiency of PTP1B in Leptin Receptor-Expressing Neurons Leads to Decreased Body Weight and Adiposity in Mice.
Deficiency of the protein-tyrosine phosphatase DEP-1/PTPRJ promotes matrix metalloproteinase-9 expression in meningioma cells.
Developmental switch from prolonged insulin action to increased insulin sensitivity in protein tyrosine phosphatase 1B-deficient hepatocytes.
Differential Regulation of Endoplasmic Reticulum Stress by Protein Tyrosine Phosphatase 1B and T Cell Protein Tyrosine Phosphatase.
Disruption of protein-tyrosine phosphatase 1B expression in the pancreas affects ?-cell function.
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses.
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice.
Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.
Essential role of protein-tyrosine phosphatase 1B in the modulation of insulin signaling by acetaminophen in hepatocytes.
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency.
Hepatic protein-tyrosine phosphatase 1B disruption and pharmacological inhibition attenuate ethanol-induced oxidative stress and ameliorate alcoholic liver disease in mice.
Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome?
Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice.
In control at the ER: PTP1B and the down-regulation of RTKs by dephosphorylation and endocytosis.
Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice.
Increased negative selection impairs neonatal B cell repertoire but does not directly lead to generation of disease-associated IgM auto-antibodies.
Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice.
Inhibiting PTPN12-Regulated RTKs May Be Therapeutic in TNBC.
IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function.
Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice.
Knockout of MAPK Phosphatase-1 Exaggerates Type I IFN Response during Systemic Escherichia coli Infection.
Levels of protein tyrosine phosphatase 1B determine susceptibility to apoptosis in serum-deprived hepatocytes.
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice.
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice.
Macrophage fusion is controlled by the cytoplasmic protein tyrosine phosphatase PTP-PEST/PTPN12.
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.
MAP kinase phosphatase 1 is necessary for T cell activation and function.
MAP Kinase Phosphatase 3 (MKP-3) Deficient Mice Are Resistant to Diet Induced-Obesity.
MAP kinase phosphatase-1 deficiency impairs skeletal muscle regeneration and exacerbates muscular dystrophy.
MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response.
MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease.
Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels.
MKP-1 Modulates Mitochondrial Transcription Factors, Oxidative Phosphorylation, and Glycolysis.
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.
Monocytic MKP-1 is a Sensor of the Metabolic Environment and Regulates Function and Phenotypic Fate of Monocyte-Derived Macrophages in Atherosclerosis.
Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene.
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells.
Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues.
Neuronal PTP1B regulates body weight, adiposity and leptin action.
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
Norathyriol reverses obesity- and high-fat-diet-induced insulin resistance in mice through inhibition of PTP1B.
Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.
p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells.
p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from ?-arrestin at early endosomes.
p66Shc deficiency in the E?-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.
P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia.
Pancreatic Protein Tyrosine Phosphatase 1B Deficiency Exacerbates Acute Pancreatitis in Mice.
Pancreatic T cell protein-tyrosine phosphatase deficiency affects beta cell function in mice.
Pancreatic T cell protein-tyrosine phosphatase deficiency ameliorates cerulein-induced acute pancreatitis.
Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge.
Protein Tyrosine Phosphatase 1B (PTP1B) Deficiency Accelerates Hepatic Regeneration in Mice.
Protein tyrosine phosphatase 1B (PTP1B) is dispensable for IgE-mediated cutaneous reaction in vivo.
Protein Tyrosine Phosphatase 1B Deficiency Ameliorates Murine Experimental Colitis via the Expansion of Myeloid-Derived Suppressor Cells.
Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury.
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Protein tyrosine phosphatase 1B deficiency potentiates PERK/eIF2? signaling in brown adipocytes.
Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases.
Protein Tyrosine Phosphatase 1B Inhibitors from the Stems of Akebia quinata.
Protein tyrosine phosphatase 1B is involved in efficient type I interferon secretion upon viral infection.
Protein tyrosine phosphatase 1B modulates GSK3?/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity.
Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation.
Protein Tyrosine Phosphatase N2 Is a Positive Regulator of Lipopolysaccharide Signaling in Raw264.7 Cell through Derepression of Src Tyrosine Kinase.
Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance.
Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans.
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
Protein tyrosine phosphatase receptor type R deficient mice exhibit increased exploration in a new environment and impaired novel object recognition memory.
Protein tyrosine phosphatase SHP-1 positively regulates TLR-induced IL-12p40 production in macrophages through inhibition of phosphatidylinositol 3-kinase.
Protein Tyrosine Phosphatase-1B Negatively Impacts Host Defense against Pseudomonas aeruginosa Infection.
Protein-tyrosine phosphatase 1B (PTP1B) deficiency confers resistance to transforming growth factor-? (TGF-?)-induced suppressor effects in hepatocytes.
Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling.
Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure.
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of PTEN-deficient prostate cancers.
PTP1B deficiency enhances liver growth during suckling by increasing the expression of insulin-like growth factor-I.
PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo.
PTP1B deficiency improves hypothalamic insulin sensitivity resulting in the attenuation of AgRP mRNA expression under high-fat diet conditions.
PTP1B deficiency increases glucose uptake in neonatal hepatocytes: involvement of IRA/GLUT2 complexes.
PTP1B negatively regulates nitric oxide-mediated Pseudomonas aeruginosa killing by neutrophils.
PTP1B negatively regulates STAT1-independent Pseudomonas aeruginosa killing by macrophages.
PTPBR7 Binding Proteins in Myelinating Neurons of the Mouse Brain.
PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy.
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
PTPN2 Deficiency Enhances Programmed T Cell Expansion and Survival Capacity of Activated T Cells.
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
PTPN22 alters the development of regulatory T cells in the thymus.
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.
PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.
PTPRR Protein Tyrosine Phosphatase Isoforms and Locomotion of Vesicles and Mice.
Redox regulation of MAPK phosphatase 1 controls monocyte migration and macrophage recruitment.
Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
Regulation of nasal airway homeostasis and inflammation in mice by SHP-1 and Th2/Th1 signaling pathways.
Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B.
Regulation of Selective B Cell Autophagy by the Pro-oxidant Adaptor p66SHC.
Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL.
Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development.
Restricted CDR3 length of the heavy chain is characteristic of six randomly isolated disease-associated VH J558+ IgM autoantibodies in lupus prone motheaten mice.
Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation.
Role of PTP1B in POMC neurons during chronic high-fat diet: sex differences in regulation of liver lipids and glucose tolerance.
Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling.
Selective Vascular Endothelial Protection Reduces Cardiac Dysfunction in Chronic Heart Failure.
Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency.
SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.
SHP-1 deficiency in B-lineage cells is associated with heightened lyn protein expression and increased lyn kinase activity.
SHP-1 deficient mast cells are hyperresponsive to stimulation and critical in initiating allergic inflammation in the lung.
SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.
Shp-2 is critical for ERK and metabolic engagement downstream of IL-15 receptor in NK cells.
Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt.
SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production.
Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase.
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
T cell developmental defects in 'viable motheaten' mice deficient in SHP-1 protein-tyrosine phosphatase. Developmental defects are corrected in vitro in the presence of normal hematopoietic-origin stromal cells and in vivo by exogenous IL-7.
T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice.
T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities.
TCPTP Regulates Insulin Signaling in AgRP Neurons to Coordinate Glucose Metabolism With Feeding.
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
The adaptor protein p66Shc inhibits mTOR-dependent anabolic metabolism.
The autoimmune susceptibility gene, PTPN2, restricts expansion of a novel mouse adherent-invasive E. coli.
The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus.
The expression of interleukin-12 is increased by MAP kinase phosphatase-1 through a mechanism related to interferon regulatory factor 1.
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases.
The pro-oxidant adaptor p66SHC promotes B cell mitophagy by disrupting mitochondrial integrity and recruiting LC3-II.
The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity.
The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity.
The protein tyrosine phosphatase SHP-1 regulates integrin-mediated adhesion of macrophages.
The role of the Syk/Shp-1 kinase-phosphatase equilibrium in B cell development and signaling.
The SHP-1 protein tyrosine phosphatase negatively modulates Akt signaling in the ghrelin/GHSR1a system.
The two faces of PTP1B in cancer.
Tyrosine phosphatase SHP-1 acts at different stages of development to regulate hematopoiesis.
Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway.
Proteinuria
Antibodies to Protein Tyrosine Phosphatase Receptor Type O (PTPro) increase Glomerular Albumin Permeability (Palb).
Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B.
Curcumin protects against fructose-induced podocyte insulin signaling impairment through upregulation of miR-206.
Early changes in gene expression that influence the course of primary glomerular disease.
Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis.
Klotho inhibits PKC?/p66SHC-mediated podocyte injury in diabetic nephropathy.
Podocyte proteins in Galloway-Mowat syndrome.
Protein tyrosine phosphatase 1B inhibition protects against podocyte injury and proteinuria.
Protein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuria.
PTPN2 improved renal injury and fibrosis by suppressing STAT-induced inflammation in early diabetic nephropathy.
Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy.
Pseudomonas Infections
Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis.
Protein Tyrosine Phosphatase-1B Negatively Impacts Host Defense against Pseudomonas aeruginosa Infection.
Psoriasis
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Associations between PTPN2 gene polymorphisms and psoriasis in Northeastern China.
Different epigenome regulation and transcriptome expression of CD4+ and CD8+ T cells from monozygotic twins discordant for psoriasis.
Evaluation of NLRP3 (rs10754558) and PTPN22 (1858C/T) (rs2476601) Functional Polymorphisms in Psoriasis Susceptibility in Egypt.
Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients.
Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22.
Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.
Genome-wide Study Identifies Association between HLA-B?55:01 and Self-Reported Penicillin Allergy.
Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes.
Integration of expression quantitative trait loci and pleiotropy identifies a novel psoriasis susceptibility gene, PTPN1.
Levels of miR-31 and its target genes in dermal mesenchymal cells of patients with psoriasis.
LITAF, HHEX, and DUSP1 expression in mesenchymal stem cells from patients with psoriasis.
MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis.
Polymorphisms in the PTPN22 region are associated with psoriasis of early onset.
Protein tyrosine kinase and protein phosphotyrosine phosphatase in normal and psoriatic skin.
Protein tyrosine phosphatase gene PTPN22 polymorphism in psoriasis: lack of evidence for association.
PTPN22 C1858T and the risk of psoriasis: a meta-analysis.
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.
SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis.
The Protein Tyrosine Phosphatase Nonreceptor 22 (
The protein tyrosine phosphatase, non-receptor type 22 R620W polymorphism does not confer susceptibility to psoriasis in the genetic homogeneous population of Crete.
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
Unraveling the genetics of complex diseases: Susceptibility genes for rheumatoid arthritis and psoriasis.
[Progress in genetic research on psoriatic arthritis].
Puberty, Delayed
Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
Pulmonary Arterial Hypertension
Berberine attenuates pulmonary arterial hypertension via protein phosphatase 2A signaling pathway both in vivo and in vitro.
The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
?1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.
Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.
Curcumin ameliorates alveolar epithelial injury in a rat model of chronic obstructive pulmonary disease.
Identification of hub genes and functional modules in colon adenocarcinoma based on public databases by bioinformatics analysis.
p66Shc Mediates Mitochondrial Dysfunction Dependent on PKC Activation in Airway Epithelial Cells Induced by Cigarette Smoke.
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.
Protein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations.
RBC membrane damage and decreased band 3 phospho-tyrosine phosphatase activity are markers of COPD progression.
Role of mitogen-activated protein kinase phosphatase-1 in corticosteroid insensitivity of chronic oxidant lung injury.
Shp2 plays an important role in acute cigarette smoke-mediated lung inflammation.
The GPx1-PTP1B-PP2A Axis: A Key Determinant of Airway Inflammation and Alveolar Destruction.
TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis.
Urban PM2.5 induces ROS generation and RBC damage in COPD patients.
Pulmonary Edema
Protection Against LPS-Induced Pulmonary Edema Through the Attenuation of PTP1B Oxidation.
Pulmonary Fibrosis
Blocking protein phosphatase 2A with a peptide protects mice against bleomycin-induced pulmonary fibrosis.
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
How Do We Know What We Are Missing? Loss of Signaling through CD148 Drives Fibroblast Activation in Pulmonary Fibrosis.
Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis.
Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis.
Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.
Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148.
Pulmonary Valve Stenosis
Bleeding diathesis in Noonan syndrome: Is acquired von Willebrand syndrome the clue?
Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results.
Cardiac Manifestations of Noonan Syndrome.
Case report: Noonan syndrome with multiple giant cell lesions and review of the literature.
Clinical and molecular characterization of 40 patients with Noonan syndrome.
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Genotype-phenotype correlation analysis in Japanese patients with Noonan syndrome.
Genotype-phenotype correlations in Noonan syndrome.
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
LEOPARD Syndrome Without Hearing Loss or Pulmonary Stenosis: A Report of 2 Cases.
Leopard syndrome: the potential cardiac defect underlying skin phenotypes.
Nonsyndromic pulmonary valve stenosis and the PTPN11 gene.
Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.
PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
PTPN11 mutations play a minor role in isolated congenital heart disease.
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome.
[Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation]
Purpura
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to Henoch-Schönlein purpura.
Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis).
Purpura, Thrombocytopenic, Idiopathic
Increased representation of the PTPN22 mutation in patients with immune thrombocytopenia.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
No impact of PTPN22, PTPRJ and ACP1 genes polymorphisms on the risk of immune thrombocytopenia in French adult patients.
PTPN22 -1123G?>?C polymorphism is associated with susceptibility to primary immune thrombocytopenia in Chinese population.
PTPN22 gene polymorphism as a genetic risk factor for primary immune thrombocytopenia in Egyptian children.
The role of PTPN22 gene polymorphism in childhood immune thrombocytopenic purpura.
Pyloric Stenosis
Mosaic partial deletion of PTPN12 in a child with interrupted aortic arch type A.
Pyoderma Gangrenosum
Alteration in the Gene Encoding Protein Tyrosine Phosphatase Nonreceptor Type 6 (PTPN6/SHP1) May Contribute to Neutrophilic Dermatoses.
The systemic autoinflammatory diseases: inborn errors of the innate immune system.
receptor protein-tyrosine kinase deficiency
PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
Rectal Neoplasms
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer.
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells.
Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.
Reperfusion Injury
Amyloid beta-peptide worsens cognitive impairment following cerebral ischemia-reperfusion injury.
Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier.
Lack of Contribution of p66shc and Its Mitochondrial Translocation to Ischemia-Reperfusion Injury and Cardioprotection by Ischemic Preconditioning.
Lentivirus-Mediated Silencing of Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase 2 Inhibits Release of Inflammatory Cytokines and Apoptosis in Renal Tubular Epithelial Cells Via Inhibition of the TLR4/NF-kB Pathway in Renal Ischemia-Reperfusion Injury.
microRNA-135a protects against myocardial ischemia-reperfusion injury in rats by targeting protein tyrosine phosphatase 1B.
Modulating the p66shc signaling pathway with protocatechuic acid protects the intestine from ischemia-reperfusion injury and alleviates secondary liver damage.
New aspects of p66Shc in ischemia reperfusion injury and cardiovascular diseases.
PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-?B.
SHP-1 inhibits renal ischemia reperfusion injury via dephosphorylating ASK1 and suppressing apoptosis.
Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo.
The Potential Role of Protein Tyrosine Phosphatase, Receptor Type C (CD45) in the Intestinal Ischemia-Reperfusion Injury.
Restless Legs Syndrome
Case-Control and Family-Based Association Study of Specific PTPRD Variants in Restless Legs Syndrome.
Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome.
Mouse model for PTPRD associations with WED/RLS and addiction: reduced expression alters locomotion, sleep behaviors and cocaine-conditioned place preference.
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome.
PTPRD as a candidate druggable target for therapies for restless legs syndrome?
Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes.
Retinal Degeneration
Deficiency of SHP-1 Protein-Tyrosine Phosphatase in "Viable Motheaten" Mice Results in Retinal Degeneration.
Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina.
Retinal Detachment
Protein tyrosine phosphatase 1B regulates the activity of retinal pigment epithelial cells.
Retinal Dystrophies
Expression of the protein tyrosine phosphatase, phosphatase of regenerating liver 1, in the outer segments of primate cone photoreceptors.
Retinal Perforations
Phagocytic and digestive activities of retinal pigment epithelium at experimentally produced retinal tears.
Retinitis Pigmentosa
Disrupted ATP synthase activity and mitochondrial hyperpolarisation-dependent oxidative stress is associated with p66Shc phosphorylation in fibroblasts of NARP patients.
PTPN11 mutation in a young man with Noonan syndrome and retinitis pigmentosa.
Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina.
Retinoblastoma
A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo.
A Conserved Amino Acid in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and Repression of Epithelial Differentiation.
A novel cAMP-stimulated pathway in protein phosphatase 2A activation.
Altered genome-wide methylation in endometriosis.
Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein.
Cdc25A Is a Critical Mediator of Ischemic Neuronal Death In Vitro and In Vivo.
Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7.
Detection of the GD2+/CD56+/CD45- immunophenotype by flow cytometry in cerebrospinal fluids from a patient with retinoblastoma.
Development of a Novel Nonradioisotopic Assay and Cdc25B Overexpression Cell Lines for Use in Screening for Cdc25B Inhibitors.
Enumeration of the simian virus 40 early region elements necessary for human cell transformation.
Expression of CDC25A and CDC25B phosphatase proteins in human retinoblastoma and its correlation with clinicopathological parameters.
Further characterization of BC3H1 myogenic cells reveals lack of p53 activity and underexpression of several p53 regulated and extracellular matrix-associated gene products.
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Identification of candidate growth-regulating genes that are overexpressed in late gestation fetal liver in the rat.
Induction of G?/M Arrest by Berberine via Activation of PI3K/Akt and p38 in Human Chondrosarcoma Cell Line.
Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery.
mel-18 negatively regulates cell cycle progression upon B cell antigen receptor stimulation through a cascade leading to c-myc/cdc25.
MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.
MYC Modulation around the CDK2/p27/SKP2 Axis.
Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation.
Overexpression of HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway.
Pathways governing G1/S transition and their response to DNA damage.
PIN1 in Cell Cycle Control and Cancer.
PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis.
Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression.
The B55? regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes.
The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis.
The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter.
Trichodermin Induces G0/G1 Cell Cycle Arrest by Inhibiting c-Myc in Ovarian Cancer Cells and Tumor Xenograft-Bearing Mice.
Using expression profiling data to identify human microRNA targets.
Rett Syndrome
PTP1B inhibition suggests a therapeutic strategy for Rett syndrome.
PTP1B: a new therapeutic target for Rett syndrome.
Rhabdomyosarcoma
Acid phosphatase response in murine rhabdomyosarcoma for various tumour volumes and after different doses of neutron irradiation, alone or combined with exogenous ATP.
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation.
Cloning and expression of PTP-PEST. A novel, human, nontransmembrane protein tyrosine phosphatase.
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Rheumatic Diseases
Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK.
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
The PTPN22 R620W polymorphism is not associated with systemic rheumatic diseases in South Africans.
[Acid phosphatase activity and the autoimmune processes in rheumatism and rheumatoid arthritis]
Rheumatic Fever
[Beta-glucuronidase and acid phosphatase activity in children with rheumatic fever]
Rheumatic Heart Disease
Influence of protein tyrosine phosphatase gene (PTPN22) polymorphisms on rheumatic heart disease susceptibility in North Indian population.
No association of PTPN22 R620 W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus.
Rhinitis, Allergic
Associations of single nucleotide polymorphisms of PTPN22 and Ctla4 genes with the risk of allergic rhinitis in a Chinese Han population.
Azelastine enhances the clinical efficacy of glucocorticoid by modulating MKP-1 expression in allergic rhinitis.
Regulation of nasal airway homeostasis and inflammation in mice by SHP-1 and Th2/Th1 signaling pathways.
Riboflavin Deficiency
Effect of riboflavin or pyridoxine deficiency on inflammatory response.
RNA Virus Infections
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Rubella
Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients.
Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.
Salmonella Infections
Role of tyrosine kinases and the tyrosine phosphatase SptP in the interaction of Salmonella with host cells.
Sarcoidosis
Dysregulation of p38 and MKP-1 in Response to NOD1/TLR4 Stimulation in Sarcoid Bronchoalveolar Cells.
Search for sarcoidosis candidate genes by integration of data from genomic, transcriptomic and proteomic studies.
[Cytochemical study of macrophages in sarcoidosis patients in skin window exudates]
Sarcoma
A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.
Copper Induces Apoptosis of Neuroblastoma Cells Via Post-translational Regulation of the Expression of Bcl-2-family Proteins and the tx Mouse is a Better Model of Hepatic than Brain Cu Toxicity.
Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease.
Heterotopically induced bone does not develop functional periosteal membrane.
High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/?-catenin target gene, CDC25A.
Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues.
Impact of Wnt/?-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas.
LMW-PTP is a positive regulator of tumor onset and growth.
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma.
Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma.
SHP2 protects endothelial cell barrier through suppressing VE-cadherin internalization regulated by MET-ARF1.
Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.
[Phosphotyrosine]protein phosphatase in rat brain. A major [phosphotyrosine]protein phosphatase is a 23 kDa protein distinct from acid phosphatase.
Sarcoma, Alveolar Soft Part
Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma.
Sarcoma, Avian
FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells.
Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes.
Neuregulin-regulated gene expression in mammary carcinoma cells.
TPCK and quercetin act synergistically with vanadate to increase protein-tyrosine phosphorylation in avian cells.
[Effect of Rous sarcoma virus on the acid phosphatase activity in cells sensitive and naturally resistant to the virus]
Sarcoma, Ewing
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.
PTPRD copy number variants and Ewing's sarcoma: Strengthening the association and therapeutic implications.
Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis.
Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.
Sarcoma, Synovial
SRC signaling is crucial in the growth of synovial sarcoma cells.
SS18-SSX fusion protein-induced Wnt/?-catenin signaling is a therapeutic target in synovial sarcoma.
Sarcopenia
Activated protein phosphatase 2A disrupts nutrient sensing balance between mTORC1 and AMPK causing sarcopenia in alcoholic liver disease.
MAP kinase phosphatase-1--a new player at the nexus between sarcopenia and metabolic disease.
Scleritis
Identification of susceptibility SNPs in CTLA-4 and PTPN22 for scleritis in Han Chinese.
Scleroderma, Systemic
Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis.
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations.
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
Enhanced frequency of a PTPRC (CD45) exon A mutation (77C-->G) in systemic sclerosis.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Lack of association of the PTPN22 gene polymorphism R620W with systemic sclerosis.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
No association between systemic sclerosis and C77G polymorphism in the human PTPRC (CD45) gene.
Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE).
The association between the PTPN22 C1858T polymorphism and systemic sclerosis: a meta-analysis.
The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis.
The PTPN22 C1858T variant as a risk factor for rheumatoid arthritis and systemic lupus erythematosus but not for systemic sclerosis in the Colombian population.
Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22.
Scoliosis
Pathogenesis of adolescent idiopathic scoliosis in girls - a double neuro-osseous theory involving disharmony between two nervous systems, somatic and autonomic expressed in the spine and trunk: possible dependency on sympathetic nervous system and hormones with implications for medical therapy.
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Scurvy
[Consequences of scurvy on testicular and muscular acid phosphatase activity in guinea pigs]
Seizures
Induction of the dual specificity phosphatase PAC1 in rat brain following seizure activity.
Kainic acid-induced convulsions cause prolonged changes in the chondroitin sulfate proteoglycans neurocan and phosphacan in the limbic structures.
MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase.
Plasmin-mediated processing of protein tyrosine phosphatase receptor type Z in the mouse brain.
Regulated expression of dual specificity protein phosphatases in rat brain.
Seizure-Induced Regulations of Amyloid-?, STEP61, and STEP61 Substrates Involved in Hippocampal Synaptic Plasticity.
Temporal and spatial regulation of the expression of BAD2, a MAP kinase phosphatase, during seizure, kindling, and long-term potentiation.
Transient expression of the mitogen-activated protein kinase phosphatase MKP-1 (3CH134/ERP1) in the rat brain after limbic epilepsy.
Seminoma
Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Sepsis
Dynamic regulation of neutrophil survival through tyrosine phosphorylation or dephosphorylation of caspase-8.
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Gene Deletion of Protein Tyrosine Phosphatase 1B Protects Against Sepsis-Induced Cardiovascular Dysfunction and Mortality.
GLUTAMINE PREVENTS ACTIVATION OF NF-kappaB AND STRESS KINASE PATHWAYS, ATTENUATES INFLAMMATORY CYTOKINE RELEASE, AND PREVENTS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) FOLLOWING SEPSIS.
Inactivation of the tyrosine phosphatase SHP-2 drives vascular dysfunction in Sepsis.
Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice.
Mitogen Activated Protein Kinase Phosphatase 2, MKP-2, regulates the Inflammatory Response in Sepsis.
MKP-2: out of the DUSP-bin and back into the limelight.
Monocyte deactivation in severe human sepsis or following cardiopulmonary bypass.
Reduced Insulin Resistance Contributes to the Beneficial Effect of Protein Tyrosine Phosphatase-1B Deletion in a Mouse Model of Sepsis.
Sepsis-induced brain mitochondrial dysfunction is associated with altered mitochondrial Src and PTP1B levels.
Sepsis-Induced Cardiac Mitochondrial Dysfunction Involves Altered Mitochondrial-Localization of Tyrosine Kinase Src and Tyrosine Phosphatase SHP2.
The inhibitory effect of ghrelin on sepsis-induced inflammation is mediated by the MAPK phosphatase-1.
Wedelolactone improves the renal injury induced by lipopolysaccharide in HK-2 cells by upregulation of protein tyrosine phosphatase non-receptor type 2.
Sepsis-Associated Encephalopathy
Disruption of Striatal-Enriched Protein Tyrosine Phosphatase Signaling Might Contribute to Memory Impairment in a Mouse Model of Sepsis-Associated Encephalopathy.
Sertoli Cell-Only Syndrome
Association of spermatogenic failure with decreased CDC25A expression in infertile men.
Severe Combined Immunodeficiency
Mitogen-activated protein kinase phosphatase-1 expression in macrophages is controlled by lymphocytes during macrophage activation.
Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease.
Sex Chromosome Aberrations
De novo and rare inherited copy-number variations in the hemiplegic form of cerebral palsy.
Sezary Syndrome
SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling.
Shock, Septic
Association Between PTPN22 Polymorphisms and IgE Responses to Staphylococcal Superantigens in Chronic Urticaria.
Deficiency of mitogen-activated protein kinase phosphatase-1 results in iNOS-mediated hypotension in response to low-dose endotoxin.
Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock.
Dual-Specificity Phosphatase 3 Deletion Protects Female, but Not Male, Mice from Endotoxemia-Induced and Polymicrobial-Induced Septic Shock.
Gene Expression of Protein Tyrosine Phosphatase 1B and Endoplasmic Reticulum Stress During Septic Shock.
MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock.
MAP Kinase Phosphatase-1 and Septic Shock.
MAP kinase phosphatase-1, a critical negative regulator of the innate immune response.
Protein tyrosine phosphatase 1B regulates endothelial endoplasmic reticulum stress; role in endothelial dysfunction.
Reduced Insulin Resistance Contributes to the Beneficial Effect of Protein Tyrosine Phosphatase-1B Deletion in a Mouse Model of Sepsis.
Regulation of innate immune response by MAP kinase phosphatase-1.
Role of protein tyrosine phosphatase 1B in cardiovascular diseases.
Shwachman-Diamond Syndrome
Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.
Silicosis
Evaluation of differential serum expression of three factors and pulmonary function in patients with silicosis.
Protein Expression Profile in Rat Silicosis Model Reveals Upregulation of PTPN2 and Its Inhibitory Effect on Epithelial-Mesenchymal Transition by Dephosphorylation of STAT3.
Sjogren's Syndrome
[Polymorphic markers of certain genes in the development of dry keratoconjunctivitis in patients with rheumatoid arthritis and Sjogren's syndrome].
Skin Diseases
Alteration in the Gene Encoding Protein Tyrosine Phosphatase Nonreceptor Type 6 (PTPN6/SHP1) May Contribute to Neutrophilic Dermatoses.
ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis.
Binding of the trichodysplasia spinulosa-associated polyomavirus small T antigen to protein phosphatase 2A: elucidation of a potential pathogenic mechanism in a rare skin disease.
Cutting Edge: Dysregulated CARD9 Signaling in Neutrophils Drives Inflammation in a Mouse Model of Neutrophilic Dermatoses.
Distinct Roles for Neutrophils and Dendritic Cells in Inflammation and Autoimmunity in motheaten Mice.
Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
RIP1-driven autoinflammation targets IL-1? independently of inflammasomes and RIP3.
SHP-1 (PTPN6) keeps the inflammation at bay: limiting IL-1?-mediated neutrophilic dermatoses by preventing Syk kinase activation.
SHP-1 and IL-1? conspire to provoke neutrophilic dermatoses.
Spontaneous insertion of a b2 element in the ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humans.
Tyrosine Kinase SYK Licenses MyD88 Adaptor Protein to Instigate IL-1?-Mediated Inflammatory Disease.
Skin Neoplasms
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin.
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death.
Epidermal-specific deletion of TC-PTP promotes UVB-induced epidermal cell survival through the regulation of Flk-1/JNK signaling.
Targeting 14-3-3? activates apoptotic signaling to prevent cutaneous squamous cell carcinoma.
The Protein Tyrosine Phosphatase H1 PTPH1 Supports Proliferation of Keratinocytes and is a Target of the Human Papillomavirus Type 8 E6 Oncogene.
Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion.
Sleep Apnea, Obstructive
Obstructive sleep apnea and intermittent hypoxia increase expression of dual specificity phosphatase 1.
Small Cell Lung Carcinoma
Coexisting amplifications of the chromosome 1p32 genes (PTPRF and MYCL1) encoding protein tyrosine phosphatase LAR and L-myc in a small cell lung cancer line.
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
[Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer]
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
Smallpox
Microbial pathogenesis and tyrosine dephosphorylation: surprising 'bedfellows'.
OH1 from Orf Virus: A New Tyrosine Phosphatase that Displays Distinct Structural Features and Triple Substrate Specificity.
Overproduction, purification, and biochemical characterization of the dual specificity H1 protein phosphatase encoded by variola major virus.
Smoldering Multiple Myeloma
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Spastic Paraplegia, Hereditary
Final Exon Frameshift Biallelic PTPN23 Variants Are Associated with Microcephalic Complex Hereditary Spastic Paraplegia.
Spinal Cord Injuries
A new role for RPTPsigma in spinal cord injury: signaling chondroitin sulfate proteoglycan inhibition.
Axonal regeneration through regions of chondroitin sulfate proteoglycan deposition after spinal cord injury: a balance of permissiveness and inhibition.
Corticospinal tract regeneration after spinal cord injury in receptor protein tyrosine phosphatase sigma deficient mice.
Decorin promotes robust axon growth on inhibitory CSPGs and myelin via a direct effect on neurons.
Decorin suppresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries.
Identification of the potential dual inhibitor of protein tyrosine phosphatase sigma and leukocyte common antigen-related phosphatase by virtual screen, molecular dynamic simulations and post-analysis.
L1 Cell Adhesion Molecule Overexpression Down Regulates Phosphacan and Up Regulates Structural Plasticity-Related Genes Rostral and Caudal to the Complete Spinal Cord Transection.
NG2 and phosphacan are present in the astroglial scar after human traumatic spinal cord injury.
Protein Tyrosine Phosphatase ? Inhibitory Peptide Promotes Recovery of Diaphragm Function and Sprouting of Bulbospinal Respiratory Axons after Cervical Spinal Cord Injury.
PTP{sigma} Is a Receptor for Chondroitin Sulfate Proteoglycan, an Inhibitor of Neural Regeneration.
Recombinant Human Erythropoietin Protects Against Experimental Spinal Cord Trauma Injury by Regulating Expression of the Proteins MKP-1 and p-ERK.
RXR? Blocks Nerve Regeneration after Spinal Cord Injury by Targeting p66shc.
Small-molecule protein tyrosine phosphatase inhibition as a neuroprotective treatment after spinal cord injury in adult rats.
Spatiotemporal distribution of chondroitin sulfate proteoglycans after optic nerve injury in rodents.
The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury.
Upregulation of PTP1B After Rat Spinal Cord Injury.
[Study on expression of mkp-1 and P-ERK in acutecontusive spinal cord injury rat's model]
Spinal Curvatures
Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
Spinocerebellar Ataxias
A Ras signaling complex controls the RasC-TORC2 pathway and directed cell migration.
Gene expression profile following stable expression of the cellular prion protein.
Generation of a human induced pluripotent stem cell line JHUi003-A with homozygous mutation for spinocerebellar ataxia type 12 using genome editing.
The spinocerebellar ataxia 12 gene product and protein phosphatase 2A regulatory subunit Bbeta2 antagonizes neuronal survival by promoting mitochondrial fission.
Spondylarthropathies
Treatment with TNF? blockers induces phenotypical and functional aberrations in peripheral B cells.
Spondylitis, Ankylosing
A functional variant of PTPN22 confers risk for Vogt-Koyanagi-Harada syndrome but not for ankylosing spondylitis.
A variant within intron 1 of the PTPN22 gene decreases the genetic susceptibility of ankylosing spondylitis in a central south Chinese Han population.
Association Between Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) Polymorphisms and Risk of Ankylosing Spondylitis: A Meta-analysis.
Association of PTPN22 polymorphsims and ankylosing spondylitis susceptibility.
Associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis.
Lack of association between ankylosing spondylitis and a functional polymorphism of PTPN22 proposed as a general susceptibility marker for autoimmunity.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Potential role of PTPN22 in ankylosing spondylitis, comment on: associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis.
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.
Squamous Cell Carcinoma of Head and Neck
AlloDriver: a method for the identification and analysis of cancer driver targets.
Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma.
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells.
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Differential molecular signature alterations of RBSP3, LIMD1 and CDC25A in normal oral epithelium during oral tumorigenesis.
Differential transmission of the molecular signature of RBSP3, LIMD1 and CDC25A in basal/ parabasal versus spinous of normal epithelium during head and neck tumorigenesis: A mechanistic study.
Down-regulation of lncRNA HCG11 promotes cell proliferation of oral squamous cell carcinoma through sponging miR-455-5p.
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.
Expression of the transmembrane protein tyrosine phosphatase RPTPalpha in human oral squamous cell carcinoma.
FAP-1 and NF-?B expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis.
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
Genomic Alteration in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Inferred from Karyotyping, Molecular Cytogenetics, and Array Comparative Genomic Hybridization.
High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Increased Expression of the PRL-3 Gene in Human Oral Squamous Cell Carcinoma and Dysplasia Tissues.
Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.
Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients.
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC).
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Noninvasive Molecular Detection of Head and Neck Squamous Cell Carcinoma: An Exploratory Analysis.
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Parathyroid Hormone-Like Hormone is a Poor Prognosis Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2 Regulation.
Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Receptor-type Protein tyrosine phosphatase ? regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
Relationship between the Levels of mRNA Expression for Protein Phosphatase 1B and Proteins Involved in Cytoskeleton Remodeling in Squamous Cell Carcinoma of the Larynx and Hypopharynx.
SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
[Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance].
Staphylococcal Infections
[Fibroblast phosphatase activity in the staphylococcal infection process]
Starvation
Changes in expression of soluble inorganic pyrophosphatases of Phaseolus vulgaris under phosphate starvation
Changes in expression of soluble inorganic pyrophosphatases of Phaseolus vulgaris under phosphate starvation.
Cytochemical determination of acid phosphatase activity in isolated rat hepatocytes during starvation-induced proteolysis.
Differential increase in activity of acid phosphatase induced by phosphate starvation in Tetrahymena.
Focal adhesion and stress fiber formation is regulated by tyrosine phosphatase activity.
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
Functional significance and morphological characterization of starvation-induced autophagy in the adult heart.
Identification of nutrient-dependent changes in extracellular pH and acid phosphatase secretion in Aspergillus nidulans.
Identification, structure analysis, and transcript profiling of purple acid phosphatases under Pi deficiency in tomato (Solanum lycopersicum L.) and its wild relatives.
Induction of p53 dependent apoptosis upon overexpression of a nuclear protein tyrosine phosphatase.
Influence of glucose starvation on the pathway of death in insect cell line Sl: apoptosis follows autophagy.
microRNA-21 Negatively Regulates Cdc25A and Cell Cycle Progression in Colon Cancer Cells.
OsUEV1B, an Ubc enzyme variant protein, is required for phosphate homeostasis in rice.
Quiescence versus apoptosis: Myc abundance determines pathway of exit from the cell cycle.
Regulation of dimorphism in Saccharomyces cerevisiae: involvement of the novel protein kinase homolog Elm1p and protein phosphatase 2A.
SHP-2 regulates myogenesis by coupling to FAK signaling pathway.
State transitions in the TORC1 signaling pathway and information processing in Saccharomyces cerevisiae.
Studies on the activities of an acid phosphomonoesterase and an alkaline pyrophosphatase during the growth of Physarum polycephalum.
The effect of starvation, restricted feed intake and refeeding on acid phosphatase activity of the hypothalamus and frontal cerebral cortex of the rat.
The effects of starvation on the planarian worm Polycelis tenuis Iijima.
The purple acid phosphatase GmPAP21 enhances internal phosphorus utilization and possibly plays a role in symbiosis with rhizobia in soybean.
The THO/TREX Complex Active in miRNA Biogenesis Negatively Regulates Root-Associated Acid Phosphatase Activity Induced by Phosphate Starvation.
Use of the p-nitrophenyl phosphate method for the demonstration of acid phosphatase during starvation and cell autolysis in the planarian Polycelis tenuis Iijima.
ZmAPRG, an uncharacterized gene, enhances acid phosphatase activity and Pi concentration in maize leaf during phosphate starvation.
[P66shc action on resistance of colon carcinoma RKO cells to oxidative stress].
Status Epilepticus
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Upregulated SHP-2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model.
stearoyl-coa 9-desaturase deficiency
Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle.
Steatorrhea
Demonstration of acid phosphatase activity in the Golgi apparatus of the jejunal epithelium cell in patients with idiopathic steatorrhea.
Stiff-Person Syndrome
Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus.
Stomach Diseases
Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: a two-stage case-control study in Chinese.
Inhibitory Effect of Artesunate on Growth and Apoptosis of Gastric Cancer Cells.
Stomach Neoplasms
A role for p21-activated kinase 7 in the development of gastric cancer.
Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency.
Anaplastic neoplasm in a patient with hairy cell leukemia.
Antitumorigenic effect of plumbagin by induction of SH2-containing protein tyrosine phosphatase 1 in human gastric cancer cells.
Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells.
Association between serum pepsinogens and polymorphismof PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese.
Association of polymorphism of PTPN 11 encoding SHP-2 with gastric atrophy but not gastric cancer in Helicobacter pylori seropositive Chinese population.
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
Associations of a PTPN11 G/A polymorphism at intron 3 with Helicobactor pylori seropositivity, gastric atrophy and gastric cancer in Japanese.
Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression.
Biological function of protein tyrosine phosphatase H-type receptor and its progress in tumor.
CD148 Serves as a Prognostic Marker of Gastric Cancer and Hinders Tumor Progression by Dephosphorylating EGFR.
Chemotherapy Effectiveness and Prognosis of Gastric Cancer Influenced by PTPN11 Polymorphisms.
Comprehensive analysis of vascular endothelial growth factor-C related factors in stomach cancer.
Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Correction: Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1.
Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding.
Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.
Dysregulation of Stem Cell Signaling Network Due to Germline Mutation, SNP, Helicobacter pylori Infection, Epigenetic Change and Genetic Alteration in Gastric Cancer.
Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.
Epigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells.
Expression and Clinical Significance of SHP2 in Gastric Cancer.
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Expression of CDC25 phosphatases in human gastric cancer.
Expression of Concern: microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer.
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.
Functions of Shp2 in cancer.
Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients.
Genetic Susceptibility on CagA-Interacting Molecules and Gene-Environment Interaction with Phytoestrogens: A Putative Risk Factor for Gastric Cancer.
Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.
Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy.
Helicobacter pylori-induced protein tyrosine phosphatase receptor type C as a prognostic biomarker for gastric cancer.
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer.
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer.
Inhibitory Effect of Artesunate on Growth and Apoptosis of Gastric Cancer Cells.
Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells.
Long Noncoding RNA UCA1 Regulates PRL-3 Expression by Sponging MicroRNA-495 to Promote the Progression of Gastric Cancer.
Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1.
Menadione induces G2/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1.
Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer.
Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3.
MicroRNA-217 suppressed epithelial-to-mesenchymal transition in gastric cancer metastasis through targeting PTPN14.
microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer.
MicroRNA-574-5p in gastric cancer cells promotes angiogenesis by targeting protein tyrosine phosphatase non-receptor type 3 (PTPN3).
MicroRNA?181a promotes cell proliferation and inhibits apoptosis in gastric cancer by targeting RASSF1A.
miR-146b Regulates Cell Proliferation and Apoptosis in Gastric Cancer by Targeting PTP1B.
miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B.
miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
Mutational analysis of the tyrosine phosphatome in colorectal cancers.
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Nonreceptor tyrosine phosphatase 14 promotes proliferation and migration through regulating phosphorylation of YAP of Hippo signaling pathway in gastric cancer cells.
Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas.
Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma.
Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
PRL PTPs: mediators and markers of cancer progression.
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
PRL-3 promotes gastric cancer migration and invasion through a NF-?B-HIF-1?-miR-210 axis.
PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo.
PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN.
Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer.
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy.
Protein tyrosine-phosphatase expression profiling in gastric cancer tissues.
PTP1B expression contributes to gastric cancer progression.
PTP4A3 (PRL-3) expression correlate with lymphatic metastases in gastric cancer.
PTPN11 hypomethylation is associated with gastric cancer progression.
PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma.
PTPRU, As A Tumor Suppressor, Inhibits Cancer Stemness By Attenuating Hippo/YAP Signaling Pathway.
Pyrophosphatase overexpression is associated with cell migration, invasion, and poor prognosis in gastric cancer.
Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives.
RING finger protein 38 induces gastric cancer cell growth by decreasing the stability of the protein tyrosine phosphatase SHP-1.
Role of silencing phosphatase of regenerationg liver-3 expression by microRNA interference in the growth of gastric cancer.
SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis.
Stability of Helicobacter pylori CagA oncoprotein in human gastric epithelial cells.
Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome-wide expression profile, and inhibits gastric cancer cell growth.
The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa.
The Critical Role of the miR-21-MEG2 Axis in Colorectal Cancer.
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
The prognostic value of Cyclin-Dependent Kinase 5 and Protein Phosphatase 2A in Gastric Cancer.
Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer.
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Unsaturated fatty acids bind Myc-Max transcription factor and inhibit Myc-Max-DNA complex formation.
YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
[CagA tyrosine phosphorylation motif structure and SHP-2 binding ability of Helicobacter pylori studied in stomach cancer and duodenal ulcer cell lines]
[Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer]
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
[Methylation of PTPRG gene and its regulation in gastric cancer]
[Role of silencing PRL-3 expression by miRNA interference in the growth of gastric cancer]
[Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]
[The overexpression and significance of MKP-1 in oxygen-deprived gastric cancer cell line SGC7901]
Stomach Ulcer
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori.
[Receptor for VacA toxin and pathogenesis of gastric ulcer]
Stomatitis
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
The protein tyrosine phosphatase PTP1B is required for efficient delivery of N-cadherin to the cell surface.
Stroke
Age and blood pressure related changes in cholesterol esterase activity and cholesterol content in aortas of stroke prone spontaneously hypertensive rats, spontaneously hypertensive rats and normotensive Wistar Kyoto rats.
Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling.
Brevican and phosphacan expression and localization following transient middle cerebral artery occlusion in the rat.
Cdc25A Is a Critical Mediator of Ischemic Neuronal Death In Vitro and In Vivo.
Deletion of a neuronal Drp1 activator protects against cerebral ischemia.
DJ-1 exerts anti-inflammatory effects and regulates NLRX1-TRAF6 via SHP-1 in stroke.
Egr-1 regulates expression of the glial scar component phosphacan in astrocytes after experimental stroke.
Inhibition of mitogen-activated protein kinase phosphatase-1 (MKP-1) increases experimental stroke injury.
Neuronal protein-tyrosine phosphatase 1B hinders sensory-motor functional recovery and causes affective disorders in two different focal ischemic stroke models.
Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke.
Protein phosphatase 2a (PP2A) binds within the oligomerization domain of striatin and regulates the phosphorylation and activation of the mammalian Ste20-Like kinase Mst3.
PTPN22 Gene Polymorphisms Are Associated with Susceptibility to Large Artery Atherosclerotic Stroke and Microembolic Signals.
Subarachnoid Hemorrhage
Tyrosine phosphatase inhibition attenuates early brain injury after subarachnoid hemorrhage in rats.
Supranuclear Palsy, Progressive
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
Sweet Syndrome
Alteration in the Gene Encoding Protein Tyrosine Phosphatase Nonreceptor Type 6 (PTPN6/SHP1) May Contribute to Neutrophilic Dermatoses.
Synovitis
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved?
T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice.
Systemic Vasculitis
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to Henoch-Schönlein purpura.
Tachycardia, Supraventricular
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.
Tachycardia, Ventricular
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.
Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His.
Takayasu Arteritis
An association study in PTPN22 suggests that is a risk factor to Takayasu's arteritis.
PTPN22 gene polymorphism in Takayasu's arteritis.
Tauopathies
Chronic Sodium Selenate Treatment Restores Deficits in Cognition and Synaptic Plasticity in a Murine Model of Tauopathy.
Hyperphosphorylation-induced tau oligomers.
Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models.
Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.
Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies.
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
Tay-Sachs Disease
FINE STRUCTURAL LOCALIZATION OF ACID PHOSPHATASE ACTIVITY IN NEURONS OF TAY-SACHS DISEASE.
Telangiectasia, Hereditary Hemorrhagic
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Telangiectasis
Erbb2 Suppresses DNA Damage-Induced Checkpoint Activation and UV-Induced Mouse Skin Tumorigenesis.
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia.
Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
Teratocarcinoma
Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C.
Testicular Neoplasms
OCT4 Represses Inflammation and Cell Injury During Orchitis by Regulating CIP2A Expression.
Tetanus
Cellular immune response to diverse islet cell antigens in IDDM.
GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Psychological stress in children may alter the immune response.
Spontaneous peripheral T-cell responses to the IA-2beta (phogrin) autoantigen in young nonobese diabetic mice.
Tetralogy of Fallot
A common variant in the PTPN11 gene contributes to the risk of tetralogy of Fallot.
Polymorphism C242T of the gene of the p22phox subunit for nicotinamide adenine dinucleotide phosphate oxidase, and erythrocytic antioxidant enzymes, in patients with tetralogy of Fallot.
thioredoxin-dependent peroxiredoxin deficiency
Peroxiredoxin II is an antioxidant enzyme that negatively regulates collagen-stimulated platelet function.
Thrombocythemia, Essential
A mutation in PTPN11 may drive leukemic transformation in a case of essential thrombocythemia.
Thrombocytopenia
A de novo T73I Mutation in PTPN11 in a Neonate with Severe and Prolonged Congenital Thrombocytopenia and Noonan Syndrome.
A new form of inherited thrombocytopenia caused by loss-of-function mutations in PTPRJ.
Interplay between the tyrosine kinases Chk, Csk and phosphatase PTPRJ is critical for regulating platelets in mice.
Polymorphisms of protein tyrosine phosphatase CD148 influence Fc?RIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.
PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
PTPRJ: a novel inherited thrombocytopenia gene.
Rapid detection by hydrops panel of Noonan syndrome with PTPN11 mutation (p.Thr73Ile) and persistent thrombocytopenia.
Thrombocytosis
Platelet-derived acid phosphatase isoenzyme in the serum in thrombocythemia.
Thrombosis
Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis.
Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta?analysis and cross?species comparison.
Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.
Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.
PECAM-1 regulates collagen-stimulated platelet function by modulating the association of PI3 Kinase with Gab1 and LAT.
Platelet Shp2 negatively regulates thrombus stability under high shear stress.
Role of sodium tungstate as a potential antiplatelet agent.
The endothelial tyrosine phosphatase SHP-1 plays an important role for vascular haemostasis in TNF? -induced inflammation in vivo.
The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis.
Total Platelet Transcriptomics and Its Network Analysis by RNA-Seq and miRNA-Seq and PCA Application in Essential Thrombocythaemia.
Thymoma
Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase ?/? Regulation in the Ventral Tegmental Area.
Association of the transmembrane 4 superfamily molecule CD53 with a tyrosine phosphatase activity.
Autophagy controls neonatal myogenesis by regulating the GH-IGF1 system through a NFE2L2- and DDIT3-mediated mechanism.
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms.
Double-Stranded RNA-Activated Protein Kinase Is a Key Modulator of Insulin Sensitivity in Physiological Conditions and in Obesity in Mice.
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Effects of low-level laser irradiation on mesenchymal stem cell proliferation: a microarray analysis.
Expression and clinical significance of protein tyrosine phosphatase nonreceptor 22 in resected thymoma.
Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.
PTPN22 and CTLA-4 gene polymorphisms in resected thymomas and thymus for myasthenia gravis.
Regulation of Pleiotrophin, Midkine, Receptor Protein Tyrosine Phosphatase ?/?, and Their Intracellular Signaling Cascades in the Nucleus Accumbens During Opiate Administration.
The PTPN22(gain-of-function)+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis.
Thyroid Cancer, Papillary
Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.
DUSP4 inhibits autophagic cell death in PTC by inhibiting JNK-BCL2-Beclin1 signaling.
DUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer.
Role of PTPRJ genotype in papillary thyroid carcinoma risk.
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Thyroid Carcinoma, Anaplastic
Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray.
Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor.
Tyr Phosphatase-Mediated P-ERK Inhibition Suppresses Senescence in EIA + v-raf Transformed Cells, Which, Paradoxically, Are Apoptosis-Protected in a MEK-Dependent Manner.
Thyroid Diseases
A type 1 diabetes subgroup with a female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene.
Analysis of chosen polymorphisms rs2476601 a/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 a/G - TSHR in pathogenesis of autoimmune thyroid diseases in children.
Analysis of PTPN22, ZFAT and MYO9B polymorphisms in Turner Syndrome and risk of autoimmune disease.
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease.
Association of Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) C1858T gene polymorphism with susceptibility to autoimmune thyroid diseases: a meta-analysis.
Association of the protein tyrosine phosphatase nonreceptor 22 haplotypes with autoimmune thyroid disease in the Japanese population.
Association Studies of the GPR103 and BCL2L15 Genes in Autoimmune Thyroid Disease in the Japanese Population.
Associations Between Autoimmune Thyroid Disease Prognosis and Functional Polymorphisms of Susceptibility Genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, Previously Revealed in Genome-wide Association Studies.
Associations of GWAS-Supported Non-MHC Genes with Autoimmune Thyroiditis in Patients with Type 1 Diabetes.
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West.
Genome-Wide Association Studies of Autoimmune Thyroid Diseases, Thyroid Function, and Thyroid Cancer.
Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.
In children with autoimmune thyroiditis CTLA4 and FCRL3 genes - but not PTPN22 - are overexpressed when compared to adults.
Novel missense mutation in PTPN22 in a Chinese pedigree with Hashimoto's thyroiditis.
PTPN22: its role in SLE and autoimmunity.
R620W polymorphism of protein tyrosine phosphatase PTPN22 in Egyptian children and adolescents with systemic lupus erythematosus: relation to thyroid autoimmunity.
Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population.
Susceptibility influence of a PTPN22 haplotype with thyroid autoimmunity in Koreans.
The Genetics of Autoimmune Thyroid Disease.
The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes.
The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population.
The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis.
The role of Fas-mediated apoptosis in thyroid autoimmune disease.
Variants in PTPN22 and SMOC2 genes and the risk of thyroid disease in the Jordanian Arab population.
[Association of polymorphism of proteintyrosine phosphatase nonreceptor-22 gene with AITD.]
Thyroid Neoplasms
An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo.
DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain dependent manner.
Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma.
Expression of cdc25A and cdc25B proteins in thyroid neoplasms.
Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis.
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.
p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
Single nucleotide polymorphism analysis in the human phosphatase PTPrj gene using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry.
The interplay between p66Shc, reactive oxygen species and cancer cell metabolism.
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.
Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles.
Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer.
Thyroiditis
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Analysis of chosen polymorphisms rs2476601 a/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 a/G - TSHR in pathogenesis of autoimmune thyroid diseases in children.
Association Studies of the GPR103 and BCL2L15 Genes in Autoimmune Thyroid Disease in the Japanese Population.
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation.
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Low bone mineral density and renal malformation in Mexican patients with Turner syndrome are associated with single nucleotide variants in vitamin D-metabolism genes.
No association between transmembrane protein-tyrosine-phosphatase receptor type C (CD45) exon A 77C>G transversion and Hashimoto's thyroiditis in a German population.
Novel missense mutation in PTPN22 in a Chinese pedigree with Hashimoto's thyroiditis.
Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population.
The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis.
Tumor necrosis factor receptor II and PTPN22 genes polymorphisms and the risk of systemic lupus erythematosus in Egyptian children.
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Thyroiditis, Autoimmune
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
In children with autoimmune thyroiditis CTLA4 and FCRL3 genes - but not PTPN22 - are overexpressed when compared to adults.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Tick Infestations
Allelic Variation in Protein Tyrosine Phosphatase Receptor Type-C in Cattle Influences Erythrocyte, Leukocyte and Humoral Responses to Infestation With the Cattle Tick Rhipicephalus australis.
Tourette Syndrome
Association between the low molecular weight cytosolic acid phosphatase gene ACP1*A and comorbid features of Tourette syndrome.
Toxemia
[Acid phosphatase activity in the neutrophils and peripheral lymphocytes in normal pregnancy and pregnancies complicated by RH-HR blood group incompatibility and toxemia]
transaldolase deficiency
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Trauma, Nervous System
A new role for RPTPsigma in spinal cord injury: signaling chondroitin sulfate proteoglycan inhibition.
Detection of Ca(2+)-dependent acid phosphatase activity identifies neuronal integrity in damaged rat central nervous system after application of bacterial melanin.
Protein Tyrosine Phosphatase ? Inhibitory Peptide Promotes Recovery of Diaphragm Function and Sprouting of Bulbospinal Respiratory Axons after Cervical Spinal Cord Injury.
The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival.
Triple Negative Breast Neoplasms
Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.
Clinicopathological significance of PTPN12 expression in human breast cancer.
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.
Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer.
Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.
Expression of receptor protein tyrosine phosphatase ? is a risk factor for triple negative breast cancer relapse.
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/?-catenin signaling.
Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.
Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer.
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.
PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.
PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
Receptor-type protein tyrosine phosphatase alpha (PTP?) mediates MMP14 localization and facilitates triple-negative breast cancer cell invasion.
Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.
Trisomy 18 Syndrome
Alkaline phosphatase and phosphotyrosine phosphatase activities of cultured amniotic cells with trisomy 18.
Evaluation of two markers of cell maturation and proliferation in cultured amniotic cells of trisomic 18 fetuses at the 15th week of gestation.
Trypanosomiasis
Inhibition of Trypanosoma evansi Protein-Tyrosine Phosphatase by Myristic Acid Analogues Isolated from Khaya senegalensis and Tamarindus indica.
Trypanosomiasis, African
Investigating mammalian tyrosine phosphatase inhibitors as potential 'piggyback' leads to target Trypanosoma brucei transmission.
Tuberculosis
A facile hydroxyindole carboxylic acid based focused library approach for potent and selective inhibitors of Mycobacterium protein tyrosine phosphatase B.
A new family of phosphoinositide phosphatases in microorganisms: identification and biochemical analysis.
A variant of PTPN22 gene conferring risk to autoimmune diseases may protect against tuberculosis.
Alterporriol-type dimers from the mangrove endophytic fungus, Alternaria sp. (SK11), and their MptpB inhibitions.
Analysis of stress- and host cell-induced expression of the Mycobacterium tuberculosis inorganic pyrophosphatase.
Analyzing the catalytic mechanism of MPtpA: a low molecular weight protein tyrosine phosphatase from Mycobacterium tuberculosis through site-directed mutagenesis.
Asperlones A and B, dinaphthalenone derivatives from a mangrove endophytic fungus Aspergillus sp. 16-5C.
Asperterpenoid A, a new sesterterpenoid as an inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase B from the culture of Aspergillus sp. 16-5c.
Association between the PTPN22 1858C/T gene polymorphism and tuberculosis resistance.
Association of PTPN22-C1858T Polymorphism With Susceptibility to Mycobacterium tuberculosis and Mycobacterium leprae Infection: A Meta-Analysis.
ATP synthase, an essential enzyme in growth and multiplication is modulated by protein tyrosine phosphatase in Mycobacterium tuberculosis H37Ra.
Backbone NMR assignment of the low-molecular-weight protein tyrosine phosphatase (MPtpA) from Mycobacterium tuberculosis.
Backbone resonance assignment and dynamics of 110 kDa hexameric inorganic pyrophosphatase from Mycobacterium tuberculosis.
Bioactive Metabolites from the Deep-Sea-Derived Fungus Diaporthe longicolla FS429.
Biosynthesis of an anti-tuberculosis sesterterpenoid asperterpenoid A.
Brunsvicamides A-C: sponge-related cyanobacterial peptides with Mycobacterium tuberculosis protein tyrosine phosphatase inhibitory activity.
Cefsulodin Inspired Potent and Selective Inhibitors of mPTPB, a Virulent Phosphatase from Mycobacterium tuberculosis.
Cis-2 and trans-2-eisocenoic fatty acids are novel inhibitors for Mycobacterium tuberculosis Protein tyrosine phosphatase A.
Combination of Gomori and Ziehl-Neelsen stains for showing acid phosphatase activity and Mycobacterium tuberculosis in macrophages.
Compound Molecular Logic in Accessing the Active Site of Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
Corticosteroids inhibit Mycobacterium tuberculosis-induced necrotic host cell death by abrogating mitochondrial membrane permeability transition.
Crystal structure of low-molecular-weight protein tyrosine phosphatase from Mycobacterium tuberculosis at 1.9-A resolution.
Deciphering the genes involved in pathogenesis of Mycobacterium tuberculosis.
Design and synthesis of nonpeptidic, small molecule inhibitors for the Mycobacterium tuberculosis protein tyrosine phosphatase PtpB.
Design, synthesis and inhibition activity of novel cyclic peptides against protein tyrosine phosphatase A from Mycobacterium tuberculosis.
Diaporisoindoles A-C: Three Isoprenylisoindole Alkaloid Derivatives from the Mangrove Endophytic Fungus Diaporthe sp. SYSU-HQ3.
Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.
Discovery of a new class of inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B by biology-oriented synthesis.
Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase A (MptpA) inhibitors based on natural products and a fragment-based approach.
Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B (PtpB) inhibitors from natural products.
Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs.
Diversity-Oriented Synthesis for Novel, Selective and Drug-like Inhibitors for a Phosphatase from Mycobacterium Tuberculosis.
Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold.
Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.
Dynamic active-site protection by the M. tuberculosis protein tyrosine phosphatase PtpB lid domain.
Dynamic substrate enhancement for the identification of specific, second-site-binding fragments targeting a set of protein tyrosine phosphatases.
Expression and localization of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.
Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.
Genetic influence of PTPN22 R620W polymorphism in tuberculosis.
High-Throughput Discovery of Mycobacterium tuberculosis Protein Tyrosine Phosphatase B (MptpB) Inhibitors Using Click Chemistry.
Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
Identification and characterization of novel inhibitors of mPTPB, an essential virulent phosphatase from Mycobacterium tuberculosis.
Identification of Bostrycin Derivatives as Potential Inhibitors of Mycobacterium tuberculosis Protein Tyrosine Phosphatase (MptpB).
Identification of fusarielin M as a novel inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB).
Identification of inhibitors for mycobacterial protein tyrosine phosphatase B (MptpB) by biology-oriented synthesis (BIOS).
Identification of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase B.
Infection-Induced Vascular Permeability Aids Mycobacterial Growth.
Inhibition of MptpB phosphatase from Mycobacterium tuberculosis impairs mycobacterial survival in macrophages.
Inhibition of Mycobacterium tuberculosis tyrosine phosphatase PtpA by synthetic chalcones: kinetics, molecular modeling, toxicity and effect on growth.
Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. Role of the Src homology 2 containing tyrosine phosphatase 1.
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
MptpB, a virulence factor from Mycobacterium tuberculosis, exhibits triple-specificity phosphatase activity.
Mycobacterium tuberculosis promotes anti-apoptotic activity of the macrophage by PtpA protein-dependent dephosphorylation of host GSK3?.
Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+-ATPase to inhibit phagosome acidification.
Mycobacterium tuberculosis protein tyrosine phosphatase PtpB structure reveals a diverged fold and a buried active site.
Mycobacterium tuberculosis suppresses innate immunity by coopting the host ubiquitin system.
Mycobacterium tuberculosis tyrosine phosphatase A (PtpA) activity is modulated by S-nitrosylation.
Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
New potential eukaryotic substrates of the mycobacterial protein tyrosine phosphatase PtpA: hints of a bacterial modulation of macrophage bioenergetics state.
New strategies in fighting TB: targeting Mycobacterium tuberculosis-secreted phosphatases MptpA & MptpB.
Ophiobolin-Type Sesterterpenoids from the Mangrove Endophytic Fungus Aspergillus sp. ZJ-68.
Organocatalytic multicomponent reaction for the acquisition of a selective inhibitor of mPTPB, a virulence factor of tuberculosis.
Peniisocoumarins A-J: Isocoumarins from Penicillium commune QQF-3, an Endophytic Fungus of the Mangrove Plant Kandelia candel.
Peniphenones A-D from the Mangrove Fungus Penicillium dipodomyicola HN4-3A as Inhibitors of Mycobacterium tuberculosis Phosphatase MptpB.
Peptides and polyketides isolated from the marine sponge-derived fungus Aspergillus terreus SCSIO 41008.
Peptides from the Soft Coral-associated Fungus Simplicillium sp. SCSIO41209.
Phosphorylation control of protein tyrosine phosphatase A activity in Mycobacterium tuberculosis.
Polypropionate Derivatives with Mycobacterium tuberculosis Protein Tyrosine Phosphatase B Inhibitory Activities from the Deep-Sea-Derived Fungus Aspergillus fischeri FS452.
Post translational modifications in tuberculosis: ubiquitination paradox.
PP2Ac Modulates AMPK-Mediated Induction of Autophagy in Mycobacterium bovis-Infected Macrophages.
Protective activity of Lentinan in experimental tuberculosis.
Protein tyrosine phosphatase PtpA is not required for Mycobacterium tuberculosis growth in mice.
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
S-nitrosylation of Mycobacterium tuberculosis tyrosine phosphatase A (PtpA) induces its structural instability.
Structural basis for selective inhibition of Mycobacterium tuberculosis protein tyrosine phosphatase PtpB.
Structural insights into mode of actions of novel natural Mycobacterium protein tyrosine phosphatase B inhibitors.
Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.
Substrate Activation of the Low-Molecular Weight Protein Tyrosine Phosphatase from Mycobacterium tuberculosis.
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Synthesis, biological evaluation and molecular docking study of 1,2,3-1H-triazoles having 4H-pyrano[2,3-d]pyrimidine as potential Mycobacterium tuberculosis protein tyrosine phosphatase B inhibitors.
Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.
Synthetic thiosemicarbazones as a new class of Mycobacterium tuberculosis protein tyrosine phosphatase A inhibitors.
Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents.
The apo-structure of the low-molecular-weight protein tyrosine phosphatase A (MptpA) from Mycobacterium tuberculosis allows for better target-specific drug development.
The domain architecture of PtkA, the first tyrosine kinase from Mycobacterium tuberculosis, differs from the conventional kinase architecture.
The Influence of Mycobacterium tuberculosis sigma factors on the promotion efficiency of ptpAt promoter in Mycobacterium smegmatis.
The metabolic behaviour of the lymphocytes from serous effusions in various benign internal diseases.
Theoretical studies on the interaction of biphenyl inhibitors with Mycobacterium tuberculosis protein tyrosine phosphatase MptpB.
Three-dimensional structure and ligand interactions of the low molecular weight protein tyrosine phosphatase from Campylobacter jejuni.
Two new bioactive steroids from a mangrove-derived fungus Aspergillus sp.
Tyrosine phosphatase MptpA of Mycobacterium tuberculosis inhibits phagocytosis and increases actin polymerization in macrophages.
Xylanthraquinone, a new anthraquinone from the fungus Xylaria sp. 2508 from the South China Sea.
[Advances in the study of Mycobacterium tuberculosis protein phosphatase and its inhibitors].
[CHANGE OF ACID PHOSPHATASE ACTIVITY OF THE LIVER AND THE SPLEEN IN EXPERIMENTAL MOUSE TUBERCULOSIS.]
[Cytochemical study of macrophages in sarcoidosis patients in skin window exudates]
[Methylation Chip Screening and Verification of Differential Genes Related to Tuberculosis Infection].
[Microspectrophotometric study of acid phosphatase activity in human neutrophils under normal conditions and in tuberculosis]
[Role of molecular adjuvants TBhsp and MT in the preparation of monoclonal antibody against phosphatase of regenerating liver-3].
Tuberculosis, Multidrug-Resistant
Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.
Tuberculosis, Pulmonary
Association of PTPN22 gene functional variants with development of pulmonary tuberculosis in Moroccan population.
Influence of the polymorphism of the DUSP14 gene on the expression of immune-related genes and development of pulmonary tuberculosis.
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene polymorphism in pulmonary tuberculosis in the Indian population.
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene single nucleotide polymorphisms and its interaction with T2DM on pulmonary tuberculosis in Chinese Uygur population.
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
R620W functional polymorphism of protein tyrosine phosphatase non-receptor type 22 is not associated with pulmonary tuberculosis in Zahedan, southeast Iran.
[Lymphocyte enzymes, activity of lipid peroxidation processes and the antioxidant protection of patients with tuberculosis of the lungs]
Tuberous Sclerosis
Developmental regulation of the activation of signaling components leading to translation initiation in skeletal muscle of neonatal pigs.
Postnatal ontogeny of skeletal muscle protein synthesis in pigs.
Turner Syndrome
Analysis of PTPN22, ZFAT and MYO9B polymorphisms in Turner Syndrome and risk of autoimmune disease.
PTPN22 polymorphism is related to autoimmune disease risk in patients with Turner syndrome.
Unverricht-Lundborg Syndrome
Advances in the genetics of progressive myoclonus epilepsy.
Ureteral Obstruction
Integrin-mediated type II TGF-? receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling.
Ureterocele
Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.
Urinary Bladder Neoplasms
A novel synthetic 2-(3-methoxyphenyl)-6,7-methylenedioxoquinolin-4-one arrests the G2/M phase arrest via Cdc25c and induces apoptosis through caspase- and mitochondria-dependent pathways in TSGH8301 human bladder cancer cells.
Acquisition of the Metastatic Phenotype Is Accompanied by H2O2-Dependent Activation of the p130Cas Signaling Complex.
Anti-tumor effects of Atractylenolide I on bladder cancer cells.
Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers.
Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer.
Exosome-transmitted microRNA-133b inhibited bladder cancer proliferation by upregulating dual-specificity protein phosphatase 1.
HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer.
High expression of Cdc25B and low expression of 14-3-3? is associated with the development and poor prognosis in urothelial carcinoma of bladder.
Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Identification of hub genes and pathways associated with bladder cancer based on co-expression network analysis.
miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells.
MKP-1 overexpression is associated with chemoresistance in bladder cancer via the MAPK pathway.
Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells.
The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA.
[Expression and correlation of CIP2A and OPN in bladder cancer].
Urticaria
Association of PTPN22 single nucleotide polymorphisms with chronic spontaneous urticaria.
PTPN22 Polymorphism Presumably Plays a Role in the Genetic Background of Chronic Spontaneous Autoreactive Urticaria.
Uterine Cervical Neoplasms
Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis.
Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein.
Divergent viral presentation among human tumors and adjacent normal tissues.
Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer.
Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.
Feedback between E2F1 and CIP2A regulated by human papillomavirus E7 in cervical cancer: implications for prognosis.
HAUSP stabilizes Cdc25A and protects cervical cancer cells from DNA damage response.
High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer.
High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation.
Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer.
Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.
Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells.
Latex of Euphorbia antiquorum-induced S-phase arrest via active ATM kinase and MAPK pathways in human cervical cancer HeLa cells.
LINC00662 contributes to the progression and the radioresistance of cervical cancer by regulating miR-497-5p and CDC25A.
Long non-coding RNA USP30-AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA-299-3p and thereby overexpressing PTP4A1.
Loss-of-Function Variants in the Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk.
MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1.
miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25?CDC25A?.
MiR-613 promotes cell proliferation and invasion in cervical cancer via targeting PTPN9.
Molecular Analysis of the Interaction between Human PTPN21 and the Oncoprotein E7 from Human Papillomavirus Genotype 18.
Oncogenic role of ALX3 in cervical cancer cells through KDM2B-mediated histone demethylation of CDC25A.
PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway.
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-? production.
SHP-2 restricts apoptosis induced by chemotherapeutic agents via Parkin-dependent autophagy in cervical cancer.
Shp2 expression is upregulated in cervical cancer, and Shp2 contributes to cell growth and migration and reduces sensitivity to cisplatin in cervical cancer cells.
Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma acuminatum and Cervical Cancer.
Uterine Neoplasms
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Uveitis
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis.
SHP-1 suppresses endotoxin-induced uveitis by inhibiting the TAK1/JNK pathway.
Uveitis, Anterior
A functional variant of PTPN22 confers risk for Vogt-Koyanagi-Harada syndrome but not for ankylosing spondylitis.
Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Uveomeningoencephalitic Syndrome
A functional variant of PTPN22 confers risk for Vogt-Koyanagi-Harada syndrome but not for ankylosing spondylitis.
Evaluation of PTPN22 polymorphisms and Vogt-Koyanagi-Harada disease in Japanese patients.
Glucocorticoid receptor ? and MKP-1 as candidate biomarkers for treatment response and disease activity in Vogt-Koyanagi-Harada disease.
Vaccinia
A protein phosphatase related to the vaccinia virus VH1 is encoded in the genomes of several orthopoxviruses and a baculovirus.
A selective Seoul-Fluor-based bioprobe, SfBP, for vaccinia H1-related phosphatase--a dual-specific protein tyrosine phosphatase.
Allosteric Impact of the Variable Insert Loop in Vaccinia H1-Related (VHR) Phosphatase.
An RNA 5'-triphosphatase related to the protein tyrosine phosphatases.
Anti-mycobacterial alkaloids, cyclic 3-alkyl pyridinium dimers, from the Indonesian marine sponge Haliclona sp.
Atomic structure of dual-specificity phosphatase 26, a novel p53 phosphatase.
Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration.
Dimeric quaternary structure of the prototypical dual specificity phosphatase VH1.
Dimerization of vaccinia virus VH1 is essential for dephosphorylation of STAT1 at tyrosine 701.
Dual-specificity protein phosphatase Yvh1p, which is required for vegetative growth and sporulation, interacts with yeast pescadillo homolog in Saccharomyces cerevisiae.
Effects of metal ions on the activity of protein tyrosine phosphatase VHR: highly potent and reversible oxidative inactivation by Cu2+ ion.
Furanoterpenes, new types of protein tyrosine phosphatase 1B inhibitors, from two Indonesian marine sponges, Ircinia and Spongia spp.
hVH-5: a protein tyrosine phosphatase abundant in brain that inactivates mitogen-activated protein kinase.
Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone.
Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence.
Molecular cloning and characterization of a novel dual-specificity protein phosphatase possibly involved in spermatogenesis.
Mutational and kinetic evaluation of conserved His-123 in dual specificity protein-tyrosine phosphatase vaccinia H1-related phosphatase: participation of Tyr-78 and Thr-73 residues in tuning the orientation of His-123.
Negative signaling pathways of the killer cell inhibitory receptor and Fc gamma RIIb1 require distinct phosphatases.
OH1 from Orf Virus: A New Tyrosine Phosphatase that Displays Distinct Structural Features and Triple Substrate Specificity.
Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase.
Protein tyrosine phosphatase 1B inhibitory activity of lavandulyl flavonoids from roots of Sophora flavescens.
Protein tyrosine phosphatase 1B inhibitory properties of seco-cucurbitane triterpenes obtained from fruiting bodies of Russula lepida.
Proteomic, cellular, and network analyses reveal new DUSP3 interactions with nucleolar proteins in HeLa cells.
Revisiting the roles of VHR/DUSP3 phosphatase in human diseases.
Small molecule tools for functional interrogation of protein tyrosine phosphatases.
Specificity Profiling of Dual Specificity Phosphatase Vaccinia VH1-related (VHR) Reveals Two Distinct Substrate Binding Modes.
Specificity profiling of protein phosphatases toward phosphoseryl and phosphothreonyl peptides.
Structural and functional analysis of PTPMT1, a phosphatase required for cardiolipin synthesis.
Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth.
The catalytic role of Cys124 in the dual specificity phosphatase VHR.
The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro.
The minimal essential core of a cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like phosphatase, VHZ.
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.
Transcription mapping and functional analysis of the protein tyrosine/serine phosphatase (PTPase) gene of the Autographa californica nuclear polyhedrosis virus.
Tyrosine phosphorylation of A17 during vaccinia virus infection: involvement of the H1 phosphatase and the F10 kinase.
Unnatural amino acid mutagenesis reveals dimerization as a negative regulatory mechanism of VHR's phosphatase activity.
Vaccinia H1-related Phosphatase Is a Phosphatase of ErbB Receptors and Is Down-regulated in Non-small Cell Lung Cancer.
VHR/DUSP3 phosphatase: Structure, function and regulation.
Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis.
Vascular Calcification
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Vascular Diseases
Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems.
Cross-talk between SIRT1 and p66Shc in vascular diseases.
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Protein-tyrosine phosphatases in the vessel wall: differential expression after acute arterial injury.
Repression of P66Shc Expression by SIRT1 Contributes to the Prevention of Hyperglycemia-Induced Endothelial Dysfunction.
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.
The Phosphatase SHP-2 Activates HIF-1? in Wounds In Vivo by Inhibition of 26S Proteasome Activity.
Vascular Malformations
Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2.
Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development.
Vascular System Injuries
Counter-regulatory function of protein tyrosine phosphatase 1B in platelet-derived growth factor- or fibroblast growth factor-induced motility and proliferation of cultured smooth muscle cells and in neointima formation.
Endothelial cell-restricted disruption of FoxM1 impairs endothelial repair following LPS-induced vascular injury.
Increase of PTP levels in vascular injury and in cultured aortic smooth muscle cells treated with specific growth factors.
Intravenous Immunoglobulins Modulate Neutrophil Activation and Vascular Injury Through Fc?RIII and SHP-1.
Mitogen-activated protein kinase phosphatase-1 in rat arterial smooth muscle cell proliferation.
Vasculitis
High Basal Activity of the PTPN22 Gain-of-Function Variant Blunts Leukocyte Responsiveness Negatively Affecting IL-10 Production in ANCA Vasculitis.
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
PTPN22: the archetypal non-HLA autoimmunity gene.
The protein tyrosine phosphatase nonreceptor 22 C1858T polymorphism and vasculitis: a meta-analysis.
The PTPN22 R620W polymorphism in anti-neutrophil cytoplasmic antibody-associated vasculitis in Mexican Mestizos.
Vasospasm, Intracranial
Recombinant osteopontin in cerebral vasospasm after subarachnoid hemorrhage.
Ventricular Dysfunction, Left
Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc.
Vesicular Stomatitis
A conserved miRNA-183 cluster regulates the innate antiviral response.
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Vestibular Diseases
Deafness and vestibular dysfunction in a Doberman Pinscher puppy associated with a mutation in the PTPRQ gene.
Virus Diseases
A conserved miRNA-183 cluster regulates the innate antiviral response.
A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system.
A role for protein phosphatase 2A in regulating p38 mitogen activated protein kinase activation and tumor necrosis factor-alpha expression during influenza virus infection.
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.
E4orf4 induces PP2A- and Src-dependent cell death in Drosophila melanogaster and at the same time inhibits classic apoptosis pathways.
Enhanced Expression of Autoantigens During SARS-CoV-2 Viral Infection.
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
Frequent occurrence of RASSF1A promoter hypermethylation and merkel cell polyomavirus in merkel cell carcinoma.
Inverse regulation of inducible nitric oxide synthase (iNOS) and arginase I by the protein tyrosine phosphatase SHP-1 in CNS glia.
MAPK Phosphatase 5 Expression Induced by Influenza and Other RNA Virus Infection Negatively Regulates IRF3 Activation and Type I Interferon Response.
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia.
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Protein tyrosine phosphatase 1B is involved in efficient type I interferon secretion upon viral infection.
PTPN1/2-mediated dephosphorylation of MITA/STING promotes its 20S proteasomal degradation and attenuates innate antiviral response.
PTPN22 C1858T polymorphism and the outcome of hepatitis C virus infection.
PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection.
PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.
SHP-1 suppresses the antiviral innate immune response by targeting TRAF3.
[Classification and etiology of hyperthyroidism].
[Molecular genetics of type 1 diabetes mellitus: achievements and future trends]
[Role of cellular organelles in the reproduction of the influenza virus]
Vitamin D Deficiency
Alterations in rat epidermis provoked by chronic vitamin D deficiency.
Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective?
Identification of rat osteoclasts in bone smears with quantification of acid phosphatase activity in vitamin D deficiency.
Vitamin E Deficiency
Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus.
Vitiligo
A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo.
Association of Functional Polymorphism in Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Gene with Vitiligo.
Association of protein tyrosine phosphatase, non-receptor type 22 +1858C?T polymorphism and susceptibility to vitiligo: Systematic review and meta-analysis.
Association of PTPN22 1858C/T polymorphism with vitiligo susceptibility in Gujarat population.
Association of PTPN22 gene polymorphism with non-segmental vitiligo in South Indian Tamils.
Clinical characteristics and PTPN22 1858C/T variant analysis in Jordanian Arab vitiligo patients.
Lack of Association between PTPN22 Gene +1858 C>T Polymorphism and Susceptibility to Generalized Vitiligo in a Turkish Population.
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Novel homozygous AIRE mutation in a German patient with severe APECED.
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Protein tyrosine phosphatase PTPN22 +1858C/T polymorphism is associated with active vitiligo.
Protein tyrosine phosphatase PTPN22 in human autoimmunity.
PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not.
The CTLA-4 +49 A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis.
The PTPN22-1858C>T (R620W) functional polymorphism is associated with generalized vitiligo in the Romanian population.
Update on the genetics characterization of vitiligo.
Werner Syndrome
Physical map of the human chromosome 8p12-p21 encompassing tumor suppressor and Werner's syndrome gene loci.
Whooping Cough
Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness.
Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion.
Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase.
Antibody binding to cell surface amyloid precursor protein induces neuronal injury by deregulating the phosphorylation of focal adhesion signaling related proteins.
Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin.
Bordetella pertussis Adenylate Cyclase Toxin Blocks Induction of Bactericidal Nitric Oxide in Macrophages through cAMP-Dependent Activation of the SHP-1 Phosphatase.
Cloning, expression and regulation of angiotensin II receptors.
Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors.
Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity.
Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells.
G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification.
Galpha(i2) enhances insulin signaling via suppression of protein-tyrosine phosphatase 1B.
Gbeta gamma -independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1.
Inactivation of raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits.
Inhibition of protein phosphatase 2A (PP2A) mimics suckling-induced sensitization of mammotropes: involvement of a pertussis toxin (PTX) sensitive G-protein and the adenylate cyclase (AC).
LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells.
Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition.
Molecular structure and function of angiotensin type 2 receptor.
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression.
Pertussis toxin modification of PC12 cells lowers cytoskeletal F-actin and enhances norepinephrine secretion: involvement of protein kinase C and protein phosphatases.
Potentiation by insulin and insulin-like growth factor-1 of glibenclamide-sensitive K+ currents in follicle-enclosed Xenopus oocytes.
Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2.
Ras-dependent activation of fibroblast mitogen-activated protein kinase by 5-HT1A receptor via a G protein beta gamma-subunit-initiated pathway.
Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in Rat-1 cells.
Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).
The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling.
Tyrosine phosphorylation of an SH2-containing protein tyrosine phosphatase is coupled to platelet thrombin receptor via a pertussis toxin-sensitive heterotrimeric G-protein.
Wilms Tumor
Early changes in gene expression that influence the course of primary glomerular disease.
Expression of phosphatase of regenerating liver-3 is associated with prognosis of Wilms' tumor.
Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.
Wiskott-Aldrich Syndrome
Role of Rho-GTPases in megakaryopoiesis.
Xanthogranuloma, Juvenile
Juvenile myelomonocytic leukaemia presentation after preceding juvenile xanthogranuloma harbouring an identical somatic PTPN11 mutation.
[phosphatase 2a protein]-leucine-carboxy methyltransferase deficiency
Circumventing embryonic lethality with Lcmt1 deficiency: generation of hypomorphic Lcmt1 mice with reduced protein phosphatase 2A methyltransferase expression and defects in insulin signaling.